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Personalized medicine – it’s all about 
concentrations
Personalized medicine remains an important topic in pharmacotherapy.1 It is 
frequently defined as the right medicine at the right dose to the right patient at 
the right time.2 From basic clinical pharmacology principles it is known that dose 
impacts drug concentration, which on its turn impacts the effect.3 This interplay 
is shown in Figure 1. Ideally, the effect of the drug is predicted from the dose. 
However, it is important to acknowledge that the same dose does not lead to 
the same concentration in different individuals due to physiological differences 
between patients that influence absorption, volume of distribution, metabolism 
or excretion. Variability in concentrations will subsequently lead to variability in 
clinical outcome. In other words, one would rather focus on a concentration-effect 
relationship instead of a dose-response relationship. This concentration-effect 
relationship is usually assumed to be sigmoidal.
Clearly, the prevailing ‘one-dose-fits-all’ approach to drug treatment is failing.4 
The role of variability in the relationship between doses administered, systemic 
exposure achieved and treatment outcome is completely ignored by these classical 
dosing methods. In order to provide a valuable advice on the optimal dose for an 
individual patient, it is important to characterize both the pharmacokinetics (PK) 
and the pharmacodynamics (PD). Therefore, one can study the PK on a population 
level, by characterising the PK within a subpopulation and identifying patterns 
in sources of variability that are similar within this population, based on their 
physiological similarities. One can also try to provide optimal pharmacotherapy 
by adapting doses of individual patients based on information on the individual 
exposure, in order to attain a predefined, well-characterized PK target.
Figure 1 Schematic overview of the relationship between the prescribed dose and the eventual 
effect, with the drug concentration as intermediate link. The relationship between concentration 
and effect is assumed to be sigmoidal. TDM, therapeutic drug monitoring.
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Drug development
In drug development, dose selection is often based on maximal tolerability, i.e. the 
dose that does not cause treatment-limiting toxicity.3 The optimal and maximal 
tolerated dose is searched for in small groups of healthy human male volunteers 
and in small homogenous groups of patients.5 Basic human PK parameters are 
determined simultaneously with dose finding experiments. Once a drug is on 
the market it is used by other patients than those investigated pre-licensing, for 
example by critically ill patients or paediatric patients. Specifically the latter group 
has often been excluded from clinical research. Even today, still up to 80% of 
prescriptions for children are off-label.6, 7
Knowledge gaps in the PK of different sub-populations
The PK of drugs may be different in sub-populations such as children or critically 
ill patients as compared to healthy male volunteers, due to factors such as 
maturation, size, body composition, fluid retention, co-morbidity, co-medication 
or genetics.4, 8-10 A difference in PK may impact both the desired effect as well as 
the adverse events. E.g., children require a higher tacrolimus mg/kg body weight 
dosing regimen in order to attain the same adult PK target.11 Alternatively, in 
contrast to adults, children show pseudo-linear PK of voriconazole in therapeutic 
plasma concentrations (1-6 mg/L). Due to the more rapid clearance in this 
population compared to adults, a three times daily regimen is often needed.12 
The increased clearance of voriconazole in paediatric patients also prompted for 
multiple empirical dose modifications after registration, illustrating the challenge 
of finding the optimal dose for every sub-population.13, 14
Clearly, in order to select the right dose for the right patient, a detailed insight 
in the PK is essential but this insight is currently not available for all drugs in every 
patient population. Thus, the PK need to be well characterized in the population 
and the relationship with PD should be clear. To further individualize the dose on 
a patient’s level, adequate drug assays are required to measure and individualize 
the exposure of the specific patient. Novel tools facilitating blood sampling may be 
useful for concentration measurement. Dried blood spot (DBS) sampling is one of 
these promising novel sampling tools.
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This thesis focuses on:
(I) Studying the PK on a population level by investigating two drug 
classes - immunosuppressants and antifungal agents - in special 
patient populations, and on 
(II) Measuring blood concentrations to further individualize drug 
treatment on a patient’s level by deploying DBS sampling. 
Both approaches have the ultimate goal of finding the optimal dose for each 
individual patient. In other words: It is all about concentrations!
Drugs studied in this thesis
The drugs that are studied in this thesis may all benefit from dose individualization to 
improve exposure and thereby clinical outcome. These include immunosuppressive, 
antifungal and anti-tuberculosis (anti-TB) agents in children and antifungal agents 
in critically ill patients.
Immunosuppressants
Tacrolimus and mycophenolic acid (MPA) are the backbone of maintenance 
immunosuppressive treatment for the prevention of the rejection of a transplanted 
kidney.15, 16 MPA is a non-competitive inhibitor of inosine monophosphate 
dehydrogenase (IMPDH), thereby reducing intracellular guanine leading to an 
arrest of B- and T-cell proliferation. MPA PK shows considerable inter-individual 
variability, which can be partly explained by albumin levels, kidney function and 
cyclosporine co-administration.17-19 Tacrolimus acts as a calcineurin inhibitor 
by suppressing T-cell activation and T-helper-cell dependent B-cell activation 
as well as suppressing the formation of lymphokines (interleukin [IL]-2,3 and 
y-interferon) and the IL-2 receptor. Total exposure (AUC) is assumed to best relate 
PK to clinical outcome.20
Antifungal agents
Azole antifungal agents are used to prevent or treat invasive fungal infections. They 
work by inhibiting fungal cytochrome P450-mediated lanosterol metabolism, 
specifically lanosterol 14α-demethylase, required for ergosterol synthesis. 
Ergosterol is an important component for fungal cell wall stability. Voriconazole, 
posaconazole and itraconazole are used to treat or prevent Aspergillus spp while 
all triazoles including fluconazole show activity against yeast such as Candida 
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spp. Patients with an impaired immune system are at high risk for developing 
such infections, such as patients with hereditary defects in their immune system 
including chronic granulomatous disease (CGD) or in case of chemotherapy-
induced immune deficiencies. The PK of triazole antifungal agents is fairly well 
described in a wide variety of patient populations including children. Specifically 
voriconazole is associated with high inter- and intra-patient variability in its 
PK challenging individualized treatment. The PK-PD index linking efficacy to 
outcome is described by the AUC over the Minimal Inhibitory Concentration 
(MIC) for both moulds and yeast (the AUC:MIC ratio).
This thesis also studies the PK of the echinocandins caspofungin and micafungin. 
Echinocandins are an important treatment option to manage candidemia or 
invasive candidiasis, a common infection among severely ill patients. They work 
by inhibiting synthesis of β(1,3)-D-glucan, an important component of the fungal 
cell wall. Inhibition of B-glucan results in loss of stability and cell death.21 The PK-
PD relationship of echinocandins is best described by the AUC:MIC ratio.22
Anti-TB drugs
Tuberculosis (TB) is caused by Mycobacterium tuberculosis, and it is the number 
one infectious disease killer globally, even though it is curable. First-line anti-
TB drugs include rifampicin, isoniazid, pyrazinamide and ethambutol. These 
drugs have been on the market since decades but their precise pharmacological 
mechanism of action remains largely unknown. Rifampicin works by inhibiting 
DNA-dependent RNA polymerase. Isoniazid probably works by inhibiting some 
processes in the cell wall lipid synthesis such as mycolic acid. It is largely unknown 
how pyrazinamide exactly works but its activity depends on pyrazinamidase, which 
turns pyrazinamide into pyrazinoic acid. It is also still unclear how ethambutol 
works, it may increase permeability of the mycobacterium by inhibiting the 
synthesis of arabinogalactan.23 Both AUC and Cmax have been used to relate the PK 
of first-line anti-TB drugs to PD but ideally MIC should be considered as well.24
Studying the PK on a population level - special patient populations
Identifying factors influencing the PK might help to understand the mechanisms 
behind the variability observed in the PK and response among different patient 
populations. This information can be used to design better a priori dosing 
regimens. The first part of this thesis focuses on the PK of immunosuppressive 
agents in paediatric patients and on the PK of echinocandin antifungal agents in 
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the critically ill. Both populations were poorly studied during drug development 
and literature shows that the optimal dosing regimen is yet to be found.
PK of immunosuppressants in the paediatric population
The PK of children is different compared to adults due to developmental and 
maturation processes that result in changes in body composition and organ 
function which may influence both volume of distribution and clearance.25 
MPA has a defined therapeutic window and plasma concentrations are measured to 
monitor exposure. In the acute post-transplantation phase, a total exposure during 
the dose interval (AUC0-12h) of 30-60 mg*h/L is aimed for.26 Trough concentrations 
of >1.3 and >1.9 mg/L in combination with cyclosporine or tacrolimus are 
targeted, respectively.26 There is little information on the PK of MPA in children 
and on the proportion of patients attaining the PK target in real life settings. This 
pharmacokinetic information is urgently needed to design dosing nomograms to 
achieve the predefined target. 
Tacrolimus exposure, like MPA, is also extensively monitored. Although AUC 
probably correlates better with outcome, often trough concentrations are drawn as 
a surrogate marker.20 Target drug concentrations differ depending on the period 
post transplantation and on the immunosuppressive regimen.27
Since 2012, children younger than 4 years are eligible for pre-emptive kidney 
transplantation with an adult-size kidney at the Radboud university medical center 
in Nijmegen, The Netherlands. This resulted in an increase in transplantations in 
very young patients. It is known that the variability in PK of tacrolimus is higher in 
young children (up to 6 years of age) and that their clearance may be increased.28, 29 
However, there is virtually no data available on the PK of tacrolimus in very young 
children. 
Gaining insight in the PK and the variability in the PK of these mainstay 
immunosuppressive agents used after kidney transplantation will help to 
individualize drug dosing in this population. 
PK of echinocandin antifungal agents in ICU patients
The PK of anti-infective agents in critically ill patients can be highly variable due 
to physiological processes such as hypoalbuminemia, changes in protein-binding, 
fluid retention with subsequent administration of diuretics, sepsis, multi-organ 
failure, capillary leak and differences in cardiac output.4 Moreover, antimicrobial 
dosing recommendations are inadequate in up to 40% of ICU patients and it is 
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thought to be one of the main drivers of treatment failure.30 Whether this high 
inter-patient variability in PK is also observed in echinocandins was unknown. 
Nor were predictors of variability adequately defined.
Two prospective studies in critically ill patients treated with caspofungin and 
micafungin for suspected or proven invasive fungal infections have been carried 
out by our group.31, 32 We observed a lower exposure and a higher variability in 
the exposure to echinocandins was observed in these patients as compared to 
healthy volunteers. This may impact treatment efficacy, as an important part of 
the population may be at risk for suboptimal exposure. It is still unknown which 
factors contribute to this increased variability and what dosing regimen would be 
optimal for the treatment of invasive candidiasis in critically ill patients. When 
investigating and designing such regimens, both the PK as well as PD should be 
taken into account.
Drug-drug interactions in the transplant patient
Drug-drug interactions may form an important source of PK variability. 
Managing interactions is a challenge in clinical practice as it requires a highly 
individualized patient approach. For instance, the transplanted patient treated 
with immunosuppressive agents to prevent graft rejection is at risk for 
developing (fungal) infections. As azole antifungals inhibit the metabolism of 
immunosuppressants (tacrolimus, cyclosporine, everolimus and sirolimus), 
starting or stopping azole antifungal agents poses the transplant patient at risk 
for either toxicity or rejection of the transplant respectively. This thesis provides 
a strategy for optimal management of the interaction between azoles and 
immunosuppressive agents, to further individualize both treatments.
Therapeutic drug monitoring
In an attempt to reduce the variability in drug exposure between patients, it can 
be helpful to monitor plasma concentrations, in the context of therapeutic drug 
monitoring (TDM).33 TDM can be defined as the measurement of plasma or blood 
concentrations to adapt dosages to achieve predefined targets that are associated 
with maximal efficacy while minimizing toxicity.34 It depends on the type of drug 
and on its indication whether or not TDM might prove useful. TDM is considered 
useful only when the following general requirements are met: (I) Large inter-
individual variability in pharmacokinetic parameters exist; (II) There is a good 
relationship between plasma drug concentrations and therapeutic or toxic effect; 
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(III) There is a narrow range of effective and tolerated concentrations; (IV) No 
direct (intermediate) measure of patient response is available; and (V) Drug 
assays are available with a short turnaround time.35, 36 In case the drug effect can be 
observed shortly after start of therapy, such as for analgesics, anti-hypertensives or 
blood glucose lowering drugs, drug plasma concentrations are of minor relevance 
and TDM is not indicated. For immunosuppressive agents, antifungal agents and 
anti-TB drugs it is proven useful to apply TDM for dose individualization.20, 24, 37 
DBS as a tool for personalized medicine on a patient level
Conventionally, the concentration of drugs is measured in plasma or whole blood 
obtained by venous sampling. Repetitive sampling can be associated with high 
patient burden especially for children, as the method is invasive and patients have 
to travel to a health-care setting, as instructed personnel is required for every blood 
sample. Children cannot attend school and parents need to take part of the day off to 
yield a blood sample for their child. Moreover, for adequate clinical interpretation, 
preferably trough concentrations are sampled, i.e. the concentrations prior to the 
next dose, which are not easy to capture on outpatient visits. In the setting of low 
resource countries and/or remote areas, conventional venous blood sampling is 
even more challenging as the shipment and storage of blood/plasma requires a 
cold-chain associated with high costs. In light of these drawbacks, blood sampling 
for the purpose of TDM can be improved.
Dried blood spot sampling
Novel sampling methods are increasingly developed and investigated such as 
sampling of saliva or DBS. In DBS, one of two drops of blood are obtained by 
means of a finger prick and applied on a filter paper (Figure 2). The spots are 
stored in their dried form until analysis. DBS was first introduced in neonatal 
heel prick screening for phenylketonuria half a century ago.38 DBS is also very 
attractive in the context of TDM as this sampling technique is associated with 
advantages, including (I) Minimally invasive sampling as the drop of blood is 
easily obtained by a finger prick which can be spotted onto filter paper; (II) The 
possibility of home sampling as patients can perform the finger prick themselves 
which may also increase patient empowerment; (III) Easy transport as the sample 
may be send to the laboratory by regular mail; (IV) The possibility to obtain trough 
concentrations which correlate best to clinical outcome; and (V) The results may 
be available prior to the outpatient visit allowing for direct dose adaptation.39, 40 
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DBS may be processed manually or fully automated, the latter method ensuring 
rapid processing of patient samples in the laboratory.41 
The advantages of DBS sampling have led to an increase in the development 
of DBS assays for the purpose of TDM.42 Despite increased availability of these 
assays, little is known about their clinical use and practical implementation 
and the economical benefit often assumed.43, 44 This might be related to the fact 
that little attention has been paid on their clinical validation and subsequent 
implementation so far.45 The second part of this thesis focuses on the analytical 
development, clinical validation and economical evaluation of DBS sampling of 
azole antifungal and immunosuppressive agents and anti-TB drugs in children. 
Figure 2 Dried blood spot sampling procedure. Picture was kindly provided by Dried Blood Spot 
Laboratory (DBSL)®.46 
Aims and scope of this thesis
(I) To study the PK on a population level: tacrolimus and MPA to 
prevent kidney rejection in children and echinocandin antifungal 
agents in critically ill patients. 
(II) To improve individualized dosing on a patient’s level using DBS 
as a sampling tool for antifungal, immunosuppressive and anti-
TB agents in children by analytically and clinically validating 
DBS sampling, exploring the possibilities of fully automated DBS 
analysis and evaluating the impact of DBS home sampling on 
total costs.
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Section I: Studying the PK on a population level - special patient populations
A retrospective observational study (chapter 2) was carried out to describe the 
PK and assess PK target attainment of MPA in all paediatric patients treated with 
MPA and intensively sampled at the Radboudumc Amalia Children’s hospital 
1998-2014. Chapter 3 covers a retrospective analysis of the PK of tacrolimus in 
very young patients (≤4 years) transplanted pre-emptively with an adult kidney 
between 2012 and mid-2015, also at the Radboudumc Amalia Children’s hospital.
Chapters 4 and 5 focus on the PK of caspofungin and micafungin respectively 
in ICU patients. Possible co-factors explaining the PK variability are assessed and 
the impact of different dosing regimens on the probability of target attainment 
(PTA) is investigated. In chapter 6, a step-wise approach to manage the interaction 
between azole antifungal agents and immunosuppressants using TDM in the 
transplant patient is presented.
Section II: DBS as a tool for personalized medicine on a patient level
Chapters 7, 8, 10 and 11 are part of the PROTECT project: Personalized treatment 
of immunosuppressive and antifungal drugs through continuous home based 
monitoring with DBS sampling techniques in paediatric patients. Two analytical 
assays of DBS sampling with subsequent clinical validation are presented. Chapter 
7 and chapter 8 cover immunosuppressive drugs (MPA and tacrolimus) and 
azole antifungal agents (fluconazole, isavuconazole, itraconazole, posaconazole 
and voriconazole), respectively. Chapter 9 involves the clinical validation and 
application of a DBS method and subsequent PK analysis of anti-TB drugs 
(rifampicin, isoniazid, pyrazinamide and ethambutol treated according to the latest 
World Health Organization (WHO) dosing schedule) in Paraguayan children.47 
In chapter 10 a fully automated DBS sample measurement was set up and 
described for the measurement of voriconazole. Finally an economical evaluation/
Health Technology Assessment (HTA) was conducted in which total costs 
associated with DBS sampling and conventional sampling were compared taking 
into account the societal, healthcare and patient perspective (chapter 11).
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Abstract 
Mycophenolic acid (MPA) is an immunosuppressive agent used to prevent graft 
rejection after renal transplantation. MPA shows considerable inter- and intra-
individual variability in exposure in children, has a defined therapeutic window 
and therapeutic drug monitoring (TDM) is applied to individualize therapy. We 
aimed to study the exposure to MPA measured as the area under the concentration 
time curve (AUC) in pediatric renal transplant patients, to identify factors 
influencing exposure and to assess target attainment. Children transplanted 
between 1998-2014 in a single center were included. Two groups were identified: 
group 1 (AUC <3 weeks post-transplantation) and group 2 (AUC >18 months 
post-transplantation). Therapeutic targets were set at: AUC0-12h of 30-60 mg*h/L. 
39 children were included in group 1 (median age 13.3 years) vs 14 in group 2 
(median age 13.4 years). AUC0-12h was 29.7 mg*h/L in group 1 and 56.6 mg*h/L 
in group 2, despite a lower dosage in group 2 (584 and 426 mg/m2, respectively). 
46% of patients reached the target AUC0-12h in group 1. Time since transplantation 
and serum creatinine were significantly associated with MPA exposure (p<0.001), 
explaining 36% of the variability. Individualization of the mycophenolate dose by 
more intense and more early TDM could improve target attainment.
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Introduction
Over the past two decades, both children and adults have shown better graft 
survival after kidney transplantation, which is largely due to improvement of 
immunosuppressive regimens.1, 2 Adequate suppression of the immune system can 
be obtained by combining different immunosuppressive agents. Mycophenolate 
mofetil (MMF) has become an important immunosuppressive drug for prevention 
of graft rejection.3-6 It is most frequently used in combination with tacrolimus or 
with cyclosporine A (CsA) as mainstay of the immunosuppressive backbone. After 
oral administration, MMF is rapidly and almost completely absorbed. It undergoes 
hydrolysis to its active metabolite mycophenolic acid (MPA).7 MPA is a non-
competitive inhibitor of inosine monophosphate dehydrogenase, thereby reducing 
intracellular guanine leading to an arrest of B and T-lymphocyte proliferation. In 
turn, MPA is metabolized to MPA-glucuronide which is not pharmacologically 
active. MPA-glucuronide is excreted in urine but a small proportion is excreted 
into the bile and can undergo enterohepatic recirculation after deconjugation back 
to MPA.7 A standardized dose does not necessarily result in identical exposure, 
resulting in both inter- and intra individual variability in exposures achieved.8-10
For immunosuppressive agents, optimizing efficacy while avoiding adverse 
effects is aimed for. Suboptimal exposure leads to insufficient suppression of 
the immune system risking graft rejection, while higher concentrations may 
lead to toxicity. It is essential to ensure adequate immune suppression direct 
after transplantation to prevent acute rejection and preserve long-term kidney 
graft function.11, 12 Therapeutic drug monitoring (TDM), i.e. individualized drug 
dosing based on the measurement and interpretation of drug concentrations, is 
an important tool to keep drug concentrations between predefined target values. 
Available evidence suggests that the area under the concentration versus time 
curve from 0-12 hours (AUC0-12h) of MPA should be 30-60 mg*h/L in order to 
decrease the risk of acute rejection and toxicity for both adults and children.13-17 In 
adults, individualized dosing of MPA by means of TDM has shown to significantly 
improve patient outcome.18 The determination of an AUC0-12h has some practical 
challenges, especially in children, as multiple samples are required in a time 
interval of 12 hours. Hence, trough concentrations or a so called limited sampling 
strategy based on the first four hours after dosing obtaining an AUC0-4h are often 
chosen to predict the AUC0-12h . Those approaches minimize patient burden and 
costs. AUC0-4h has demonstrated to adequately predict AUC0-12h when compared to 
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intensive pharmacokinetic (PK) sampling.7, 19 Yet, AUC0-4h as a predictor of total 
exposure is only valid when the ratio AUC0-4h/AUC0-12h is constant over time that 
a patient is on treatment.
Limited data are available on exposures achieved after administration of MPA 
in children both early and late after transplantation. This study aimed to describe 
the PK of MPA in a cohort of pediatric patients after renal transplantation and 
to identify which patient factors are associated with exposure. In addition, we 
intended to assess target attainment rates.
Patients and methods
Patients and study design
This was a retrospective, descriptive PK study among pediatric patients undergoing 
renal transplantation between August 1998 and June 2014 in whom exposure to 
MMF was measured in the context of TDM. All patients were admitted at the 
department of Pediatric Nephrology of the Radboud university medical center in 
Nijmegen, The Netherlands. Patients were selected based on the presence of a PK 
curve of MMF, measured as MPA. A seven point PK curve recorded within three 
weeks after transplantation has been standard of care in our institution since 2009. 
In the Radboud university medical center, the target AUC0-12h is 30-60 mg*h/L 
both short and late after transplantation.13-16
Patients were treated by standard of care and MMF dosage was based on body 
surface area (BSA, 600 mg/m2 oral twice daily). Two different immunosuppressive 
regimes were used. Dose adjustments prior to the PK curve were allowed based 
on trough concentrations aiming at ≥1.9 or ≥1.3 mg/L in case of tacrolimus 
or CsA co-medication, respectively.15, 20 Until 2011, patients received a pre-
transplantation induction therapy of MMF, basiliximab and methylprednisolone, 
and after transplantation continued with MMF, CsA and a slowly tapering dose 
of prednisolone. After a year, renal transplant recipients without any signs of 
rejection continued low dose prednisolone with either CsA or MMF. From 2011 
onwards, patients received a similar induction scheme but tacrolimus was used 
as a calcineurin inhibitor and prednisolone was tapered and stopped in five days. 
These patients were maintained on low dose tacrolimus in combination with 
MMF.21
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In addition, a PK curve was drawn on clinical indication late after 
transplantation, i.e. >18 months post transplantation in patients without an 
AUC0- 12h early after transplantation. 
Collection of samples was done under routine patient care. Data processing 
and analysis of the data was performed anonymously. The study was approved by 
our local medical-ethics committee (Commissie Mensgebonden Onderzoek regio 
Arnhem-Nijmegen, number 2015-2081). No informed consent was required for 
this retrospective analysis.
Sample collection and analysis
At seven predefined time points, venous blood was drawn to obtain an AUC0-12h: 
just prior to MMF administration (trough concentration, C0) and at t=1h (C1), 
t=2h (C2), t=4h (C4), t=6h (C6), t=8h (C8) and t=12h (C12) post administration. In 
addition, an AUC0-4h curve was obtained using the concentrations up to 4h post 
dose. MPA was analysed using either a validated immune-assay (Roche Cobas 
Integra 400/800, accuracy was always within ±10-15%; precision (CV) 4.5, 1.8 
and 1.3% for concentration levels low, medium and high respectively; lower limit 
of quantitation (LLOQ) 0.4 mg/L) or a validated liquid chromatography tandem 
mass spectrometry (LC-MS/MS) method (accuracy at lower concentration level 
97.2% and at higher concentration level 104.9%; within-day precision 2.5% and 
between day precision 3.1%; LLOQ 0.1 mg/L). The methods were cross-validated 
by analysis of 21 patient samples across the therapeutic range of mycophenolic 
acid. Bland-Altman analysis confirmed a mean difference (systematic bias) of 
-0.56 mg/L (95%CI -1.4 -0.3) between LC-MS/MS and Cobas. As to correct for 
this statistically and clinically significant difference, all concentrations measured 
by LC-MS/MS were increased with 0.56 mg/L.
Patient and biochemical parameters
Patient-related factors and biochemical parameters were obtained from the 
medical records and included age, gender, dose of MMF, steroid and CsA co-
medication (known for its interaction with MMF), body weight (BW), height, 
serum creatinine and albumin.22, 23 Further patient related parameters, calculated 
based on the above mentioned values, included body mass index (BMI, BW/
height2), BSA ((BW*height[cm]/3600)0.5), dose/BSA and estimated glomerular 
filtration fate (eGFR, Schwartz formula).24
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Pharmacokinetic analysis
Non-compartmental pharmacokinetic analysis was used to estimate PK 
parameters (Phoenix version 6.3, Pharsight Corporation, Mountain View, 
California, USA). AUC0-12h and AUC0-4h were estimated through the linear-log 
trapezoidal method.7, 19 In addition, C0, maximum concentration (Cmax), C12 and 
time to maximum concentration (Tmax), were directly observed from the data.
 
Statistical analysis
We defined two groups of patients: group 1 for patients having their AUC0-
12h determined within 3 weeks post-transplantation and group 2 for patients 
having their AUC0-12h determined >18 months post-transplantation. None of the 
individuals belonged to both groups, as the late curve was performed in those 
patients in whom a first AUC0-12h was absent. 
Baseline demographic characteristics were described and included median 
with inter quartile range (IQR). To assess differences between demographic values 
in the two groups independent T-test was used for continuous variables and Chi-
squared test for categorical variables. 
PK parameters were described as geometric means with minimal and maximal 
values. Interindividual variability in pharmacokinetics of MMF was expressed as 
fold difference between the minimum and maximum AUC0-12h values and geometric 
coefficient of variation (GCV). Parameters of exposure (AUC, C0, Cmax and C12) 
were corrected for dose. An independent T-test on logarithmically transformed PK 
parameters (uncorrected as well as corrected for dose) was performed to assess the 
differences in AUC0-12h, AUC0-4h, ratios of AUC0-4h/AUC0-12h, C0, C12 and Cmax between 
group 1 and group 2. Tmax values were compared using Wilcoxon rank sum test.
Associations between logarithmically transformed MPA AUC0-12h values and 
patient-related factors including age, BW, height, BSA, BMI, dose, albumin, 
serum creatinine, eGFR, time since transplantation were analysed with Pearson 
correlations and independent T-tests were used to compare the logarithmically 
transformed MPA AUC0-12h values between concomitant CsA therapy and gender. 
Within each group, univariate linear regression analysis was performed for 
those patient-factors that had a relationship with the log transformed values of 
AUC0-12h, based on visual inspection of scatter plots and correlation outcome. 
Next, stepwise multiple linear regression analyses between patient factors and log 
transformed AUC0-12h values was performed for those patient factors showing a 
significant linear regression in the univariate regression. Forward inclusion was 
based on p-values <0.05 and backward deletion was based on p-values >0.1. 
45151 Lisa Martial.indd   32 16-05-17   20:09
Pharmacokinetics of MPA in children
33
2
Finally, the proportion of patients with MPA exposures within the pre-defined 
target AUC0-12h and the proportion of patients who had at least one single trough 
concentration measurement with subsequent dose modification prior to AUC0-12h 
were determined.
All statistical analyses were performed with IBM SPSS Statistics version 20. 
Results
Demographics
A total of 53 children (30 male, 23 female) undergoing renal transplantation had 
an evaluable MPA AUC0-12h with 39 in group 1 and 14 in group 2 (demographic 
characteristics shown in Table 1). A single patient underwent a re-transplantation 
in group 1. In brief, median age was 13.3 years in group 1 (IQR 7.7-15.5 years) 
and 13.4 years in group 2 (IQR 11.1-15.6 years). Median BW was 40 kg in group 
1 (IQR 23-49 kg) and 44 kg in group 2 (IQR 37-55 kg). Most patient factors were 
comparable between the two groups. The dose showed to be significantly different, 
i.e. 584 mg/m2 in group 1 versus 426 mg/m2 in group 2 (p<0.001). Also, concomitant 
use of CsA was different, i.e. 68% in group 1 vs. 14% in group 2 (p=0.001). 
Table 1 Demographic characteristics at the time of pharmacokinetic analysis
Group 1 
<3 weeks post 
transplantation
(n=39)
Group 2 
>18 months post 
transplantation
(n=14*)
Male, n (%) 22 (56%) 8 (57%)
Age (years), median (IQR) 13.3 (7.7-15.5) 13.4 (11.1-15.6)
BW (kg), median (IQR) 40 (23-49) 44 (37-55)
Height (m), median (IQR) 1.42 (1.22-1.61) 1.50 (1.39-1.57)†
BSA (m2), median (IQR) 1.30 (0.89-1.45) 1.35 (1.20-1.56)†
BMI (kg*m-2), median (IQR) 17.5 (16.2-19.6) 20.1 (17.3-21.4)†
Dose (mg), median (IQR) 750 (500-1000) 500 (500-750)
Dose/BSA (mg*m-2), median (IQR) 584 (540-646) 426 (370-575)
Serum creatinine (µmol*L-1), median (IQR) 69 (45-100) 80 (61-88)‡
eGFR (mL*min-1*1,73m-2), median (IQR) 85 (62-107) 71 (67-78§
Albumin (g*L-1), median (IQR) 32 (28-36) 40 (39-43)‡
Days after transplantation, median (IQR) 11 (10-13) 1669 (858-2912)
Concomitant use of CsA, n (%) 27 (68%) 2 (14%)
Concomitant use of steroids, n (%) 31 (79%) 14 (100%)
BW body weight, BSA body surface area, BMI body mass index, eGFR estimated glomerular filtration 
rate. 
* n=14 except when differently indicated; † n=13; ‡ n=11; § n=10
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Pharmacokinetic analysis
The geometric mean AUC0-12h of MPA after administration of MMF were 29.7 and 
56.6 mg*h/L in group 1 and 2, respectively (Table 2). Median concentration time 
curves are shown in Figure 1. Large interindividual variability was observed in the 
PK of MPA as reflected in a 10-fold range in AUC0-12h values observed in group 
1 and a GCV of 48%. In group 2, this variability appeared to be smaller, with a 
4-fold range in AUC0-12h (GCV of 39%). Other PK parameters including AUC0-4h, 
C0, Cmax and Tmax are shown in Table 2. In addition to the different AUC0-12h in both 
groups, AUC 0-4h (p<0.01) and ratios of AUC0-4h/AUC0-12h (p<0.01) showed to be 
significantly different as well. 
Small but significant correlations between the log transformed values of AUC0-
12h and C0 (R2=0.49, p<0.01) or C12 (R2=0.56, p<0.01) were observed. In addition, 
AUC0-4h was significantly associated with AUC0-12h in group 1 (R2=0.72, p<0.001) 
and in group 2 (R2=0.55 in group 2, p=0.002). 
Table 2 Pharmacokinetic parameters in group 1 and 2
Group 1 
<3 weeks post 
transplantation
Group 2
>18 months post 
transplantation
Difference*
N GM (range) N GM (range)
AUC0-12h (mg*h/L) 39 29.7 (8.0-80.2) 14 56.6 (21.9-95.3) p<0.001
AUC0-12h/dose 39 0.04 (0.01-0.12) 14 0.11 (0.07-0.22) p<0.001
AUC0-4h (mg*h/L) 39 17.7 (4.3-56.1) 14 26.6 (11.3-46.7) p<0.01
AUC0-4h/dose 39 0.03 (0.01-0.07) 14 0.05 (0.03-0.16) p<0.001
AUC0-4h /AUC0-12h 39 0.6 (0.3-0.9) 14 0.5 (0.2-0.7) p<0.01
Cmax (mg/L) 39 8.5 (1.6-55) 14 11.7 (6.3-25.8) p=0.07
Cmax/dose 39 0.01 (0.003-0.07) 14 0.02 (0.01-0.09) p<0.01
C0 (mg/L) 38 1.0 (0.1-4.5) 14 4.0 (1.5-9.8) p<0.01
C0/dose 38 0.002 (0.0002-0.009) 14 0.01 (0.002-0.02) p<0.01
C12 (mg/L) 28 0.9 (0.2-3.5) 13 3.4 (1.0-7.6) p<0.001
C12/dose 28 0.001 (0.0002-0.006) 13 0.01 (0.001-0.01) p<0.001
Tmax (mg/L) 39 1 (0.5-4.5)
b 14 1 (0.5-4.5)† p=0.33
AUC, area under the concentration time curve, Cmax maximal concentration, C0 pre-dose concentration, 
C12 concentration 12h post administration, GM geometric mean, Tmax time of maximal concentration
* Based on independent T-tests on logarithmically transformed data, apart from Tmax (Wilcoxon rank 
sum test)
† Tmax given in median (range) 
Predictors of exposure to MMF
Only data from patients from group 1 were subject of regression analyses, as 
the number of patients in group 2 (n=14) was considered too low to draw valid 
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conclusions. The outcomes of the linear regression analyses are shown in Table 
3. Age, days post transplantation, BSA, BW, dose and serum creatinine showed 
a significant relationship with AUC0-12h. Figures 2a and 2b show the correlation 
of AUC0-12h and dose in group 1 and 2, respectively. All these parameters but BW 
(inter-correlated with BSA) were selected for stepwise multiple linear regression 
analysis. Other variables, including use of CsA, were not significantly associated 
with AUC0-12h in univariate analyses. Multiple linear regression revealed that 
days post transplantation and serum creatinine could explain 36% (R2=0.355, 
p<0.001) of the variance in AUC0-12h, formula: logAUC=1.704-0.034*days post 
Tx +0.002*creatinine. Other parameters did not predict the MMF AUC0-12h 
significantly in the multiple linear regression.
Table 3 Linear regressions between logAUC0-12h and patient-factors in group 1 (n=39)
Univariate linear regressions
logAUC0-12h versus R
2 p
Age 0.18 <0.01
Gender <0.001 0.97
CsA co-medication 0.02 0.34
Steroid co-medication 0.04 0.24
Days post Tx 0.19 <0.01
BSA 0.13 0.02
BW 0.10 0.05
BMI <0.001 0.92
Dose 0.18 <0.01
Serum creatinine 0.15 0.01
eGFR 0.05 0.16
Albumin 0.04 0.21
AUC area under the concentration time curve, BMI body mass index, BSA body surface area, BW body 
weight, eGFR estimated glomerular filtration rate, Tx transplantation. 
Target attainment
Almost 80% of the patients in group 1 had their trough concentrations determined 
at least once before AUC0-12h estimation, against 100% in group 2. In group 1, 
the dose was adapted in six individuals prior to AUC determination, based on 
clinical status or low trough concentrations (range 0.9-2.5 mg/L). 46% (18/39) of 
all individuals in group 1 reached the target AUC0-12h of 30-60 mg*h/L with 51% 
(20/39) showing an AUC <30 mg*h/L and 3% (1/39) showing an AUC0-12h >60 
mg*h/L. Target attainment was 50% (7/14) in group 2, with 7% (1/14) showing 
an AUC0-12h <30 mg*h/L and 43% (6/14) showing an AUC0-12h >60 mg*h/L. The 
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boxplots of the AUC0-12h values in both groups are shown in Figure 3. When only 
looking at the lower limit (>30 mg*h/L), about 49% of patients in group 1 and 93% 
in group 2 attained this. 
One acute biopsy-proven25 rejection was observed not resulting in loss of graft 
in the whole cohort.
Figure 1 Median concentration time curve in group 1 (<3 weeks after transplantation) and group 2 
(>18 months after transplantation). Error bars represent inter quartile range.
Figure 2a Correlation between AUC0-12h and dose for group 1 (<3 weeks post-transplantation), 
R2=0.16; p=0.01. Dotted lines represent the target range for AUC0-12h (30-60 mg*h/L).
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Figure 2b Correlation between AUC0-12h and dose for group 2 (>18 months post- transplantation), 
R2=0.55; p<0.01. Dotted lines represent the target range for AUC0-12h (30-60 mg*h/L).
Figure 3 Boxplots of AUC0-12h in group 1 and group 2. Whiskers are minimal and maximal values. 
Dotted lines represent the target range for AUC0-12h (30-60 mg*h/L).
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Discussion
This retrospective study describes MPA exposures achieved after administration 
of MMF, assessed target attainment rates in the early and late post transplantation 
period and identified patient factors influencing exposure in pediatric renal 
transplant recipients.
A large interindividual variability in exposure to MPA was observed, poorly 
correlated with dose (Figures 2a and b), supporting the need for TDM to 
individualize treatment. A significant difference in exposure between early and 
late post transplantation was observed, with higher AUC0-12h and AUC0-4h late in 
treatment. These observations confirm what has been observed previously in 
adults18, 26-29 and children.16, 30, 31 Two studies are of particular interest, showing 
an increase in AUC0-12h over time in pediatric renal transplant patients, with the 
strongest increase observed at 3-6 months.16, 31 The increase in MPA exposure may 
be explained by a time-dependent clearance of MPA influenced by hemoglobin, 
creatinine clearance, albumin and cyclosporine.32 As to CsA, this drug is known to 
interact with MPA by reducing its plasma concentration, which was hypothesized 
to be based on inhibition of multidrug resistance-associated protein 2 (Mrp2).22, 
23 Inhibiting Mrp2 might reduce the biliary excretion of the metabolite MPA-
glucuronide. Subsequently, less MPA-glucuronide is available for deconjugation 
and for re-uptake as part of the entero-hepatic recirculation. This could explain 
the smaller exposure observed in group 1 of our cohort as compared to group 2, as 
in group 1 more patients were treated with CsA. More recent literature, however, 
suggests that CsA has no inhibitory effect on the uptake of MPA-glucuronide by 
Mrp2-expressing membrane vesicles.33 Within group 1 of our cohort, no effect of 
CsA co-administration was noted on MPA exposure (Table 3). 
Our study identified that days post transplantation alone or in combination 
with creatinine were the two significant predictors of AUC0-12h of MPA, in the 
early post-transplantation period. These two variables could only explain 36% of 
the variability in exposure, leaving the main part unexplained. Other parameters, 
including age, dose, CsA or steroid co-medication, BSA, albumin or eGFR did not 
predict exposure to MPA in the multiple linear regression. We observed a decrease 
in exposure when days post transplantation increased. This phenomenon has been 
observed previously although opposite effects are seen as well.16, 30 The early post-
transplantation phase is a turbulent period, with important changes in protein 
homeostasis, renal function and hemodynamic state. Therefore, pathophysiological 
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factors, such as renal function, are implicated in changes in exposure to MPA. Our 
study found serum creatinine to be a significant predictor of AUC0-12h, which is in 
line with another study where creatinine clearance significantly correlated with 
the AUC0-12h of MPA.30 Our study could, however, not find a significant correlation 
between eGFR and AUC0-12h, contrary to another study in a similar population that 
showed a correlation between GFR and AUC of MPA, but only in the first week 
post transplantation.16 Evidence exists that a decrease in renal function can lead to 
accumulation of MPA-glucuronide, subsequently leading to competition between 
MPA and MPA-glucuronide for binding on serum proteins such as albumin.34 
More MPA will be displaced from albumin by MPA-glucuronide, leading to an 
increased availability of MPA for metabolism.10, 16 In agreement with this theory, 
decreased exposure to MPA is seen with lowering levels of albumin, associated 
with an increased free fraction of MPA.16, 30 Also, in delayed graft function, uremic 
state has impact on the binding capacity of MPA to albumin, thereby influencing 
exposure.35 Different processes in the acute-post transplantation period might 
influence the PK of MPA, but this study could not identify all of them.
AUC0-12h target attainment was lower than reported previously in adult studies18, 
36 despite dose adaptation based on TDM. In another study, 68% of patients reached 
an AUC >30 mg*h/L, against 30% in the fixed dose arm.18 Suboptimal exposure 
is associated with an increased risk of graft loss.13-16 In clinical practice, trough 
levels or AUC0-4h are used as a surrogate of total exposure but our results indicate 
that this is not the best option as C0 and AUC0-4h correlated weakly with AUC0-12h. 
The correlation between C0 and AUC0-12h was R2=0.49 for the whole cohort and 
the correlation between AUC0-4h and AUC0-12 was R2=0.72 and R2=0.55 for groups 
1 and 2 respectively. A different ratio in AUC0-4h/AUC0-12h was observed between 
group 1 and 2. In other words, the AUC0-4h does not reflect the total exposure 
(AUC0-12h) similarly in different phases after renal transplantation. Previous 
research already showed that different limited sampling strategies are needed 
depending on the period post-transplantation.37 Moreover, when using AUC0-4h, a 
very strict adherence to the sampling protocol is required.7
As patients show low target attainment in the post-acute transplantation 
period, and a large part of the variance is left to be explained, more frequent TDM 
starting sooner after transplantation can be rational.29 Full AUC determination 
before the third week after start with MMF, as is now standard in our institute, 
might be a good option towards tailored therapy. Other techniques, such as 
Bayesian estimators using sparse data (e.g. 3 time points within the first 3 hours 
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post dose) can help to estimate the AUC and pharmacokinetic parameters.38-41 
Another option is intensive sampling to cover the whole AUC but this requires 
more blood and can be challenged by practical issues, especially in children. New 
sample techniques such as the dried blood spot require very limited amounts of 
blood and can overcome those challenges.42
This study has some limitations, attributable to its retrospective nature. As 
the groups consisted of different patients, no repeated AUCs in the same patients 
were available, making it difficult to investigate the influence of time on exposure. 
Group 2 consisted of a limited number of patients that did not allow for an 
exploration of predictors of exposure in the late transplantation phase. Due to the 
non-compartmental nature of the pharmacokinetic analysis, it was impossible to 
adequately estimate half-life, clearance and volume of distribution. Genetic factors 
such as UGT-genotype might influence MPA exposure, but were not taken into 
account.43 Also, different analytical methods were used and although we corrected 
for the difference, total exposure could have been influenced by this fact. Lastly, 
total exposure and target attainment rates may have been biased by TDM, and 
patients selected before the implementation of AUC determination (2009) as 
routine clinical care could have been selected based on low trough concentrations 
or clinical status.
Conclusion
High interindividual variability in exposure to MPA in children exists, supporting 
the need for TDM, especially shortly after renal transplantation. Factors explaining 
less than half of the variability were identified, leaving us with a great part to be 
clarified. Significant differences in exposures were observed in PK parameters 
early and late after transplantation. Only 46% of patients reached the target AUC0-
12h short after transplantation. More intense TDM earlier post-transplantation 
might lead to higher probability of target attainment. Our group will continue 
investigating the PK of MPA in the pediatric renal transplant population and the 
use of new sampling methods such as the dried blood spot will be explored.
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Abstract
The Radboudumc Amalia Children’s hospital in the Netherlands has a program 
for renal transplantation in children aged ≤4 years. Children receive chronic 
corticosteroid sparing immunosuppressive therapy that consists of tacrolimus 
and mycophenolate mofetil. This work aimed to describe the PK of tacrolimus in 
children ≤4 years with renal transplants.
Pediatric renal transplant patients aged ≤4 years were included in this analysis. 
A PK curve of tacrolimus recorded ≤3 weeks after transplantation has been 
standard of care in our institution and aided in adjusting the dose in each patient 
to attain a target AUC0-12h of 210 µg*h/L early after transplantation.
Eight patients were included. The first two patients received an initial twice-
daily regimen and the subsequent six patients a three-times daily regimen. Median 
dose-corrected AUCtau was 63 µg*h/L. AUC target attainment was 37.5%. Out of 
the remaining patients, 2 had an AUC very close to (around 10% below) the target.
Large inter-individual variability of tacrolimus was observed and suboptimal 
AUC target attainment. In this population, an even more aggressive approach of 
higher doses (e.g. 0.4 mg/kg/day) and more early AUC determination should be 
considered. This should be evaluated prospectively in a larger group of patients.
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Introduction
The Amalia Children’s hospital of the Radboud university medical center has a 
dedicated program for renal transplantation in children aged 4 years and below. 
Since 2012, this very young population is transplanted pre-emptively with an 
adult kidney, resulting in an adult-sized kidney in a small child. Tacrolimus is 
used as part of the maintenance immunosuppressive therapy after pediatric renal 
transplantation.1-5 Little is known about the optimal dose-strategy of tacrolimus to 
prevent graft rejection in this very young population. 
Higher tacrolimus trough concentrations (>10 µg/L) in the first three months 
post transplantation were found to prevent graft rejection and were associated 
with a better renal function (as measured by a higher glomerular filtration 
rate) in adults and children.6, 7 On the other hand, too high tacrolimus trough 
concentrations (>15-20 µg/L) were associated with increased risk of renal 
insufficiency or other types of toxicity requiring dose adaptation in adolescents 
and adults.7, 8 For the purpose of achieving adequate targets, therapeutic drug 
monitoring (TDM) is often applied to individualize the therapy with tacrolimus, 
although the evidence for the target range is sometimes debated.9 For TDM guided 
dosing, trough concentrations (Ctrough) are most often used. Yet the total area under 
the concentration time curve (AUC) may be preferred to assess exposure as this 
measure is considered the best parameter linking to efficacy.9
Small studies have shown that the pharmacokinetics of tacrolimus in children 
are different from adults with children showing an increased clearance.10-12 As a 
result children need a higher weight-corrected dose to reach the same target trough 
concentrations.13-15 The difference in clearance is especially apparent in younger 
children (<5-7 years). This is hypothesized to be explained by age-dependent 
differences in expression of metabolizing enzymes (specifically CYP3A).14, 16, 17 It 
has also been demonstrated that the variability in expression of these enzymes was 
higher in children aged 1-6 years compared to other age groups.16 Lastly, genetic 
variability in CYP3A can explain differences in exposure.18, 19 If indeed clearance is 
more rapid, this might prompt for therapeutic interventions such as increasing the 
dose or increasing the frequency of drug administration. TDM based on intensive 
sampling (AUC determination) provides extra information to guide optimal 
dosing.
Up to now, the pharmacokinetics of tacrolimus post renal transplantation are 
poorly described in this very young population. The objective of this work was 
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to describe the pharmacokinetics of tacrolimus in a case series in young children 
(≤4 years) with renal transplants using two and three times daily regimens. To 
our knowledge, this is the first report on the pharmacokinetics of tacrolimus 
exclusively in children ≤4 years of age. 
Materials and Methods
This was a descriptive pharmacokinetic study among children aged 4 years and 
younger undergoing a renal transplantation between 2012 and 2015. All patients 
were admitted to the Pediatric Nephrology ward of the Radboudumc Amalia 
Children’s Hospital. Since 2012, this population (≤4 years of age) is eligible for 
renal transplantation in our institution. An adapted program exists with modified 
surgical procedures including the location of the transplant, which is intra- or 
retroperitoneal in the abdomen, instead of in the fossa iliaca.20, 21 Patients from 
the age of 6 months up to 4 years can participate to this dedicated program and 
the preferred minimal weight is 10 kg although children with a weight ≥6 kg are 
eligible.
All patients (≤4 years) that underwent a renal transplantation as part of 
this program were eligible to participate. Patients receive a pre-transplantation 
induction therapy of mycophenolate mofetil, basiliximab and methylprednisolone 
and after transplantation continue with mycophenolate mofetil and tacrolimus 
while prednisolone is tapered and stopped in five days (TWIST protocol).1 A 
tacrolimus suspension was administered to all patients. This suspension was 
prepared using a validated standardized method in a Good Manufacturing Practice 
(GMP)-certified hospital pharmacy, as is common practice in The Netherlands. 
The suspension is conserved with methyl paraben. Release specifications include 
identity, appearance, content of both tacrolimus (active pharmaceutical ingredient 
API) and preservative (methyl paraben) and extractable volume. For the complete 
list of ingredients see Box 1. The first two patients started on a tacrolimus dose 
of 0.3 mg/kg daily orally divided into two doses. A new algorithm based on 
allometric scaling of body weight (power of 0.75) was chosen and given three-
times daily from patient 3 onwards based on the publication of Anderson et al. 
(2008), see Table 1.22 As an early assessment of exposure, tacrolimus dose could 
be adjusted based on Ctrough despite the draw backs of this sampling time.15 As 
primary determinant a seven-point pharmacokinetic curve of tacrolimus before 
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discharge is standard of care (generally ≤3 weeks post transplantation). Venous 
blood is drawn just prior to tacrolimus administration and 1, 2, 4, 6, 8 (and, if 
applicable 12) hours after administration to obtain an AUC of the dosing interval 
(AUC0-tau). 
Although not validated in pediatrics, AUC0-12h target in the first 6-12 weeks 
post transplantation is defined as 210 µg*h/L based on literature and consensus 
in our institution.9, 23, 24 When Ctrough concentrations are used, the target is set to a 
concentration of 10-20 µg/L in the first month. Thereafter, a target of 5-15 µg/L 
applies until 6 months post transplantation.7, 23
Validated liquid chromatography–tandem mass spectrometry (LC-MS/MS) 
was used to determine tacrolimus whole blood concentrations. The range of the 
assay was 1-300 µg/L. Intra-assay precision and accuracy was 3.4%, 2.2%, 3.0% and 
102%, 94% and 94%, respectively at 3.04, 6.23 and 13.0 µg/l (n=6), respectively.25
Non-compartmental pharmacokinetic analysis was used to estimate 
pharmacokinetic parameters (Phoenix version 6.3, Pharsight Corporation, 
Mountain View, California, USA). The AUC0-8h or AUC0-12h (depending on the 
dose regimen) was estimated through the linear-log trapezoidal method. For 
comparison, estimated AUCs were further recalculated to AUC0-24h. The subsequent 
AUC0-24h target was 420 µg*h/L. In addition, Ctrough, maximum concentration (Cmax), 
C8 or C12 and time to maximum concentration (Tmax), were directly observed from 
the data. To allow for comparison of exposure between patients, dose-corrected 
pharmacokinetic parameters were calculated. The correlation between Ctrough and 
the AUC of the dosing interval (AUCtau) was assessed by means of Spearman 
correlations. To assess whether a twice-daily regimen leads to a relative higher Cmax 
as compared to a three-times daily regimen, the Cmax/AUC0-24h ratio was calculated.
All data were gathered retrospectively and were analysed anonymously. 
The study was approved by our local medical-ethics committee (Commissie 
Mensgebonden Onderzoek regio Arnhem-Nijmegen, number 2016-2284, date 
21st of January 2016). No informed consent was required for this retrospective 
analysis.
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Box 1 List of ingredients of the tacrolimus suspension 0.5 mg/mL
Tacrolimus
Methyl paraben 
Hypromellose 
Lactose monohydrate
Magnesium stearate
Colloidal Aluminum Magnesium Silicate 
Carmellose sodium
Citric acid
Sucrose
Hydrochloric acid
Distilled water
Table 1 Allometric dosing table of tacrolimus, based on 22
Age Weight (kg) Allo WT % Adult dose
Birth 3.2 0.10 5
2 months 4.5 0.13 13
4 months 6.5 0.17 17
12 months 10 0.23 23
18 months 11 0.25 25
4 years 16.7 0.34 35
5 years 18 0.36 36
WT weight
Results
A total of eight patients had their exposure of tacrolimus determined by means of 
intensive sampling. Demographic information and pharmacokinetic parameters 
are shown in Table 2. The first two patients were initially treated with a twice daily 
regimen, the remaining six patients received a three-times daily regimen, based on 
low exposure observed in the first two patients and based on clinical experience, 
literature26 and discussions with other experts in the field. Patients 1 and 2 used 
a topical formulation of miconazole zinc oxide, which may potentially increase 
tacrolimus concentrations by CYP3A4 inhibition. No other interacting drugs 
known to alter tacrolimus exposure were identified. 
Tacrolimus Ctrough measurement prior to AUC estimation was performed in 
all patients (range 1-3 times). The first assessment of Ctrough was performed after a 
median of 3.5 days (range 1-8 days) post transplantation and the median Ctrough was 
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8.9 µg/L (dose-corrected Ctrough 4.1 µg/L/mg) for 7/8 patients on oral tacrolimus. 
At first assessment, 4/8 patients showed sub-therapeutic concentrations (<10 
µg/L), 2 on a twice-daily regimen and 2 on a three-times daily regimen. Dose 
adaptations based on Ctrough concentrations prior to AUC measurement were done 
in all patients: the dose was increased in 6/8 patients (1-2 times) and decreased in 
2/8 patients (one dose adaptation in patients 3 and 7).
Table 2 Demographics and pharmacokinetic parameters
Demographic details at time of AUC determination
Patient 1 2 3 4 5 6 7 8
Age (yr) 4.2 2.9 3.0 3.5 3.2 2.1 3.4 3.0
BW (kg) 15 13 18 15 14 14 16 12
Days post Tx 12 19 12 7 14 12 13 13
Dose regimen at time of AUC (oral) 3 mg 
b.i.d.
4 mg 
b.i.d.
2 mg 
t.i.d.
3 mg 
t.i.d.
3 mg 
t.i.d.
2 mg 
t.i.d.
2 mg 
t.i.d.
2.5 mg 
t.i.d.
Dose 
(mg/kg/24h)
0.40 0.62 0.33 0.60 0.64 0.42 0.38 0.60
Pharmacokinetic parameters
AUCtau (µg.h/L) 191 38 145 126 89 125 187 164
Dose-corrected AUCtau (µg.h/L/ mg) 64 9.5 73 42 30 63 94 66
AUC0-24h (µg.h/L) 381 76 435 377 268 375 562 491
Ctrough (µg/L) 10.4* 2.0† 14‡ 4.5‡ 9.2‡ 16.2‡ 13.8‡ 10.4‡ 
Dose-corrected Ctrough (µg/L/ mg) 3.5 0.5 7 1.5 3.1 8.1 6.9 4.2
Cmax (µg/L) 34 5.5 21 29 16 20 39 31
Dose-corrected Cmax (µg/L/mg) 11 1.4 10 9 5 10 19 13
Cmax/AUC0-24h 0.09 0.09 0.03 0.01 0.03 0.04 0.07 0.06
BW body weight; Tx transplantation; AUC area under the concentration time curve; Cmax maximal 
concentration; AUC0-24h area under the concentration time curve over 24 hours; Ctrough concentration 
prior to next dosing; AUCtau area under the concentration time curve for one dosing interval; b.i.d. 
twice-daily regimen; t.i.d. three times daily regimen; sd standard deviation.
*Concentration at t=12h post administration; †Pre-dose concentration; ‡Concentration at t=8h post 
administration.
Tacrolimus AUC was determined after the first week post transplantation 
(median 12.5 days) (Table 2). Individual and (dose-corrected) median AUCs are 
shown in Figure 1 and Table 2. The median AUCtau was 136 µg*h/L (variability 
6-fold variation; coefficient of variation [CV] 40%) and the median dose-corrected 
AUCtau showed to be 63 µg*h/L/mg. Only 3/8 children (37.5%) attained the AUC0-
24h target of at least 420 µg*h/L. Of the remaining five patients, two had an AUC0-24h 
that was very close (around 10% below 420 µg*h/L) to the target. 
Dose did not correlate with AUC (by visual inspection). As an example, the highest 
AUC corresponded to the second-lowest dose and the lowest AUC corresponded 
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to the second-highest dose. Further to this, tacrolimus Ctrough correlated poorly with 
AUCtau as Spearman correlation yielded an r of 0.41 (p=0.317). 
Based on visual inspection, the Cmax/AUC0-24h ratio appeared to be higher in 
patients on a twice-daily regimen as compared to children on a three-times daily 
regimen (median 0.09 versus 0.04 µg/L).
Patient and graft survival are both 100% with a median follow-up of 32 months. 
All patients are still treated with tacrolimus. Five biopsies were done because 
of decline in renal function. In patient 1, a biopsy 3 years post transplantation 
suggested chronic humoral rejection which was treated successfully with ‘pulse’ 
steroid therapy (prednisolone), intravenous immunoglobulin and Rituximab. 
In patient 2, a biopsy 15 days post transplantation ruled out an acute rejection 
and a biopsy 2 year post transplantation showed a tubule-interstitial nephritis 
with minimal tubulitis without positive signs for rejection. This was treated 
with prednisolone 15 mg during six months. In patient 5, a biopsy 2 years post 
transplantation showed calcineurin toxicity. Mycophenolic acid was increased, 
prednisolone started and tacrolimus trough concentration target lowered to 4-8 
µg/L. In patient 7, a biopsy 1 year post transplantation suggested mild signs of 
calcineurin toxicity. Tacrolimus target trough concentrations were kept low (5-7 
µg/L) and everolimus was started in addition to azathioprin and tacrolimus. No 
other clinical or subclinical acute rejections occurred.
Figure 1 Continued lines represent patients 1 and 2 (twice daily dosing regimen); dotted lines 
represent patients 3-8 (thee-times daily dosing regimen); thick black line represents the median 
concentration time curve. 
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Discussion
This is the first report on the pharmacokinetics using intensive sampling 
(AUCtau) of tacrolimus in eight children ≤4 years of age in the early post-renal 
transplantation period. As our group is the first to report on pharmacokinetics in 
this special patient population, it is not feasible to draw comparisons with other 
reports. Comparisons are therefore made using Ctrough despite the drawback of 
using this parameter. In addition reports on the PK of tacrolimus in older children 
are available and used for reflection of our findings.
After initial TDM-based dose adjustments, the median dose-corrected Ctrough in 
our cohort was lower (4.1 µg/L/mg) compared with kidney transplant patients <5 
years old three months post transplantation (5.6 µg/L/mg, n=32).14 The difference 
between our cohort and this report may be driven by the time of sampling relative 
to transplantation (within 3 weeks in our cohort versus three months). Median 
Ctrough in a cohort of 90 patients with a median age of 12 years and 34 kg was 9 
µg/L in the first two weeks post transplantation and therefore comparable to our 
cohort.13
A study among 15 pediatric renal transplant patients reported an AUC from 
time zero to infinity (AUC0-∞) thus comparison of total exposure is not feasible.26 
They found a Ctrough of about 8 µg/L (not dose-corrected) and lower average dose-
corrected Cmax of 5.9 µg/L/mg compared with our median (10 µg/L/mg).26 Our 
findings likely reflect findings from this study although different parameters are 
reported.
AUC target attainment was only 37.5% (3/8) in our cohort, even after dose 
adjustments based on previous Ctrough. This low target attainment reflects the 
daily challenge clinicians face to attain target concentrations. An initial higher 
(allometrically scaled) dose of 0.4 instead of 0.3 mg/kg/day might be an option 
to ensure for adequate target attainment direct after transplantation. Other 
dosing algorithms taking into account CYP3A genotype and/or age have been 
proposed.27 Most of them still need a prospective clinical validation before they 
can be implemented into routine care. As to increase the probability of early target 
attainment, AUC should be determined as soon as possible and replace Ctrough 
driven dose adaptations.
An interesting finding was the higher peak concentration-to-AUC ratios 
observed with a twice-daily regimen as compared with three-times daily regimens. 
Under the assumption that clearance remains constant, higher peak concentrations 
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are required to attain the same AUC with two-times daily regimens compared with 
three-times daily regimens. It is not clear from literature what the consequence of 
high peak concentrations may be. Up until now, there is only limited evidence 
suggesting that high Ctrough is associated with (nephro)toxicity.7
During the course of the program we have changed our initial dosing regimen. 
On the basis of low Ctrough target attainment in the first two patients, and based on 
clinical experience, literature26 and discussions with professionals, our treatment 
strategy was adapted. Now, a three-times daily regimen based on allometric scaling 
is standard of care in our institute for this population.22 This regimen is very well 
tolerated. Other dosing algorithms have been described that include bodyweight, 
CYP3A genotype and/or hematocrit.13, 28 In our institution, dosing is further guided 
by therapeutic drug monitoring for which genotyping does not guide initial dosing. 
Based on pharmacological grounds we speculate that a three times daily regimen 
is the optimal dosing strategy for tacrolimus, as younger children show increased 
clearance8, 10, 12 and they had low Ctrough. Several other management options can 
be identified to optimise tacrolimus treatment. One could give higher doses but 
remain on a twice-daily regimen, which is a patient-friendly regimen but risks high 
(maybe toxic?) peak concentrations. A four-times daily regimen avoids high peak 
concentrations but challenges adherence. A patient-friendly once-daily controlled 
release (QD) formulation can be used, which avoids high peak concentrations due 
to a flatter concentration-time profile. For young children, this option might not 
be feasible as the capsules are big and therefore difficult to swallow (almost all our 
patients below 4 years of age receive their medication by a gastrostomy). As Ctrough 
and peak concentrations showed to be lower with controlled release (once daily) 
formulations29, 30 they do not predict the AUC similarly.31-35 So a drawback is that 
different sampling strategies to estimate total exposure36 require to be redesigned 
for new formulations.37
A limitation of this report is the small number of patients inherent to a 
preliminary study. Another limitation is that based on the available samples, no 
clearance nor volume of distribution could be estimated due to insufficient time 
points taken in the elimination phase. Another drawback is that variable AUC 
targets of tacrolimus exist in literature. We adhere to an AUC target from Scholten 
et al. but we are aware that AUC targets can vary across institutions.9, 23, 24 Lastly, 
as to compare twice and three-times daily regimens, an AUC0-24h was calculated 
although we are aware of a circadian rhythm of tacrolimus, that can lead to lower 
exposure over night.38, 39 This could have led to an overestimation of AUC0-24h.
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We conclude to use the AUC (the primary parameter linked to efficacy) as 
driver for dose adaptations rather than Ctrough as this parameter is a poor predictor 
of exposure. Ctrough should only be used to adapt either extremely low or high 
concentrations. From studies in older patients and adults it is known that Ctrough do 
not always predict AUC adequately15 and this is confirmed in our study. For AUC 
determination, intensive sampling (6-8 samples) is required, which is challenged 
by practical issues. As alternative strategy a limited sampling strategies (LSS) with 
2-4 samples can be used.40 LSS allows for more accurate AUC predictions than 
using Ctrough only.15 LSS are not ideal to implement either, as strict adherence to the 
sampling protocol is mandatory if multiple linear regression approach is used.15 
With Bayesian approaches, this strict adherence to the sampling protocol is not 
necessary. For long term follow-up novel sampling strategies, such as with dried 
blood spot (DBS) finger pricks (require only one drop of blood applied on filter 
paper) could be of great value to address the challenges with AUC determination 
and LSS encountered in children. A tacrolimus DBS assay is currently used for 
clinical practice in adults in our institute.25, 34, 41
Conclusion
This preliminary study on the PK of tacrolimus in very young children (≤4 years) 
after renal transplantation showed suboptimal pharmacokinetic target attainment. 
Ctrough correlated very poorly with AUC. After switching from a twice to a three-
times daily regimen, target attainment was still low. We suggest a higher initial 
tacrolimus dose of 0.40 mg/kg/day divided into three dosing moments with early 
AUC determination, e.g. in the first week post transplantation. Dose adaptations 
based on this total exposure will individualize treatment and should ensure 
for adequate exposure. Our findings encourage a prospective evaluation for 
superiority of such an approach in a larger group of patients.
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Abstract
Caspofungin is an echinocandin antifungal agent used as first-line therapy for 
the treatment of invasive candidiasis. The maintenance dose is adapted to body 
weight (BW) or liver function (Child-Pugh score B or C). We aimed to study the 
pharmacokinetics (PK) of caspofungin and assess PK target attainment for various 
dosing strategies.
Caspofungin PK data from 21 ICU patients was available. A population PK 
model was developed. Various dosing regimens (loading dose/maintenance dose) 
were simulated: licensed regimens (I) 70/50 mg (for BW <80kg); 70/70 mg (for 
BW>80kg) and (II) 70/35 mg (for Child-Pugh score B); adapted regimens (III) 
100/50 mg (for Child-Pugh score B); (IV) 100/70 mg; (V) 100/100 mg. Target 
attainment based on a preclinical PK target for C. albicans was assessed for relevant 
MICs.
 A 2-compartment model best fitted the data. Clearance was 0.55 L/h and 
volumes of distribution 1 and 2 were 8.9 and 5.0 L respectively. The median area 
under the plasma concentration-time curve from time zero to 24 h on day 14 
for regimens I-V were 105, 65, 93, 130 and 186 mg*h/L respectively. PK target 
attainment was 100% (MIC 0.03 µg/mL) irrespective of dosing regimen but 
decreased to (I) 47% (II) 14% (III) 36% (IV) 69% and (V) 94% for MIC 0.125 µg/
mL.
Caspofungin maintenance dose should not be reduced in non-cirrhotic 
ICU patients based on the Child-Pugh score if this classification is driven by 
hypoalbumenia as it results in significantly lower exposure. A higher maintenance 
dose of 70 mg in ICU patients results in target attainment of >90% of the ICU 
patients with species with an MIC up to 0.125 µg/mL.
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Introduction
Critically ill patients are at increased risk for infections and about 20% of infections 
in ICU patients are caused by fungal infections such as by Candida or Aspergillus 
spp.1 Caspofungin is an echinocandin antifungal agent licensed as first-line therapy 
for invasive candidiasis in patients with moderate to severe illness and/or recent 
exposure to azoles.2 Efficacy of echinocandin therapy for the treatment of invasive 
candidiasis is higher than with other antifungal agents. Adequate response to 
echinocandins is generally achieved in 66-90% of patients.3, 4 Echinocandins work 
by inhibiting the synthesis of β-(1,3)-D-glucan, an important component of the 
fungal cell wall.
Caspofungin is administered intravenously and dosed based on body weight 
(BW). The clinical guideline of the International Infectious Disease Society 
recommends a loading dose of 70 mg and subsequent daily maintenance doses of 
50 mg.2 In addition, the maintenance is recommended to be increased to 70 mg 
for patients with BW >80kg and decreased to 35 mg for patients with moderate or 
severe hepatic impairment, classified with Child-Pugh B or C.5, 6 Child-Pugh score 
is a marker for severity of liver function impairment, composed of several markers 
of liver function such as albumin serum values and the presence of ascites.7
Recently, we analyzed the pharmacokinetics (PK) of caspofungin in 21 
intensive care unit (ICU) patients using a non-compartmental approach.8 Total 
caspofungin exposure (AUC0-24h) did not seem to be altered in this population as 
compared to other populations, even though dose reductions would have been 
indicated in most patients based on their Child-Pugh scores.8 It should be noted 
that Child-Pugh scoring was developed in patients with cirrhosis and not in ICU 
patients. Large interindividual variability in caspofungin exposures was observed 
among ICU patients.8
Next to PK considerations, pharmacodynamic (PD) factors should be taken 
into account to identify the best dose strategy for caspofungin in ICU patients. 
Various studies have shown that AUC/MIC best described the PK-PD relationship 
for caspofungin, micafungin and anidulafungin.9-11 Murine infection models of 
caspofungin explored the target AUC/MIC ratio associated with efficacy.9, 11 An 
AUC/MIC ratio of 865 was associated with a 1-log kill/24 hours in a neutropenic 
mouse model of disseminated C. albicans.11, 12 To date, a caspofungin PK-PD target 
in humans has not been established yet.
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The current study analyzed the PK of caspofungin in ICU patients using non-
linear mixed effects modelling, to obtain a better mechanistic understanding of 
the PK properties of the drug and to be able to characterize potential covariate 
relationships with higher statistical power. We were specifically interested in 
the effects of BW and Child Pugh scores on exposures, as the current dosing of 
caspofungin is adapted based on these parameters. In addition, non-linear mixed 
effects model allows simulations of different dosing regimens with corresponding 
exposure and assess target attainment for these regimens.
Methods
Study design, drug regimen and population
The study was approved by the local ethics committee (Commissie Mensgebonden 
Onderzoek regio Arnhem-Nijmegen number 2011/346, clinical trials.gov 
NCT01533558) and informed consent was given by all participants. Inclusion 
criteria included admission to the ICU, caspofungin therapy for suspected or 
proven infection or for prophylaxis, age >18 years when starting caspofungin, 
started therapy a maximum of 2 days before inclusion and management with a 
central venous catheter. Exclusion criteria included allergy for echinocandins or 
excipients, known HIV, hepatitis B or C infection, or a history of drug or alcohol 
abuse.
Dosing was as prescribed by the physician in attendance: a 70 mg loading dose 
on day 1 followed by either 50 mg maintenance daily for patients weighing ≤80 kg 
or a 70 mg maintenance for patients with BW >80 kg. Maintenance dose should 
be reduced to 35 mg for patients classified as Child-Pugh B or C. Caspofungin was 
administered intravenously over approximately one hour. Patients were treated as 
long as clinically relevant but the duration of the study (i.e. sampling of patients) 
was limited to 14 days of caspofungin treatment. If patients stopped treatment 
before 14 days, PK washout samples until 3 days after cessation of therapy were 
taken.
Patient demographics were collected and included gender, age, race, weight, 
BMI, lean body mass (LBM13), indication for ICU admission, indication for 
caspofungin, clinical characteristics, chemistry and hematological parameters. 
In addition, APACHE II score (Acute Physiology and Chronic Health Evaluation 
II; severity of disease classification) within 24 h of ICU admission, SOFA score 
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(Sequential Organ Failure Assessment score, to assess patients during their stay 
at an ICU) and Child–Pugh class, co-medication and (type of) renal replacement 
therapy were recorded.
PK sampling and analysis
Patients were intensively sampled (2 mL) on day 3(±1) and 7(±1) of therapy at 
t=0 (pre-dose) and 0.5, 1, 2, 4, 6, 8, 12, 16, 20 and 24h post-dose and additional 
trough samples (pre-dose) were taken on other study days. Details on the sample 
preparation and the assay (validated UPLC-fluorescence method) have been 
described previously.8
Pharmacokinetic model
One-, two- and three-compartment models were considered based on a review 
of the literature and on visual inspection of the data. Inter-individual variability 
(IIV) was estimated using an exponential model. The primary PK parameters 
were clearance (CL) and volume of distribution (V). Proportional, additive and 
combined additive and proportional models were evaluated for residual variability. 
Both a single covariance matrix on the first compartment as multiple omega blocks 
for the individual compartments as a full covariance matrix on all compartments 
were considered for the inter-individual random effects.
Model selection was initially based on the objective function value (OFV) 
computed as -2 log likelihood, where a decrease in OFV of ≥3.84 was considered 
significant (χ2, 1df, p<0.05). In addition, standard goodness of fit (GOF) 
plots, including the observed versus the population and individual-predicted 
concentrations, and conditional weighted residuals versus time after dose and 
population predicted concentration were used for model evaluation. Also, the 
precision of the parameter estimates, eta-shrinkage and IIV was assessed. Good 
candidate models were further evaluated by a visual predictive check (VPC). 
After selection of the base model, various covariates were tested on CL and V 
by a stepwise covariate model (scm) as implemented in Perl-speaks-NONMEM 
(PsN 4.2.0), using forward selection and backward elimination.14 Only baseline 
values were considered. Continuous covariates included age, BW, length, LBM, 
body mass index (BMI), body temperature, serum creatinine, ureum, albumin, 
liver enzymes (alanine aminotransferase, aspartate aminotransferase, c-glutamyl 
transpeptidase, alkaline phosphatase, bilirubin), C-reactive protein, blood pH, 
glomerular filtration rate (GFR). Categorical covariates included gender, Child-
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Pugh score and ab-/normal GFR (breakpoint >60 ml/min). All covariates were 
tested on both CL and V1. Linear, exponential and power conditions were tested 
for continuous covariates and linear conditions on categorical data, all using 
a forward inclusion criterion of p<0.05 (OFV decrease of ≥3.84, χ2, 1df) and a 
backward exclusion criterion of p<0.01 (OFV increase of ≥6.64, χ2, 1df).
Based on physiological plausibility and extensive previous evidence, BW 
was incorporated a priori as covariate, both on CL (allometrically with a power 
exponent of 0.75) and on V (power exponent of 1) and was standardized to a 
typical 70 kg patient.15-18
To assess the predictive performance of the final model, a prediction-corrected 
(pc) VPC was made, based on 1000 Monte Carlo simulations. The precision of 
the parameter estimates of the final model was further evaluated using a non-
parametric bootstrap method in which re-sampling of the data set was performed 
1000 times to produce new data sets with the same size but containing a different 
combination of individuals and yielding new parameter estimates and confidence 
intervals.
Population PK modelling was carried out by nonlinear mixed effect modelling 
using NONMEM version 7.2 (ICON Development solutions, Elliocott City, MA, 
USA), Perl-speaks-NONMEM (version 4.2.0), and Xpose (version 4.5.3).14, 19, 
20 Pirana interface was used for run interpretation.21 The first order conditional 
estimation method with interaction was used for the analysis. R (version 3.1.10) 
was used for exploratory graphical analysis and for evaluation of the goodness of 
fit.22
Monte Carlo simulations of different dosing regimens
After selection of the final model, a simulation study was performed using this model 
to assess exposure and probability of target attainment following various alternative 
dosing regimens. As our ICU cohort was too small (n=21) for a representative weight 
distribution for the population, the weight distribution from a hospital based cohort 
of 1706 adult patients from the hematology department (2007-2014) was used to 
build a valid dataset for simulation purposes. Based on our clinical experience 
and on literature 23, 24 it was assumed that the anthropometric characteristics in 
this cohort were similar to that of a typical ICU population. The cohort consisted 
of 61% men (n=672) and had a median age (range) of 59 years (18-81), median 
weight (range) was 76 kg (39-154) and median BMI (range) was 24.7 (13-42). 
Five different caspofungin dosing regimens were simulated, two licensed regimens 
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and three alternative regimens. These regimens were chosen at the discretion of 
the researcher and based on empiric rationale. The concentration-time curves 
for these regimens were simulated for aforementioned patient cohort, without 
replications. Licensed regimens included (I) a loading dose of 70 mg followed 
by 50 mg maintenance in patients with BW ≤80 kg or by 70 mg maintenance in 
patients with BW>80 kg; (II) 70 mg loading dose followed by 35 mg as labeled for 
patients with moderate or severe hepatic dysfunction.2, 5, 6 Alternative regimens, 
all irrespective of BW, included (III) a 100 mg loading dose followed by 50 mg 
maintenance; (IV) a 100 mg loading dose followed by 70 mg maintenance and (V) 
a 100 mg loading dose followed by 100 mg maintenance.
Predicted exposure to caspofungin in terms of AUC0-24h was assessed on 
days 3 and 14 of therapy. Differences in exposure both between treatment days 
within the same regimen and between regimens on the same day of treatment 
were statistically tested with Wilcoxon signed rank and Wilcoxon rank sum test 
respectively.
Pharmacokinetic target attainment
The human clinical PK-PD target for caspofungin in the treatment of invasive 
candidiasis remains non-elucidated. Nevertheless, the preclinical target has been 
determined in a neutropenic murine model of disseminated Candida infection 
for which a minimally required AUC0-24h/MIC ratio of 865 (1-log kill/24 hours) 
was determined for C. albicans.11 This AUC/MIC ratio was set as preclinical 
pharmacokinetic target to attain the current study. Target attainment at day 14 
following the different dosing regimens was assessed for a wide range of clinically 
relevant MIC values (0.007-1.0 µg/mL). The mode MIC for C. albicans is 0.03 µg/
mL and the epidemiological cut-off value 0.12 µg/mL.25, 26
Results
Patients, dosing and samples
In total, 21 ICU patients treated with caspofungin were included yielding a total 
of 419 PK observations. Patient characteristics and their baseline values are 
summarized in Table 1. All patients were classified with Child-Pugh score B and 
all patients had hypoalbuminemia (≤34 g/L). Despite the fact that all patients 
should have received a reduced maintenance dose (35 mg/day) according to the 
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label based on their Child Pugh score, only 1/21 patients actually received this 
reduced dose. This patient received 35 mg/day for 3 of the total 13 treatment 
days. In addition, 4/8 patients with BW >80 kg received 50 mg/day maintenance 
dose instead of the label-indicated 70 mg/day and 2/13 patients with BW ≤80 kg 
received 70 mg/day maintenance dose instead of the label-indicated 50 mg/day. 
Table 1 Patient demographics of the ICU cohort used to develop the population PK model
Evaluable ICU patients (n=21)
Demographics
Female, n (%) 8 (38%)
Age (year), median (range) 71 (45-80)
Weight (kg), median (range) 75 (50-99)
BMI (kg/m2), median (range) 24.9 (19.0-36.4)
Clinical characteristics (at baseline)
Hepatic dysfunction, Child-Pugh B, n (%) 21 (100)
Neutropenia, n (%) 0 (0)
Hypoalbuminemia, n (%)
 25-34 g/L 4 (19)
 15-24 g/L 14 (68)
 <15 g/L 3 (14)
Infection location, n (%)
 Normally sterile location 16 (76)
 Blood 4 (19)
Prophylaxis n (%) 1 (5)
BMI body mass index, ICU intensive care unit
Population PK model
A two-compartment disposition model with first-order elimination from the 
central compartment and a combined proportional and additive residual error 
model fitted the data best. The addition of a third compartment led to a significant 
increase in OFV. IIV on CL, V1 and V2 improved the model, while the data did 
not support estimation of IIV on Q (intercompartmental clearance). Allowing a 
correlation between the IIV on CL and V1 further improved the model (difference 
in OFV=8.6). Parameter estimates of the final model are shown in Table 2. CL, 
V1, Q and V2 were estimated to be 0.55, 8.93, 0.71 and 4.98. IIV of CL, V1 and 
V2 were estimated to be 30.7, 25.6, and 75.8% and eta shrinkage of 0, 6, and 
16% respectively. Stepwise covariate modelling could not identify any additional 
covariates significantly affecting CL or V1. Of note, Child Pugh score could not be 
confirmed as a covariate for CL or V1 either.
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A pcVPC of the final model is shown in Figure 1. No deviating trends were 
observed in the pcVPC suggesting a good predictive performance of the model to 
the data. This was confirmed by the numerical predictive check which indicated 
that 1.4% (95%CI 0-7.9%) of the observed values lied below the 95% prediction 
interval, and 4.1% (95CI% 0-7.7%) fell above the 95% prediction interval. 
Parameter precisions using a bootstrap re-sampling approach of the final model 
are listed in Table 2. Basic GOF plots are shown in Figure 2. No major deviations 
were detected from the plots.
Table 2 Pharmacokinetic parameter estimates of the final model and bootstrap analysis
Parameter 
estimates [RSE] 
(Shrinkage) 
Bootstrap results parameter estimates 
(n=904)a
Mean (95%CI) [Rel SE]
CL (L/h)b 0.55 [7%] 0.55 (0.46-0.62) [6.6%]
V1 (L)b 8.93 [8%] 8.98 (7.90-10.43) [7.0%]
Q (L/h) c 0.707 [3%] 0.70 (0.46-0.92) [17.1%]
V2 (L) c 4.98 [17%] 4.99 (3.50-6.94) [16.7%]
IIV CL (CV%) 30.7 [31%] (0%) 29.4 (19.8-38.3) [31.0%]
IIV V1 (CV%) 25.6 [51%] (6%) 25.5 (14.0-37.8) [48.7%]
IIV Q 0 Fix 0 Fix
IIV V2 (CV%) 75.8 [65%] (16%) 73.4 (16.5-145) [71.7%]
Proportional residual error 0.148 [17%] 0.147 (0.127-0.167) [6.8%] 
Additional residual error (mg/L) Fix 0.01 
a Based on 904/1000 successfully converged runs).
b Clearance and volume of distribution were standardized to a body weight of 70 kg.
c Intercompartmental clearance and second volume of distribution are scaled to the mean of the 
population. 
CL clearance; V1 volume of distribution of compartment 1; V2 volume of distribution of compartment 
2; Q intercompartmental clearance; IIV interindividual variability; RSE root square error (based on 
covariance step in NONMEM); Rel SE Relative standard error (100%*standard deviation/mean)
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Figure 1 Visual predictive check for the final PK model of caspofungin, based on n=1000 simulations. 
Prediction- corrected simulated (areas) and observed (circles and lines) caspofungin concentrations 
versus time after dose (hours). The thick red line connects the observed median values per bin. The 
solid thinner blue lines connect the 5th and 95th percentiles of the observations. The blue areas are 
the 95% CI of the 5th and 95th percentiles. The red area indicates the confidence interval (CI) of the 
median. 
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Figure 2 Goodness-of-fit plots for the final PK model of caspofungin. The thin black lines indicate 
the unit line or the line of identity. The thick lines (red or blue) are smooth lines showing the trend 
in the observations. 
CWRES conditional weighted residuals. 
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Monte Carlo simulations of alternative dosing regimens
Alternative dose regimen simulations were performed in a cohort of 1706 
hospitalized patients. AUC0-24h on days 3 and 14 achieved by different dosing 
regimens are shown in Figure 3. Median (range) AUC0-24h on day 3 for 
regimens I-V were 96 (39-405), 65 (22-241), 93 (33-344), 122 (44-444), 167 
(62-594) mg*h/L. Median (range) AUC0-24h on day 14 for regimens I-V were 
105 (39-459), 65 (22-271), 93(32-387), 130 (44-541) and 186 (64-772) mg*h/L 
respectively, showing that the regimen with 70 mg loading dose followed by 
35 mg as labeled for patients with Child Pugh score B (regimen II) resulted in 
the lowest median exposure (65 mg*h/L). Wilcoxon signed rank test confirmed 
significant differences in exposure between days 3 and 14 within one regimen 
for all regimens, p<0.01. There was also a significant difference in exposure 
(AUC0-24h) between all five regimens at day 14 (p<0.01, Wilcoxon rank-sum). 
Predicted variability in exposure was considerable, with %CV in AUC0-24h of 44-
45% and 46-47% for days 3 and 14 respectively, for all regimens.
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Figures 3 a-b  
a. AUC0-24h on day 3 for the whole cohort, irrespective of bodyweight. 
b. AUC0-24h on day 14 for the whole cohort, irrespective of bodyweight Horizontal line represents 
AUC0-24h for healthy volunteers. Regimens: (I) loading dose of 70 mg followed by 50 mg maintenance 
in patients with BW≤80 kg or by 70 mg maintenance in patients with BW>80 kg, (II) 70 mg loading 
dose followed by 35 mg, (III) a 100 mg loading dose followed by 50 mg maintenance, (IV) a 100 mg 
loading dose followed by 70 mg maintenance and (V) a 100 mg loading dose followed by 100 mg 
maintenance.  AUC area under the concentration-time curve; BW body weight
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Typical simulated plasma concentration-time profiles with 95% confidence 
intervals during two weeks of treatment following the different dosing regimens 
are shown in Figure 4. As expected, a higher loading dose resulted in higher 
exposure early in therapy (regimes III and IV versus regimen I). Steady-state was 
usually reached at day 7 (168h).
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Figures 4 a-e a Caspofungin concentration-time curve for regimen I:a loading dose of 70 mg 
followed by 50 mg maintenance in patients with BW≤80 kg or by 70 mg maintenance in patients 
with BW>80 kg; b Caspofungin concentration-time curve for regimen II: 70 mg loading dose followed 
by 35 mg as labeled for patients with moderate or severe hepatic dysfunction2, 5, 6; c Caspofungin 
concentration-time curve for regimen III: a 100 mg loading dose followed by 50 mg maintenance; d 
Caspofungin concentration-time curve for regimen IV: a 100 mg loading dose followed by 70 mg 
maintenance; e Caspofungin concentration-time curve for regimen V: a 100 mg loading dose 
followed by 100 mg maintenance.
Thick black lines are medians and dotted lines are 5 and 95% percentiles. Conc concentration
Pharmacokinetic target attainment
Simulated attainment of pharmacokinetic targets for the various dose regimens 
is shown in Figure 5 and Table 3 shows the probabilities of target attainment 
stratified by BW.
Both licensed regimen I (based on BW) and II (reduced based on Child-Pugh 
B) resulted in a pharmacokinetic target attainment of >99% using a MIC of 0.03 
µg/mL (mode).
45151 Lisa Martial.indd   70 16-05-17   20:09
PK of caspofungin in ICU patients
71
4
Not surprisingly, the probability of target attainment increased with increasing 
doses. For example, a substantial difference in target attainment was observed 
between the licensed regimen II (reduced dosing based on Child-Pugh score B) 
and the alternative regimen V (100 mg loading + 100 mg/day maintenance): 14% 
versus 97% respectively, for an MIC of 0.125 µg/mL. From a MIC of 0.125 µg/mL, 
the differences in pharmacokinetic target attainment between the dosing regimens 
become more important. So for infections with species with higher MICs, though 
less frequently occurring, dose will probably have an important effect on outcome.
Higher BW consistently resulted in a decreased target attainment (Table 3), and 
this effect was statistically significant (p<0.01). This decreased target attainment 
was the direct result of a relatively decreased AUC0-24h for higher BW patients. 
Certainly for the higher BW ranges combined with a Child-Pugh B score, better 
target attainment was observed with higher maintenance doses (regimen II versus 
III) (Table 3).
Better target attainment was observed with higher loading and maintenance 
doses than suggested by the label, as depicted in Table 3. For example, 35 mg/day 
maintenance (regimen II) resulted in 59-81% and 70-100 mg/day (regimens IV 
and V) resulted in >99.5% target attainment, with an MIC of 0.06 µg/mL.
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Figure 5 Target attainment versus MIC for all five simulated regimens based on a preclinical target 
AUC/MIC ratio of >865. Asterics indicate that regimen is based on BW: maintenance dose was 50 mg 
for patients with BW≤80 kg and 70 mg for BW>80kg.
MIC minimal inhibitory concentration; BW body weight; AUC area under the concentration-time 
curve
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Table 3 Preclinical target attainment
Preclinical target attainment (%)
MIC (µg/mL) 0.016 0.03 0.06 0.125 0.25 0.5 1.0
Regimen Ia
BW≤80kg 100 100 98 43 6 1 0
BW>80kg 100 100 99,5 55 8 1 0
Regimen IIb
BW≤80kg 100 100 81 17 0,4 0
BW>80kg 100 99,5 59 9 0,4 0
Regimen IIIc
BW≤80kg 100 100 98 43 6 0
BW>80kg 100 100 90 22 3 0
Regimen IVd
BW≤80kg 100 100 100 78 17 0,3 0
BW>80kg 100 100 99,5 55 9 0,4 0
Regimen Ve
BW≤80kg 100 100 100 97 43 6 0
BW>80kg 100 100 100 88 22 3 0
a Licensed regimens (I) loading dose of 70 mg followed by 50 mg maintenance 
in patients with BW≤80 kg or by 70 mg maintenance in patients with BW>80 kg
b (II) 70 mg loading dose followed by 35 mg 
Experimental regimens all irrespective of body weight
c (III) a 100 mg loading dose followed by 50 mg maintenance
d (IV) a 100 mg loading dose followed by 70 mg maintenance 
e (V) a 100 mg loading dose followed by 100 mg maintenance
MIC minimal inhibitory concentration; BW body weight
Discussion
This is the first study reporting a population pharmacokinetic model of 
caspofungin in ICU patients. The developed model was successfully used to assess 
the probability of pharmacokinetic target attainment for various caspofungin 
dose regimens. The simulations revealed insufficient target attainment with the 
currently licensed regimens. In non-cirrhotic ICU patients classified with Child-
Pugh B, reducing the dose of caspofungin is not recommended. 
Caspofungin population PK were comparable to those reported in earlier 
studies.18, 27 In contrast to other reported studies, our data did not support a third 
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structural peripheral PK compartment, possibly due to the sparseness of the data 
in the late elimination phase. The typical CL for caspofungin was 0.55 L/h and 
was slightly higher than reported in earlier studies amongst other patient groups 
(0.40 and 0.46 L/h).18, 27 Volumes of distribution were also slightly higher as 
compared to earlier studies.18, 27 Moderate IIV was observed for both CL (30.7%) 
and V1 (25.6%) and also confirmed earlier literature.18, 27 No additional covariates, 
including Child Pugh score, could be identified that significantly affected CL or 
V1 of caspofungin in the current study. On the basis of previous results and on 
the well established general physiological mechanisms supporting the standard 
allometric scaling of compound metabolism and disposition28-30, BW was added 
a priori allometrically on CL (exponent of 0.75) and V1 (exponent of 1). This 
approach is widely accepted if the drug of choice distributes widely into tissues, 
strengthening the assumption of BW relating to V1.31 Metabolism of caspofungin 
involves spontaneous degradation, hydrolysis and N-acetylation, processes 
expected to be related to BW too.5, 31
Conflicting results on covariates and caspofungin PK exist in the literature. 
One study could not find any covariates significantly affecting the PK parameters27 
whereas another study found a linear relationship between BW and CL and V1.18 
In a study on the PK of caspofungin in obese subjects, it was found that BW was 
allometrically related to CL (power 0.75) for subjects weighing >66.3 kg (n=14). In 
addition, increased BW was associated with both lower peak concentrations (Cmax) 
and lower AUC0-72h.16
Despite our attempt to approach this by non-linear mixed effect modelling, 
no covariate could be identified on top of a priori allometric scaling of CL and 
V1 by BW. In our cohort all ICU patients were classified with Child-Pugh score 
B (mainly driven by their albumin status) making it impossible to distinguish 
between classes. To accurately identify the effect of cirrhosis (using Child Pugh 
classification) on caspofungin exposure, a more heterogeneous cohort in terms 
of liver function should be studied. In addition, PK in ICU patients is infamously 
variable, due to a whole mixture of factors (e.g. systemic inflammatory response, 
capillary leak, protein binding capacity).32 As such, covariates might be obscured 
due the overall high variability in ICU patients and our limited sample size.
Simulation of different dosing regimens showed that reducing the maintenance 
dose to 35 mg, which is recommended for patients with moderate to severe hepatic 
dysfunction (classified with Child-Pugh score B or C), resulted in the lowest average 
exposure. Median AUC0-24h was 65 mg*h/L for this regimen, which is far below 
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the 100 mg*h/L typically observed for caspofungin.8, 33 As the Child-Pugh score is 
highly driven by albumin, ICU patients with hypoalbuminemia are often unfairly 
classified with Child-Pugh score B. In our cohort, all patients had an albumin of 
<28 g/L, scoring them automatically with 7 points (Child-Pugh B). Decreasing the 
dose in ICU patients for Child-Pugh B score without liver cirrhosis will lead to 
unnecessary low exposure risking loss of efficacy of caspofungin. As caspofungin 
is highly protein bound (92-97%), hypoalbuminemia might lead to changes in 
caspofungin free fraction.31 It is currently unknown whether hypoalbuminemia 
can influence the pharmacokinetics of caspofungin.
Due to a lack of a clinically validated PK-PD target for caspofungin, a preclinical 
PK-PD target was used. Not the target attainment itself, but rather the magnitude 
change with various dosing regimens in relation to pathogen susceptibility 
is important. Despite the use of a preclinical target, our results are in line with 
reported response rates of caspofungin in literature, that clinical and mycological 
cure at the end of therapy is usually 72-73%.2, 34 Low exposure might result in 
clinical failure. High exposure to caspofungin on the other end does not appear to 
lead to safety precautions: caspofungin has an overall favorable safety profile, and 
therapy with 150 mg daily is well tolerated in patients with invasive candidiasis.35-37 
To achieve optimal probability of target attainment, we recommend the use of 
70-100 mg caspofungin maintenance dose in the setting of an infection with 
pathogens with attenuated MIC (>0.125 µg/mL). Irrespective of the susceptibility 
profile in the invading pathogen, patients may benefit from a higher loading dose 
of 100 mg on day 1 to achieve early adequate exposure (see Figure 4). 
Some challenges remain for future work. First of all, data pooling is clearly 
needed to achieve sufficient power to detect relevant covariates specifically 
in the light of the heterogeneous ICU population. Clearly a more stratified 
approach taken into account pathogen susceptibility needs to be validated in 
terms of general mycological and clinical cure. A study designed to identify the 
clinical breakpoint for caspofungin in invasive candidiasis is warranted. In the 
mean time, caspofungin dose reductions based on Child-Pugh B scores do not 
appear to be valid for non-cirrhotic ICU patients. Ultimately, therapeutic drug 
monitoring (TDM), i.e. individualized drug dosing based on the measurement 
and interpretation of drug concentrations recognizing the pathogen susceptibility, 
could be an important tool to derive an optimal exposure in the individual patient.
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Abstract
To study the pharmacokinetics (PK) of micafungin in intensive care patients and 
assess PK target attainment for various dosing strategies.
Micafungin PK data from 20 intensive care unit patients was available. A 
population PK model was developed. Various dosing regimens were simulated: 
licensed regimens (I) 100 mg daily; (II) 100 mg daily with 200 mg from day 5; 
and adapted regimens 200 mg on day 1 followed by (III) 100 mg daily; (IV) 150 
mg daily; (V) 200 mg daily. Target attainment based on a clinical PK target for 
Candida as well as non-C. parapsilosis infections was assessed for relevant MICs 
(CLSI). Parameter uncertainty was taken into account in simulations.
A 2-compartment model best fitted the data. Clearance was 1.10 (RSE 8%) 
L/h and volumes of distribution of compartments 1 and 2 were 17.6 (RSE 14%) 
and 3.63 (RSE 8%) L respectively. Median AUC0-24h (IQR) on day 14 for regimens 
I-V 91 (67-122), 183 (135-244), 91 (67-122), 137 (101-183) and 183 (135-244) 
mg*h/L, respectively for a typical patient of 70 kg. For the MIC/AUC >3,000 target 
(all Candida spp), PK target attainment was >91% on day 14 (MIC 0.016 mg/L 
epidemiological cut-off) for all of dosing regimens but decreased to (I) 44% (II) 
91% (III) 44% (IV) 78% and (V) 91% for MIC 0.032 mg/L. For the MIC/AUC 
>5,000 target (non-C. parapsilosis spp), PK target attainment varied between 62-
96% on day 14 for MIC 0.016.
The licensed micafungin maintenance dose results in adequate exposure based 
on our simulations with a clinical PK target for Candida infections but only 62% 
of patients reach the target for non-C. parapsilosis. In case of pathogens with an 
attenuated micafungin MIC’s, patients may benefit from dose escalation to 200 mg 
QD. This encourages future study.
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Introduction 
Candida or Aspergillus species are the fourth most dominant pathogens causing 
disease complication in the intensive care unit and account for approximately 
20% of infections in ICU.1, 2 Micafungin is an antifungal agent that belongs 
to the class of echinocandins that act by inhibiting the synthesis of β-(1,3)-D-
glucan, an important component of the fungal cell wall. It is a semi-synthetic 
compound, freely soluble in water and it has a molecular weight of 1292.26.3, 4 
Micafungin shows in vitro and in vivo activity against Candida species and it is 
licensed as first-line treatment for invasive candidiasis.3-5 Micafungin, like other 
echinocandins, achieves adequate clinical responses in about 70% of patients with 
invasive candidiasis or candidaemia.2, 6
The recommended micafungin dose is a daily (QD) intravenous infusions of 
100 mg (infusion time approximately 1 hour).4 In case of insufficient response, 
such as when the clinical condition does not improve or in case of persistent 
positive cultures, the dose may be increased to 200 mg QD.4
Recently, we analysed the pharmacokinetics (PK) of micafungin in 20 
critically ill patients (ICU patients) by means of a non-compartmental approach.7 
A lower total exposure (AUC0-24h) was observed in this cohort as compared to 
healthy volunteers, although the total exposure was comparable to other patient 
populations.7
The pharmacodynamic index of the echinocandins is best described by the 
AUC:MIC ratio.8, 9 To design optimal dosing regimens for micafungin in critically 
ill patients, both PK and pharmacodynamic (PD) factors need to be incorporated 
into a model. A non-compartmental analysis is not sufficient for the purpose of 
modeling and simulations. Hence, we will deploy an additional PK-PD analysis 
using non-linear mixed effect modeling to obtain a further understanding of the 
PK of micafungin. Defining such a PK model will enable us to simulate different 
dosing regimens and assess the corresponding exposure (AUC) and PK target 
attainment, taking into account the susceptibility profiles of the pathogen.
Micafungin clinical breakpoints have been defined in a phase III clinical study 
among patients with invasive candidiasis. An AUC:MIC between 3,000 and 12,000 
was associated with 98% success for all Candida species. A specific target was 
defined of an AUC:MIC ratio of 5,000 to 12,000 for non C. parapsilosis species and 
above 285 for C. parapsilosis.10 Micafungin has an overall favorable safety profile; 
therapy with 150-200 mg daily is well tolerated.3
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We aimed to combine our PK data and the clinical breakpoints data to determine 
the probability of target attainment (PTA) in a population of critically ill patients. 
This will enable us to make simulations for other regimens to investigate the gain 
in PTA in pathogens with altered susceptibility profiles.
Materials and Methods
Ethics
This study was conducted in compliance with the Declaration of Helsinki and 
approved by the local medical ethics committee (Commissie Mensgebonden 
Onderzoek region Arnhem-Nijmegen number, clinical trials.gov NCT01783379). 
Informed consent was given by all participants. 
Study design, drug regimen and population
All data were collected in a prospective pharmacokinetic study published 
previously.7 Patients admitted to the ICU and receiving micafungin for suspected 
or proven fungal infection were eligible if they met the following inclusion 
criteria: ≥18 years of age on the day of the first micafungin dose, not receiving 
micafungin treatment for >2 days before enrollment, and having an indwelling 
central venous or arterial catheter. Exclusion criteria included patients with a 
history of hypersensitivity to echinocandins or excipients similar to those found 
in the micafungin preparation, HIV or hepatitis B/C infection, or abuse of alcohol 
or drugs. All participants received micafungin 100 mg QD. Micafungin was 
administered intravenously over approximately 1 hour. Micafungin therapy was 
continued as long as was considered clinically indicated, but the duration of the 
study was limited to a maximum of 14 days with an additional three days after end 
of therapy.
Demographic information was gathered and included age, gender, race, weight 
(available from the medical record previous to ICU admission, estimated or 
weighted on the ICU), height, relevant co-medication, indication for micafungin 
use, clinical characteristics, chemistry and hematological parameters. In addition, 
acute physiology and chronic health evaluation II (APACHE II), sequential organ 
failure assessment (SOFA), Child-Pugh score and (type of) renal replacement 
therapy were recorded.
45151 Lisa Martial.indd   82 16-05-17   20:09
PK of micafungin in ICU patients
83
5
PK sampling and analysis
At day 3(±1) patients were intensively sampled (2 mL) at t=0 (pre-dose) and 0.5, 1, 
2, 4, 6, 8, 12, 18 and 24h post start infusion during a dosing interval. At day 7(±1), 
a second PK curve of six samples was drawn at t=0, (pre-dose) and 1, 4, 8, 12 and 
24h post start infusion. Additional daily trough concentrations were drawn daily 
until 3 days after cessation of micafungin therapy. A validated UPLC-fluorescence 
assay was used to analyse the samples, details have been described previously.7
Pharmacokinetic model
Population PK analysis of micafungin was performed with non-linear mixed effects 
modeling using the first-order conditional estimation method with interaction 
between random effects and residual variability as implemented in NONMEM 
(version 7.3, ICON Development Solutions, USA).11 Piraña interface (PiranaJS 
version 1.01)12, 13 was used as an interface for NONMEM, Perl-Speaks-NONMEM 
(PsN) (version 4.2.0); Xpose (version 4.5.3); and R (version 3.2.1).14
As body weight is a known confounder for pharmacokinetics, the impact 
of body weight on the pharmacokinetics of micafungin were accounted for by 
allometric scaling, as proposed previously, with an allometric exponent of 0.75 for 
all flow parameters and an exponent of 1 for all volume parameters standardized 
to a 70 kg patient as proposed previously.15-18 One-, two- and three-compartment 
models were considered to describe the drug disposition. The primary PK 
parameters were clearance (CL) and volumes of distribution (V). Inter-individual 
(IIV) and inter-occasion variability (IOV) was estimated using an exponential 
model. Residual variability was evaluated by proportional, additive and combined 
additive and proportional models. Inter-individual random-effects were evaluated 
with a single covariance matrix on the parameters of the first compartment as 
well as with a full covariance matrix on the parameters of all compartments. IOV 
was considered on CL and V. Structural model selection was guided by objective 
function value (OFV) as computed by NONMEM, corresponding to minus 
twice the log-likelihood (a Δ of -3.84 with 1 degree of freedom, Chi-squared [χ2] 
distribution, corresponds with a significance level of p= 0.05) goodness-of-fit 
plots and physiological plausibility. In addition, the precision of the parameter 
estimates, eta shrinkage and IIV and IOV were assessed, as well as parameter 
correlation. Candidate models were further evaluated by a prediction-corrected 
visual predictive check (VPC, n=1000 simulations) and numerical predictive 
check (NPC) based on n=1000 simulations.19 With this VPC the observed data 
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were compared to the model simulated data to evaluate internal validity of the 
model. 
After selection of the base model, the following covariates were tested on CL 
and V based on physiological plausibility: albumin, CVVH and SOFA. The effect 
of albumin was assessed on V1 and CL. The effect of CVVH was assessed on V1 
(dichotomous covariate). SOFA scores were obtained on different days. Missing 
values of non-sampling days before the observation were replaced by the first 
value (usually at 48h) and missing values after observations were carried forward. 
In case of completely missing SOFA scores, the median of 7 was used. SOFA 
score was divided into low score (<10) and high score (>10) based on associated 
mortality risks20, 21 and was assessed as a categorical covariate on CL and V.
Covariates were tested in a stepwise fashion (forward inclusion, backward 
elimination). A covariate was included when it was physiologically plausible and 
the OFV decreased with 3.84 points (χ2 distribution, p= 0.05). 
The precision of the parameter estimates was assessed using a non-parametric 
bootstrap method in which resampling of the data to create new datasets with the 
same size but containing different sets of individuals and yielding new parameter 
estimates and confidence intervals (n=1000 replications).
Monte-Carlo simulations of pharmacokinetics and target attainment with 
various dosing regimens.
The final model was used to perform a simulation study exploring various 
dosing regimens. As the ICU cohort used for model building was considered too 
small for simulation purposes (n=20), a cohort of 1000 hypothetical individuals 
with mean BW of 70 kg with 20% coefficient of variation [CV] in BW, was 
generated for each dosing regimen. This variation in weight (20% CV) was based 
on the weight distribution of a hematological cohort from our hospital (n=1706, 
median 76.4 kg and standard deviation 14.5, resulting in 18.96% CV). Simulations 
were performed also propagating parameter uncertainty, with the TNPRI function 
in NONMEM, using priors from the final model.
Five dosing regimens were simulated including licensed regimens and 
alternative regimens, chosen at the discretion of the researchers. Licensed regimens 
included (I) 100 mg QD for 14 days, (II) 100 mg QD the first 4 days with 200 
mg QD from day 5 (labeled indication for non-responders); alternative regimens 
included (III) 200 mg loading dose on day 1 followed by 100 mg QD from day 2, 
(IV) 200 mg loading dose followed by 150 mg QD from day 2 and (V) 200 mg QD. 
A 200 mg dose is not expected to be associated with toxicity as micafungin doses 
of 8 mg/kg are well tolerated.4
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Probability of target attainment
The PK-PD target for micafungin in the treatment of invasive candidiasis 
was determined by the group of Andes et al. (2011).10 The exposure- response 
relationship of micafungin has been well-established: an AUC/MIC ratio of 
3,000-12,000 has previously been associated with 98% mycological response for 
all Candida infections, while a target of 5,000-12,000 has been associated with 
97.8% mycological response for non-C. parapsilosis infections.10 We used both 
an AUC/MIC ratio of >3,000 well as 5,000 as PK-PD target for the simulations. 
Furthermore, the model presented will allow other researchers to use our PK model 
for simulations on different Candida species whenever needed. However, this is 
beyond the scope of this article as the focus is on PK variability in a population of 
critically ill patients. 
Target attainment at day 3 and 14 was assessed for a range of clinically relevant 
MIC values (0.002-1 mg/L) Clinical and Laboratory Standards Institute [CLSI]. 
This range includes both the modal MIC for micafungin for C. albicans (0.015 
mg/L) as the epidemiological cut-off MIC (0.03 mg/L, CLSI reference method).22, 23
MIC distribution
In addition to the determination of the PTA for each individual MIC, also the 
PTA considering the population distribution was evaluated. For each MIC, the 
fraction of simulated patient who attained the PK target was multiplied by the 
fraction of the MIC distribution of C. albicans. The cumulative fraction of response 
was calculated as the sum of fraction products over all MICs. The population 
distribution of C. albicans was gathered from Pfaller et al. (2010) as this species is 
often involved in candidaemia in ICU patients.22
Results
Patients, dosing and samples
Twenty patients completed the first PK curve on day 3 and were eligible for 
analysis. A total of 356 time-concentration observations were available to build 
the model. Baseline patient characteristics are summarized in Table 1. Median age 
was 68 years (range 20-84) and median BW 77 kg (range 50-134). All patients 
had pronounced hypoalbumemia (serum albumin ≤ 34 g/L). All patients received 
micafungin 100 mg QD. No dose adaptations were performed.7
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Table 1 Patient demographics of the ICU cohort used to develop the population pharmacokinetic 
model
Demographics Evaluable ICU patients (n=20)
Female, n (%) 12 (60%)
Age (year), median (range) 68 (20-84)
Weight (kg), median (range) 76.5 (50-134)
BMI (kg/m2), median (range) 24.6 (16.3-47.5)
Clinical characteristics (at baseline)
Renal replacement therapy, n (%)
 CVVH 5 (25)
 Intermittent hemodialysis 1 (5)
Neutropenia 0 (0)
Hypoalbuminemia, n (%)
 25-34 g/L 2 (10)
 15-24 g/L 13 (65)
 <15 g/L 5 (25)
Infection location, n (%)
 Blood 3 (15)
 Other 20 (100)
Species, n (%) 1 (5)
Candida spp. 20 (100)
 C. albicans 11 (55)
non-albicans 11 (55)
 C. tropicalis 2
 C. glabrata 2
Candida not specified 7
Saccharomyces cerevisiae 1
Aspergillus spp.a 2 (10)
 A. fumigatus 1
 A. niger 1
Candida and Aspergillus spp. a 2 (10)
a Mixed infection (Candida and Aspergillus).
BMI body mass index; ICU intensive care unit
Population PK model
A two-compartment disposition model with first-order elimination from the 
central compartment and a proportional residual error model fitted the data 
best. IIV on CL and V1 further improved the model while data did not support 
the addition of IIV on Q or V2. Allowing a correlation between IIV of CL and 
V1 further improved the model (difference OFV = 13.98). High IOV on V1 
was observed indicating important variation in V1 from day to day within this 
population. Parameter estimates of the model are shown in Table 2. CL, V1, Q 
and V2 were estimated to be 1.10 L/h, 17.6 L, 0.363 L/h and 3.63 L. The IIV on CL 
and V1 were estimated to be 40 and 73% CV with eta shrinkage of 1.2 and 41% 
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respectively while IOV on V1 was estimated to be 37% CV. No covariates were 
identified to significantly affect CL or V1.
Basic goodness-of-fit plots (GOF) are shown in the supplementary file (Figure 
S1). The plots did not show major deviations. A prediction-corrected visual 
predictive check (pcVPC) of the final model is shown in the supplementary file 
(Figure S2). Predictions observed to be consistent with the observations, suggesting 
a good validity of the model to the data. The NPC showed that 0.9% (95% 
confidence interval [CI] 0-6.8%) of observations fell below the 95% prediction 
interval (PI) and 2.0% (95% CI 0-8.8%) fell above the 95% PI. Parameter precision 
was assessed using a bootstrap re-sampling approach of the final model, the result 
of which are listed in Table 2. 
Table 2 Pharmacokinetic parameter estimates of the final model and bootstrap analysis
Parameter Parameter estimates [RSE] 
(Shrinkage) 
Bootstrap results parameter 
estimates (n=841)a
Mean (95%CI) [RSE]
CL (L/h)* 1.10 [8%] 1.10 (0.92-1.32) [8.8%] 
V1 (L)* 17.6 [14%] 16.8 (12.53-21.54) [12.7%] 
Q (L/h)* 0.363 [20%] 0.363 (0.30-3.82) [26.2%] 
V2 (L)* 3.63 [8%] 3.85 (3.20-7.77) [30.9%] 
IIV CL (CV%) 40.1 [23.2%] (1.2%) 38.5 (28-47) [23%] 
IIV V1 (CV%) 73.2 [62.7%] (41%) 72.1 (32-119) [53%] 
IOV V2 (CV%) 37.0 [77.5%] (25-70%) 35.8 (14-60) [60%] 
Proportional residual error 17% [24%] 17% (14-20%) [20%]
a Based on 841/1,000 successfully terminated runs (minimization successful and no boundaries).
*Parameters allometrically scaled to a body weight of 70 kg
CL clearance; V1 volume of distribution of compartment 1; V2 volume of distribution of compartment 
2; Q intercompartmental clearance; IIV inter-individual variability; IOV inter-occasion variability; RSE 
root square error (based on covariance step in NONMEM) 
Monte-Carlo simulations of alternative dosing regimens
Monte-Carlo simulations were performed to assess daily exposure (AUC0-24h) 
obtained with licensed and alternative dosing regimens. AUC0-24h values on day 
14 of therapy are shown in Figure 1. Median (IQR) AUC0-24h values on day 3 for 
the five regimens (I-V) were 86 (62-116), 86 (62-116), 92 (66-125), 132 (95-180), 
172 (124-232) mg*h/L and on day 14: 91 (67-122), 183 (135-244), 91 (67-122), 
137 (101-183) and 183 (135-244) mg*h/L respectively. 
Simulated plasma concentration time profiles of the first week of therapy in a 
typical patient weighing 70 kg following the different dosing regimens are shown 
in the supplementary file (Figure S3). Administration of a loading dose resulted in 
higher exposure early in therapy (regimens III-IV). 
45151 Lisa Martial.indd   87 16-05-17   20:09
Chapter 5
88
Figure 1 Area under the concentration time curve (AUC0-24h) on day 14 based on Monte-Carlo 
simulations. The horizontal line represents the AUC0-24h for healthy volunteers. Licensed regimens (I) 
100 mg QD; (II) 100 mg QD followed by 200 mg QD from day 5. Alternative regimens (III) a 200 mg 
loading dose followed by 100 mg maintenance; (IV) a 200 mg loading dose followed by 150 mg 
maintenance; (V) 200 mg QD.
Pharmacokinetic target attainment 
The PTA on day 3 of therapy based on the Monte-Carlo simulations are shown in 
Figures 2 and 3. As can be expected, the PTA increased with increasing doses and 
decreased with higher MIC values. For example, adding a loading dose together 
with increasing the maintenance dose to 150-200 mg daily led to increased target 
attainment: ≤46% vs >74% on day 3 for a micafungin MIC of 0.032 mg/L for the 
target of >3,000.
The main differences in PTA between days 3 and 14 are observed for regimen 
II, as with this regimen the maintenance dose is increased from 100 to 200 mg on 
day 5 of therapy. The PTA for all simulated regimens is also given as supplementary 
file (Supp Tables 1 and 2). Table 3 shows the results of the PTA integrated with 
the distribution of the MIC for C. albicans and non-C. parapsilosis resulting in 
the cumulative fraction of the predicted response. Higher maintenance dose 
(regimens II, IV and V) resulted in higher cumulative PTA.
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Figure 2 Predicted target attainment at day 3 versus minimal inhibitory concentration (MIC) for all 
five simulated regimens based on a clinical target area under the concentration time curve over 
24h (AUC0-24h)/MIC ratio of ≥3,000 (valid for all Candida spp). Bars represent wild type population 
distribution of C. albicans for micafungin, as gathered from22.
Figure 3 Predicted target attainment at day 3 versus minimal inhibitory concentration (MIC) for all 
five simulated regimens based on a clinical target area under the concentration time curve over 
24h (AUC0-24h)/MIC ratio of ≥5,000 (valid for non-C. parapsilosis spp). Bars represent wild type 
population distribution of C. albicans for micafungin, as gathered from22.
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Table 3 Cumulative fraction of predicted probability of target attainment for C. albicans and 
non-C parapsilosis based on the five different simulated regimens
Cumulative fraction of predicted PTA 
(%) AUC/MIC >3,000
Cumulative fraction of predicted PTA 
(%) AUC/MIC >5,000
Regimen Day 3 Day 14 Day 3 Day 14
Regimen I 79 83 53 58
Regimen II 79 97 53 90
Regimen III 81 83 57 58
Regimen IV 91 94 76 80
Regimen V 95 97 86 90
Licensed regimens (I) 100 mg QD; (II) 100 mg QD followed by 200 mg QD from day 5. Alternative 
regimens (III) a 200 mg loading dose followed by 100 mg maintenance; (IV) a 200 mg loading dose 
followed by 150 mg maintenance; (V) 200 mg QD.
PTA pharmacokinetic target attainment
Discussion
We developed a population PK model for micafungin in ICU patients. The model 
was successfully used to assess different dosing regimens of micafungin in order 
to predict the corresponding PTA taking into account parameter uncertainty. The 
simulations revealed that the majority of the population is treated sufficiently with 
the current licensed dosing regimen, but the PTA for infections with Candida 
species with a MIC of 0.032 mg/L can be improved by increasing the maintenance 
dose a priori to 200 mg.
CL in our cohort was 1.10 L/h and modestly higher compared to CL in healthy 
volunteers.24, 25 Three population PK models have been published previously. CL 
in our cohort was similar to ICU patients on CVVH, mechanical ventilation or 
intra-abdominal infection.26-29 IIV on CL was 40% CV in our cohort and therefore 
higher than observed in healthy volunteers24 or ICU patients on CVVH (17-20% 
CV)26 but similar to ICU patients with sepsis and mechanical ventilation (34%).29 
Distribution volume was higher than in healthy volunteers (13.3 L for a healthy 
70 kg patient)24 and the central V was higher than in ICU with severe peritonitis, 
sepsis or burn injuries27-29 but very similar to ICU patients on CVVH (22.5 L for 
a 70 kg patient).26 IIV on in V1 was 73% CV in our cohort and thereby 2-10 fold 
higher compared to other studies (8-38% CV).24, 26, 29 One explanation could be that 
healthy volunteers and subjects on CVVH are more homogenous populations, in 
which less variability is observed, while our cohort consisted of ICU patients with 
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and without CVVH. The here estimated IIV may also have been inflated by one 
influential individual (BW 134 kg) who seems to be responsible for the improved 
model fit when including IIV on V1. V2 was lower in our analysis but the total 
volume of distribution (V1 + V2) was comparable to other PK.26, 29
BW was a priory added in the model on CL and V1 in agreement with 
physiological plausibility and based on previous work. 15-18, 26, 29 It remains a matter 
of debate whether one should estimate or fix the allometric exponents. One 
group empirically estimated this for micafungin29 while another one fixed it.26 
For illustration purposes, we have estimated the allometric exponent of BW to 
CL, which resulted to be 1.26 and this did not significantly improve the model 
fit (ΔOFV -2.97). 1.26 is very different from what is physiologically plausible and 
from the results of another group (0.59).29 Based on our data (n=20 patients), the 
true exponent is not identifiable and using an empirical estimate would not allow 
for extrapolation beyond our dataset.
Although not present in our cohort, in case of morbidly obese critically ill 
patients, BW may not be the ideal parameter to relate size to PK. Other weight-
derived parameters such as fat free mass (FFM) could be alternative descriptors to 
explain variability in PK parameters in this subpopulation.30 As micafungin has a 
relative low distribution volume, only a small fraction is metabolized and kidney 
function does not play an important role.3, 26 BW is assumed to adequately describe 
the relationship between body size and the PK parameters for the normal weight 
ICU patients.3
We found an important IOV on V which means that distribution volume may 
change considerably from day to day within one patient. While our data also 
supported the addition of IOV on CL, we considered IOV on V more physiologically 
plausible as we observed important fluctuations in peak concentrations of 
micafungin. Day to day fluctuations in V may be explained by hemodynamic 
changes including fluid retention or fluid loss due to capillary leak which may 
occur in ICU patients.31, 32 Moreover, including IOV on both CL and V1 resulted 
in an unidentifiable model with parameter correlation and including both was, 
therefore, not considered. A study among 10 ICU patients on CVVH found an 
IOV on V1 and V2 of 27-28% CV, lower compared to our cohort (37% CV).26 This 
difference might be explained by the difference in clinical condition: patients on 
CVVH might be hemodynamically more stable and controlled in terms of fluid 
retention and diuresis than ICU patients not on CVVH. This is reflected in lower 
IOV of V1.
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As referenced we have now conducted several pop-PK studies of echinocandins 
in ICU patients. We observed some differences between the various echinocandins. 
Unlike caspofungin that had identical CL and V in critically ill patients compared 
to healthy volunteers, micafungin showed a higher CL (1.10 L/h compared to 0.55 
L/h) and a higher V (21.2 L compared to 13.9 L for V1 and V2 together) in ICU 
patients.33 Anidulafungin showed similar changes in CL when comparing critically 
ill patients with healthy volunteers, while V was equal in both populations.34 It 
remains unclear why micafungin PK does change but caspofungin is less affected 
by critical illness as we could not find any covariates - apart from BW - explaining 
variability in PK parameters. Covariates might be obscured due to the overall 
high variability in pharmacokinetics among ICU patients, caused by a mixture 
of factors (e.g. systemic inflammatory response, capillary leak, protein binding 
capacity).35 Combining datasets and thereby increasing sample size may help to 
further clarify this. 
Our results confirm that the exposure (AUC0-24h) in the ICU population after 100 
mg QD is much lower than the exposure with the same dose in healthy volunteers, 
which is consistent to our previous analysis.7 Increasing the maintenance dose in 
ICU patients to 150 mg led to equal exposure compared to healthy volunteers. 
When the labeled 200 mg is chosen, this would lead to higher exposure compared 
to healthy volunteers. Theoretically, lower exposure risks decreased efficacy it is 
known that AUC is inversely linked to disease outcome when exposed to pathogens 
with increasing MICs.9
We have simulated the licensed regimens, as well as alternative regimens. Based 
on our simulations and PTA assessment with the 3,000 target (all Candida spp), 
the majority (83%) of the ICU population is treated adequately with the currently 
licensed 100 mg maintenance dose. Higher maintenance doses are of 200 mg QD 
only required in case of infections with species with decreased susceptibility. But 
based on the 5,000 target (non-C. parapsilosis) the majority of the population may 
benefit from a dose increase to 200 mg QD due to low target attainment with the 
100 mg QD (62% attains the 5,000 target with MIC 0.016) Although this can be 
considered a worst-case scenario, no susceptibility profiles are available upon start 
of therapy, for which a 200 mg dose QD may be beneficial until the results of the 
microbiology are available. If the MIC allows, one can scale down to 100 mg QD. 
This should be evaluated prospectively. Alternatively, a 200 mg loading dose for all 
ICU patients can be beneficial, in order to achieve early adequate exposure (also 
shown in Figure S3). Especially given the high IOV of V1, it is of great importance 
to adequate saturate all compartments with micafungin. 
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Our results are comparable to previous work26, 29 and confirm that species with 
attenuated MICs may benefit from higher maintenance doses.
It should be noted that PK-PD targets vary considerable among Candida 
species and the target greatly influences outcome: PTA decreases when the target 
increases.8 So correct selection of the target is crucial for adequate interpretation 
of the PTA. When starting therapy, the MIC is often unknown. With this in mind, 
our results encourage the prospective evaluation of a higher initial dose (e.g. 200 
mg maintenance) as it may have the potential to decrease the rate of patients not 
attaining the target. This should be evaluated for superiority in a prospective trial.
In addition, modeling and simulation is always associated with uncertainty, 
further challenging the interpretation of estimated PTA. We therefore took 
parameter uncertainty into account when performing Monte-Carlo simulations of 
micafungin in ICU patients, subsequently used for PTA predictions. The variability 
in exposure (Figure 1) is a combination of parameter uncertainty and variability 
in BW. Although this uncertainty is taken into account in the PTA predictions, 
Figure 2 does not show any variability as it was based on the proportion of 
patients attending the PK target. Another approach could be to perform multiple 
simulations (e.g. 1000 times) using parameter precision information from a 
bootstrap and calculate confidence intervals around the PTA.36
The current work is inevitable associated with some limitations which are 
discussed below. The first relates to the high IIV on V1 which may have been 
inflated by an influential individual with a BW of 134 kg, the highest BW of the 
cohort. However, the inclusion of the parameter improved the model fit to the 
data significantly and it is not surprising to encounter deviating individuals in 
heterogeneous IC cohorts. We therefore decided to retain this individual in the 
cohort and proceed with IIV on V1, but at the same time underline the uncertainty 
in the estimated value of this parameter. The second limitation relates to the fact 
we did not have information on the unbound micafungin concentrations. As 
micafungin is highly protein bound, fluctuations in albumin – likely to occur 
among ICU patients – may influence total concentrations and thereby PTA. This 
might have led to an underestimation rather than an overestimation of PTA.
In summary, a population PK model of micafungin in ICU patients was 
developed and used to assess PTA for licensed as well as alternative dosing 
regimens. We are the first to incorporate uncertainty in parameter estimates in 
Monte-Carlo simulations. We conclude that the majority of the population is 
adequately treated with a 100 mg maintenance dose based on the 3,000 target 
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but not with the 5,000 target. Candida species with higher MIC’s require higher 
maintenance doses of 200 mg. As it takes several days before microbiology results 
are obtained, starting with a higher initial dose (e.g. 200 mg QD) may result in 
superior treatment outcome. Although this alternative dosing strategy may be off-
label, our findings encourage its investigation.
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Supplementary File
Table S1 Exposure to micafungin after simulations with different dosing regimens
Dose regimen Median (IQR) AUC0-24h day 3 (mg*h/L) Median (IQR) AUC0-24h day 14 (mg*h/L)
Regimen I 86 (62-116) 91 (67-122)
Regimen II 86 (62-116) 183 (135-244)
Regimen III 92 (66-125) 91 (67-122)
Regimen IV 132 (95-180) 137(101-183)
Regimen V 172 (124-232) 183 (135-244)
Licensed regimens (I) 100 mg QD ; (II) 100 mg QD followed by 200 mg QD from day 5. Alternative 
regimens (III) a 200 mg loading dose followed by 100 mg maintenance; (IV) a 200 mg loading dose 
followed by 150 mg maintenance ; (V) a 200 mg QD.
Table S2 Fraction of the predicted probability of target attainment for C. albicans based on the five 
different simulated regimens
Pharmacokinetic target attainment (%)
MIC (µg/mL) 0.002 0.004 0.008 0.016 0.032 0.064 0.125 0.25 0.5 1.0
Day 3
Regimen I 100 99.7 98 86 40 3 0.09 0 0 0
Regimen II 100 99.7 98 86 40 3 0.09 0 0 0
Regimen III 100 100 98 88 46 4 0.22 0 0 0
Regimen IV 100 100 99.4 95 74 20 0.97 0 0 0
Regimen V 100 100 99.7 98 86 40 3 0.1 0 0
Day 14
Regimen I 100 100 99.7 91 44 4 0.1 0 0 0
Regimen II 100 100 100 99.7 91 44 5 0.1 0 0
Regimen III 100 100 99.7 91 44 4 0.1 0 0 0
Regimen IV 100 100 100 99 78 21 1 0.03 0 0
Regimen V 100 100 100 99.7 91 44 5 0.1 0 0
Licensed regimens (I) 100 mg QD; (II) 100 mg QD followed by 200 mg QD from day 5. Alternative 
regimens (III) a 200 mg loading dose followed by 100 mg maintenance; (IV) a 200 mg loading dose 
followed by 150 mg maintenance; (V) a 200 mg QD. MIC; minimal inhibitory concentration.
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Figure S1 Goodness-of-fit plots for the final pharmacokinetic model of micafungin. 
The thin lines indicate the unit line or the line of identity. The thick lines are smooth lines showing 
the trend in the observations. CWRES conditional weighted residuals
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Figure S2 Visual predictive check for the final pharmacokinetic model of micafungin, based on n = 
1000 simulations. 
Prediction-corrected simulated (shaded areas) and observed (circles and lines) micafungin 
concentrations versus time after dose (h). The thick line connects the observed median values per 
bin. The solid thin lines connect the 5th and 95th percentiles of the observations. The areas around 
this line are the 95 % confidence interval of the 5th and 95th percentiles. The area around the thick 
line indicates the confidence interval of the median.
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Figure S3 Population concentration time curves of a typical patient of 70 kg. 
Licensed regimens (I) 100 mg QD; (II) 100 mg QD followed by 200 mg QD from day 5. 
Alternative regimens (III) a 200 mg loading dose followed by 100 mg maintenance; (IV) a 200 mg 
loading dose followed by 150 mg maintenance; (V) a 200 mg QD. 
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Abstract
The management of drug-drug interactions (DDIs) between azole 
antifungals (fluconazole, itraconazole, posaconazole and voriconazole) 
and immunosuppressants (cyclosporine, tacrolimus, everolimus and 
sirolimus) in transplant patients remains challenging, as the impact of altered 
immunosuppressant concentrations puts the patient at high risk for either toxicity 
or transplant rejection. As a result, it is a complex task for the clinician to maintain 
immunosuppressant concentrations within the desired therapeutic range and this 
requires a highly individualized patient approach. We provide important tools 
for adequate assessment of the drug interactions that cause this pharmacokinetic 
variability of immunosuppressants. A stepwise approach for the evaluation and 
subsequent management options, including a decision flow chart, are provided for 
optimal handling of these clinically relevant DDIs. 
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Introduction
Immunosuppressants are standard of therapy for the prevention and treatment 
of graft-versus-host-disease (GvHD) in hematopoietic stem cell and transplant 
rejection in solid organ transplant recipients. Because of the wide application of 
chemosuppressive or immunosuppressive therapy, these patients are at risk for the 
development of invasive fungal infections (IFIs). Azole antifungals (i.e. fluconazole, 
itraconazole, posaconazole and voriconazole) are often used for prevention as well 
as therapy of these infections. Unfortunately, azoles interfere with the metabolism 
and transport of immunosuppressants (i.e. cyclosporine, tacrolimus, sirolimus and 
everolimus), causing clinically relevant drug-drug interactions (DDIs).1 Initiation 
of azoles increases immunosuppressant exposure introducing side effects of these 
drugs2, whereas subsequent discontinuation of azoles without dose adjustment 
of the immunosuppressant may lead to sub-therapeutic immunosuppressant 
exposure and risk of transplant rejection or GvHD. 
Although changes in exposure of immunosuppressants upon coadministration 
with azoles have been extensively described1, 3-5, it remains a challenge for the 
clinician to adequately manage these DDIs (see Box 1 for an example). This article 
provides strategies for the management of these DDIs, ultimately increasing patient 
safety by reducing the risk of immunosuppressant toxicity or loss of efficacy.
Box 1 Management of drug-drug interaction of voriconazole and cyclosporine
In seven kidney transplant recipients with stable renal function, coadministration of 
voriconazole (200 mg twice/day for 7.5 days) and cyclosporine (150-375 mg/day) increased 
cyclosporine AUC(0-12h), Cmax and Cmin by 1.7, 1.13 and 2.5-fold, respectively, compared to 
cyclosporine alone.6 Vice versa, discontinuation of voriconazole without dose adjustments 
of cyclosporine resulted in inadequate exposure of cyclosporine.7 The great interindividual 
variability in cyclosporine AUC during concomitant voriconazole use indicates the 
magnitude of this interaction is widely variable.8, 9 At initiation of voriconazole, the 
cyclosporine dose should be reduced by 50%, with subsequent monitoring of cyclosporine 
blood concentrations. At discontinuation of voriconazole, the cyclosporine dose should be 
increased and cyclosporine blood concentrations should be carefully monitored.6-10
Principles of drug-drug interactions between azoles and immunosuppressants
Drug interactions can be categorized as either pharmacokinetic (PK; involving drug 
absorption, distribution, metabolism, or excretion) or pharmacodynamic (PD; 
antagonistic, synergistic or additive actions on the same receptor/physiological 
process) in nature.11 Although we are aware that concomitant use of azoles and 
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immunosuppressants can result in PD interactions, this review will focus solely 
on PK interactions between azoles (‘precipitant drug’; causing the interaction) and 
immunosuppressants (‘object drug’; affected by the interaction).
These PK interactions involve azole inhibition of drug metabolizing enzyme 
cytochrome (CYP) P450 3A4/5 and/or drug transporter P-glycoprotein (P-gp) 
within the gastro-intestinal tract and the liver, for which immunosuppressants 
are substrates.1, 4, 12 The magnitude of these interactions varies greatly, as azole 
inhibition of relevant enzymes can be dose-dependent and differs in potency 
and selectivity1 As an example, itraconazole and voriconazole are reported to be 
more potent inhibitors of CYP3A4 than posaconazole and fluconazole, and only 
itraconazole and posaconazole are capable of inhibiting P-gp.1, 13, 14
Multiple genetic polymorphisms of CYP3A4, CYP3A5 and P-gp have been 
identified, associated with altered metabolic turnover.15 These polymorphisms can 
also influence the magnitude of DDIs between azoles and immunosuppressants.16, 17 
The details of the interplay between DDIs and genetic variability in metabolizing 
enzymes are beyond the scope of this review and will not be further discussed.
Tools to assess drug-drug interactions
Different approaches can be distinguished in order to adequately assess DDIs 
between azoles and immunosuppressants. In the next paragraphs a lay out of tools 
necessary for assessment of DDIs is presented. 
Sources of information on drug-drug interactions
Multiple sources on PK and DDIs between azoles and immunosuppressants are 
available and one should consider how the multidisciplinary team could use this 
information.18 The summary of product characteristics (SmPC) is freely accessible 
and regularly updated, but unfortunately often lacks clinical guidance.19 Regarding 
primary literature, in vitro, in vivo, case-reports and DDI studies can be assessed. 
In vitro and in vivo studies are prone to uncertainties regarding extrapolation to 
the clinical setting.20 Case-reports can help in the management of the individual 
patient, generate hypotheses, and stimulate further research. DDI studies have 
the advantage that they are specifically designed to identify and quantify a DDI. 
Unfortunately, such studies are often not performed in the specified patient 
population but rather in healthy volunteers, making the translation to the 
patient population difficult. Commercially available drug compendia such as 
Micromedex® or Lexicomp®Online™ provide valuable and updated information 
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on DDIs. As a licence is costly, not all healthcare professionals have access to 
these drug compendia. Drug-interaction databases, such as the recently launched 
Fungal Pharmacology (http://www.fungalpharmacology.com) might offer a 
solution. This web-based interaction tool is freely available and provides up-to-
date peer-reviewed advice on DDIs with antifungal agents to improve patient 
safety and strengthen health systems.21 
In the case of few or no data on DDIs, a theoretical interaction can be predicted 
based on the pharmacological mechanisms involved (e.g. evidence for a DDI with 
itraconazole based on its strong inhibition of CYP3A can be assessed to predict non-
described DDIs with the (weaker) CYP3A4-inhibitor posaconazole). Conflicting 
data on DDIs require assessment of the external validity of the existing literature. 
Note that conflicting data may sometimes exist due to different concentrations, 
duration of therapy, route of administration, and time-effects of DDIs for example, 
inhibition followed by induction as seen with voriconazole and St. John’s wort.22 
Actual medication overview
An actual medication overview including prescribed and over-the-counter drugs 
is essential. For an accurate overview, medication reconciliation at admission to 
the hospital, before transfer and discharge is pivotal. Ideally, patients adhere to one 
outpatient pharmacy for all their prescriptions in order to keep the medication 
record of the individual patient complete and up-to-date.
Multidisciplinary team in interaction checks
A multidisciplinary team is imperative for the management of DDIs.23 The clinician 
(together with the microbiologist and infectious disease doctor) is responsible for 
the diagnosis, treatment plan and selection of drugs and will first consider whether 
a DDI may occur. The hospital pharmacist/clinical pharmacologist has expertise 
on the PK of azoles and immunosuppressant drugs and their DDIs. Especially in 
complex patient populations, using multiple interacting drugs, it is advisable to 
actively involve a hospital pharmacist/clinical pharmacologist as a team member 
to review medication charts and interpret the magnitude of the DDI in light of the 
individual patient. 
Computerized provider order entry
Importantly, the use of computerized provider order entry (a system which allows 
clinicians to directly enter medication orders into a computer system, which then 
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will be directly transmitted to the pharmacy) paired with clinical decision support 
systems (yielding automated warnings in case of possible DDIs) enables clinicians 
and pharmacists to identify DDIs.24 Ideally, no ‘alert fatigue’ exist and warnings 
are tailored and graded for severity to increase the usefulness for assessment of 
DDIs.25, 26 So, if well designed, this tool can facilitate decision-making in DDIs, 
although its use might be restricted in resource-limited settings due to its high 
costs.
Clinical monitoring
Clinical monitoring (i.e. check for signs and symptoms of altered drug response, 
side effects/toxicity and monitoring of biochemical and haematological parameters) 
is essential to assess the impact of DDIs during coadministration. Especially at 
start, in case of dose-adjustments, during changes in clinical condition and upon 
discontinuation of an interacting drug, regular monitoring (e.g. liver and/or renal 
function tests) is indicated.
Therapeutic drug monitoring
Therapeutic drug monitoring (TDM), that is, individualized drug dosing based 
on the measurement and interpretation of drug concentrations, is an important 
tool to maintain drug concentrations between predefined target concentrations.27, 
28 Blood concentration measurement should be performed using an assay that 
is internally and externally validated according to international guidelines.29-31 
Information on sampling time, dose, frequency, route of administration, 
formulation, co-medication and patient characteristics is essential for adequate 
interpretation of the drug concentration.27, 32 TDM should ideally be used in every 
patient using immunosuppressants and azoles concomitantly. 
Because the inhibiting effect on CYP450 enzymes starts immediately after the 
azole is initiated3, TDM of the immunosuppressive agent is ideally performed 
before initiation of the azole and 2 times a week for 2 weeks afterwards33 with 
regular drug concentration measurement (e.g. every 2-3 weeks) thereafter.34 Upon 
discontinuation of the azole, the duration of the inhibitory effect depends on the 
triazole’s half-life.3 Monitoring of immunosuppressant blood concentrations can 
then guide dose optimization, until immunosuppressant concentrations are within 
the therapeutic window. Novel sampling techniques such as dried blood spot 
(DBS) sampling can be performed at home and samples are sent to the laboratory 
by mail, facilitating sampling in the outpatient setting. Only a single drop of blood 
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is required, which can easily be obtained by a finger prick and sampled on filter 
paper.35
Teaching on knowledge and awareness in relation to drug-drug interactions
Dedicated education and lifelong learning helps to develop awareness towards 
possible DDIs. Clearly, understanding the underlying mechanism of DDIs 
optimizes subsequent management. An important item to be covered during 
teaching is the narrow therapeutic window of immunosuppressants. Although 
pharmacists are well positioned to provide education on DDIs, using the combined 
expertise of all team members will result in better understanding of all aspects 
concerning the management of DDIs. Patients should also be taught for awareness 
of DDIs by careful medication education and counselling, to avoid unsupervised 
discontinuation of the azole and to provide insight in the interactions with over-
the-counter drugs (e.g. omeprazole36, 37 and herbs such as St John’s wort 22, 38). 
Evaluation of drug-drug interactions: a stepwise approach
The following paragraph aims to guide clinicians in the evaluation of DDIs using 
a stepwise approach, thereby contemplating the pharmacological mechanism of 
DDIs between immunosuppressants and azoles and using the tools described 
above to adequately assess the interaction.
Step 1: predict
Understanding the pharmacological mechanisms underlying DDIs (substrate/
inhibitor for CYP-enzymes and/or drug transporters) together with the 
pharmacological properties of azoles and immunosuppressants enables predicting 
potential DDIs. In this, the SmPC or drug compendia provide good sources of 
information (see tool: Sources of information), and teaching on these underlying 
mechanisms raises awareness towards these DDIs (see tool: Teaching on knowledge 
and awareness).
Step 2: identify
Identification of DDIs can be facilitated using sources of information (see Sources 
of information). To determine the extent and quality of evidence on the DDI, the 
study design and possible limitations in primary literature should be taken into 
account.39 For example, DDI studies (e.g. cross-over steady-state PK studies with 
AUCs) provide better quality compared to case reports.
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Step 3: quantify
The expected change in blood concentration (e.g. Cmin, AUC, Cmax) of the object 
drug following the DDI should be determined using available evidence (see step 
2). The DDI effect may be influenced by dose or concentration, duration of therapy 
and route of administration (intravenous versus oral). Co-medication is also of 
importance, since the object drug can be influenced by more than one precipitant 
drug. The predicted time of onset and off-set should be determined, which depends 
on the interaction mechanism that is inhibitory or inducing (inhibitory in case of 
azole antifungals and immunosuppressants).1 In clinical practice, the effect of the 
DDI can be quantified by means of TDM (see tool: Therapeutic drug monitoring).
Step 4: classify 
Changes in exposure should be regarded in light of the therapeutic window of the 
object drug to estimate the clinical significance of the DDI. Because of the narrow 
therapeutic window of immunosuppressants, relatively small changes in exposure 
may lead to adverse drug reactions or loss of efficacy. Vice versa, drugs with a wide 
therapeutic window allow for large changes in exposure without affecting patient 
response.
Risk classification as used by specified drug-interaction databases (see Sources 
of information) can be of help in classifying the severity of DDIs (Table 1).21 
Step 5: assess patient-related factors 
Patient-related factors capable of altering drug blood concentrations (e.g. disease 
status, co morbidities, and co-medication) may influence the magnitude of the 
effect and significance of a DDI.40 For example, the addition of erythromycin to a 
patient already treated with voriconazole and cyclosporine will intensify the DDI, 
due to additional CYP3A inhibition, resulting in increased cyclosporine exposure.
Step 6: appropriately circumvent or manage the DDI
Taking into account the tools for assessment and the above steps (steps 1-5, Table 
1) for evaluation of DDIs, the management options to handle DDIs between 
azoles and immunosuppressants are provided below. The ultimate goal of these 
management options is to maintain immunosuppressant concentrations within 
predefined target concentrations, thereby avoiding unnecessary toxicity or loss of 
efficacy. A structured management plan, based on the clinical significance of the 
DDI is provided in Figure 1.
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Table 1 Rating, classification and interpretation of drug-drug interactions
Rating Classification Interpretation
A No known 
interaction
Data have not demonstrated pharmacokinetic/pharmacodynamic 
alterations following concomitant use
B No action needed Data demonstrate that the drugs may interact, but this DDI is of 
limited clinical significance
C Monitor therapy Data demonstrate that the DDI may be clinically significant, but 
generally would not require a major alteration in therapy. An 
appropriate monitoring plan should be implemented to identify 
possible negative effects. Dose adjustments are only required in a 
minority of patients.
D Consider therapy 
modification
Data demonstrate that the DDI may be clinically significant 
and requires specific clinical decision making (e.g empiric dose 
adaptation, continuous TDM, alternative agents) to realize the 
benefits and minimize or prevent the risk of toxicity.
X Avoid combination Data demonstrate that the DDI may be clinically significant and 
concomitant use is contraindicated. The risks of interaction usually 
outweigh the benefits of therapy.
 • Discontinue the azole antifungal drug if possible
If allowed by the antifungal therapy management, discontinuation of the azole 
(or switch to a non-azole, see below) can be an option to prevent a DDI. For 
instance antifungal prophylaxis can be discontinued, for example posaconazole 
prophylaxis in hematopoietic stem cell transplant (HSCT) recipients. When doing 
so, the risk profile of the patient has to be taken into account and countermeasures 
must be taken (e.g. a proper diagnostic driven approach for fungal infections must 
be instituted in these cases to safeguard early detection of possible invasive fungal 
infection). 
 • Empirically decrease the dose of the immunosuppressive agent
Empirically decreasing the dose of the immunosuppressant can decrease the risk 
of adverse effects associated with increased immunosuppressant concentrations 
(e.g. nephrotoxicity). The magnitude of dose reduction during concomitant azole 
use depends on the selected immunosuppressant.4 For example, when starting 
therapy with voriconazole in a patient treated with tacrolimus, a dose reduction of 
about 66% is indicated.10
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Drug-drug 
interaction?
Relevant 
interaction? 
(A, B, C, D, X, 
see Table 1)?
No
Dose adaptation 
immunosuppressive 
agent required?
No (C)
TDM 
immunosuppressive 
agent
Concentration 
adequate?No Yes Continue therapy
Alternative 
strategies:
Stop azole
Transplant patient treated with 
azole and immunosuppressive agent*
Yes
Yes (C, D or X)No (A or B)
Yes (D, X)
Repeat
Switch to non-
azole antifungal 
agent
*Rational clinical decision guided by immunosuppressive therapy and antifungal stewardship
†Target attainment not possible for individual patient 
Adapt dose
Desired effect 
not obtained?†  Not recommended:
•  Spacing dosing times
•  Decrease dose of azole
•  Changing route of administration of 
immunosuppressant and azole (oral to intravenous)
No intervention 
required
Figure 1 Decision flow chart for treatment options in the management of drug-drug interactions
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 • Decrease the dose of the immunosuppressive agent based on TDM
Although it should be acknowledged that not all healthcare settings have access to a 
validated assay for the measurement of immunosuppressant blood concentrations, 
TDM is considered helpful in the management of the DDIs between azoles and 
immunosuppressant, both in the case of empirical dose reductions as when no 
empirical dose reductions are required. The latter can be explained by the DDI 
between fluconazole and cyclosporine. In our institute, we have chosen not to 
emperically decrease the dose of cyclosporine in case of coadministration with 
low-dose fluconazole (e.g. 100–200 mg/day), given the low inhibitory potency 
of this azole antifungal against CYP3A4.41 Instead, TDM is used to guide dose 
adaptations of cyclosporine.
 • Switch to a non-azole antifungal agent
In case the DDI is difficult to manage despite dose adaptations and TDM, either 
the immunosuppressant or the antifungal can be substituted. Alternatives to 
azoles are lipid formulations of amphotericin B or echinocandins. It is advisable to 
consult an ID specialist and/or a clinical microbiologist for the determination of 
the susceptibility of the offending pathogen in relation to the alternative agent.42 
Both these agents show little to no interference with CYP-enzymes and therefore 
do not significantly impact exposure of immunosuppressants.42, 43 Of note, one 
should be aware of a pharmacodynamic interaction between amphotericin B and 
calcineurin inhibitors as both classes of drugs have nephrotoxic properties.44
Alternative considerations not recommended
Some strategies suggested in the literature45 are not recommended for the 
management of DDIs between azoles and immunosuppressants. Spacing dosing 
times, that is introducing a time-gap between intake of the azole antifungal 
and the immunosuppressant, or increasing the dose interval of azoles are not 
recommended as the inhibitory effects of azoles are considered independent of 
dosing time. Decreasing the dose of the azole antifungal also is not recommended 
as the efficacy of azoles is strongly correlated with plasma concentrations.46 The 
strategy to change the route of administration of the immunosuppressant and 
azole from oral to intravenous to circumvent inhibitory effects of triazoles in the 
GI-tract on immunosuppressant metabolism is not patient friendly and difficult to 
implement in outpatient settings.33, 47 
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Conclusions and future directions
Because of the narrow therapeutic window of immunosuppressants, transplant 
patients are at high risk for DDIs when concomitantly treated with azole 
antifungals, compromising patient safety. Increased understanding of the 
pharmacological mechanism underlying the DDI is a critical step to reduce adverse 
outcomes. Although literature extensively describes the changes in exposure to 
immunosuppressants introduced by azoles, strategies for optimal management in 
clinical practice are currently lacking. Adequate management of these interactions 
is challenging and requires a systematic approach.
We distinguished different tools for the assessment of DDIs. In the optimal 
situation, healthcare professionals cooperate by a multidisciplinary approach 
and have access to all tools to safely assess DDIs. Our stepwise approach helps to 
predict, identify, quantify and classify DDIs as basis for the actual management 
of the DDI. We feel that the best management option for these DDIs is empirical 
dose reduction of the immunosuppressant upon the initiation of the azole, taking 
into account the magnitude of the interaction. Subsequent individualization of 
immunosuppressant doses by means of TDM is highly recommended. One should 
bear in mind that although the focus of this review is on DDIs between azoles and 
immunosuppressive agents, other interactions with these drugs in the transplant 
setting are common.
By using the provided tools, following the stepwise approach and management 
options, we provide the optimal strategy to manage the DDIs between azoles and 
immunosuppressants. This should ultimately promote patient safety, minimize 
complications and optimize treatment outcome. Future directions should focus 
on the implementation of the proposed strategies in clinical practice.
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Abstract
Azole antifungal agents are used for the prevention and treatment of invasive 
fungal infections. In clinical practice, these compounds are subject of intensive 
therapeutic drug monitoring (TDM) in order to individualize drug dosing and 
assure adequate exposure. Dried blood spot (DBS) sampling may be an attractive 
alternative to conventional venous sampling. We aimed to develop and clinically 
validate a DBS method for all azole antifungals currently used in clinical practice.
A joint DBS LC-MS/MS assay was developed for itraconazole, posaconazole, 
voriconazole, isavuconazole and fluconazole. DBS-specific parameters included 
the effects of hematocrit and spot volume and sample stability. Subsequently, a 
clinical validation study among children aged 2-18 years treated with itraconazole 
or posaconazole for prophylaxis of invasive fungal infections. The agreement 
between observed and DBS-predicted plasma concentrations was assessed using 
Passing-Bablok regression analysis, Bland-Altman plots and quantification of the 
predictive performance. Ideally, all ratios of predicted/observed concentrations 
are between 0.80-1.20 limits and the median (absolute) percentage prediction 
errors are <15%.
The analytical method complied with guidelines on bioanalytical method 
validation (EMA, FDA). Average accuracy varied between 93.6-102.3%. Within 
day precision varied between 3.6-14.9% coefficient of variation (CV) and between-
day precision varied between 0-5.2% CV. The method was accurate for clinically 
relevant hematocrit values and samples remained stable for over 3 months. A total 
of 20 itraconazole and 14 posaconazole paired DBS & plasma samples were available 
from 16 children. Conversion factors were used to predict venous concentrations 
from DBS concentrations. Bland-Altman analyses showed considerable variability 
between observed and predicted concentrations: for itraconazole 65% of all 
predicted/observed concentration ratios were between 0.80-1.20 while this was 
86% for posaconazole. MPPE was 4.8% for itraconazole and 0.6% for posaconazole 
and MAPE was 7% for itraconazole and 6.2% for posaconazole.
A DBS assay was successfully developed for 5 azole antifungal agents. 
Clinical validation in pediatric patients showed that posaconazole DBS could 
adequately predict plasma concentrations but itraconazole DBS was associated 
with considerable variability in predicted versus observed plasma concentrations. 
Increasing the sample size will clarify the exact agreement between DBS predicted 
and observed plasma concentrations.
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Introduction 
Therapeutic drug monitoring (TDM), i.e. measurement of drug concentrations 
and subsequent individualization of the dose, is an important tool to optimize 
therapy with some drug classes, including immunosuppressants, anti-epileptics 
and anti-infective agents.1 TDM is also indicated for azole antifungal agents.2-5 
Azoles require regular blood concentration monitoring because efficacy and 
toxicity of these drugs are related to their exposure in blood, which cannot be 
predicted from the administered dose due to high inter- and intrapatient variability 
in pharmacokinetics.6
Conventionally, the concentration of azoles is measured in plasma or serum 
obtained by venous blood sampling. Sampling is performed in a health care facility 
and requires the intervention of a health care professional. Especially for children, 
repeated sampling is associated with additional visits to the hospital causing 
anxiety and interferes with their daily activities like school attendance. Dried 
blood spot (DBS) sampling by means of a finger prick is an attractive alternative. 
This sampling technique was first introduced by Guthrie et al. (1963) for the ‘heel 
prick’ screening of phenylketonuria in newborns.7 Important advantages of DBS 
sampling include the possibility of home sampling, its minimally invasive nature, 
the need for only a minimal amount of blood (1-2 drops), the stability of samples 
upon transport and storage, the convenience to sample at desirable sampling 
times (e.g. trough concentrations), and the reduction in costs involved with the 
TDM process.8 DBS sampling is also used in large epidemiologic studies and in 
preclinical and clinical PK research.9-11 
There has been an important increase in the development of DBS assays for 
drugs used in different therapeutic fields.12-14 Despite this broad interest and 
the effort put in developing DBS assays, home based sampling for TDM is not 
implemented widely and does not have a place in current treatment guidelines yet. 
To increase the changes of successful implementation of DBS, a clinical validation 
in the target patient population is essential. In the clinical validation both a venous 
sample (gold standard) and a finger prick sample are taken simultaneously in 
patients from the target population. Agreement of the methods is then assessed 
by appropriate statistical methods. Ideally, the acceptance and feasibility of home 
based sampling is also evaluated in clinical practice.
The aim of this study was to develop an analytical DBS assay for 5 azole 
antifungal agents; itraconazole and posaconazole, agents used mainly for 
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prophylaxis of invasive fungal infections, whereas voriconazole and isavuconazole 
are primarily used for treatment purposes. Fluconazole is used for both prophylaxis 
and treatment. In addition, we have chosen to clinically validate a first subset of 
drugs used in the setting of prophylaxis (itraconazole and posaconazole), thereby 
assessing the patients’ acceptability of DBS sampling in an outpatient setting.
Methods
Experimental
Chemicals and materials
Methanol absolute ULC/MS was bought from Biosolve (Valkenswaard, The 
Netherlands), Merck acetonitrile hypergrade for LC-MS was purchased at VWR 
(Amsterdam, The Netherlands) and formic acid eluent additive for LC-MS from 
Sigma Aldrich (Zwijndrecht, The Netherlands).
Itraconazole, posaconazole and fluconazole were purchased from Sigma-
Aldrich Chemie B.V (Zwijndrecht, The Netherlands) and voriconazole from 
USP (Rockville, USA). The labeled internals standards, 13C22H3-voriconazole, 
2H5-itraconazole, 2H5-posaconazole were purchased at Alsachim (Illkirch 
Graffenstaden, France) and 2H4-fluconazole at Toronto Research Chemicals Inc. 
(North York, Canada). Isavuconazole and 2H5-isavuconazole were kindly provided 
by Basilea Pharmaceutica (Basel, Switerland). Ultrapure water was generated by a 
purelab flex 4 system purchased from Veolia Water Technologies Netherlands b.v. 
(Ede, The Netherlands).
DBS sampling paper and equipment was purchased from dried blood spot 
laboratory (DBSL) consisting of Whatman 903® filter paper and BD Microtainer® 
lancets (pink or blue) for finger prick sampling.
Preparation of DBS calibration standards, QC solutions and IS solution
Two series of stock solutions of each azole, one for calibration samples and one for 
QC samples, were prepared in methanol (fluconazole, voriconazole, posaconazole 
and isavuconazole) or dimethyl sulfoxide (itraconazole) at a concentration of 1.0 
mg/ml, were dispensed in polypropylene tubes and kept at −40 °C. Stock solutions 
of IS were prepared at a concentration of 1.0 mg/L in methanol.
For the preparation of calibration standards and QC samples, fresh drug-free 
blood was collected from a healthy volunteer in lithium heparine BD Vacutainer® 
tubes. Hematocrit (Hct) was determined by centrifugal force. A capillary tube was 
45151 Lisa Martial.indd   124 16-05-17   20:09
DBS sampling of azole antifungal drugs in children
125
7
dipped into the blood tube, and after filling this capillary tube for about 75% with 
blood it was sealed at the dry end and transferred to the hematocrit centrifuge 
rotor. This centrifuge rotor was placed into the centrifuge (rotor radius 85mm, 
relative centrifugal force [RCF] 16000, centrifuge time 7 min). As the Hct of the 
patient population is expected to have a Hct around 0.30 [personal inventarisation 
of hospitalized patients], the Hct of the blood used for method validation was 
measured and corrected to obtain a Hct of 0.30 by mixing an adequate volume of 
plasma (prepared from the same drug-free blood) with the drug-free blood. 
Standard 1 (only for fluconazole [30 mg/L] and voriconazole [15 mg/L] and 
standard 2 (10 mg/L for all azoles) were prepared by directly spiking drug-free 
blood with stock solutions. Standard 2 was further diluted to create standards 3, 
4, 5 and 6 (5, 2.5, 1 and 0.5 mg/L respectively). Standard 6 was further diluted to 
create standard 7 (0.10 mg/L) and standard 8 (0.05 mg/L).
The QC samples QC ‘extra high’ (XH) of fluconazole [27.5 mg/L] and 
voriconazole [12.5 mg/L] and QC H (7.5 mg/L for all components) were prepared 
by spiking drug-free blood with stock solutions. QC H was diluted to create QC M 
(0.7 mg/L). QC L was created by further dilution of QC M (0.07 mg/L).
The internal standard (IS) stock solutions were diluted in extraction solvent 
(methanol: H20 70:30 (v/v) with 0.1% formic acid) to create [2H4]-fluconazole, 
[2H5]-posaconazole and [2H4]-isavuconazole concentrations of 40 µg/L, as well 
as a [13C2,2H3]-voriconazole concentration of 16 µg /L, and a [2H5]-itraconazole 
concentration of 80 µg/L and these IS solutions were stored at 4-8 ⁰C.
DBS sample preparation 
Immediately after preparation, 25 µL blood spots were applied on Whatman 903® 
sampling paper with a volumetric pipette yielding the calibration and QC paper 
samples. The blood spots were left to dry at least for 3 hours and were stored at 4-8 
⁰C in sealed plastic bags containing desiccant. 
A paper disk with a diameter of 7 mm was punched out of the dried blood spots 
in a 2 mL safe-lock tube (Eppendorf) and 250 µL of extraction solution (methanol: 
H20 70:30 (v/v) with 0.1% formic acid) was added. The sample was then vortexed 
on a multi tube vortex for 30 min at 1200 revolutions per minute (RPM) and 
centrifuged at 18620 RCF. Subsequently, an aliquot of 200 µL was transferred into 
a vial with glass insert and centrifuged again at 1910 RCF. 10 µL was injected into 
the LC–MS/MS system.
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LC-MS/MS instrumentation and conditions
All experiments were performed on an AB Sciex API 3000 triple quadrupole mass 
spectrometer (Concord, ON, Canada) with an Agilent 1100 series HPLC system 
(Agilent Technologies, Palo Alto, CA), equipped with a pump with separately 
operated pump heads A and B and cooled autosampler. 
During injection, the initial eluent composition was 90% H2O + 0.1% formic 
acid (pump A) and 10% acetonitrile + 0.1% formic acid (pump B), which was held 
at a flow rate of 0.250 mL/min. After injection, the initial conditions were held 
for 0.10 min and then the composition changed linearly to 10% A and 90% B in 
7.9 min. At 8.1 min the eluent composition was immediately set back to its initial 
composition and held until the 12th min. The total analysis time was 12 min. To 
avoid unnecessary contamination of the curtain plate, the first 2 minutes and last 
4 minutes were directed to the waste via the Valco 10-port valve. A Waters Xbridge 
C18 3.5 µm 2.1x50 mm column and its Phenominex Security guard AQ C18 2.00 
x 4.0 mm was continuously held at 40°C.
The AB Sciex API 3000 mass spectrometer was operated in TurboIonSpray-
positive ionization mode and performed scheduled multiple reaction monitoring 
(MRM). The MRM detection window was set at 90 seconds and the target scan 
time of 2 seconds. The TurboIon Spray voltage and temperature were set at 4000 
V and 450°C, respectively. The collision (6 psi), curtain (8 psi) and nebulizer 
(10 psi) gasses consisted of pure nitrogen. Precursor ions of all compounds were 
determined from spectra obtained during the infusion of a standard solution in 
methanol:water 70:30 (v/v) with 0.1% formic acid directly to the electrospray 
source inlet. The precursor ions were subjected to collision-induced dissociation 
to determine the product ions. The transitions of the precursor/product ions used 
for quantitation are presented in Table 1.
Concentrations were determined from the peak area ratios of analyte to IS. 
Calibration curves were calculated using linear least square regression analysis 
with 1/x2 weighting. Data were processed using Analyst Software (V1.4.2 Sciex).
DBS validation procedures
The DBS assay was validated according to the most recent versions of the 
guidelines on bioanalytical method validation.15-17 We are not aware of any DBS 
specific guidelines, yet consensus exist on a number of parameters important 
for validation. A review was written on the validation steps of DBS assays (e.g. 
hematocrit effect, spot size).14
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Table 1 Transitions of the precursor/product ions
Name Precursor m/z (Da) Product m/z (Da) Scheduled Rt (min)
ISA 438.3 224.1 7.2
2H5-ISA 442.2 219.0 7.2
ITR 705.5 392.1 7.2
2H5-ITR 710.4 397.3 7.2
FLU 307.2 220.1 3.2
2H4-FLU 311.2 242.0 3.2
POS 351.4 342.3 6.2
2H5-POS 354.2 344.8 6.2
VOR 350.4 281.3 5.2
13C2
2H3-VOR 355.4 284.0 5.2
ISA isavuconazole; ITR itraconazole; FLU fluconazole; POS posaconazole; VOR voriconazole
LLOQ, HLOQ, accuracy, precision 
The lower limit of quantification (LLOQ) was set at 0.05 mg/L for all components. 
Higher limits of quantifications (HLOQ) were measured at 10 mg/L for 
isavuconazole, itraconazole and posaconazole and at 15 mg/L for voriconazole 
and at 25 mg/L for fluconazole. These limits are well within the desired limits for 
purposes of TDM.
Five replicates of samples at the LLOQ, at the HLOQ, and three in-between 
concentrations of QC samples were analyzed during three different days to 
determine the accuracy and within-day and between-day precision of the method. 
To analyze these samples, eight calibration concentration levels were used in 
addition to the blank sample (processed matrix sample without analyte and 
without IS) and a ‘zero’ sample (processed matrix with IS). The eight calibrators 
were analyzed in duplicate in each validation run. Acceptance criteria for the 
LLOQ were accuracy and precision <20%; for all other concentrations, accuracy 
and precision had to be <15%. For each replicate measurement, the concentration 
obtained was divided by the nominal concentration. Accuracy was calculated by 
the mean ratio of measured versus nominal concentrations (n=15 for each drug), 
multiplied by 100.
Next one-way analysis of variance (ANOVA) was used to assess the within-
day and between-day precision at each of the five concentrations, using the run 
day as the classification variable. The error mean square or mean square within 
groups (ErrMS), the day mean square or mean square among groups (DayMS), 
and the grand mean (GM) of all 15 measurements across the three run days 
were obtained from the ANOVA. The estimate of the within-day and between-
day precision at every concentration were calculated as follows; Within – day 
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precision = ((ErrMS)^0.5 / GM) x 100% and Between day precision: ([DayMS – 
ErrMS)/n]^0.5/GM) x 100%, in which n is the number of replicate measurements 
within each day.
Selectivity, matrix effect, recovery and carry over
As to assess the interference of endogenous compounds, six blank matrices from 
different individuals who did not receive antifungal agents were used. Acceptance 
criteria were as following: peak area should be <20% of the LLOQ of the analyte 
and <5% of the IS peak area.
For all components, the matrix factor (MF) was calculated by the ratio of the 
peak area in the presence of matrix (measured by analyzing a DBS sample of 
blank blood spiked with analyte after extraction) to the peak area in the absence 
of matrix (pure solution of the analyte). The IS-normalized MF was calculated by 
dividing the MF of the analyte by the MF of the IS. The CV of the IS-normalized 
MF calculated from the 6 lots of plasma or blood should be <15%. 
Extraction recoveries of all components were calculated by the ratio of the 
peak area of the blank blood spiked with analyte before extraction to the peak area 
of the same DBS spiked with analyte after extraction. These determinations were 
performed in duplicate, both at a high, medium, and low concentration.
Carry-over effect was assessed for every compound by injecting a blank sample 
after injection of a HLOQ calibrator sample. This procedure was repeated 5 times. 
If the response was <20% of the LLOQ for compounds, and <5% of LLOQ for the 
IS, the carry-over effect was considered acceptable.
Influence of hematocrit
As Hct influences the viscosity of the blood it can possibly influence the results 
of the analyses. Therefore it is an important parameter in DBS validation. Plasma 
and blood cells were mixed to obtain blood with Hct values of 0.15, 0.20, 0.30, 
0.40 and 0.50. This blood was spiked with the compounds of interest at medium 
concentration (QCM). Spots were analyzed in quadruple. Hct effect was considered 
acceptable if the mean concentrations were between 85-115% as compared to the 
standardised hematocrit (0.30).
Blood spot volume
Spot volumes of 20, 25 (standardised), 40 and 60 µL were analyzed in quadruple 
at QCM concentration level in order to assess the influence of blood spot volume. 
45151 Lisa Martial.indd   128 16-05-17   20:09
DBS sampling of azole antifungal drugs in children
129
7
The effect of spot size was considered acceptable if the mean concentration per 
was between 85-115% as compared to the standardised spot size (25 µL).
Stability of DBS samples
The stability of DBS samples was assessed at room temperature and at 4 ⁰C at all 
QC concentrations in quadruple. Stability in the auto sampler was also assessed: 
extracted samples were stored for 96h in the auto sampler. In addition, stability at 
60 ⁰C was assessed in quadruple for the QCL, QCM and QCH levels.
Routine plasma assay
A validated routine UPLC-UV plasma assay was used as reference method in 
the clinical validation study for voriconazole, posaconazole, itraconazole and 
isavuconazole and an LC-MS/MS assay was used for fluconazole. Our UPLC-UV 
analytical assay has been previously published and externally validated.18, 19 Details 
of this assay and the validation parameters for each of the azoles are summarized 
in Supplementary File. 
Clinical validation
Patients
The newly developed DBS assay was tested in an observational multi-center clinical 
study involving pediatric patients receiving azole antifungal agents. The protocol 
was approved by the Ethical Review Board of Radboud university medical center 
(‘Commissie Mensgebonden onderzoek Regio Arnhem-Nijmegen’, dossier number 
2014-1282) and was conducted in the Radboudumc Amalia Children’s hospital 
in Nijmegen, the Department of Paediatric Infectious Diseases of the University 
Medical Center Utrecht and the Princess Maxima Center for Paediatric Oncology 
in Utrecht. Informed consent was obtained from all parents from the participants 
and additional assent was obtained from patients above 12 years of age. Patients 
between 2-18 years and treated with at least one of the compounds of interest were 
eligible to participate. They had to be admitted to the pediatric ward or visited their 
physician on an outpatient basis. Blood samples were only collected if a (central) 
venous catheter was in place or if blood was drawn for regular patient care. Patients 
were excluded if they or their parent(s) could not understand or speak the Dutch 
language. 
A total of 40 samples per drug was aimed for, in agreement with guidelines 
on cross validation of analytical methods.15 Based on consultation of a statistician 
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from the Department for Health Evidence of the Radboud University, a maximum 
of three samples per patient was decided for to ensure for enough variation across 
the whole concentration range. Admitted patients were sampled in a time span of 
6 hours covering both trough, peak and mid range concentrations. Patients treated 
on an outpatient basis were allowed to participate on three different occasions to 
obtain three samples.
Clinical validation procedures
Basic demographic information was collected from the medical records. To assess 
agreement between DBS sampling and venous sampling using the routine drug 
concentration assays, both a finger prick and a venous sample was obtained 
simultaneously. A maximum of 5 minutes delay between the venous sample and 
the finger prick was aimed for. Directly after the arrival of the blood tube and the 
DBS samples in the laboratory, a venous DBS (VDBS) was prepared by spotting 25 
µL onto filter paper. The drug concentration was determined batch wise in three 
matrices: plasma, capillary DBS and VDBS.
Questionnaire for patient acceptability
In addition, questionnaires were filled in by all participants (and parents of 
children) who agreed with at least one finger prick (see Supplementary File). 
The questionnaire was composed of 9 items for the children and 12 items for the 
parents, and participants were free to comment on the procedure of the finger 
prick. Patients were asked to complete this questionnaire together with their 
parent(s) or with the nurse if the parents were absent - after completing the first 
finger prick. Patients’ as well as parents’ attitudes towards and preferences for blood 
sampling were assessed. They evaluated the importance of four relevant attributes 
of blood sampling, i.e. location of blood draw, time investment, pain associated 
with blood draw and the performer of the blood draw. The pain experienced with 
the finger prick was assessed by means of a face scale (ranging from 0-6) based 
on a visual analogue scale, with 0 being no pain and 6 being the worst imaginable 
pain, validated for children.20
Assessment of agreement between methods
The agreement between predicted and observed plasma concentrations was 
assessed by means of regression analysis, Bland-Altman plots and the quantification 
of the predictive performance. Passing-Bablok regression assesses the presence of 
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a systemic bias (intercept ≠ 0) or a proportional error (slope ≠ 1). Bland-Altman 
plots show the variability in agreement over the concentration range. The x-axis 
usually represents the mean of the DBS and plasma concentration while the 
y-axis can represents either the ratio [DBS concentration:plasma concentration] 
or the absolute difference of the two. If necessary, a conversion factor was first 
calculated before Passing-Bablok regression analysis and deriving Bland-Altman. 
The conversion factor was the geometric mean plasma / DBS concentration ratio 
derived from the sample pairs. The performance of DBS concentrations to predict 
plasma concentrations was assessed by calculation of conversion factors based on 
datasets in which one out of the total amount of samples was omitted (jackknife 
method). The derived conversion factors were used to predict the plasma 
concentration of the remaining sample. The median percentage prediction error 
(MPPE) is given by the median [100% x (Predicted concentration – Observed 
concentration) / Observed concentration] while the median absolute percentage 
prediction error (MAPE) is given by [100% x |(Predicted concentration – 
Observed concentration)| / Observed concentration]. MPPE is a measure of bias 
and MAPE is a measure of precision.21, 22 Acceptance criteria can vary but often 
values of MMPE and MAPE <15% are applied.23
Results
Experimental
LLOQ, precision, accuracy and linearity
Results of accuracy, within-day and between-day precision are shown in Table 
2. All compounds complied with the specified limits. Average accuracy varied 
between 93.6-102.3%. Within day precision varied between 3.6-14.9% CV and 
between-day precision varied between 0-5.2% CV. 
The calibration curves were linear for all components over their corresponding 
concentration range. The correlation coefficients (r) of all 3 calibration curves 
during validation of azoles in DBS were all >0.9951.
Selectivity, matrix effect, recovery, carryover
The DBS method appeared to be highly selective, matrix effect was minimal and 
was well within the limits (Table 2). Average recoveries were 82, 74, 47, 45 and 
38% for fluconazole, voriconazole, posaconazole, isavuconazole and itraconazole 
respectively. Carry-over proved to be <20% of the LLOQ and <5% for the IS. 
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Hematocrit effect
The Hct effect was acceptable between 0.20 and 0.43 for all compounds (Table 3). 
Higher (>0.43) or lower (<0.20) Hct values were associated with a deviation of 
>15% from measurements performed at the standardized Hct for all components 
except for posaconazole and itraconazole (accurate between Hct of 0.15-0.54).
Blood spot volume
All recoveries were within 85-115% for spot sizes between 20 and 60 µL, except for 
posaconazole which could be assessed adequately up to spot sizes of 40 µL (Table 4). 
Table 2 Results of accuracy, precision and matrix effect
ISA ITR FLU POS VOR Requirements
Accuracy % (n=15)
LLOQ 102.3 101 98.6 99.8 98.9 80%≤ x ≤120%
QC Low 100.3 99.4 98.5 96.7 99.3 85%≤ x ≤115%
QC Medium 100 97.8 100.3 98.3 101.1 85%≤ x ≤115%
QC High 98 99.4 NA 97.5 NA 85%≤ x ≤115%
QC XH NA NA 95.8 NA 93.6 85%≤ x ≤115%
Within-day precision (n=5) (%CV)
LLOQ 7.4, 7.2, 5.1 7.5, 10.4, 3.5 7.7, 11.2, 5.8 7.3, 9.6, 7.7 2.1, 5.7, 2.5 ≤20%
QC Low 6.8, 10.6, 5.9 6.3, 5.1, 5.5 6.7, 5.1, 7.4 14.9, 6.9, 9.2 4.5, 7.8, 4.8 ≤15%
QC Medium 3.5, 3.8, 3.5 10.7, 6.6, 4.3 2.9, 3.8, 3.8 4.6, 6.8, 5.1 3.0, 3.6, 3.4 ≤15%
QC High 2.4, 4.0, 3.7 4.8, 5.6, 4.6 NA 7.9, 6.2, 5.7 NA ≤15%
QC XH NA NA 5.7, 4.2, 3.3 NA 4.5, 5.0, 2.5 ≤15%
Between-day precision* (n=15) (%CV)
QC LLOQ 7.0 8.7 8.1 8.8 5.7 ≤20%
QC Low 8.3 6.3 6.3 10.4 5.7 ≤15%
QC Medium 3.9 8.4 3.4 5.5 3.5 ≤15%
QC High 5.3 7.5 NA 7.7 NA ≤15%
QC XH NA NA 6.2 NA 4.3 ≤15%
Average matrix factor (%CV)
Low 1.11 (1.8%) 1.01 (1.7%) 1.01 (2.6%) 0.95 (0.4%) 0.99 (2.1%) %CV <15%
High 1.04 (1.7%) 1.02 (1.2%) 1.02 (0.8%) 0.94 (1.7%) 0.98 (1.5%) %CV <15%
ISA isavuconazole; ITR itraconazole; FLU fluconazole; POS posaconazole; VOR voriconazole; CV 
coefficient of variation; QC quality control. 
*Between-day precision at each concentration level was calculated as the CV based on all 15 
measurements over the 3 days. Others may refer to this precision as “overall precision.”
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Stability assessment of DBS
DBS of all investigated azoles resulted to be stable for over 3 months, both at RT 
(119 days) and at 4 ⁰C (154 days). Processed samples remained stable during 96h 
in the auto sampler. As to extreme temperatures, isavuconazole and fluconazole 
remained stable at 60 ⁰C for at least 48h. DBS of posaconazole remained stable at 
60 ⁰C for 24h except for QCH (accuracy 119 %) and DBS of itraconazole remained 
stable up to 48h at 60 ⁰C except for QCL (accuracy 117 %). DBS of voriconazole 
remained stable at 60 ⁰C for 48h for except for QCL (accuracy 77 %).
Table 3 Influence of Hct
Mean concentration compared to standardized 0.30 Hct (%)
Hct ISA ITR FLU POS VOR
0.15 78.4 85.0 84.4 88.0 83.6
0.20 91.4 94.2 95.8 96.1 93.7
0.30 (standardized) 100.0 100.0 100.0 100.0 100.0
0.43 104.3 104.7 105.9 107.3 107.8
0.54 138.8 117.2 124.4 115.2 128.9
Results based on n=4 per Hct level at quality control medium concentration. 
Hct hematocrit; ISA isavuconazole; ITR itraconazole; FLU fluconazole; POS posaconazole; VOR 
voriconazole 
Table 4 Influence of spot volume
Mean concentration compared to standardized 25 µL spot volume (%)
Spot volume (µL) ISA ITR FLU POS VOR
20 93.5% 91.7% 97.4% 93.8% 101.0%
25 (standardized) 100% 100% 100% 100% 100%
40 98.0% 100.1% 105.3% 110.1% 107.5%
60 103.3% 110.2% 112.1% 124.6% 115.0%
ISA isavuconazole; ITR itraconazole; FLU fluconazole; POS posaconazole; VOR voriconazole.
Results based on n=4 per spot size at quality control medium concentration.
Clinical validation
We present the results of itraconazole and posaconazole as drugs most frequently 
used in the outpatient setting. The clinical validation of voriconazole and fluconazole 
is still ongoing. Up to December 1st 2016, 21 children participated in the clinical 
validation study (10 for itraconazole, 3 for fluconazole, 6 for posaconazole and 2 
for voriconazole) yielding a total of 41 samples (20 itraconazole, 5 fluconazole, 
14 posaconazole and 2 voriconazole). Demographic information is shown in 
Table 5. Patients were aged between 2-17 years (median 11 yrs) and received azole 
antifungal agents mostly for prophylactic purposes (81%).
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Table 5 Demographic information
Parameter Value
Female, n (%) 8 (50%)
Age years, median (range) 11 (2-17)
Hct, median (range) 0.30 (0.16-0.38)
Indication of drug use
 Prophylaxis, n (%) 13 (81%)
 Treatment, n (%) 3 (19%)
Number of samples per patient 
 One, n (%) 6 (37.5%)
 Two, n (%) 2 (12.5%)
 Three, n (%) 8 (50%)
Number of samples per compound
 ITR, n 20
 POS, n 14
Hct hematocrit, ISA isavuconazole; ITR itraconazole; FLU fluconazole; POS posaconazole; VOR 
voriconazole
Agreement between capillary DBS and plasma concentrations
From the 20 samples collected of itraconazole, three of them were below the LLOQ 
resulting in 17 matched pairs. Agreement improved with the use of a conversion 
factor of the geometric mean of the venous/DBS concentration ratio (1.317). 
Using this conversion factor, Passing-Bablok regression indicated a non significant 
proportional bias of 11% and a significant systematic bias as the intercept was 
significantly different from ‘0’ (Figure 1). The mean difference between predicted 
and observed itraconazole plasma was -0.10 mg/L (Figure 2) and the median 
ratio of predicted:observed itraconazole plasma concentration was 1.03 (95% 
levels of agreement 0.58-1.48) (Figure 2). 65% of all ratios predicted:observed 
were between 0.80-1.20. MPPE was 4.8% and MAPE was 7% (measure of bias 
and precision, respectively, based on jackknife). This is well below the 15% set as 
acceptance criterion.
For posaconazole, all 14 matched samples resulted to be above LLOQ. Passing-
Bablok regression indicated no systematic bias or proportional error (Figure 3). 
Bland Altman plots are shown in Figure 4. The mean ratio of predicted:observed 
concentrations was 1.01 (95% level of agreement was 0.73-1.29). 86% of all 
ratios predicted:observed concentrations were between 0.80-1.20. MPPE was 
0.6% and MAPE was 6.2%, indicating adequate predictive performance of DBS 
concentrations.
In the Supplementary File, the results of the agreement between VDBS and 
plasma concentrations are presented.
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Figure 1 Passing-Bablok regression of itraconazole DBS.
Passing-Bablok regression (n=17) of observed vs. predicted itraconazole concentrations (by means 
of DBS), conversion factor 1.32. Slope is 0.89 (95% CI 0.45-1.03) and intercept is 0.11 (95% CI 0.010-0.47).
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Figure 2 Bland-Altman plots of itraconazole (n=17). 
The upper plot shows the mean of the predicted and observed itraconazole plasma concentration 
(x-axis) vs. the difference between the predicted and observed itraconazole plasma concentration 
(y-axis), conversion factor 1.32. The mean difference is -0.10 mg/L and 95% levels of agreement for 
this difference are -0.82 - 0.63 mg/L.
The lower plot shows the mean of the predicted and observed itraconazole plasma concentration 
(x-axis) vs. the ratio predicted:observed itraconazole plasma concentration (y-axis), conversion 
factor 1.32. The mean ratio is 1.03 and 95% levels of agreement are 0.59 – 1.47.
ULA upper limit of agreement; LLA lower limit of agreement
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Figure 3 Passing-Bablok regression of posaconazole
Passing-Bablok regression (n=14) of observed vs. predicted itraconazole concentrations (by means 
of DBS), conversion factor 1.25. Slope is 1.08 (95% CI 0.83 - 1.31) and intercept is -0.12 (95% CI -0.57 - 0.43).
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Figure 4 Bland-Altman plots of posaconazole (n=14).
The upper plot shows the mean of the predicted and observed posaconazole plasma concentration 
(x-axis) vs. the difference between the predicted and observed posaconazole plasma concentration 
(y-axis), conversion factor 1.25. The mean difference is 0.03 mg/L and 95% levels of agreement are 
-0.41-0.46 mg/L.
The lower plot shows the mean of the predicted and observed posaconazole plasma concentration 
(x-axis) vs. the ratio predicted:observed posaconazole plasma concentration (y-axis), conversion 
factor 1.25. The mean ratio is 1.01 and 95% levels of agreement are 0.73 – 1.29.
ULA upper limit of agreement; LLA lower limit of agreement
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Acceptance of DBS sampling
The majority of patients (63%) agreed to have more than one finger prick (Table 5). 
Fifteen children and sixteen parents completed the questionnaire. Some answers 
were left blank, as some children were too young for the attributes but old enough 
for the pain scale or participants did not have a preference for any of the scenarios. 
45% (5/11) of children rated the pain associated with blood drawing as ‘(very) 
important’ and 27% (3/11) of children scored this as ‘(very) unimportant’ - the rest 
rated pain as ‘averagely important’. In contrast to children, 88% (14/16) of parents 
rated pain as a ‘(very) important’. 80% (12/15) of children rated pain associated 
with the finger prick with a score of 2 or lower based on the face scale, with 0 
being no pain and 6 being the worst imaginable pain. Upon the question what 
was the worst aspect of the finger prick, 21% (3/14) of children rated ‘fear’, 14% 
(2/14) rated ‘pain’ and 64% (9/14) rated ‘other’. From this ‘other’ category they 
could freely comment what they least liked about the finger prick; 43% (6/14) of 
children commented to not dislike anything, 14% (2/14) disliked squeezing of the 
finger to obtain blood, and one child commented to least like both the fear and the 
blood involved. If children had to choose between finger prick and normal sample 
(either venous or port-a-cath sample), 77% (10/13) would choose for the finger 
prick and 23% (3/13) would chose for a normal blood sample. 92% of parents 
favoured the finger prick (12/13) and 80% of parents (12/15) would be willing to 
perform the finger prick. 43% (6/14) of parents trusted the DBS method ‘much’, 
57% (8/14) ‘averagely’ and no one scored ‘no trust’. Free comments on the possible 
advantages included saving of time (67%), the possibility to draw the sample at 
home (20%), easier method (27%) and less burden for the child (20%) or less pain 
(13%).
Discussion
We publish a complete assay of 5 azole antifungal agents including the novel and 
promising new agent isavuconazole. The strengths of the current work include 
the extensive analytical validation study which covered both general validation 
parameters and DBS specific items such as Hct effect and the effect of spot size.16, 17 
In addition, an elaborate stability assessment of DBS samples was performed. 
We assessed the agreement between plasma and DBS concentrations in pediatric 
patients receiving itraconazole or posaconazole, with robust statistical methods 
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which allow for quantification of the predictive performance. Patients’ and 
parents’ preferences were assessed by means of a questionnaire, which allows to 
better prepare future clinical implementation.
Two DBS assays for azole antifungal agents were published previously.24, 25 The 
first group published a LC-MS/MS assay of posaconazole.24 The main differences 
between their assay and our assay were the standards and QCs, which were prepared 
with blood with a Hct value of 41% and a standardized spot size of 15 µL. Our QCs 
have a standardised Hct value that lies closely to the median Hct of the target 
population, which may improve analytical performance [personal inventarisation 
of hospitalized patients]. The second group based their DBS assay on an LC-MS/
MS serum assay of voriconazole, fluconazole and posaconazole.25, 26 One of the 
differences with our assay was their internal standard, cyano-imipramine, while 
we used labelled isotopes, and their standardised spot volume was 50 µL while we 
used 25 µL.25 
The general validation parameters (not specific to DBS analysis) were validated 
according to the international guidelines on method validation.16, 17 In addition, 
we assessed two very important parameters for DBS which are not covered in 
the guidelines; Hct effect and spot size. Recovery was adequate with Hct values 
between 0.20 and 0.43 for all azoles and between 0.15 and 0.43 for posaconazole and 
itraconazole. For azole antifungal agents it is important to assess the influence of 
lower Hct values as the population median value may be lower due to chemotherapy 
induced cytopenia. Higher or lower Hct values may influence the analytical result. 
Among our 16 patients, only one patient had a Hct <0.20 (0.16). Similarly, spot size 
may be an influential item for accuracy and precision. It remains a challenge for 
patients to provide reproducible spots of uniform size. Based on our analysis of the 
influence of spot size, all azoles may be adequately measured with spot sizes between 
20-60 µL and posaconazole between 20-40 µL. As a consequence, the size of DBS of 
posaconazole should be verified with a mould to ensure only spots with a validated 
size are taken into consideration for analysis. Nevertheless, the exact volume of a 
spot will always remains unknown as it is influenced by the patient’s hematocrit. The 
stability of DBS samples was investigated extensively. Samples remained stable over 3 
months at RT and for up to 24-48h at 60 ⁰C. It is very important to assess also extreme 
temperatures as it is known that during summertime, temperatures of 20 ⁰C above 
outside temperatures can occur in mail boxes.27 Prior to implementing DBS home 
sampling, a thorough assessment of the influence of these extreme temperatures is 
mandatory as DBS samples are likely to be transported with regular post.
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Based on our preliminary clinical validation study, itraconazole was associated 
with considerable variability, which was only party caused by two outliers. These 
two paired samples came from one individual who was sampled twice on the 
same day. A week later, the same patient was sampled a third time and plasma 
and DBS concentrations were in good agreement. Re-analysis in the laboratory of 
the first two paired samples with the remaining plasma and blood spots resulted 
in similar analytical outcome. Passing-Bablok regression analysis without these 
two outliers showed a smaller systemic bias (6% instead of 11%, both statistically 
significant) and a smaller proportional bias (slope was 0.98 instead of 0.89, both 
non-significant). Bland-Altman analysis without these two outliers showed a ratio 
predicted:observed concentrations of 0.83-1.36 (instead of 0.59-1.47) and 73% of 
the ratios were within 0.80-1.20. Due to this high variability, the DBS assay of 
itraconazole is not yet suitable to use in clinical practice. Further clinical validation 
with a bigger sample size will clarify the true agreement between plasma and DBS 
of itraconazole. No clinical validation studies for itraconazole have been published 
so far.
Posaconazole plasma concentrations could be relatively well predicted from 
DBS. One other group assessed the agreement between plasma concentrations 
and DBS of posaconazole among adults.25 They concluded that the agreement 
was acceptable but predictive performance was not quantified and the variability 
between DBS and plasma concentrations was difficult to extract from the data. 
Our results point to more variability with the VDBS in predicting plasma 
concentration as compared to DBS, especially for itraconazole. This is surprising 
as VDBS spots of uniform size (25 µL) were all prepared in the laboratory using 
calibrated pipettes. Increasing the sample size will clarify whether this difference 
remains to exist or whether it is a consequence of the small sample size.
We are the first to report pediatric hemato-oncology patients’ and parents’ 
attitudes towards finger prick sampling. Although a number of DBS assays have 
been published for various agents12, 14, we are not aware of any group who assessed 
pediatric patients’ attitudes. DBS sampling is thought to be an excellent sampling 
method for children, as limited amounts of blood are required and because it is less 
invasive. Indeed, 77% of children would prefer a finger prick over regular sampling. 
Our results may be subject to some selection bias as only patients who agreed 
with participation were asked to fill in the questionnaire. As physicians sometimes 
did not want to inform patients on the study, due to their severe illness, it was 
impossible to quantify the proportion of patients who agreed with participation in 
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the clinical validation. Nevertheless, most patients (63%) who participated, agreed 
with more than 1 sample, which reflects the acceptance of the new method.
Despite all efforts, the current work is inevitably associated with limitations. 
First, the pharmacologically active metabolite of itraconazole, OH-itraconazole 
was not suitable for DBS measurement because it was difficult to ionize. Similar, 
the N-oxide metabolite of voriconazole was not included in the assay because it 
showed to be very instable on DBS filter paper [results not shown]. Second, no 
temperatures below zero were assessed for stability, although these temperatures 
may occur in mailboxes during winter time. This should be evaluated prior to 
implementation of home based sampling. Lastly, although we present a clinical 
validation study with promising results for posaconazole, our results should be 
considered preliminary. The clinical validation study of all components is still 
ongoing until a sample size of 40 is reached. The final outcomes will inform 
us whether implementation of DBS sampling into routine clinical care or for 
pharmacokinetic studies is possible.
Conclusion
The 5 azole antifungal agents currently used for the treatment and prevention of 
invasive fungal infections proved to be suitable for DBS measurement. Based on 
our preliminary clinical validation study, posaconazole plasma concentrations can 
be predicted from DBS finger prick samples but itraconazole is associated with 
more variability and requires further clinical validation or improvement of the 
assay. Patient acceptability of this approach is good among participants and most 
parents (80%) would agree to take a blood sample from their child using DBS as 
an alternative to a venous sample being drawn in the hospital.
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Supplementary File 1 
Details on the plasma assays for ITR, POS, VOR, ISA and FLU
An Acquity UPLC BEH Phenyl column was coupled to a Waters tuneable UV 
detector. The ITR LLOQ was determined at 0.052 mg/L, the range was 0.052-
10.4 mg/L, the accuracy varied between 96.0-101.5%, the within-day precision 
was 5.3-7.6% CV and the between-day precision was between 0-3.8% CV. The 
POS LLOQ was 0.053 mg/L, the range was 0.053-10.6 mg/L, accuracy was 95.5-
102.0% dependent on concentration, within-day precision varied between 2.2-
5.1% CV and between-day precision was 1.5-4.2% CV. The VOR LLOQ was 0.050 
mg/L, the range was 0.050-9.94 mg/L, accuracy was 96.8-103.2% dependent on 
concentration, intra-day precision varied between 0.9-3% CV, and between-day 
precision was 0-1.9% CV. The ISA LLOQ was 0.054 mg/L, the range was 0.054-10.7 
mg/L, the overall accuracy varied between 98.0-103.8%, the within-day precision 
varied between 1.9-3.4% CV and the between day precision was 0.7-2.4% CV. 
The routine plasma assay of FLU consisted of a validated LC-MS/MS assay using 
an X bridge C18 column (Waters) coupled to an API3000 AB SCIEX with turbo 
ionspray source (ESI). The LLOQ of FLU in plasma was 0.030 mg/L, the range 
was 0.030-30.2 mg/L, accuracy was 98.0-101.1% based on 5 concentration levels, 
within-day precision was 1.8-5.2 % CV and between-day precision was 0-1.5% CV. 
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Supplementary File 2 
Questionnaire – translated from Dutch
Questionnaire taken after the first finger prick sample
Name child: Date of birth child: _ _-_ _-_ _ _ _
Name parents/guardian: Date of questionnaire:__ / __ /_ _ _ _
Time finger pricks: _ _-_ _  / _ _-_ _  / _ _-_ _  /  _ _-_ _   Time of filling in questionnaire:  _ _- _ _
Name researcher: Initials researcher:
Ranking the features of blood sampling
The finger prick is a new method for blood collection for determining drug 
concentrations. We want to know what children and their parents/caregivers think 
is important about blood collection. In the future the finger prick method will be 
used for children who are discharged from the hospital, but are in need of regular 
blood monitoring. Parents can perform the finger prick together with the child and 
send the sample to the laboratory of the hospital by mail. The drug concentration 
is determined from the blood spot. The finger prick method replaces the tube of 
blood normally collected at the clinic. 
Five attributes related to blood sampling are mentioned below. We would like 
to know how important they are when choosing between blood sampling methods 
(finger prick or the regular tube of blood). The questions concern methods of 
blood sampling for children which are already discharged from the hospital. We 
would like to ask you to score these attributes by encircling your choice on the 
form below. 
  
Questions for the parent(s):
1. Location (at home or in the hospital)
 very important / important/ averagely important / unimportant / very unimportant
2.  Time investment (all the time together like travelling, waiting room, blood sampling)
 very important / important/ averagely important / unimportant / very unimportant
3. Pain related to the blood draw
 very important / important/ averagely important / unimportant / very unimportant
4. Performer (nurse, child or the parent)
 very important / important/ averagely important / unimportant / very unimportant
5.  Are there any other important attributes which influence your choice of the blood 
sampling method?
 If yes, which? 1 
 How important is this feature?
 very important / important/ averagely important / unimportant / very unimportant
 If yes, which? 2 
 How important is this feature?
  very important / important/ averagely important / unimportant / very unimportant
    Parent(s) and child filled in this first part together     
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Questions for the child*:
1. Location (at home or in the hospital)
 very important / important/ averagely important / unimportant / very unimportant
2. Time investment (all the time together like travelling, waiting room, blood sampling)
 very important / important/ averagely important / unimportant / very unimportant
3. Pain related to the blood draw
 very important / important/ averagely important / unimportant / very unimportant
4. Performer (nurse, child or the parent)
 very important / important/ averagely important / unimportant / very unimportant
5. Are there any other important attributes which influence your choice of the blood 
sampling method?
 If yes, which? 1  
 How important is this feature?
 very important / important/ averagely important / unimportant / very unimportant
 If yes, which? 2  
 How important is this feature?
  very important / important/ averagely important / unimportant / very unimportant
*Only for children who are old enough. In case parent(s) and child filled in the first part together, the 
child is not required to fill in this part. 
Questions for the child on the experience of the finger prick
1. How much did the finger prick hurt?
FACE scale: nr ..........
2.  Do you still suffer from pain from the 
finger prick at this moment?
Tick your answer:
 Yes, FACE scale: nr ……….
 No
3.  What did you find the most 
unpleasant about the finger prick?
Tick your answer:
 The fear for the prick
 The pain
 The blood involved with the prick
 Otherwise, namely:
.
4. Which do you prefer? Tick your answer:
 A normal prick
 A finger prick
Who filled in these questions? Tick your answer:
 Child
 Parent(s)
 Nurse
FACE pain scale
          1.                        2.                           3.                         4.                         5.                            6. 
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Questions for the parent(s)
1.  Wat did you find the most unpleasant about 
the finger prick for your child?
Tick your answer:
	The fear  for the prick
	The pain
	The blood involved with the prick
	Otherwise, namely
2. Which do you prefer for your child? Tick your answer:
	A normal prick
	A finger prick
3.  Would you be prepared to perform the finger 
prick yourself with your child, if required for 
patient care?
Tick your answer:
	Yes
	No
4.  Do you trust this new method of blood sampling?
Much confidence / average confidence / no confidence
5.  What could be the main beneftis of the finger 
prick method?
6.  What could be the main disadvantages of the 
finger prick method?
7.  Do you have any comments about the finger 
prick method?
If yes, write your comments below:
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Supplementary File 3
Agreement between venous DBS and plasma concentrations
The agreement between plasma and venous DBS (VDBS) of ITR improved by using 
a conversion factor of the geometric mean of the venous/VDBS concentration 
ratio (1.30). Passing-Bablok showed no significant systematic or proportional 
errors, Bland-Altman analysis indicated a mean ratio predicted:observed plasma 
concentration of 1.0 (95% levels of agreement 0.33-1.76). MPPE was 4.9% and 
MAPE was 18.6%. For POS, a conversion factor or 1.25 improved the agreement. 
Passing-Bablok regression indicated no significant systematic or proportional 
errors, Bland-Altman plots showed a mean ratio predicted:observed of 1.02 (95% 
level of agreement 0.65-1.38). 71% of all ratios lied between 0.80 and 1.20. MPPE 
was 7% and MAPE was 18%.
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Abstract
Tacrolimus and mycophenolic acid (MPA) are the backbone of immunosuppressive 
therapy after pediatric kidney transplantation. Dosing of these drugs is 
individualized by therapeutic drug monitoring (TDM). Dried blood spot (DBS) 
sampling may prove beneficial over conventional venous sampling. We aimed to 
develop and clinically validate a DBS method for tacrolimus and MPA in children.
A joint DBS LC-MS/MS assay for tacrolimus and MPA was developed. DBS-
specific items included the hematocrit-effect and influence of spot volume. 
Subsequently, a clinical validation study among children aged 2-18 years was 
performed to assess the agreement between observed and DBS-predicted venous 
concentrations. Agreement of the methods was assessed with Passing-Bablok 
regression, Bland-Altman plots and quantification of the predictive performance 
in terms of bias (median percentage prediction error; MPPE) and precision 
(median absolute percentage prediction error; MAPE), both should be <15%.
A total of 40 tacrolimus and 32 MPA samples were available from 28 children. 
Conversion factors were used to predict venous concentrations from DBS. For 
tacrolimus, 95% of the individual ratios of predicted and observed concentrations 
were within a range of 0.74-1.28, with 85% of these ratios between 0.80-1.20 
(Bland-Altman plots). 
For MPA, the 95% limits of agreement represented a broader range of 0.49-1.49 
and 72% of individual ratios were between the 0.80-1.20 limits. MPPE and MAPE 
were less than 15% for both drugs.
A DBS assay was developed for tacrolimus and MPA. Tacrolimus venous 
concentrations could be adequately predicted from DBS. DBS analysis of MPA 
appeared to be a semi-quantitative measurement at the most when compared to 
conventional plasma analysis, considering the high variability between observed 
and predicted concentrations. Next, home-based DBS sampling of tacrolimus for 
the purpose of TDM will be implemented into routine clinical care.
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Introduction
Tacrolimus and the two preparations of mycophenolic acid (Mycophenolate mofetil 
(MMF) and enteric coated mycophenolate sodium (EC-MPS)) are the most widely 
used drugs to prevent graft rejection after pediatric renal transplantation.1, 2 Efficacy 
and toxicity of these drugs are related to their exposure in blood, which cannot be 
predicted from the dose due to high inter-patient variability in pharmacokinetics.3, 
4 Therapeutic drug monitoring (TDM) is therefore an important part of lifelong 
immunosuppressive drug therapy.5-8 Conventionally, immunosuppressants are 
measured in blood obtained by venous sampling performed at a health-care 
facility. Especially for children, such conventional sampling is associated with 
patient burden, for instance they miss school and spend more time in the hospital. 
Dried blood spot (DBS) sampling by means of a finger prick is an attractive 
alternative to venous sampling. Important advantages of DBS sampling include 
the low amount of blood required, the possibility of home based sampling after 
which the sample is sent to the laboratory, easier sampling at desirable sampling 
times (e.g. trough concentrations) and the results being available to the physician 
prior to the next outpatient visit of the patient.9 This process of TDM with DBS 
sampling has recently been demonstrated to be cost-saving, certainly with lifelong 
concentration monitoring.10
There has been an increase in the development of DBS assays for the purpose 
of TDM for a wide range of drug therapies including immunosuppressants.11, 12 
Specific challenges remain, however, to be tackled before widespread use of DBS 
sampling and analysis. First, to increase the applicability of DBS sampling an 
adequate clinical validation of the analytical assay in the intended target patient 
population is mandatory. To this end both a venous sample (gold standard) and 
a capillary DBS sample are obtained simultaneously in a sufficiently large group 
of the intended population. Agreement of the analytical methods is assessed by 
appropriate statistical methods including regression analysis, Bland-Altman plots 
and assessment of predictive performance.13, 14 Second, the acceptability of DBS 
sampling needs to be evaluated to assess possible bottlenecks for implementation 
at an early stage. Only then can home based sampling for TDM be widely 
implemented and receive a place in TDM guidelines.
The goal of the current study was to analytically and clinically validate a DBS 
assay for tacrolimus and MPA in children post renal transplantation and assess 
the acceptability and attitude of the patient population towards this new sampling 
method
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Materials and Methods
The initial step consisted of setting up the analytical assay that could be used for 
clinical validation. Tacrolimus and MPA were measured in a joint assay building 
on the past experience with DBS of tacrolimus.15
Chemicals, materials and reagents
Chemicals, materials and reagents are described in the Supplementary File.
DBS sample preparation
Paper disks with a diameter of 7.5 mm were punched with an electromagnetic 
driven hole puncher, especially developed for blood spot analysis of drugs by 
P. Edelbroek (SEIN, Hoofddorp, The Netherlands) in cooperation with the 
department of Mechatronics Engineering, Leiden University Medical Centre, 
The Netherlands. Two hundred and fifty µL of extraction solution was added to 
the paper disk. The sample was then shaken on a mechanical shaker for 60 min. 
Subsequently, an aliquot of 50 µL was injected into the HPLC–MS/MS system for 
tacrolimus. For MPA, an aliquot of 20 µL was used.
HPLC-MS/MS analysis
A Waters 2795 Alliance HPLC system (Watford, UK) was used. Eluent A consisted 
of 2 mM ammonium acetate in Milli-Q water + 0.1% (v/v) formic acid, prepared 
by dissolving 0.31 g ammonium acetate in 2000 mL water and adding 2 mL formic 
acid. Eluent B consisted of 2 mM of ammonium acetate in methanol + 0.1% (v/v) 
formic acid, prepared by dissolving adding 0.31 g ammonium acetate in 2000 mL 
methanol and adding 2 mL formic acid. The bloodspot extract was injected on a 
Waters Oasis HLB cartridge column (2.1mm×20 mm, 25 µm, cat. no. 186000706). 
After flushing 0.5 min with eluent A:eluent B = 40:60 (v/v) at a flow rate of 3 
mL/min, the analytes were fore flushed to a Waters Atlantis dC18 column (3.0× 
100 mm, 5µm), with eluent A:eluent B= 3:97 (v/v) at a flow rate of 0.75 mL/
min. Four minutes later the flow rate was set to 1.5 mL/min. After 6 minutes, the 
column switching device was switched to the starting position (Waters Oasis HLB 
cartridge column) to equilibrate for the next injection 30 s later and analysed by 
on line solid phase extraction with eluent A:eluent B = 40:60 (v/v) at a flow rate of 
3 mL/min. The analytical column was maintained at 60 °C. The cycle time was 6.5 
min from injection to injection.
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A Quattro Micro tandem mass spectrometer was operated in the electrospray-
positive ionization mode and was directly coupled to the HPLC system. A solution 
of tacrolimus, MPA or ascomycin (1 mg/L) in mobile phase was infused into the 
ion source, and the cone voltage was optimized to maximize the intensity of the 
(M+NH4)+ precursor ions of tacrolimus and ascomycin (m/z 821.4 and 809.4, 
respectively) and the (M+H)+ precursor ion of MPA (m/z 321.0). The collision 
energy was then adjusted to optimize the signal for the most intense product ions 
of tacrolimus, MPA and ascomycin (m/z 768.3, 207.3 and 756.3 respectively). 
Typical tuning conditions were as follows: electrospray capillary voltage, 1.0 
kV; sample cone voltage, 24V; and collision energy, 19 eV. Source temperature 
was set at 120 °C and desolvation temperature was 350 °C. Desolvation gas flow 
(nitrogen) was 797 L/h. Collision gas was argon. Sample analysis was performed 
in the multiple reaction monitoring mode of the mass spectrometer with a dwell 
time of 0.2 ms per transition. Calibration curves were calculated with linear least 
square regression with 1/x weighing. Data were processed using Masslynx (V4.1). 
Per sample, two individual spots were analysed and the reported concentration 
was a mean of the two. 
DBS validation procedures
The DBS assay was validated according to the most recent versions of the 
guidelines on bioanalytical method validation.16, 17 We are not aware of any DBS 
specific guidelines, yet consensus exists on a number of parameters important for 
validation and a review on the validation steps of DBS assays is available.9 The 
current validation includes the influence of hematocrit, spot volume, matrix effect 
and stability on paper. 
Accuracy, precision, lower limits of quantitation (LLOQ)
The LLOQ was set at 2.5 µg/L and 0.5 mg/L for tacrolimus and MPA, respectively, 
and the upper limit of quantitation (ULOQ) was set at 50 µg/L for tacrolimus and 
at 40 mg/L for MPA. These limits are well within the desired limits for purposes 
of TDM.
Five replicates of samples at the LLOQ, at the ULOQ, and three in-between 
concentrations of QC samples were analysed during three different days to 
determine the accuracy and within-day and between-day precision of the method. 
To analyze these samples, 6 calibration concentration levels were used in addition 
to the blank sample (processed matrix sample without analyte and without IS) 
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and a ‘zero’ sample (processed matrix with IS). The 6 calibrators were analysed in 
duplicate in each validation run. Acceptance criteria for the LLOQ were: accuracy 
and precision (% coefficient of variation [CV]) less than 20%; for all other 
concentrations, accuracy and precision: less than 15%. 
For each replicate measurement, the concentration obtained was divided 
by the nominal concentration. Accuracy was calculated by the mean ratio of 
measured versus nominal concentrations (n=15) and multiplying this by 100. 
Within-day precision was calculated at each concentration level as the CV based 
on the 5 replicate measurements on a day. As replicate analyses were performed 
on 3 different days, 3 measures of within-day precision were obtained for each 
concentration level. Overall precision at each concentration level was calculated 
as the CV based on all 15 measurements over the 3 days.
Selectivity
As to assess the interference of endogenous compounds six blank whole blood 
matrices from different individuals who did not receive any of the investigated 
immunosuppressants were used to prepare DBS samples. Acceptance criteria were 
as following: response should be lower than 20% of the LLOQ for the analyte and 
5% of the IS. 
Matrix effect
The matrix effect was assessed at two concentration levels (QCL and QCH) by 
spiking 6 different blank matrices. The mean concentration should be within 85-
115% of the nominal value and CV of the calculated concentration of the drug of 
interest and of the IS should be <15%.
Carryover
Carryover effect was assessed for every compound by injecting a blank sample 
after injection of an ULOQ calibrator sample. This procedure was repeated 5 
times. If the response in the blank sample was less than 20% of the LLOQ for 
the compounds, and less than 5% of LLOQ for the IS, the carryover effect was 
considered acceptable.
Influence of hematocrit
Hematocrit is an important validation parameter for DBS assays as it influences the 
viscosity of the blood and thereby possibly influences the results of the analysis. In 
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order to assess this influence, plasma and blood cells were mixed to obtain blood 
with hematocrit values of 0.15, 0.20, 0.25, 0.30, 0.35, 0.40, 0.45 and 0.50. This blood 
was spiked with tacrolimus and MPA at the QC medium (QCM) concentration 
level and measured in quadruple. Acceptance criterion: the mean concentration 
should be between 85-115% as compared to the standardised hematocrit (0.30).
Influence of spotting volume
The influence of the spot volume was assessed by analyzing a range of blood 
spot volumes i.e., 20, 30, 40, and 60 µL spots at the QCM level in quadruple. If 
the mean concentration measurement was between 85-115% as compared to 
the standardized spot volume (30 µL), the effect of spot volume was considered 
acceptable.
Stability of DBS samples
Stability of DBS samples was assessed at different temperatures at two concentration 
levels. Short term stability (1 week) was assessed at -80 ⁰C, -20 ⁰C, 4 ⁰C, room 
temperature (RT) and 72 ⁰C. Long-term stability was assessed at RT and at 4 ⁰C. 
All samples were analysed in two-fold.
 
Assay for tacrolimus and MPA after venous sampling
All DBS concentrations were compared with the venous concentrations. Details 
on the assay of the venous concentration measurement are presented in the 
Supplementary File.
Clinical validation
Patients
DBS sampling by means of a finger prick was evaluated in a clinical study among 
pediatric patients post kidney transplantation. The protocol was approved by the 
Ethical Review Board of the Radboud university medical center (‘Commissie 
Mensgebonden onderzoek Regio Arnhem-Nijmegen’) under number 2014-1282 
and was conducted in the Radboudumc Amalia Children’s hospital in Nijmegen 
(ClinicalTrials.gov NCT02329808). Patients between 2-18 years and treated with 
at least one of the compounds of interest were eligible to participate. Informed 
consent was obtained from the parents of all participants and assent was provided 
by all children ≥ 12 years. They had to be admitted to the pediatric ward or visit 
their physician on an outpatient basis. Blood samples were only collected if a 
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(central) venous catheter was in place or if blood was drawn for regular patient 
care. Patients were excluded if they or their parent(s) could not understand or 
speak the Dutch language.
A total of 40 paired samples per drug was aimed for, in agreement with guidelines 
on cross validation of analytical methods (not DBS-specific).18 A maximum of 
three samples per patient was considered rational to ensure for enough variation 
across the whole concentration range. Admitted patients were sampled in a time 
span of 6 hours covering trough, peak and mid range concentrations. Outpatients 
visiting their physician were allowed to participate three times on three different 
occasions to obtain three random samples. Basic demographic information was 
collected from the medical records.
Sampling of patients and preparation of samples
To assess agreement between DBS sampling and venous sampling, both a finger 
prick and a venous sample were obtained with a maximum of 5 minutes delay 
between the venous sample and the finger prick. After warming of the hands (if the 
fingers felt cold, as judged by the nurse) the finger was punched and a maximum 
of four drops were spotted onto the filter paper, including the first drop. After 
drying for 15 minutes, samples were stored at RT in an envelope containing silica 
desiccant. All samples were transported at ambient temperature to the laboratory 
and then stored at 4 ⁰C until analysis.
Venous samples (~ 2 mL) were transported at room temperature to the 
laboratory. Subsequently, tacrolimus samples were stored at 4 ⁰C until analysis and 
MMF samples were centrifuged within maximally 12h at 1900 rpm for 5 minutes 
to obtain plasma and stored at -40 ⁰C until analysis.
Assessment of agreement of methods
Agreement of the predicted and observed venous concentrations was assessed 
by Passing-Bablok regression, Bland-Altman plots and quantification of the 
predictive performance. Bland-Altman plots described the association between 
the observed venous concentrations and the venous concentrations as predicted 
based on DBS analysis (both finger prick).13 The 95% Limits of Agreement (i.e. the 
range within ± 2 SD of the mean difference or ratio of the two techniques) contain 
95% of the data and this range should be sufficiently narrow. We calculated the 
percentage of samples inside the 0.80-1.20 interval for the ratio between predicted 
and observed venous concentrations. This was based on the fact that a 15-20% 
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difference in concentrations is often used as a clinically relevant difference in 
bio-analysis and pharmacokinetic data-analysis. In case of discrepancies between 
DBS and venous concentrations, it was assessed whether the use of a conversion 
factor or taking into account the patients’ hematocrit (for MPA) with the formula 
{ DBS[drug] / (1 – hematocrit) = plasma[drug] } or { DBS[drug] / ((1 – hematocrit) + 
KBCplasma) = plasma[drug], with KBCplasma being the blood cell-to-plasma partitioning 
coefficient, could improve the agreement.19 Passing-Bablok and Bland-Altman 
analysis were then repeated with this correction factor. 
The predictive performance of DBS sampling was assessed by calculating 
the median percentage prediction error (MPPE) as given by {median [100% x 
(Predicted concentration – Observed concentration) / Observed concentration]} 
and the median absolute percentage prediction error (MAPE) given by {median 
[100% x |(Predicted concentration – Observed concentration)| / Observed 
concentration]}.14, 20 MPPE is a measure of bias while MAPE is a measure of 
precision. Acceptance criteria can vary but often values of MPPE and MAPE <15% 
are applied.21
Data were processed in Microsoft Excel™ and graphics were made with 
Rstatistics™ (using ggplot2, grid, gridExtra and mcr) and Microsoft Excel™.
Acceptability study
The acceptability of DBS sampling in this patient population was assessed by means 
of a questionnaire composed of 9 items for the children and 12 items for the parents, 
and participants were free to comment on the procedure of the finger prick (see 
Supplementary File). Children were asked to complete this questionnaire together 
with their parent(s) or with the nurse if the parents were absent - after completing 
the first finger prick. In this questionnaire, patients’ as well as parents’ attitudes 
towards and preferences for blood sampling were assessed. They evaluated the 
importance of four relevant attributes of blood sampling, i.e. location of blood 
draw, time investment, pain associated with blood draw and the performer of the 
blood draw. For instance, patients and parents had to rate the importance of the 
attribute ‘pain associated with blood sampling’, ranging from ‘very important’ to 
‘very unimportant’. The pain experienced with the finger prick was assessed by 
means of a face scale (ranging from 0-6) based on a visual analogue scale, with 0 
being no pain and 6 being the worst imaginable pain, validated for children.22 
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Table 1 Results of LLOQ, accuracy, precision and matrix effect
Tacrolimus MPA Requirements
Accuracy % (n=15)
LLOQ 86.2 92.5 80%≤ x ≤120%
QC Low 107.6 102.6 85%≤ x ≤115%
QC Medium 103.5 101.9 85%≤ x ≤115%
QC High 96.2 92.8 85%≤ x ≤115%
QC XH 98.2 92.2 85%≤ x ≤115%
Within-day precision (n=5) (%CV)
LLOQ 18.3 14.2 ≤20%
QC Low 6.2 12.8 ≤15%
QC Medium 6.6 10.5 ≤15%
QC High 12.8 14.3 ≤15%
QC XH 10.3 7.8 ≤15%
Between-day precision* (n=15) (%CV)
QC LLOQ 4.7 15.2 ≤20%
QC Low 8.3 9.5 ≤15%
QC Medium 0.9 2.7 ≤15%
QC High 2.2 5.1 ≤15%
QC XH 5.1 1.7 ≤15%
Average matrix factor 
Mean concentration (%) and (%CV)
Low 102.7 (4.3) 98.0 (7.2) 85-115% (%CV <15)
High 96.2 (10.1) 112.0 (9.7) %CV <15
*Between-day precision at each concentration level was calculated as the CV based on all 15 
measurements over the 3 days. Others may refer to this precision as “overall precision.”
CV coefficient of variation; QC quality control; LLOQ lower limit of quantitation; XH extra high; MPA 
mycophenolic acid
Results
Analytical validation of the DBS assay
Accuracy, precision, selectivity, matrix effect, carryover
The accuracy and precision of all QC samples including LLOQ are shown in Table 1. 
All values were within the specified limits. The correlation coefficients of all 3 
calibration curves during validation of tacrolimus and MPA in DBS were >0.95.
Matrix effect showed to be lower than 15% CV (Table 1).
For tacrolimus, two out of five blank samples showed carryover, and all blank 
MPA samples showed carryover. The amount of carryover of these compounds 
were all well below 20% of LLOQ. Carryover was observed in two out of five blank 
samples of the IS for tacrolimus, which were well below 5% of the LLOQ. For 
MPA, none of the blank showed carryover for the IS.
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Effect of hematocrit and spot size 
The influence of hematocrit was assessed over a wide range (Table 2). Acceptable 
accuracy (between 85-115% compared to the standardized hematocrit) was 
observed for tacrolimus and MPA within the 0.25-0.50 hematocrit range. For 
both tacrolimus and MPA, spot volumes between 20-60 µL resulted in measured 
concentrations within 85-115% of standardized 20 µL spot volume (Table 3).
Table 2 Influence of Hct
Mean concentration compared to standardized 0.30 Hct (%)
Hct Tacrolimus MPA
0.15 76 74
0.20 84 83
0.25 101 91
0.30 standardised 100 100
0.35 104 104
0.40 99 108
0.50 101 110
Results based on n=4 for every Hct level at quality control medium concentration.
Hct hematocrit; MPA mycophenolic acid
Table 3 Influence of spot volume
 Mean concentration compared to standardized 20 µL spot volume (%)
Spot volume (µL) Tacrolimus MPA
20 standardized 100 100
30 92 87
40 96 91
60 94 93
Results based on n=4 for every spot size at quality control medium concentration.
MPA mycophenolic acid
Stability
Table 4 shows the results of the stability assessments. At the higher concentration 
levels, short-term exposure to extreme temperatures, e.g. -80 to +72 ⁰C did not 
influence tacrolimus concentrations, but lower concentrations were more prone 
to instability. These results may have been influenced by the fact that the lower 
concentration approached the lower end of the analytical assay. MPA showed to be 
less stable upon storage at these temperatures (up to +75% at the low concentration 
and about +25% at the higher concentration, both compared to their nominal 
values, Table 4).
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Concerning long-term stability, tacrolimus and MPA proved to be stable for 
very long periods at RT and 4 ⁰C.
Table 4 Stability of dried blood spot samples upon storage 
Storing condition Mean concentration compared to nominal value (%)
Tacrolimus MPA
2.5 µg/L 40 µg/L 0.24 mg/L 32 mg/L
Short term (1 week)
-80 ⁰C 127 108 128 124
-20 ⁰C 132 113 173 112
4 ⁰C 125 102 120 108
RT 118 99 152 110
72 ⁰C 101 89 175 127
Long term (3 months)
4 ⁰C 109 87 111 93
RT 103 87 92 95
Long term (8 months)
4 ⁰C 89 83* 108 110
RT 86 74 128 104
All concentrations measured in two-fold. 
All stability tests have been performed with a previous method with lower limit of quantitation of 
tacrolimus 1.0 µg/L and LLOQ MPA 0.1 mg/L. 
* this concentration is stable for at least 6 months at 4 ⁰C.
RT Room temperature; MPA mycophenolic acid
Clinical validation
Fifty pediatric patients treated with tacrolimus and/or MPA were asked to 
participate, of which 30 (60%) gave informed consent. The main reason not to 
participate was because patients disliked finger pricks. Of the 30 patients signing 
informed consent, two (7%) withdrew just prior to the first sample due to anxiety 
for the finger prick. Of the remaining 28 patients, 22 were treated with tacrolimus of 
whom 13 also had MPA and 6 patients were treated with MPA without tacrolimus. 
Table 5 shows the baseline demographic information of the participants. 
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Table 5 Baseline demographic information
Parameter Value
Female, n/n (proportion) 13/28 (46%)
Age in year, median (range) 13.5 (3-17)
Race, n/n (proportion)
 Caucasian 20/28 (71%)
 Black 4/28 (14%)
 Hispanic 1/28 (4%)
 Other (Turkish) 3/28 (11%)
Weight in kg, median (range) 46 (13-93)
Height in cm, median (range) 151 (92-180)
Indication for drug use n (proportion)
 Prevention transplanted kidney rejection 27 (96%)
 Nephrotic syndrome 1 (4%)
Tacrolimus pre-sample dose in mg, median (range) 3 (0.5-8)
Tacrolimus pre-sample dose in mg/kg, median (range) 0.08 (0.01-0.3)
MPA pre-sample acid dose in mg, median (range) 500 (180-1000)
MPA pre-sample acid dose in mg/m2, median (range) 362 (125-621)
Hematocrit, median (range) 0.36 (0.26-0.43) 
Hemoglobin in mmol/L, median (range) 7.3 (5.3-9.1)
Creatinine in umol/L, median (range) 89 (29-321)
Urea in mmol/L, median (range) 7.9 (0.7-30.2)
Albumin in g/L, median (range) 38 (17-44)
eGFR*, mL/min/1.73m2 
 0-29 2/27 (7%)
 30-59 6/27 (22%)
 60-89 14/27 (52%)
 >90 5/27 (19%)
Physiological characteristics were gathered at the first day of participation
*As measured by Schwartz formula23, based on 27 patients.
MPA mycophenolic acid, eGFR estimated glomerular filtration rate
Agreement between methods for tacrolimus
A total of 22 patients treated with tacrolimus participated from whom a total of 
41 tacrolimus DBS samples were available. The concentration of one DBS sample 
was below the LLOQ (<2.5 µg/L) but not the venous concentration, resulting in 40 
evaluable pairs. A correction factor using the geometric mean of the venous/DBS 
concentration ratio of 0.763 resulted in better agreement between both methods. 
After application of this correction factor, Passing-Bablok regression analysis 
showed a significant proportional bias as the slope was different from zero, being 
1.1 (95% Confidence Interval [CI] 1.0 – 1.2) and no systematic bias (intercept 
-0.57 µg/L (95% CI -1.1 – 0.12) (Figure 1). Bland-Altman plots showed acceptable 
variation in the ratio between DBS and venous sampling and no trend in variation 
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over the concentration range (Figure 2). The 95% limits of agreement of the ratio 
predicted/observed venous concentrations were minimally outside 0.80-1.20 with 
0.74-1.28, but 85% of all ratios of concentration pairs were within this 0.80-1.20 
limit. The bias and precision in the predictive performance for tacrolimus given by 
the MMPE and MAPE were 0.3% and 10.7%, both were well below 15%.
Figure 1 Passing-Bablok regression of observed tacrolimus concentrations vs. predicted venous 
concentrations (by means of dried blood spot [DBS]). Method 1 represents the observed venous 
concentration. The slope is 1.1 (95%CI 1.0-1.2) and the intercept -0.57 µg/L (95%CI -1.1-0.12). 
The highest observation does not significantly impact the regression plot (Pearson’s r= 0.98 without 
the observation) nor the regression formula (DBS = -0.48 + 1.1* Method 1).
In the ideal situation, the concentrations obtained with both analyses are identical resulting in 
a slope (b) of 1 and an intercept (a) of 0 in the Passing-Bablok regression.24 The slope represents 
a proportional error at any concentration level; the intercept represents a systematic error. 95% 
confidence intervals (95%CI) were provided and showed whether the slope and intercept were 
significantly different from 1 and 0, respectively.
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Figure 2 Bland-Altman plots of tacrolimus (n=40). 
The upper plot shows the mean of the predicted and observed tacrolimus concentration (x-axis) vs 
the difference between predicted and observed tacrolimus concentration (y-axis). 
The lower plot shows the mean of predicted and observed tacrolimus concentration (x-axis) vs the 
ratio predicted/observed tacrolimus concentration (y-axis).
ULA upper limit of agreement; LLA lower limit of agreement
Agreement between methods for MPA
A total of 19 children treated with MPA participated, yielding 38 MPA spots. Of 
these 38 spots, four spots were below LLOQ (<0.5 mg/L) and from two other 
samples there was not enough plasma left to quantify the concentration with LC-
MS/MS, resulting in a total of 32 evaluable pairs of DBS and venous concentrations 
pairs. A conversion factor using the geometric mean of the plasma/DBS 
concentration ratio (1.30) resulted in better agreement between both methods. 
After the application of this correction factor, Passing-Bablok regression analysis 
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showed no proportional bias (slope 1.0, 95% CI 0.93-1.1) and no systemic bias 
(intercept was -0.20 mg/L, 95%CI -0.39 - 0.18) (Figure 3). Bland-Altman plots are 
shown in Figure 4. The mean ratio of predicted:observed plasma concentrations 
was 0.99, with 95% Limits of Agreement of 0.49-1.49 representing a wide interval 
which were well outside the 0.80-1.20 limits. Only 72% of all values were within 
0.80-1.20 limits. 
The predictive performance given by MMPE was -3.5% and by MAPE was 
12.8%, both were well below 15%.
Figure 3 Passing-Bablok regression of observed MPA plasma concentrations vs. predicted plasma 
concentrations (by means of dried blood spot [DBS]). Method 1 represents the observed plasma 
concentration. The slope is 1.0 (95% CI 0.93 - 1.1) and the intercept is -0.2 mg/L (95% CI -0.39- 0.18). The 
highest observation influences Pearson’s r importantly. Without this observation, Pearson’s r = 0.82 
and the regression formula stays similar with or without this observation.
MPA mycophenolic acid
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8Figure 4 Bland-Altman plots of MPA (n=32).
The upper plot shows the mean of the predicted and observed MPA plasma concentration (x-axis) 
vs the difference between the predicted and observed MPA plasma concentration (y-axis). 
The lower plot shows the mean of the predicted and observed MPA plasma concentration (x-axis) 
vs the ratio predicted/observed MPA plasma concentration (y-axis).
MPA mycophenolic acid; ULA upper limit of agreement; LLA lower limit of agreement 
Acceptability
Questionnaires were filled in by all participants (and parents of children) who 
agreed with at least one finger prick (N=28). The majority of patients agreed with 
more than 1 finger prick (71%). Not all questions were filled in by all patients, 
some patients were too small, or the finger prick was performed under sedation 
(for routine clinical care) or parents were absent. 45% (10/22) of children rated the 
pain associated with blood drawing as ‘very important’ or ‘important’ and another 
41% (9/22) of children scored this as ‘unimportant’. In contrast to children, 72% 
(18/25) of parents rated pain as a ‘very important’ or ‘important’ attribute and 
only 16% (4/25) of parents scored pain as ‘(very) unimportant’, and another 12% 
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(3/25) thought this was ‘averagely important’. 82% (23/28) of children scored pain 
associated with the finger prick with a score of 2 or lower based on a FACE scale, 
with 0 being no pain and 6 being the worst imaginable pain. Upon the question 
what was the worst aspect of the finger prick, 35% (9/26) of children rated ‘nothing’, 
23% (6/26) rated ‘fear’ and 19% (5/26) rated ‘pain’. Free comments of the children 
on the procedure of the finger prick included that the sampling time took long, 
they disliked the sharp needle and one patient was scared of the sound of the 
click of the automated lancet. If children had to choose between finger prick and 
normal prick (usually venous sample by vena puncture), 50% would choose for 
the finger prick, 42% would chose for a normal blood sample and 8% did not have 
preference. 62% of parents favoured the finger prick and 38% favoured normal 
venous blood drawing. 92% of parents (23/25) would be willing to perform the 
finger prick themselves if required for routine clinical care. 72% (13/18) of parents 
trusted the DBS method ‘much’, 28% (5/13) ‘averagely’ and no one scored ‘no trust’.
Discussion
To our knowledge, this is the first report of an analytical assay with a clinical 
validation study of a DBS sampling method for tacrolimus and MPA acid in 
pediatric patients. Herein, we assessed the acceptability of this sampling method 
within the target population. For tacrolimus, 95% of the individual ratios of 
predicted and observed concentrations were within a range of 0.74-1.28, with 85% 
of these ratios between 0.80-1.20, and there was adequate predictive performance, 
indicating the sampling methods are interchangeable. For MPA, the 95% limits 
of agreement were 0.49-1.49 and only 72% of individual ratios were between 
the 0.80-1.20 limits, despite use of a conversion factor. MMPE and MAPE were 
adequate for MPA, but these are median values that do not capture variability 
between individual pairs of data. Clearly this indicates that DBS analysis of MPA 
is a semi-quantitative measurement at the most when compared to conventional 
plasma analysis. 
Our DBS assay was based on a previously developed tacrolimus assay, with as 
main difference the somewhat higher LLOQ’s and the standardized hematocrit 
of 0.30.15, 25 All validation parameters complied with international guidelines on 
method validation.16, 17 
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The development of a DBS assay can be challenging mainly because of the 
unknown volume that is handled. Therefore, assessment of the influence of 
hematocrit and spot size is necessary during analytical validation. For tacrolimus 
as well as MPA results of the assay were acceptable for hematocrit values between 
0.25-0.50. As to spot size, we observed that patient’s finger prick samples were 
much smaller than anticipated, and decided to validate our method based on 20 
µL QC and standards instead of our previously developed assay based on 30 µL. 
20 µL QC and standards better matched the patient’s samples. We observed that 
different conversion factors were required for tacrolimus, dependent on the spot 
size of the standards and QC’s.
Although some other groups have investigated the influence of relatively 
extreme temperatures on DBS sample stability15, 26, 27 we present the most extensive 
assessment over longer time periods. Thorough assessment of the influence of 
these temperatures is mandatory before home based sampling can be implemented 
as DBS samples are likely to be transported with regular post. In summertime 
temperatures of 20 ⁰C above outside temperature can occur in mail boxes.28 Our 
results confirm that exposure to these extreme temperatures up to one week are 
not associated with stability issues for higher concentrations of tacrolimus but 
MPA is more instable upon storage at high temperatures.
Various groups published an analytical validation of a DBS method of 
tacrolimus.26, 27, 29-36 Five groups published a clinical validation study among adult 
patients, consisting of 18-65 paired capillary and venous samples.15, 25, 31, 37, 38 Two 
other groups assessed the relationship between venous concentrations and DBS 
prepared from the tube of blood in the laboratory32, 34, which can be considered 
as a ‘proof of concept’. In contrast to our methods, none of these groups used a 
conversion factor. The relative difference between venous and DBS concentration 
was below 15% in two papers15, 25 or not assessed in three others.31, 37, 38 None of 
the groups assessed the predictive performance. Two clinical validation studies 
among pediatric patients were published.39, 40 Webb et al. (2005) performed a 
clinical validation study among 36 pediatric patients yielding 172 paired samples.40 
Although a small mean difference between both methods was observed with 
DBS showing higher concentrations than venous samples, no relative differences 
were shown nor was the predictive performance quantified.40 Dickerson et al. 
(2015) performed a clinical validation of tacrolimus among pediatric patients 
(26 samples) and concluded that although DBS concentrations over-predicted 
the venous concentration, the difference between DBS and venous sampling 
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was within acceptable limits.39 However, the variability seemed considerable but 
was not quantified nor was the predictive performance.41 Consistent with these 
studies39, 40, we also observed higher concentrations with DBS sampling for which 
a conversion factor was introduced. This led to acceptable predictive performance. 
Due to the lack of quantification of predictive performance in other groups it is 
difficult to put our results into perspective. The large cohort of pediatric patients 
with tacrolimus studied by Webb et al. provides very promising results but we 
feel that the relative differences of both methods or the ratios and quantification 
of predictive performance should be assessed before drawing conclusions on the 
clinical applicability.40 Based on our results, we consider our DBS method suitable 
for TDM of tacrolimus.
Two DBS assays for the measurement of MPA have been published previously42, 43, 
and one clinical validation study among adults.44 Hematocrit showed to influence 
MPA concentration measurement in both assays42, 43 and this was accounted for in 
the prediction of plasma concentrations in the clinical validation study by Aripini 
et al. (2013).44 While our analytical analysis confirmed this hematocrit effect, using 
the actual hematocrit did not improve the prediction of the plasma concentration. 
Using the plasma/DBS concentration ratio improved the prediction of the plasma 
concentration and thereby the agreement between both methods, although the 
variability between predicted and observed MPA plasma concentrations remained 
important and is considered unacceptable for TDM. The variability was probably 
comparable to the previous study (among adults)44, although this group did 
not show relative differences or ratios. The observed variability may represent a 
sum of different sources of noise which may relate to the process of finger prick 
sampling, the hematocrit effect and/or spot size effects and the analytical method. 
In our hands, DBS sampling and analysis of MPA in children appeared to be semi-
quantitative at the most. 
Acceptability of DBS finger prick sampling was also assessed among patients 
and parents. Children tolerated the finger prick well and pain was considered 
acceptable. Half of the children would chose a finger prick over conventional 
sampling and most parents (92%) would be willing to perform a finger prick with 
their child when required for clinical care. As our questionnaire was filled in under 
controlled study circumstances after the sample was taken by instructed personnel 
in a hospital setting, extrapolation of the outcome to home settings may be subject 
of some uncertainty. Only patients who agreed to participate were asked to fill 
in the questionnaire, which may have led to selection bias. The current cohort 
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may be more positive about DBS sampling than the patients who did not agree 
to participate. From other DBS clinical validation studies it is unknown what 
proportion of patients agreed with participation. Webb et al. (2005)40 included 
36 patients of which 2 withdrew earlier than the 5th sampling occasion due to 
discomfort with sampling. Dickerson et al. (2015)39 included 34 patients of 
which only 10 wanted to participate more than once with a maximum of three 
times, while >70% of our cohort accepted to participate with more than one DBS 
sample. Once the DBS sampling method is validated, the chance of successful 
implementation into clinical practice will probably also be determined by the 
attitudes of physicians and policy makers and implementation will benefit from 
careful instruction and feedback to the patient.
The current work is inevitable associated with limitations. The first limitation 
concerns the absence of a formal sample size calculation. We have chosen to use 
an empirical sample size based on the CLSI guideline.18 Although a sample size of 
40 was aimed for, only 32 samples were available for assessment of the agreement 
between both MPA methods. Despite our sample size, we think our results do 
highlight our problems in replacing a conventional MPA plasma assay with DBS 
measurement. Some alternatives exist to overcome the hematocrit effect and 
unknown volume handled, that is inherent to classic DBS analysis, e.g. dried plasma 
spots45, 46, a device to spot fixed blood volumes47, hematocrit analysis within the 
spot.48-50  The second limitation relates to the fact no biochemical parameters were 
determined within the same assay. Ideally, not only the drug concentration but 
also a measure of kidney function, such as creatinine, is measured from the same 
DBS sample. Although several DBS assays of creatinine have been published31, 33, 
they require additional development as they are now associated with unacceptably 
high variability (± 15% against less than 2% with plasma assays). Another option 
to improve home-based sampling could be the use of point-of-care testing of 
creatinine. The capillary blood obtained from the finger prick may be used both 
for the DBS for the purpose of TDM and for the creatinine point-of-care meter. 
Especially in the early transplantation phase, combining a measure for kidney 
function with tacrolimus home based sampling may significantly improve patient 
care and reduce costs, as visits to the hospital may be avoided.10 A third limitation is 
related to the fact that only instructed personnel performed the finger prick, under 
study circumstances, while after implementation, patients will do this together 
with their child. This may introduce some pre-analytical sample variability which 
is not present under study circumstances.
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Conclusion
The current study describes the analytical and clinical validation of a combined 
DBS assay of tacrolimus and MPA for pediatric renal transplant patients and 
thoroughly assessed patient’s attitudes and perception. Based on our results, 
tacrolimus is suitable for DBS sampling for the purpose of TDM in children, 
whereas DBS sampling and analysis for MPA can only be considered semi-
quantitative. DBS sampling proved feasible and patient’s and parent’s attitudes 
were generally positive towards this novel sampling method. The next step is the 
implementation of tacrolimus DBS sampling in the home situation for the purpose 
of TDM and the assessment of the impact on patient care and pharmacokinetic 
target attainment.
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Supplementary File
Chemicals, materials and reagents
Tacrolimus and MPA were purchased from Sigma-Aldrich (St. Louis, USA). The 
internal standard (IS), ascomycin was obtained from LC Labs (Woburn, Massa-
chusetts, USA). Methanol and formic acid 99% (ULC/MS quality) were obtained 
from Biosolve (Valkenswaard, The Netherlands) and ethanol, acetonitrile, ammo-
nium acetate (Pro Analysi) and zinc sulphate heptahydrate (Pro Analysi) from 
Merck (Darmstadt, Germany). DBS sampling paper consisting of Whatman 903® 
filter paper and BD microtainer® automated lancets for finger prick sampling were 
purchased from Dried Blood Spot Laboratory (DBSL, Geleen, The Netherlands). 
CPD (citrate phosphate dextrose) donor blood for the venous routine tacrolimus 
assay was obtained from Sanquin blood bank (Nijmegen, The Netherlands). Fresh 
EDTA blood from volunteers was used for DBS calibration standard and quality 
control (QC) preparation. 
1. Stock and working solutions 
Stock solutions of tacrolimus (1000 mg/L) and ascomycin (1000 mg/L) were 
prepared in ethanol and were used to prepare working solutions (10 mg/L) in 
ethanol. MPA working solution (1000 mg/L) was directly prepared in ethanol. All 
solutions were stored at +4 °C and protected from light. All working solutions 
proved stable for at least 12 months.
2. Calibration standards and QC samples for DBS
Tacrolimus working solution (10 mg/L) was diluted with Mili-Q water to a 
concentration of 500 µg/L. This solution was added to fresh tacrolimus-free EDTA 
blood with a standardized hematocrit of 0.30 (obtained by mixing of plasma and 
blood cells) to obtain a 250 µg/L solution of tacrolimus in blood. After further dilution 
with fresh (tacrolimus free) EDTA blood, the following calibration standards were 
obtained: 2.5, 7.5, 15, 20, 30 and 50 µg/L. A blank standard was also included. 
MPA working solution (1000 mg/L) was diluted with water to 200 mg/L. Two 
solutions were subsequently prepared by adding fresh MPA-free EDTA blood to 
obtain 4 mg/L and 80 mg/L solutions. Those solutions were used to obtain 0.5, 2.5, 
10, 20, 30 and 40 mg/L calibration solutions.
QC samples were prepared in the same way as calibration standards but from a 
different batch of stock solution. QC concentrations of tacrolimus and MPA were 
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7.5, 25 and 40 µg/L and 1.5, 18 and 32 mg/L respectively. All calibration standards 
and QC samples were stored at 4 °C and proved to be stable for 8 months.
Twenty µL spots of each calibration standard or QC sample were applied onto 
sampling paper and kept overnight at room temperature to dry. They were kept in 
a sealed plastic bag and stored at 4 °C.
 
3.Extraction solution for blood spot analysis with IS
Sixty µL of IS working solution (10 mg/L) was diluted to 25.0 mL with methanol. 
This solution was further diluted (10 times) with methanol:acetonitrile 80:20 
(v/v) resulting in a final concentration of 2.4 µg/L in Methanol:acetonitril 82:18 
(extraction solution).
Assay for tacrolimus and MPA after venous sampling
The tacrolimus routine assay for venous concentration measurement is essentially 
the same as the DBS method with the exception of the sample preparation. The 
chromatography part of the routine tacrolimus venous assay was performed 
on a Surveyor Thermo Scientific (San Jose, California, USA) coupled to a TSQ 
Quantum (San Jose, California, USA). This assay for tacrolimus is linear from 1 
to 300 µg/L, the calibration line has a window from 1-30 µg/L, with intra-assay 
(within-day) precision of 8.2%, 6.1% and 5.7% at 3.3, 6.7 and 13.3 µg/L (n = 6), 
respectively. Inter-assay (between-day) precision was 4.5%, 7.3% and 6.1% at 3.3, 
6.7 and 13.3 µg/L (n = 6), respectively. The limit of quantification was 1.0 µg/L. 
The results of our quality control (7.49 µg/L) analyses were on average 97% of the 
nominal value with a CV of 5.8% (n = 137). Our laboratory also participates in an 
international tacrolimus proficiency testing scheme. Results of the last 21 months 
were satisfactory with accuracy of 97.9% on average (standard deviation 5.7%) (n 
= 63). 
MPA was quantified using a Thermo Scientific (Waltham, MA) TSQ Quantum 
Access Max LC-MS/MS system with an Ultimate 3000 UHPLC. The TSQ Quantum 
mass spectrometer was operated in positive electrospray ionization and selected 
reaction monitoring mode. The analytical column was a HyPurity C18 50 × 2.1 mm 
column with 3 µm particle size (Thermo Scientific). The autosampler temperature 
was set at 10°C, and the column temperature was kept at 60°C. Chromatographic 
separation was performed by means of a gradient with a flow rate of 600 µL/min 
and a total run time of 2.1 minutes. For the eluent a gradient was used which 
consisted of three mobile phases: water with 0.2 M ammonium formate buffer at 
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pH 3.5, water and methanol. The method was validated in accordance with FDA 
guidelines.17 The lower limit of quantification was 0.5 mg/L with a linear dynamic 
range of 0.5-9.0 mg/L. The inaccuracy and imprecision for the determination of 
mycophenolate concentrations showed a maximum bias <3 % and maximum 
CV <10 %.
Questionnaire – translated from Dutch
Questionnaire taken after the first finger prick sample
Name child: Date of birth child: _ _-_ _-_ _ _ _
Name parents/guardian: Date of questionnaire:__ / __ /_ _ _ _
Time finger pricks: _ _-_ _  / _ _-_ _  / _ _-_ _  /  _ _-_ _   Time of filling in questionnaire:  _ _- _ _
Name researcher: Initials researcher:
Ranking the features of blood sampling
The finger prick is a new method for blood collection for determining drug 
concentrations. We want to know what children and their parents/caregivers think 
is important about blood collection. In the future the finger prick method will be 
used for children who are discharged from the hospital, but are in need of regular 
blood monitoring. Parents can perform the finger prick together with the child and 
send the sample to the laboratory of the hospital by mail. The drug concentration 
is determined from the blood spot. The finger prick method replaces the tube of 
blood normally collected at the clinic. 
Five attributes related to blood sampling are mentioned below. We would like 
to know how important they are when choosing between blood sampling methods 
(finger prick or the regular tube of blood). The questions concern methods of 
blood sampling for children which are already discharged from the hospital. We 
would like to ask you to score these attributes by encircling your choice on the 
form below. 
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Questions for the parent(s):
1. Location (at home or in the hospital)
 very important / important/ averagely important / unimportant / very unimportant
2. Time investment (all the time together like travelling, waiting room, blood sampling)
 very important / important/ averagely important / unimportant / very unimportant
3. Pain related to the blood draw
 very important / important/ averagely important / unimportant / very unimportant
4. Performer (nurse, child or the parent)
 very important / important/ averagely important / unimportant / very unimportant
5.  Are there any other important attributes which influence your choice of the blood sampling 
method?
 If yes, which? 1 
 How important is this feature?
 very important / important/ averagely important / unimportant / very unimportant
 If yes, which? 2 
 How important is this feature?
 very important / important/ averagely important / unimportant / very unimportant
	Parent(s) and child filled in this first part together     
Questions for the child*:
1. Location (at home or in the hospital)
 very important / important/ averagely important / unimportant / very unimportant
2. Time investment (all the time together like travelling, waiting room, blood sampling)
 very important / important/ averagely important / unimportant / very unimportant
3. Pain related to the blood draw
 very important / important/ averagely important / unimportant / very unimportant
4. Performer (nurse, child or the parent)
 very important / important/ averagely important / unimportant / very unimportant
5.  Are there any other important attributes which influence your choice of the blood sampling 
method?
 If yes, which? 1 
 How important is this feature?
 very important / important/ averagely important / unimportant / very unimportant
 If yes, which? 2 
 How important is this feature?
  very important / important/ averagely important / unimportant / very unimportant
*Only for children who are old enough. In case parent(s) and child filled in the first part together, the 
child is not required to fill in this part. 
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Questions for the child on the experience of the finger prick
1. How much did the finger prick hurt?
FACE scale: nr ..........
2. Do you still suffer from pain from the 
finger prick you at this moment?
Tick your answer:
 Yes, FACE scale: nr ……….
 No
3. What did you find the most unpleasant 
about the finger prick?
Tick your answer:
 The fear for the prick
 The pain
 The blood involved with the prick
 Otherwise, namely:
………………….………………………………………..
4. Which do you prefer? Tick your answer:
 A normal prick
 A finger prick
Who filled in these questions? Tick your answer:
 Child
 Parent(s)
 Nurse
FACE pain scale
 
       1.                    2.                      3.                      4.                     5.                    6. 
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Questions for the parent(s)
1. What did you find the most unpleasant 
about the finger prick for your child?
Tick your answer:
 The fear  for the prick
 The pain
 The blood involved with the prick
 Otherwise, namely
………………….………………………………………..
2. Which do you prefer for your child? Tick your answer:
 A normal prick
 A finger prick
3. Would you be prepared to perform the 
finger prick yourself with your child, if required 
for patient care?
Tick your answer:
 Yes
 No
4. Do you trust this new method of blood sampling?
Much confidence / average confidence / no confidence
5. What could be the main benefits of the 
finger prick method?
………………………………………………………………………
………………………………………………………………………
………………………………………………………………………
………………………………………………………………………
6. What could be the main disadvantages of 
the finger prick method?
………………………………………………………………………
………………………………………………………………………
………………………………………………………………………
………………………………………………………………………
7. Do you have any comments about the 
finger prick method?
If yes, write your comments below:
………………………………………………………………………
………………………………………………………………………
………………………………………………………………………
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Abstract
Dried blood spot sampling (DBS) for pharmacokinetic (PK) studies and Thera-
peutic Drug Monitoring has unique advantages over venous sampling, including 
decreased patient burden. We aimed to clinically validate a DBS method for first-
line anti-TB drugs in children, and directly implement DBS to assess PK param-
eters.
Children were treated according to the revised WHO dosing scheme for children. 
A 4-point PK curve was performed with DBS and conventional venous sampling. 
Passing-Bablok regression and Bland-Altman plots were used to assess agreement 
between DBS and plasma concentrations. The percentage of patients attaining 
(adult) population PK values for Cmax (R 8-12; H 3-6; Z 20-50 and E 2-6 mg/L) and 
AUC0-24h was calculated.
Fifteen patients completed PK sampling. Use of a conversion factor resulted in 
good predictive performance for rifampicin and pyrazinamide. Ethambutol DBS 
showed low precision. PK parameters (geometric means) were: isoniazid Cmax 
3.1 mg/L, AUC0-24h 12.7 mg*h/L ; rifampicin Cmax 5.5 mg/L, AUC0-24h 25 mg*h/L; 
pyrazinamide Cmax 40 mg/L, AUC0-24h 519 mg*h/L and ethambutol Cmax 2.3 mg/L, 
AUC0-24h 15 mg*h/L. Cmax target attainment was 62.5% for isoniazid, 25% for 
rifampicin, 100% for pyrazinamide and 75% for ethambutol.
We validated DBS for rifampicin and pyrazinamide in Paraguayan children 
and detected low target attainment of rifampicin.
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Introduction
With an annual incidence over nine million, tuberculosis (TB) is one of the lead-
ing public health problems worldwide. In children, the total estimated incidence 
of tuberculosis in 2015 was about 1 million.1 Different factors are known to af-
fect TB treatment outcome, including adherence to TB drugs, co-morbidity and 
drug resistance. In addition, variability in the pharmacokinetics (PK) of first line 
TB drugs is a major determinant of treatment outcome.2 From adult studies it is 
known that low plasma concentrations of TB drugs are related to treatment failure 
and to acquired TB drug resistance.3-8 Little data is available on the PK of first line 
TB drugs in children.9-12 The association between low plasma concentrations of 
anti-TB drugs and treatment response has not been determined in children so 
far. To reach the same drug concentrations as in adults, children require higher 
doses of TB drugs on a mg/kg base.13-16 Therefore, the World Health Organisation 
(WHO) increased the recommended dose of first line anti-TB drugs in children 
in 2010.17 Verhagen et al. (2012) underscribed this new dosing regimen based on 
the only PK study of anti-TB drugs among South American children so far.16 In 
addition to this revision, a new fixed-dose combination has been developed with 
a rifampicin:isoniazide ratio 3:2, suiting the new dosing regimen.18 Despite these 
efforts, recent studies suggest that even this revised dose is not sufficient to reach 
appropriate plasma concentrations of rifampicin and ethambutol in children.9-11 
Therapeutic drug monitoring (TDM) may be a helpful tool to further optimize 
and individualize TB treatment.5, 19-21 TDM can be defined as the measurement of 
plasma or blood concentrations to adapt dosages to achieve predefined targets that 
are associated with maximal efficacy while minimizing toxicity.22 Conventionally, 
TB drugs are measured in plasma or serum obtained by venous sampling. In high 
incidence countries, frequently with poor resource settings, TDM is very difficult 
to implement due to economical and logistic challenges. For instance, isoniazid 
and rifampicin are instable in plasma, for which they must be shipped and stored 
at low temperature until analysis, which is associated with high costs.23
Dried blood spot (DBS) sampling may offer an alternative over conventional 
sampling as it only requires a few drops of blood easily obtained with a finger 
prick. These drops are applied on filter paper and kept dry until analysis, and drug 
concentrations usually remain stable under these circumstances. DBS sampling 
may facilitate the implementation of TDM of anti-TB drugs, in limited resource 
countries and in remote areas.23, 24 The practical advantages of DBS sampling also 
hold for PK research.
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No paediatric PK studies have been performed examining DBS techniques to 
evaluate plasma concentrations of anti-TB drugs. Moreover, no studies used the 
recommended rifampicin:isoniazide dosing ratio of 3:2. Therefore, we aimed to 
validate a DBS sampling method of rifampicin, pyrazinamide and ethambutol and 
describe the PK of all first line anti-TB drugs using limited sampling in children.
Methods
Patients and setting
The study was carried out at the hospital ‘Instituto Nacional de Enfermedades 
Respiratorias y del Ambiente (INERAM)’ in Asunción, Paraguay. From June 
2015 to February 2016 both hospitalized and ambulatory patients were asked 
to participate in the study. Informed consent was obtained from all parents and 
from children aged 12 years and older. Treatment-naive children (1-15 years) 
with pulmonary or extra-pulmonary TB, who started treatment with a fixed dose 
combination of first-line anti-TB drugs, were eligible for inclusion. There were 
no exclusion criteria. A sample size of 10-20 patients was aimed for this study 
to obtain a minimal amount of 40 paired DBS and plasma samples.25 The study 
protocol was approved by the ethics committee of Laboratory Central De Salud 
Pública, Asunción (number: 58/180615).
Drug doses and study procedures
In the absence of a paediatric formulation in Paraguay, all patients were treated 
with the adult fixed dose combination tablets of rifampicin 150 mg, isoniazid 75 
mg, pyrazinamide 400 mg and ethambutol 275 mg (H75R150Z400E275) from Svizera 
Europe B.V. Those tablets are on the World Health Organization (WHO) list 
of prequalified Medicinal Products.26 The dosage scheme for these tablets was 
according to the Paraguayan national TB guideline that adopted the revised WHO 
dosing scheme for children: rifampicin 15 mg/kg (range 10-20), isoniazid 10 mg/
kg (range 10-15), pyrazinamide 35 mg/kg (range 20-40) and ethambutol 20 mg/
kg (range 15-25).17 
Basic demographics were collected and co-medication recorded. Baseline 
biochemical parameters were determined including hematocrit, serum creatinine 
and liver enzymes. On the PK sampling day biochemical parameters were repeated. 
PK sampling was performed just prior to observed TB drug intake (pre-dose 
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sample [t =0 h]) and at t=2, 4 and 8h post administration after reaching steady-
state conditions (7 - 10 days after start of treatment). Patients had to remain sober 
from 4 hours prior to the TB drug intake until the last sample at t=8 was taken. In 
practice, all patients refrained from food intake between midnight until four hours 
after observed drug intake of the fixed dose tablet(s). At each time point, both a 
venous sample and a DBS finger prick sample was taken, by a study doctor. The 
DBS sampling procedure was as described before.27 Venous blood samples (3.5 
mL EDTA) were centrifugated directly after sampling and afterwards the plasma 
was stored in a liquid nitrogen container until transport to the University Medical 
Center Groningen, The Netherlands. 
Sample analysis
Plasma samples were measured based on previously published assays.28, 29 DBS 
samples were measured using an assay validated for linearity, accuracy, precision, 
matrix effect, hematocrit effect, spot volume and stability upon storage. 
Assessment of agreement between DBS and conventional sampling
The assessment of agreement between the venous plasma concentrations and 
the predicted plasma concentrations from DBS sampling was assessed by means 
of regression analysis, Bland-Altman plots and quantification of the predictive 
performance (see also Supplementary File 1). 
Pharmacokinetic analysis
The following PK parameters were assessed: area under the concentration time 
curve (AUC) during the sampling interval (AUC0-8h), AUC during the dosing 
interval (AUC0-24h), apparent clearance (CL/F), apparent volume of distribution 
(Vd/F), maximal concentration (Cmax) and half-life (T1/2). In addition, the 
proportion of patients attaining adult population values for Cmax and AUC values 
were computed.19, 30 Detailed information is provided in Supplementary File 2. 
Pain score 
Pain was assessed after DBS finger prick sampling by a parent (and children if ≥ 12 
years) with a facial pain score based on Tse et al. (2013) 31 Photos taken during the 
DBS sampling procedure were scored afterwards by 3 independent observers and 
translated by them into a facial score.
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Results
Demographic information
From June 2015 to February 2016 a total of 15 parents and/or patients gave 
informed consent. From those patients, 15 patients completed the PK sampling 
day of whom 11 had samples evaluable for PK parameter determination (one 
patient had missing sampling times). Baseline demographic information is shown 
in Table 1. Thirty-six percent of the children was female; their median age was 1.5 
years (range 0.5 – 15 years) and median weight was 11 kg (range 6-53 kg); none of 
the patients had co-morbidities. 
Table 1 Baseline demographic information
Demographics Value 
Number of patients (n) 14*
Gender, % female 36
Median age in years (range) 1.5 (0.5-15)
Median body weight in kg (range) 10.6 (5.5-53)
Median length in cm(range) 74 (50-162)
Ethnicity; mixed/indigenous 5/9
Type of TB 
Pulmonary (n) (%) 12 (86%)
Extra pulmonary (n) (%) 2 (15%)#
HIV co-infection (n) (%) 0 (0%)
Dose information
Median rifampicin dose in mg/kg(range) 14 (8-27)
Median isoniazid dose in mg/kg (range) 7 (4-14)
Median pyrazinamide dose in mg/kg (range) 38 (22-72)
Median ethambutol dose in mg/kg (range) 26 (15-49)
Biochemical parameters
Creatinine (mg/dL) median (range) 0.45 (0.10-0.80) (n=8)
Liver enzymes
 ALT (U/L) 19 (12-79) (n=8)
 AST (U/L) 21 (10-110) (n=10)
 AF (U/L) 311 (94-905) (n=8)
 GGT (U/L) 12 (7-102) (n=5)
Hemoglobin (g/dL) 10.7 (6.2-12.7) (n=13)
Hematocrit (%) 34 (19-39) (n=12)
*Demographic information was lost from one patient. #Information missing from one subject. 
TB tuberculosis, HIV human immunodeficiency virus; ALT alanine aminotransferase; AST aspartate 
aminotransferase; AF alkaline phosphatase; GGT Gamma-glutamyl transferase
Assessment of agreement between methods
A total of 60 DBS samples and 50 plasma samples were available, of whom 47 samples 
matched in time. From those 47 matched pairs, 33 rifampicin, 39 pyrazinamide 
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and 35 ethambutol pairs were above the limit of quantification. A conversion 
factor using the inverse geometric mean of the DBS:plasma concentration ratio 
resulted in better agreement between both methods. The ratio was 0.75 for 
rifampicin, 0.81 for pyrazinamide and 0.51 for ethambutol. After application of 
the conversion factor, Passing-Bablok regression analysis showed no significant 
proportional or systematic bias for each of the compounds (Figures 1 and 2 
and supplementary Figure S1), as the slope was not significantly different from 
‘1’ indicating no proportional error and the intercept not significantly different 
from ‘0’ indicating no systematic bias. Bland-Altman plots showed that 95% of the 
ratios of the predicted:observed plasma concentrations lied between 0.6-1.4 for 
rifampicin, 0.5-1.6 for pyrazinamide and -0.4-2.8 for ethambutol (Figures 3 and 
4 and supplementary Figure S2). In addition, for rifampicin, pyrazinamide and 
ethambutol 76%, 77% and 20% of the samples lied between 0.80-1.20 of the ratio 
of predicted:observed respectively. No trend in variation over concentration range 
was observed from the Bland-Altman plots (Figures 3 and 4 and supplementary 
Figures S2-S5). Ethambutol had the lowest agreement between predicted and 
observed plasma concentration (Figures S2 and S5). The bias and precision in the 
predictive performance given by the MMPE and MAPE was 1.8% and 16% for 
rifampicin, 1.6% and 9.7% for pyrazinamide and -2.3% and 47% for ethambutol. 
Using the actual hematocrit levels did not improve this agreement. 
Figure 1 Passing-Bablok regression of rifampicin. Intercept 0.003871 (95% confidence interval 
-0.2606 – 0.1961) no significant systemic error; slope 0.9938 (95% confidence interval 0.9007 – 1.193) no 
significant proportional error. 
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Figure 2 Passing-Bablok regression of pyrazinamide. Intercept 1.193 (95% confidence interval -5.027 
– 0.5064) no significant systemic error; slope 1.057 (95% confidence interval 0.9773 – 1.186) no 
significant proportional error.
Figure 3 Bland-Altman plot of rifampicin. Ratio of the predicted and observed rifampicin plasma 
concentration plotted against the average of the predicted and observed plasma concentration. 
Level of agreement: 95% of pairs lied between 0.6-1.4 and 76% of pairs lied between 0.80-1.20. 
ULA upper limit of agreement; LLA lower limit of agreement
Pharmacokinetic parameters
The median treatment period on the PK sampling day was 18 days (range 11-
62). Given the good predictive performance for rifampicin and pyrazinamide, 
PK parameters were calculated by plasma concentrations as well as by DBS 
predicted plasma concentrations for these drugs. Table 2 and Table 3 display 
the PK parameters for each compound as assessed by the plasma concentration 
measurements and the PK parameters of rifampicin and pyrazinamide based on 
DBS predicted plasma concentrations, respectively.
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Figure 4 Bland-Altman plot of pyrazinamide. Ratio of the predicted and observed pyrazinamide 
plasma concentration plotted against the average of the predicted and observed plasma 
concentration. Level of agreement: 95% of pairs lied between 0.5-1.6 and 77% of pairs lied between 
0.80-1.20.
ULA upper limit of agreement; LLA lower limit of agreement
Attainment of reference exposure was especially low for rifampicin; this was 
25% for Cmax (≥8 mg/L) and 38% for AUC (30.8 mg*h/L). Sixty-three percent 
of patients reached isoniazid Cmax (3 mg/L) and 57% reached AUC target (11.4 
mg*h/L). All patients attained pyrazinamide Cmax (20 mg/L) and AUC (285 
mg*h/L). Ethambutol Cmax (2 mg/L) target was achieved in 75% of patients and 
AUC target (17.6 mg*h/L) was reached in 29% of patients.
Table 2 PK Parameters of all TB drugs as measured by plasma concentrations
Parameter Isoniazid 
 (n=8)
Rifampicin 
(n=8)
Pyrazinamide 
(n=8)
Ethambutol  
(n=8)
Cmax geom. mean (range) 3.1 (1.4-6.4) 5.1 (2.3-9.2) 42.5 (29.7-63.3) 2.3 (1.1-3.7) 
AUC0-8h geom. mean (range) 11.0 (4.9-23.1) * 19.7 (8.4-37.8) 214 (168-282) * 9.6 (5.9-14.0) *
AUC0-24h geom. mean (range) 12.7 (5.4-26.7) * 21.4 (8.9-50.0) 395 (310-509) ** 14.5 (7.4-23.3) *
CL (L/h/kg) geom. mean (range) 0.50 (0.19-1.32) * 0.6 (0.2-1.6) 0.10 (0.07-0.14) * 1.6 (1.0-2.5) *
Vd (L/kg) geom. mean (range) 1.7 (0.7-3.7) * 1.6 (0.9-3.9) 0.8 (0.6-1.2) * 12.6 (7.2-27.1) *
T1/2 (h) geom. mean (range) 2.3 (1.9-3.4) 1.8 (1.1-3.3) 6.0 (4.9-9.2) * 4.8 (2.2-8.6) 
*n=7; **n=4.
Cmax maximal concentration; AUC area under the concentration time curve; T1/2 half-life; CL clearance; 
Vd volume of distribution
Pain score and feasibility
Median pain scores as indicated/evaluated by the independent observers with the 
facial pain score was 5 (range 2-6) (n=13). One patient was sedated and for this 
patient no pain score was assessed. In 3 patients, two finger pricks were required 
for a single time point to obtain sufficient blood for the DBS sample.
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Table 3 PK parameters derived from predicted plasma concentrations as measured by DBS
Parameter Rifampicin (n=11) Pyrazinamide (n=11)
Cmax geom. mean (range) 5.5 (1.9-13.4) 40.1 (23.6-70.6) 
AUC0-8h geom. mean (range) 24.2 (9.2-53.6) 218 (133-444) ** 
AUC0-tau geom. mean (range) 24.6 (9.7-57.6) * 519 (329-874) ***
CL (L/h/kg) geom. mean (range) 0.53 (0.25-1.5) 0.1 (0.05-0.31) **
Vd (L/kg) geom. mean (range) 1.3 (0.65-2.9) 0.8 (0.5-1.8) **
T1/2 (h) geom. mean (range) 1.7 (0.8-4.6) 5.8 (3.9-12.4) *
*n=10 ; **n=9; ***n=4.
Cmax maximal concentration; AUC area under the concentration time curve; T1/2 half-life; CL clearance; 
Vd volume of distribution
Discussion
To our knowledge, this is the first clinical validation study of a DBS sampling 
method for three first-line anti-TB drugs in children, i.e. rifampicin, pyrazinamide 
and ethambutol. The concentration measured by means of DBS sampling could 
accurately predict rifampicin and pyrazinamide plasma concentrations and this 
innovative sampling method was successfully applied to assess individual PK 
parameters among Paraguayan children. 
Various DBS assays of anti-TB drugs in adults have been described in 
literature, one for rifampicin and clarithromycin and their metabolites27, some for 
linezolid32-34, a multiplex assay of second-line anti-TB drugs35, and another one for 
moxifloxacin.36 The current assay was based on the published DBS rifampicin and 
clarithromycin assay.27
Our study assessed the agreement between the concentrations measured 
with DBS and their corresponding plasma concentration in a group of paediatric 
TB patients. When taking into account drug-specific conversion factors, DBS 
concentrations could adequately predict the rifampicin and pyrazinamide plasma 
concentrations, with bias and precision of less than 16%. Despite the observed 
hematocrit effect for rifampicin during method development27, correction for 
hematocrit did not further improve the agreement or the predictive performance 
in our study. The median hematocrit in our cohort was equal to the standardized 
hematocrit of 0.35 in the analytical method development procedures. Rifampicin 
and pyrazinamide DBS samples were successfully used to assess PK parameters 
in the current cohort. Ethambutol appeared be unsuitable for DBS concentration 
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measurement. Although bias was well below 15%, the precision was unacceptably 
high (47%), due to important variability around the DBS:plasma pairs of the 
inverse geometric mean ratio of 0.51. The agreement could not be improved 
with the patient’s hematocrit. This low ratio of ethambutol DBS:plasma pairs 
lies below the lower limit of 0.55 given by Emmons and Rowland, (2010).37 Low 
ratios suggests relatively little affinity of ethambutol to enter erythrocytes. Based 
on Emmons’ theory, blood:plasma ratios between 0.55 and <2.0 suggest high 
influence of fluctuations of unbound ethambutol fractions. This low affinity is 
contradictory to what is known from literature. According to the Summary of 
Product Characteristics (SPC), ethambutol erythrocyte concentrations were 2 
times higher than in plasma.38 Moreover, plasma protein binding is 10-40% for 
which fluctuations in protein concentrations will probably not result in important 
changes in unbound fraction. It remains unclear why the ethambutol DBS:plasma 
ratio was so low in the current study and what might have led to the variability in 
agreement between both sampling methods.
The feasibility of finger prick sampling for DBS measurement was assessed 
after the first finger prick in every patient by means of the visual analogue scale31; 
median pain score was 5 out of a maximum of 6. This was relatively high compared 
to our experience with finger prick sampling in a clinical validation study in the 
Netherlands. Pain scores from 47 paediatric nephrology and hemato-oncology 
patients treated with immunosuppressants and azole antifungal drugs (median 
age 13 years) who underwent a finger prick gave a median score of 1 (range 0-6) 
(Martial et al., unpublished data). Cultural differences in pain perception may 
have played a role. Moreover, the majority of the population in the current study 
was very young (median 1.5 years). Our participants may have been traumatized 
by the insertion of a venous catheter for venous blood sampling which may have 
influenced the outcomes hereafter. 
From a few small studies it is known that children require higher mg/kg 
body weight doses of TB drugs to attain Cmax and AUC targets.13-15 Based on this 
observation, and the knowledge that low plasma concentrations are associated 
with worse outcome in adults, the WHO recently recommended a new dosing 
regimen for children, with a 3:2 ratio of rifampicin:isoniazid instead of 2:1.39 Three 
groups assessed the PK of anti-TB drugs in which the new higher rifampicin dose 
was used.9-11 Their results suggested that even higher rifampicin doses are required 
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in order to reach the adult-based targets. Our results confirm this as only 25% and 
29% of children reached rifampicin Cmax and AUC respectively. No data exist on 
the relative higher recommended isoniazid dose. 
We used adult fixed-dose combinations with rifampicin:isoniazid 2:1 ratios, and 
the number of tablets were adjusted to reach the recommended rifampicin dose 
per kg bodyweight, as only this formulation is available in Paraguay. The median 
rifampicin dose was 14 mg/kg body weight (WHO recommended 15 mg/kg [range 
10-20 mg/kg]) while the median isoniazid dose was 7 mg/kg (recommended 10 
mg/kg [range 10-15 mg/kg]). Our cohort did not fully reach target doses and 
concentrations of both drugs. The currently available adult formulation fixed-
dose tablets in Paraguay do not facilitate adapting to the recommended dosing 
regimens. 
Despite the worldwide availability of paediatric fixed-dose combinations, in 
Paraguay adult fixed-dose combinations were used for children. For now, the new 
paediatric fixed-dose formulation, which are water soluble, kid-friendly tablets 
with rifampicin 75 mg, isoniazid 50 mg and pyrazinamide 150 mg are only available 
in Kenya.40 Factors such as procurability, licence and costs/reimbursement policy 
may hamper the introduction of the new formulation. Based on the current 
knowledge on the importance of rifampicin and pyrazinamide on TB treatment 
outcome results in adults, we recommend investigating higher dosages of these 
two drugs in children with the final aim to shorten treatment duration. The use 
of the new paediatric formulations will facilitate optimal dosing and drug-intake 
enormously.
This study has a few limitations. The first relates to the adult fixed-dose 
combination tablets that were used instead of the new formulation with the 3:2 
ratio of rifampicin:isoniazid. Although it would have been very valuable to evaluate 
the new formulation, this did not impact the first aim of the study: assessment of 
the agreement between DBS and plasma concentrations. The second relates to the 
relatively small sample size available for clinical validation of DBS sampling, as a 
total of 40 pairs was aimed for the assess agreements between sampling methods.25 
However, we feel that the available sample size is sufficient to draw conclusions on 
agreement. Third, the PK was described in a relatively limited group of patients 
(n=8-11). Also this limitation did not impact the main aim of the study. 
In summary, we clinically validated a DBS method for rifampicin and 
pyrazinamide and successfully assessed PK characteristics with this method in 
a group Paraguayan children. In future paediatric research with high dosages of 
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rifampicin and pyrazinamide it will be feasible to include PK, or even apply TDM 
on an individual basis, in order to optimize treatment. 
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Supplementary File
Statistical analysis of agreement between methods
Passing-Bablok regression between observed and predicted concentrations 
assessed the presence of a systemic bias (intercept ≠ 0) or a proportional error 
(slope ≠ 1). Bland-Altman plots illustrated the variability in agreement between 
two methods over the concentration range. Improvement of the agreement was 
explored by using a conversion factor or by accounting for the actual haematocrit. 
The haematocrit is a well-known factor that influences DBS concentrations as it 
determines the volume of blood on the surface of filter paper.41 When a fixed amount 
of paper is punched from the DBS sample, hematocrit may influence the total 
amount of blood present and thus the total amount measured. With the formula [ 
DBS[drug] / (1 – hematocrit) = plasma[drug] ], one can take into account the influence 
of the haematocrit.42 After assessment of agreement, the predictive performance 
was quantified by a jackknife approach. Prediction errors were determined by 
calculation of conversion factors based on datasets in which one out of the total 
amount of samples was omitted. The derived conversion factors were used to 
predict the plasma concentration of the remaining sample. The bias was assessed by 
calculating the median percentage prediction error (MPPE) by the median [100% 
x (Predicted concentration – Observed concentration) / Observed concentration]. 
Precision was assessed by calculating the median absolute percentage prediction 
error (MAPE), which is given by [100% x |(Predicted concentration – Observed 
concentration)| / Observed concentration].43, 44 While acceptance criteria can vary, 
the current study accepted MMPE and MAPE <15-20%.45
PK parameter assessment
Non-compartmental pharmacokinetic analysis was used to estimate PK 
parameters (Phoenix version 64, Certara). Derived pharmacokinetic parameters 
included area under the concentration time curve (AUC) during the sampling 
interval (AUC0-8h), AUC during the dosing interval (AUC0-24h), apparent clearance 
(CL/F), apparent volume of distribution (Vd/F), maximal concentration (Cmax) 
and half-life (T1/2). These parameters were determined per individual. PK data 
were both analysed based on plasma concentrations and on DBS predicted plasma 
concentrations if the predictive performance was sufficient.
The following assumptions were made concerning the PK analysis: (1) In case 
of missing t=2 values no PK parameters except for T1/2 could be determined, (2) 
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In case of missing rifampicin trough concentrations, t=0 was set at ‘0 mg/L’, (3) 
Pyrazinamide and ethambutol t=0 concentrations were used as t=24h samples 
only for samples above the limit of quantitation, and (4) AUC0-24h was calculated 
by means of extrapolation based on the elimination rate constant only when the 
extrapolated area did not exceed 25% of the total AUC.
Attainment of reference values for Cmax and AUC
The percent of patients attaining adult population values for Cmax were computed. 
For rifampicin this was ≥ 8 mg/L, based on a once daily 600 mg dose30; for isoniazid 
this was ≥3 mg/L based on 300 mg once daily30; for pyrazinamide this was ≥ 20 
mg/L based on once daily 25 mg/kg 30 and for ethambutol ≥2 mg/L based on 15-
25 mg/kg once daily. 30 In addition, the proportion (%) of patients who attained 
at least 75% of AUC0-24h population mean adult values as found by Magis-Escurra 
et al., (2014) was computed; rifampicin 41.1; isoniazid 15.2; pyrazinamide 380; 
ethambutol 23.5 mg*h/L.19
Figure S1 Passing-Bablock regression of ethambutol. Intercept 0.1513 (95% confidence interval 
–0.6153 –0.2909); slope 0.8879 (95% confidence interval 0.6148 – 1.560).
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Figure S2 Ratio of the predicted and observed ethambutol plasma concentration plotted against 
the average of the predicted and observed plasma concentration. Level of agreement: 95% of pairs 
lied between 0.4-2.8 and 20% of pairs lied between 0.80-1.20.
ULA upper limit of agreement; LLA lower limit of agreement
Figure S3 Difference between predicted and observed rifampicin plasma concentrations plotted 
against the average of the predicted and observed plasma concentrations.
ULA upper limit of agreement; LLA lower limit of agreement
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Figure S4 Difference between predicted and observed pyrazinamide plasma concentrations 
plotted against the average of the predicted and observed plasma concentrations.
ULA upper limit of agreement; LLA lower limit of agreement
Figure S5 Bland-Altman plots of ethambutol – absolute difference. Difference between predicted 
and observed ethambutol plasma concentrations plotted against the average of the predicted and 
observed plasma concentrations
ULA upper limit of agreement; LLA lower limit of agreement
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Abstract
Dried blood spot (DBS) sampling is a patient-friendly alternative for plasma 
sampling for the purpose of therapeutic drug monitoring (TDM). To speed 
up the analysis time, an automated flow-through desorption method of 
DBS samples may be beneficial. This article describes the cross-validation 
of a manual punch method with an automated desorption method (DBSA) 
for the DBS analysis of the antifungal drug voriconazole, followed by cross 
validation of both DBS methods, and a clinical validation in which the 
agreement between DBS and regular plasma concentration measurements (gold 
standard) was assessed in samples from patients on voriconazole treatment. 
DBS/DBSA LC-MS/MS assays for voriconazole were validated according to the 
latest guidelines on bioanalytical method validation (FDA, EMA). Additional 
DBS-specific validation parameters included hematocrit and spot volume. 
Passing-Bablok regression and Bland-Altman plots were used to cross validate the 
DBS/DBSA methods. Clinical validation also involved the performance of DBS/
DBSA measurements to predict voriconazole plasma concentrations. 
Both DBS methods complied with all validation parameters and sample 
pre-processing time was reduced from 1.5 hours to 3 minutes when using the 
DBSA. Cross-validation of both DBS methods showed a proportional bias and 
a correction factor was needed to interchange voriconazole concentrations of 
both DBS methods. Clinical validation showed no consistent bias, but limits of 
agreement of the DBS and plasma assays in Bland-Altman analysis were relatively 
wide, i.e. 0.75-1.28) for the DBS punch method versus plasma method and 0.57-
1.38 for the DBSA versus plasma assay. Clinical interpretation of DBS, DBSA 
and plasma samples in terms of concentrations in or outside of the voriconazole 
therapeutic range agreed in 82-86% of the cases. The variability in paired DBS/
DBSA and plasma concentration measurements is considered high for TDM 
purposes and this limitation should be balanced against the advantages of DBS 
sampling of voriconazole and the speed of flow through desorption.
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Introduction
Conventionally, drug concentrations are measured in plasma or serum obtained 
after venous sampling of whole blood. Dried blood spot sampling (DBS) involves 
sampling of whole blood by means of a finger prick and is followed by bio-analysis 
of the whole blood (rather than plasma or serum) sample. DBS has unique 
advantages over conventional plasma sampling, specifically for the purpose of 
therapeutic drug monitoring (TDM), which is the individualization of drug doses 
based on drug concentration measurements. These advantages of DBS sampling 
include (I) minimally invasiveness as 1-2 drops of blood are easily obtained by 
means of a finger prick which can be spotted onto filter paper; (II) the possibility 
of home based sampling as patients can perform the finger prick themselves, 
possibly also increasing patient empowerment; (III) the possibility to obtain 
correctly timed drug samples (e.g. peak or trough concentrations, dependent on 
the drug) more easily; (IV) convenient transport of the sampling paper by regular 
mail; (V) after analysis of drug on the sampling paper the results may be available 
prior to the next outpatient visit, allowing for direct dose adaptation, and (VI) 
drugs may be more stable upon storage. In addition, our recent data show that 
DBS sampling may decrease costs involved with TDM.1 These advantages have 
been acknowledged by many groups and there has been an important increase in 
the development of DBS assays over the past decade.2
Good candidate drugs for DBS sampling are those that meet the requirements 
for TDM and that require repetitive concentration measurement. Voriconazole, 
the pivotal azole antifungal agent used to treat invasive fungal infections, is 
frequently sampled for the purpose of TDM. It requires TDM to individualize 
drug dosing due to its high inter and intra-individual pharmacokinetic variability 
with nonlinear pharmacokinetic properties and pharmacokinetic interactions 
involving cytochrome P450 (CYP) iso-enzymes.3 Therefore, voriconazole may be 
an excellent candidate drug for DBS sampling. 
With conventional DBS methods, the blood spots are punched out manually 
after which they undergo sample pre-treatment such as liquid-liquid extraction 
with subsequent LC-MS/MS analysis.4 Several innovative methods have been 
developed in order to improve the recovery of drugs or to speed up the analysis, 
such as (semi-) automated punch5 or automated flow-through desorption.6, 7 The 
current article describes the development of a manual punch and a flow-through 
desorption (DBS auto-sampler, DBSA) method for voriconazole. Voriconazole 
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was measured by means of LC-MS/MS. Next, we performed a cross-validation 
comparing both DBS methods as well as a clinical validation with both DBS 
methods in which the agreement between DBS and regular plasma concentration 
measurements (gold standard) was assessed in samples obtained from patients on 
voriconazole treatment. 
Methods
Chemicals, reagents and materials
Detailed information can be found in the Supporting Information.
Preparation of DBS calibration standards, Quality Control (QC) solutions and IS 
solution
Two series of stock solutions of voriconazole were prepared (one for calibration 
standards and one for QC samples) in methanol at a concentration of 1.0 mg/mL, 
dispensed in polypropylene tubes and kept at −40 °C. Stock solutions of internal 
standard (IS) were prepared at a concentration of 1.0 mg/L in methanol and kept 
at −40 °C.
For the preparation of calibration standards and QC samples, fresh drug-
free blood was collected in lithium heparin BD Vacutainer® tubes from a healthy 
volunteer. Hematocrit (Hct) was determined by centrifugal force (Hettich 
centrifuge). A capillary tube was dipped into the blood tube, and after filling 
this capillary tube for about 75% with blood it was sealed at the dry end and 
transferred to the hematocrit centrifuge rotor. This centrifuge rotor was placed 
into the centrifuge (rotor radius 85 mm, relative centrifugal force [RCF] 16000, 
centrifuge time 7 min). A Hct of 0.30 was created by adding an adequate volume 
of plasma from the same drug-free blood.
The preparation of standard 1 (15 mg/L voriconazole) and standard 2 (10 
mg/L) was performed by directly spiking voriconazole stock solution into drug-
free blood. Standard 2 was further diluted to create standards 3, 4, 5 and 6 (5, 2.5, 
1 and 0.5 mg/l respectively). Standard 6 was further diluted to create standard 7 
(0.10 mg/L) and standard 8 (0.05 mg/L).
QC sample QC H (12.5 mg/L) was prepared by spiking drug-free blood with 
voriconazole QC stock. QC H was diluted to create QC M (0.7 mg/L). QC L was 
created by further dilution of QC M (0.07 mg/L).
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Immediately after preparation, 25 µL spots were applied on Whatman 903® 
sampling paper with a volumetric pipette yielding the calibration and QC samples. 
The blood spots were left to dry at least for 3 hours and were stored at 4-8 ⁰C in 
sealed plastic bags containing desiccant. 
The IS stock solutions were diluted into extraction solvent (methanol/water 
70:30 (v/v) + 0.1% formic acid) to create concentrations [13C2,2H3]-voriconazole of 
16 µg/L and were stored at 4-8 ⁰C.
Sample preparation punch method
A paper disk with a diameter of 7 mm was punched out of the dried blood spots in 
a 2 mL safe-lock tube (Eppendorf) and 250 µL of extraction solution with IS was 
added. The sample was then vortexed on a multi tube vortex for 30 minutes at 1200 
revolutions per minute and centrifuged at 18620 RCF. Subsequently, an aliquot of 
200 µL supernatant was transferred into a vial with glass insert and centrifuged 
again at 1910 RCF to be sure all the remaining waist was at the bottom and not 
injected. 10 µL was injected into the HPLC-MS/MS system.
On-line DBS SPE
To perform flow-through elution of the DBS card, we used a DBS card auto-
sampler (DBSA) coupled to an automated SPE cartridge exchange module (ACE) 
for on-line SPE and a high-pressure dispenser pump (HPD) to deliver solvents 
(Spark Holland, Emmen, The Netherlands, see Figure 1). 
The DBS card was transferred from the card rack to the sliding cardholder by 
the robot arm of the DBSA. To determine the exact position of desorption, the 
DBSA took a picture of the card. Subsequently, the spot was eluted with a 2 mm 
internal clamp diameter. Deuterated internal standard solution was added via the 
loop (20 µL) and flushed through the DBS card together with 1 mL desorption 
solvent (water + 0,1% formic acid at a flow rate of 2 mL/min). After desorption, 
the DBSA took a second picture. These pictures identify the card before and after 
extraction, which may help to identify the source of unexpected results.
A disposable Hysphere C18HD SPE cartridge was used (7 µm, 2x 10 mm) and 
conditioned with 1 mL acetonitrile at a flow rate of 5 mL/min. It was subsequently 
equilibrated with 1 mL water + 0.1% formic acid at a flow rate of 5 mL/min before 
the compounds were eluted from the card onto the SPE system. After loading 
the SPE with the components, it was washed with 1.5 mL water/acetonitrile 95:5 
(v/v) + 0,1% formic acid at a flow rate of 5 mL/min. The HPLC pump eluted the 
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trapped component from the SPE cartridge to the LC-MS/MS system via the same 
conditions described in Mass spectrometry in the Supporting Information, with 
the following composition of mobile phase: 95% water + 0.1% formic acid (pump 
A) and 5% acetonitrile + 0.1% formic acid (pump B). After a gradient program of 
exactly 8.1 minutes, the DBSA-SPE system was washed with 1 mL water + 0.1% 
formic acid and 2 mL water/formic acid 30:70 (v/v) + 0.1% formic acid at flow rates 
of 5 mL/min. The online DBS-SPE system was controlled by SparkLink software 
and the LC-MS/MS via Analyst software.
Mass spectrometry
Detailed information of LC-MS/MS instrumentation and conditions as well 
as on transitions of precursor and product ions can be found in the Supporting 
Information. For both the manual punch as well as the DBSA method the same 
analytical assay was used.
 
Figure 1 Instrumental setup for the dried blood spot autosampler (DBSA)
HPD high pressure dispenser; SPE solid phase extraction 
Validation procedures
The DBS assays were validated on general validation parameters (accuracy, 
precision, lower limit of quantitation, selectivity, matrix effect, recovery and 
carryover) according to the most recent versions of the guidelines on bioanalytical 
method validation.8-10 Details on can be found in the Supporting Information. 
We are not aware of any DBS specific guidelines, but a review on the validation 
steps of DBS assays is available and yet consensus exist on a number of parameters 
important for validation.11 These are described below.
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Influence of hematocrit and blood spot volume
As Hct influences the viscosity of the blood it can possibly impact the result of 
the analysis. Therefore it is an important parameter in DBS validation. Plasma 
and blood cells were mixed to obtain blood with Hct values of 0.15, 0.20, 
0.30, 0.40 and 0.50. This blood was spiked with voriconazole at a medium 
concentration (QCM) and spots on paper were analyzed in quadruple. The 
Hct effect was considered acceptable if the mean voriconazole concentration 
measured was between 85-115% as compared to measurements at the 
standardized Hct of 0.30 which is expected to be the mean of the population. 
Spot volumes of 20, 25 (spot size used for validation), 40, and 60 µL were analyzed 
in quadruple at QCM to assess the influence of blood spot volume. The effect of 
spot volume was considered acceptable if mean concentration measurements were 
85-115% as compared to the standardized spot size (25 µL).
Stability of DBS samples
The stability of DBS samples was assessed at room temperature (RT), 4 ⁰C and 60 ⁰C 
and at three concentration levels (QCL, QCM and QCH), with all measurements 
performed in quadruple. In addition, stability of processed samples within the LC-
MS/MS auto sampler was assessed during 96h. Stability tests were assessed using 
the punch method, not the DBSA method.
Cross validation between punch and DBSA
Blood for routine TDM analysis was used for cross validation purposes and 
samples were coded prior to processing. Spots were prepared from the blood 
tubes (preparation of DBS described in the ‘Experimental section’, found in the 
Supplementary Information). DBS samples were processed with both the punch and 
DBSA method. Passing-Bablok regression12 and Bland-Altman plots13 were used to 
determine the agreement between DBS and DBSA voriconazole concentrations. 
If these analyses revealed bias between the punch and DBSA concentration 
measurements, a correction factor was derived to calculate one concentration from 
the other (i.e. the geometric mean - or inverse geometric mean - of DBS/DBSA 
ratios), and the analyses were repeated after application of the correction factor. 
Clinical validation
A validated routine UPLC-UV assay for voriconazole in plasma14 served as 
reference method in this clinical validation (detailed information on this 
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method can be found in the Supporting Information). The agreement between 
voriconazole DBS (or DBSA) concentrations on the one hand and voriconazole 
plasma concentrations on the other hand was assessed using Passing-Bablok 
regression and Bland-Altman plots. In addition, the predictive performance for 
the estimation of plasma concentrations based on DBS and DBSA concentrations 
was calculated by the median percentage prediction error (MPPE) as given by 
median (100% x [Predicted concentration – Observed concentration) / Observed 
concentration]) and the median absolute percentage prediction error (MAPE) 
defined as median (100% x |[Predicted concentration – Observed concentration]| / 
Observed concentration).15, 16 MPPE is a measure of bias while MAPE is a measure 
of precision. Acceptance criteria can vary but often values of MPPE and MAPE 
<15% are applied.17 Prediction errors were determined by calculation of conversion 
factors based on datasets in which one out of the total amount of samples was 
omitted (jackknife method). Similar to the cross validation between the DBS and 
DBSA analytical methods, a correction factor could first be assessed to calculate 
plasma concentrations based on DBS (or DBSA) concentrations, after which 
Passing-Bablok regression, Bland-Altman analysis and predictive performance 
assessment were performed once more. If required, it was also assessed whether 
using the patient’s Hct improved the prediction of plasma concentrations, based 
on the formula: plasma concentration[Drug] = DBS concentration[Drug] * (1- Hct).18
As a sensitivity measure, it was assessed whether the clinical interpretation of 
the DBS punch or DBSA concentration was different as compared to the plasma 
concentration. This was done by calculating the proportion of samples that lied 
inside the voriconazole therapeutic window of 1.5 – 4.0 mg/L for one method and 
outside this window for the other method, or the other way around.19
Results
Analytical methods
The main difference between the manual punch and DBSA methods were the 
sample pre-processing time and the number of samples analyzed per hour. Sample 
pre-processing of a single sample was 1.5 hours with the manual punch method 
and decreased to 3 minutes with the DBSA method. 
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Validation of DBS methods
Accuracy, precision and linearity
Accuracy and within-day and between-day precision complied with the specified 
limits (Table 1) for both DBS methods.
Calibration curves were linear and correlation coefficients (r) of all 3 calibration 
curves during validation of voriconazole in DBS were >0.98 with both methods.
Selectivity, matrix effect, recovery, carryover
The DBS methods were highly selective (adequate chromatographic separation) 
and matrix effect lied well within the limits (Table 1). The average recovery of 
voriconazole was 74% with the punch method and could not be determined with 
the DBSA method (see Discussion section). Carryover proved to be <20% of the 
LLOQ and <5% for the IS for both methods.
Table 1 Results of accuracy, precision and matrix effect
Accuracy % (n=15) Punch method DBSA
LLOQ 98.9 102.9
QC Low 99.3 88.3
QC Medium 101.1 89.3
QC High 93.6 88.4
QC HLOQ 92.6 100.3
Within-day precision %CV (n=5) 
LLOQ 2.1, 5.7, 2.5 4.0, 1.6, 11.2
QC Low 4.5, 7.8, 4.8 4.3, 2.6, 3.3
QC Medium 3.0, 3.6, 3.4 6.6, 1.2, 3.8
QC High 4.5, 5.0, 2.5 4.1, 1.5, 3.4
QC HLOQ 4.9, 2.3, 3.6 5.5, 6.2, 5.7
Between-day precision %CV (n=15) 
QC LLOQ 5.7 7.1
QC Low 5.7 3.4
QC Medium 3.5 4.2
QC High 4.3 3.5
QC HLOQ 4.7 5.5
Average matrix factor (%CV)
Low 0.99 (2.1%) 1.0 (1.7%)
High 0.98 (1.5%) 1.0 (1.4%)
CV coefficient of variation; QC quality control; DBSA Dried blood spot auto-sampler; LLOQ lower limit 
of quantitation; HLOQ higher limit of quantitation
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Hematocrit effect and influence of spot volume
No significant Hct effect was observed for Hct values between 0.20-0.43 for the 
punch method and between 0.20-0.51 for the DBSA method (Table 2). A trend 
towards higher recovery with higher Hct was observed and higher or lower Hct 
values were associated with >15% bias compared to the standardized Hct (0.30).
Spot sizes between 20-60 µL for the punch method and sizes between 20-40 µL for 
the DBSA lied well between the 85-115% recovery.
Table 2 Influence of Hct
Mean concentration compared to standardized Hct (%)
Punch-method DBSA
Hct
0.15 83.6 79.6
0.20 93.7 88.6
0.31 (standardized) 100.0 100.0
0.34 99.2
0.39 103.4
0.43 107.8
0.51 109.0
0.54 128.9
Results based on n=4 for every hematocrit level at QCM concentration.
Hct hematocrit; DBSA dried blood spot autosampler
Stability
DBS sample stability upon storage at RT was at least 119 days (maximum decrease 
in concentration: 7.2%) and this was 154 days at 4 ⁰C (maximum increase: 9.7%). 
Stability at 60 ⁰C was at least 48 h (maximum decrease 13.7%) with the exception 
of the QCL of voriconazole (decrease: 23%). Processed DBS remained stable for at 
least 96 hours in the LC-MS/MS auto-sampler (maximal decrease: 1.05%). 
Cross validation of DBS methods
A total of 28 TDM venous blood samples of voriconazole were available for cross 
validation and were used to make spots for the analysis of DBS with the punch 
method and with the DBSA. The median population Hct was 0.30 (range 0.19-
0.50). A correction factor (0.909) was used to predict DBS concentrations from 
the DBSA measurements. Passing-Bablok regression (Figure 2) then showed no 
significant systematic or proportional error between both methods; not using a 
correction factor resulted in a significant proportional bias of 18%. The mean ratio 
of DBSA predicted and punch method observed DBS concentrations was 1.01 
with 95% limits of agreement of 0.71-1.32 (Figure 3).
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Figure 2 Passing-Bablok regression (n=28) of observed (with DBS punch method) vs. predicted 
(based on DBSA measurement) DBS voriconazole concentrations. A correction factor of 0.909 was 
used to predict DBS concentrations based on DBSA measurements. The line of identity is presented 
as the dashed line and the Passing-Bablok regression line is continuous. The slope of the regression 
line is 1.08 (95% CI 0.99 -1.12) and the intercept is -0.05 (95% CI -0.13 – 0.03). Formula of the line: y= -0.05 
+ 1.08*x. The relative outlier did not impact the results.
Figure 3 Bland-Altman plot (n=28) of voriconazole DBS concentrations measured with the punch 
method versus predicted DBS concentrations with the DBSA, after using a correction factor of 0.909. 
The plot shows the mean of the predicted (based on DBSA measurements) and observed 
voriconazole DBS concentration (x-axis) vs the ratio predicted/observed voriconazole DBS 
concentration (y-axis). The mean ratio is presented with the dashed line while the lines depicting 
the 95% limits of agreement, containing 95% of the data points, are continous (0.71-1.32). Without 
the relative outlier, the 95% limits of agreement were 0.80 – 1.26.
ULA upper limit of agreement; LLA lower limit of agreement
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Clinical validation
The same 28 TDM samples were used for clinical validation. For the punch 
method, agreement between DBS and plasma concentrations improved when a 
correction factor of 1.16 was used (i.e. the geometric mean of the ratio plasma:DBS 
concentrations). Passing-Bablok regression showed no significant systematic or 
proportional error between the observed vs. predicted plasma concentrations 
when using the correction factor (Figure 4). The mean ratio of predicted:observed 
plasma concentrations was 1.0 with 95% limits of agreement of 0.75-1.28 (Figure 
5). MPPE was 1.1% and MAPE was 8.0%. 
For the DBSA method, Passing-Bablok regression showed no significant 
systematic or proportional error (Figure 6). The mean ratio of DBSA 
predicted:plasma concentration was 0.98 (95% limits of agreement 0.57-1.38) 
(Figure 7). MPPE was 1.2% and MAPE was 13.6%. The use of a correction factor 
(1.05) did not result in improved agreement between plasma concentrations and 
DBSA concentrations, nor did the patients actual Hct.18 
Figure 4 Passing-Bablok regression (n=28) of observed vs. predicted (based on DBS punch 
measurement) voriconazole plasma concentrations. A correction factor of 1.16 was used to predict 
plasma concentrations based on DBS measurements. The line of identity is presented as the 
dashed line and the Passing-Bablok regression line is continuous. The slope of the regression line 
is 1.0 (95% CI 0.87-1.11) and the intercept is 0.04 (95% CI -0.06 – 0.18). Formula of the line: y= 1.0*x + 0.04.
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Figure 5 Bland-Altman plot (n=28) of voriconazole plasma concentrations predicted by the punch 
DBS method versus voriconazole measured in plasma, after using a correction factor of 1.16. The 
plot shows the mean of the predicted (based on DBS measurement) and observed voriconazole 
plasma concentration (x-axis) vs the ratio predicted/observed voriconazole plasma concentration 
(y-axis). The mean ratio is presented as the dashed line while the lines depicting the 95% limits of 
agreement, containing 95% of the data points, are continuous (0.75-1.28). 
ULA upper limit of agreement; LLA lower limit of agreement
Figure 6 Passing-Bablok regression (n=28) of observed vs. predicted (based on DBSA measurement) 
voriconazole plasma concentrations. The line of identity is presented as the dashed line and the 
Passing-Bablok regression line is continuous. The slope of the regression line is 0.97 (95% CI 0.87-
1.14) and the intercept is 0.04 (95% CI -0.15 – 0.19). Formula of the line: y= 0.97 *x + 0.04. The relative 
outlier did not impact the results.
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Figure 7 Bland-Altman plot (n=28) of voriconazole plasma concentrations predicted by the DBSA 
method versus voriconazole measured in plasma. The plot shows the mean of the predicted (based 
on DBSA measurement) and observed voriconazole plasma concentration (x-axis) vs the ratio 
predicted/observed voriconazole plasma concentration (y-axis). The mean ratio is presented as the 
dahsed line while the lines depicting the 95% limits of agreement, containing 95% of the data 
points, are continuous (0.57-1.38). Without the relative outlier the 95% limits of agreement were 0.64-
1.36.
ULA upper limit of agreement; LLA lower limit of agreement
Sensitivity analysis 
Considering the clinical interpretation, 14% of DBS sample measurements would 
have led to a different clinical interpretation than the plasma analyses (sensitivity 
was 86%) and 18% of the DBSA measurements would have led to a different clin-
ical interpretation as compared to the plasma concentration analyses (sensitivity 
was 82%).
Discussion
We developed a punch method as well as an automated extraction method 
(DBSA) for the DBS analysis of the azole antifungal agent voriconazole, cross-
validated the two methods and compared these methods to a conventional, well-
validated assay of voriconazole in plasma (clinical validation). To the best of our 
knowledge, no flow-through analysis of DBS analysis for azole antifungal drugs 
has been described previously. This online technique enabled a strong decrease 
in sample pre-processing time. We used a comprehensive set of techniques to 
compare the agreement of DBS assays to the plasma method. Results over all 
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paired voriconazole concentration data showed no consistent bias, but 95% limits 
of agreement of the DBS assays, specifically the DBSA assay, and the plasma assay, 
were relatively wide.
Two LC-MS/MS DBS assays for azole antifungal agents have been published 
previously, one for posaconazole20 and another one for voriconazole, fluconazole 
and posaconazole.21 These assays were comparable to our punch method and 
consisted of a manual punch, extraction with organic solvent, vortexing and 
centrifugation followed by LC-MS/MS measurement.
Our DBSA method decreased the pre-processing time of a single DBS sample 
from 1.5 hours to only 3 minutes. Various other approaches have been published 
to speed up DBS assays. Ooms et al. (2011) first published their efforts on DBS 
flow-through desorption with a Spark apparatus and tested several compounds 
as a proof of concept (i.e. imipramine, haloperidol, amitriptyline, propranolol 
and verapamil). Their total runtime also decreased to approximately 3 minutes.7 
Another group analyzed opioids with Spark hardware (5 minutes runtime).22 
Déglon et al. (2012) speeded up a punch method for benzodiazepines to a more 
cost-effective process with micro spot analysis (5 µL) using minimal volumes of 
organic solvent.23 All those efforts illustrate the potency to quantify compounds 
measured with DBS more efficiently. As costs are a very important topic both in 
regular patient care and in biomedical research, more efficient sample processing 
and measurement is fundamental. Our group recently investigated the impact of 
DBS home based sampling on costs and showed that DBS home based sampling 
significantly reduces sampling costs.1 Improving DBS assays with more automated 
techniques may further reduce costs in terms of personnel time.
The current work provided us with further insight in working with automated 
flow-through desorption of DBS samples. It appeared that punch DBS and DBSA 
voriconazole concentration measurements were not interchangeable without 
application of a correction factor for a proportional bias between the two methods. 
This proportional bias is probably due to differences in recovery of voriconazole 
after liquid-liquid extraction versus automated flow-through desorption. 
Unfortunately it appeared difficult to determine the exact recovery with the DBSA 
coupled to the on-line SPE. In theory, there are two possible ways to assess the 
recovery of a DBS assay when using the DBSA, which we both tested during 
method development. The first would be a whole spot analysis of a very small 
spot (5 µL) spiked with the drug of interest, which is fully desorbed. This result is 
compared to a blank spot (5 µL) desorbed with a fluid with a known quantity of 
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the drug of interest via the 20 µL internal standard loop. The major problem with 
this method is that a bigger clamp head (desorption part of the DBSA) is required, 
which would mean a change from a 2 mm clamp (used for validation) to a 6 mm 
clamp. The larger clamp may give very different flow patterns through the filter 
paper, with the risk of an unreliable recovery. In addition, the spot became blurry 
instead of nice and white, indicating that not all blood was desorbed from the paper. 
A second possibility to assess recovery is the repetitive desorption of the same 
spot, e.g. 5 times, using the validated 2 mm clamp. This allows for the detection of 
a decrease in concentration/peak are and results in a ‘white spot’ within the blood 
spot. The problems related to this method were incorrect recognition of the spot 
by the software after multiple desorption steps. There was also a risk of perforation 
of the spot following multiple desorption steps which may have been caused by the 
clamp force and/or the type of filter paper (Whatman 903®).
In our clinical validation of the two DBS methods we wanted to assess by 
how much the DBS methods were likely to differ from the voriconazole assay in 
plasma. Visual inspection of regression plots is known to be misleading in this 
respect and correlation coefficients are wrong measures of agreement.13 Passing-
Bablok regression, Bland-Altman plots and assessments of predictive performance 
showed no consistent bias between DBS/DBSA and plasma methods over all paired 
samples, but individual DBS/DBSA and plasma concentration results could differ 
substantially, i.e. there is relatively large imprecision when comparing DBS methods 
against the plasma assay. The DBSA did not need a correction factor, in contrast to 
the DBS punch method. In terms of the Bland-Altman analysis, the 95% limits of 
agreement (containing 95% of all ratios of DBS predicted versus actually measured 
plasma concentrations) were 0.75-1.28 for the DBS and 0.57-1.38 for the DBSA 
method, respectively. Considering that the average ratio of DBS(A) versus plasma 
concentrations was equal to one, these limits of agreement can be interpreted as 
95% confidence intervals around a predicted plasma concentration based on a 
DBS/DBSA measurement. In line with this, one out of 6 of the DBSA and 1 out of 7 
of the DBS punch samples would have led to another clinical interpretation as the 
plasma measurement. Both DBS methods are clearly capable in differentiating low, 
intermediate and high voriconazole concentrations, but the observed variability 
limits the interchangeable use of the DBS methods and the plasma assay for the 
purpose of TDM, as voriconazole has a narrow therapeutic window. This means 
that the voriconazole DBS methods should be considered as semi-quantitative 
tests and this may possibly apply to more DBS methods when clinically validated 
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using appropriate methods. The source of the observed variability may be a sum 
of errors related to measurement in another matrix (whole blood versus plasma), 
differences in voriconazole recovery, Hct effect, spot volume and/or matrix effect. 
Still the advantages of DBS sampling apply and should be balanced against the 
observed imprecision in DBS analysis of voriconazole.
The current work is inevitably associated with limitations. A first limitation is 
that our clinical validation involved DBS samples that we prepared ourselves after 
venous sampling of blood from patients. This procedure is different from actual 
finger prick sampling of capillary whole blood by patients. Such an extended 
clinical validation is ideally required before the method is implemented in routine 
clinical care as an actual patient sample may differ from our samples, although 
we have validated for variability caused by Hct effect and spot size. Such a clinical 
validation study of four azole antifungal agents (itraconazole, fluconazole, 
posaconazole and voriconazole) is currently ongoing in a multi-center trial 
at various pediatric wards of specialized healthcare centres for oncology in the 
Netherlands (Clinicaltrial.gov NCT02329808). Data will be published separately. 
A second limitation relates to the routine plasma assay for voriconazole used 
for method comparison, which was an extensively validated UPLC-UV rather than 
UPLC-MS/MS assay. Although MS detection is more selective than UV detection, 
it is not very likely that co-eluting substances were measured in our UPLC-UV 
reference assay, considering its adequate validation in terms of accuracy, precision 
and selectivity.14 The other way around, we can not completely exclude that an MS 
signal could be disturbed by co-eluting substances causing ion suppression and 
such differences may have contributed to variability between the DBS and plasma 
assays.
As a third limitation, we had access to 28 samples for our cross validation and 
clinical validation and more samples are always preferable. On the other hand, 
our samples covered a wide concentration range and illustrated the magnitude 
of agreement and variability between DBS, DBSA and plasma concentration 
measurements. 
In conclusion, we successfully developed a conventional punch method as well 
as a DBSA method for the analysis of the azole antifungal agent voriconazole, 
cross-validated the two methods and compared these methods to a conventional 
plasma assay of voriconazole (clinical validation). Sample pre-processing time 
decreased from 1.5 hours to 3 minutes when using the DBSA method. Our results 
showed no consistent bias between DBS/DBSA methods and the plasma assay, 
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but limits of agreement of the DBS and plasma assays were relatively wide. This 
variability should be balanced against the advantages of DBS sampling and the 
speed of flow through desorption. A future step will be the clinical validation of 
capillary DBS samples obtained by means of a finger prick, as a last step prior to 
clinical implementation.
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Supplementary File 
Experimental section
Chemicals, reagents and materials
Methanol absolute ULC/MS was bought from Biosolve (Valkenswaard, The 
Netherlands) and formic acid eluent additive for LC-MS from Sigma Aldrich 
(Zwijndrecht, The Netherlands).
Voriconazole was purchased from USP (Rockville, USA). The labeled internal 
standard, 13C22H3-VOR, was purchased at Alsachim (Illkirch Graffenstaden, 
France). Ultrapure water was generated by a PURELAB flex 4 system purchased 
from Veolia Water Technologies Netherlands b.v. (Ede, The Netherlands). 
This water was used to create a mobile phase solvent A with 0.1% formic acid. 
Mobile phase solvent B consisted of Merck acetonitrile hypergrade for LC-MS, 
purchased at VWR (Amsterdam, The Netherlands). For the mobile phase and 
extraction solvent, formic acid eluent additive for LC-MS was used. Due to small 
volumes, preparation of calibrator and QC samples pipetting was done by a Brand 
multistepper pipet. A Hettich centrifuge was used for analysis of the hematocrit. 
DBS sampling paper and equipment was purchased from Dried Blood Spot 
Laboratory (DBSL, Geleen, The Netherlands), consisting of Whatman 903® filter 
paper and BD Microtainer® lancets (pink or blue) for finger prick sampling.
LC-MS/MS instrumentation and conditions
All experiments were performed on an AB Sciex API 3000 triple quadrupole mass 
spectrometer (Concord, ON, Canada) with an Agilent 1100 series HPLC system 
(Agilent Technologies, Palo Alto, USA), equipped with a pump with separately 
operated pump heads A and B and cooled autosampler. 
During injection, the initial eluent composition was 90% water + 0.1% formic 
acid (pump A) and 10% acetonitrile + 0.1% formic acid (pump B) continuously 
held at a flow rate of 0.250 mL/min. After injection, the initial conditions were 
held for 0.10 min and then the composition changed (linearly) to 10% A and 90% 
B in 7.9 min. At 8.1 min the eluent composition was immediately set back to its 
initial composition and held until the 12th min. The total analysis time was 12 
min. To avoid unnecessary contamination of the curtain plate, the LC flow first 
2 minutes and last 4 minutes were directed to the waste via the Valco 10-port 
valve. The Waters Xbridge C18 3.5 µm 2.1x50 mm column and its Phenomenex 
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Security guard AQ C18 2.00 x 4.0 mm were continuously held at 40°C. All these 
components were controlled with Analyst software (V1.4.2 Sciex). 
The AB Sciex API 3000 mass spectrometer was operated in TurboIon Spray-
positive ionization mode and performed scheduled multiple reaction monitoring 
(MRM). The MRM detection window was set at 90 seconds and the target scan 
time at 2 seconds. The TurboIon Spray voltage and temperature were set at 4000 V 
and 450° C, respectively. The collision (6 psi), curtain (8 psi) and nebulizer (10 
psi) gasses consisted of pure nitrogen. Precursor ions of all compounds were 
determined from spectra obtained during the infusion of a standard solution 
in 70/30 methanol/water + 0.1% formic acid directly to the electrospray source 
inlet. The precursor ions were subjected to collision-induced dissociation to 
determine the product ions. The transitions of the precursor/product ions used 
for quantitation are presented in table 1.
Concentrations were determined from the peak area ratios of analyte to IS. 
Calibration curves were calculated using linear least square regression analysis 
with 1/x2 weighting. Data was processed using Analyst Software.
DBS validation parameters 
Accuracy, precision, linearity, LLOQ, HLOQ
Lower limit of quantification (LLOQ) was determined at 0.05 mg/L. Higher limit 
of quantification (HLOQ) was determined as 15 mg/L. These limits are well within 
the desired limits for purposes of TDM.
Five replicates of samples at the LLOQ, at the higher limit of quantification, 
and 3 in-between concentrations of QC samples were analyzed during 3 different 
days to determine the accuracy and within-day and between-day precision of the 
method. To analyze these samples, 8 calibration concentration levels were used in 
addition to the blank sample (processed matrix sample without analyte and without 
IS) and a 0 sample (processed matrix with IS). The 8 calibrators were analyzed in 
duplicate in each validation run. Acceptance criteria for the LLOQ were: accuracy 
and precision less than 20%; for all other concentrations, accuracy and precision: 
less than 15%. For each concentration level, per day, the concentration obtained 
was divided by the nominal concentration, based on the five replicate samples. 
Next one-way analysis of variance (ANOVA) was used to assess the within-
day and between-day precision at each of the five concentrations, using the run 
day as the classification variable. The error mean square or mean square within 
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groups (ErrMS), the day mean square or mean square among groups (DayMS), 
and the grand mean (GM) of all 15 measurements across the three run days 
were obtained from the ANOVA. The estimate of the within-day and between-
day precision at every concentration were calculated as follows; Within – day 
precision = ((ErrMS)^0.5 / GM) x 100% and Between day precision: ([DayMS – 
ErrMS)/n]^0.5/GM) x 100%, in which n is the number of replicate measurements 
within each day.
The calibration curves were calculated using linear least square regression with 
1/x2 weighting and peak area ratio.
Selectivity, matrix effect, recovery and carry over
As to assess the interference of endogenous compounds six blanco matrices from 
different individuals who did not receive antifungal agents were used. Matrix effect 
was determined at 2 concentration levels (LLOQ and HLOQ). Acceptance criteria 
were as following: peak area should be lower than 20% of the LLOQ for the analyte 
and lower than 5% of the IS.
For all components, the matrix factor (MF) was calculated by calculating the 
ratio of the peak area in the presence of matrix (measured by analyzing a DBS 
sample of blank blood spiked after extraction with analyte) to the peak area in 
the absence of matrix (pure solution of the analyte). The IS-normalized MF was 
calculated by dividing the MF of the analyte by the MF of the IS. The CV of the 
IS-normalized MF calculated from the 6 lots of plasma or blood should be less 
than 15%. 
For the DBSA, the matrix effect experiment was performed by injecting a 
known concentration of voriconazole (concentration corresponding to peak 
height/surface of LLOQ and HLOQ) via the internal standard loop, through a 
blank DBS (6 different matrices used).
Extraction recoveries of all components were calculated by the ratio of the 
peak area of the blank blood spiked with analyte before extraction to the peak area 
of the same DBS spiked with analyte after extraction. These determinations were 
performed in duplicate, both at a high, medium, and low concentration. For the 
DBSA on-line SPE method, recovery was not quantified.
Carry-over effect was assessed for every compound by injecting a blank sample 
after injection of a HLOQ calibrator sample. This procedure was repeated 5 times. 
If the response was <20% of the LLOQ for compounds, and <5% of LLOQ for the 
IS, the carryover effect was acceptable.
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Routine plasma assay
A validated routine UPLC-UV plasma assay was used as reference method for 
voriconazole. An Acquity UPLC BEH Phenyl column was coupled to a Waters 
tunable UV detector. Voriconazole LLOQ was 0.050 mg/L, range 0.050-9.94 
mg/L, accuracy (n=15) 96.8-103.2%, intra-day precision 0.9-3% CV, between-day 
precision (n=15) 0-1.9% CV. Our UPLC-UV analytical assay has been previously 
published and externally validated.14, 24
Table S1 Transitions of the precursor/product ions
Name Precursor m/z (Da) Product m/z (Da) Scheduled Rt (min)
VOR 350.4 281.3 5.2
13C2
2H3-VOR 355.4 284.0 5.2
IS Internal standard; VOR voriconazole; Da Dalton; Rt retention time
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Abstract
Dried blood spot (DBS) sampling for the purpose of therapeutic drug monitoring 
can be an attractive alternative for conventional blood sampling, especially in 
children. This study aimed to compare all costs involved in conventional sampling 
versus DBS home sampling in two pediatric populations: renal transplant patients 
and hemato-oncology patients. Total costs were computed from a societal 
perspective by adding up healthcare cost, patient related costs and costs related 
to loss of productivity of the caregiver. Switching to DBS home sampling was 
associated with a cost reduction of 43% for hemato-oncology patients (€277 to 
€158) and 61% for nephrology patients (€259 to €102) from a societal perspective 
(total costs) per blood draw. From a healthcare perspective, costs reduced with 
7% for hemato-oncology patients and with 21% for nephrology patients. Total 
savings depend on the number of hospital visits that can be avoided by using home 
sampling instead of conventional sampling.
45151 Lisa Martial.indd   234 16-05-17   20:10
Cost evaluation of DBS sampling
235
11
Introduction
Therapeutic drug monitoring (TDM) is an important way to individualize drug 
dosing for a variety of drug classes, such as anti-epileptics, antimicrobial agents 
(e.g. aminoglycosides and glycopeptides, azole antifungal agents), antimetabolites 
(e.g. methotrexate) and immunosuppressants (e.g. cyclosporine, tacrolimus).1-3 
The purpose of concentration guided dose adaptation is to maintain drug 
exposure within predefined targets to ensure adequate efficacy and to decrease the 
likelihood of adverse events.4 Conventionally, drug concentrations are measured 
in plasma, serum or whole blood obtained by venous sampling in a specialized 
healthcare facility.2, 3 For patients treated on an outpatient basis, regular blood 
sampling can be challenging. It is time consuming, as patients have to attend 
their hospital outpatient clinic for blood sampling, and especially for children, 
frequent blood draws are associated with patient burden. For example, after renal 
transplantation, we perform TDM of immunosuppressants weekly in the first 
month post-discharge based on local practice, as guidelines on the frequency of 
TDM are lacking.5 This frequency is slowly tapered to once every three months but 
this tapering usually takes 6-9 months.
Dried blood spot (DBS) sampling could be a more convenient and less costly 
alternative to conventional blood sampling. DBS sampling was first introduced 
for the screening of phenylketonuria in newborns (‘heel prick’ screening) in 
1963.6 Especially over the last ten years, the development of DBS assays for drug 
concentration measurements has increased considerably.7, 8 
DBS sampling is used in different settings, from preclinical and clinical research 
including large epidemiological studies to clinical settings.9-15 The advantages of 
DBS sampling over conventional venous sampling include the minimal invasive 
nature, the small amount of blood required, the stability of the sample and the ease 
of self-sampling at home. Moreover, DBS sampling allows for optimal sampling 
times (usual trough concentrations), which is often difficult to implement with 
outpatient visits. In addition, DBS sampling might potentially be cost-saving as 
no healthcare professionals are involved in the sampling process. Although this 
financial benefit of DBS sampling has been proposed in different clinical fields16-18, 
no thorough cost evaluation on DBS home sampling for TDM has been performed 
so far.
The objectives of this study were (1) to develop an analytical framework for an 
integral cost evaluation of both conventional sampling and DBS home sampling; 
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(2) to estimate and compare all costs associated with the two sampling methods 
and; (3) to identify factors that influence total cost. The results are presented in a 
format suitable for input into further health economic evaluations including cost-
effectiveness analysis.
Methods
Setting
This cost evaluation is part of the PROTECT project funded by the Dutch 
Government, Rational Pharmacotherapy program, grant 836021012 from The 
Netherlands Organisation for Health Research and Development (ZonMW). 
PROTECT is coordinated by the Department of Pharmacy of the Radboud 
university medical center in close collaborations with the Departments of 
Pediatric Nephrology and Pediatric Infectious Diseases and Immunology of 
the Radboudumc Amalia Children's Hospital, the Princess Máxima Center for 
oncology in Utrecht, the Wilhelmina Children's Hospital in Utrecht and the 
Department of Pharmacy of the Maastricht University Medical Center. 
Cases
Two pediatric patient populations, ‘cases’, were identified that are likely to 
benefit from DBS home sampling: children treated with immunosuppressants 
(tacrolimus, mycophenolic acid, cyclosporine) for the prevention of graft rejection 
after renal transplantation and children with (risk of) invasive fungal infections 
treated with azole antifungal agents (voriconazole, posaconazole, itraconazole). 
The main difference between these populations, relevant for this cost-evaluation, 
is the travel time from home to the hospital. Only three hospitals perform renal 
transplantation in children in The Netherlands for which their travel distance is 
expected to be higher than for pediatric hemato-oncology patients.
Framework for cost calculation
The literature was searched for articles to identify relevant cost items to be 
incorporated in the framework for the cost evaluation (the search can be found in 
S1 Text) and revealed no articles on the costs of DBS home sampling relevant for 
our cases. 
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As a result the framework was designed without a prior format by evaluating 
the whole process of blood sampling and TDM in patients treated on an outpatient 
basis. This included the subsequent steps: the request of the analysis, travelling to 
the healthcare facility, the process of blood sampling, analysis of the sample in the 
laboratory, interpretation of the results by the pharmacist, and feed-back to the 
patient. DBS home sampling contained an additional step of ‘instruction of DBS 
sampling’ as patients performing DBS home sampling require an introduction 
with instruction from a specialized healthcare professional (e.g. a nurse).
Input from patient-organizations representing the specific patient populations, 
pediatricians, hospital pharmacists, nurses, a hospital manager and a consultant 
hospital from “Consultancy Group Process Improvement and Innovation” from 
the Radboud university medical center was obtained to develop the framework 
for the two patient cases. Experts were asked to list all resources used, from a 
societal perspective, so irrespective of who incurred the costs. The time horizon 
was one single blood sample. This resulted in a list of resources used in the process 
of conventional sampling and a list of resources used in the process of DBS home 
sampling. 
Resources used in each of the steps of the TDM process were subdivided into 
three categories, i.e. healthcare costs, patient costs and resources related to loss 
of productivity. Each category consisted of different items representing invested 
time, material, or overhead. The final framework was approved by the consulted 
experts. The sources of estimates for volume and cost units and basic assumptions 
on the base-case can be found in S1 Table.
Analyses
Calculation sheet
The list of resources for both blood sampling methods was incorporated in a 
calculation sheet in Excel™ (Microsoft, USA). The calculation sheet contained all 
cost units, the volume per unit, and the cost per unit. 
Base-case analysis
Total costs for a single blood sample for the purpose of TDM were computed by 
calculating all costs per cost unit (multiplying volume [e.g., minutes or parking 
tickets] and cost per unit); and summing up over all categories of healthcare 
costs, patient costs and resources related to loss of productivity; for both types 
of blood sampling: conventional sampling and DBS home sampling; and for the 
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two patient cases. Given the learning effect in interpretation of the results after 
repeated analysis within the same patient, both patient cases were considered as 
new patients in the base-case. The step ‘instruction of DBS home sampling’ was 
not included in the integral costs of the DBS home sampling but was reported 
separately. The number of occasions of DBS home sampling required to earn back 
the costs of the instruction was also computed.
Sensitivity analyses
The following items were included in the sensitivity analysis: (1) patient travel time; 
(2) travelling by public transport instead of by car; (3) time spend in the hospital; 
(4) caregiver time valued as informal care; (5) caregiver time valued as loss of 
productivity for paid work; (6) sampling time; (7) costs of the laboratory analysis 
equals the formal Dutch national tariff (College Tarieven Gezondheidszorg, CTG 
tariff)19; (8) time related to review of the outcome of the sample analysis by the 
hospital pharmacist; (9) doctor’s time related to feedback to the patient. Resources 
(1-4) were unique to conventional sampling while resource (5) was unique to DBS 
home sampling. For details on the estimates used in the sensitivity analyses see S2 
Table.
Scenario analyses
Total costs for blood sampling for the purpose of TDM during disease episode were 
calculated for each case for conventional sampling as well as for DBS sampling. 
In pediatric nephrology, total costs on blood sampling for TDM of tacrolimus 
during the first three months post discharge after pediatric transplantation was 
calculated. This time period represents the most intense period in terms of 
outpatient visits with focus on blood analysis. Total costs for both a stable and 
an instable patient were computed. It was assumed that only instable patients 
may benefit from DBS homes sampling, as they require more intensive blood 
sampling. Details on the frequency of sampling can be found in S3 Table. Only 
costs associated with visits with the sole purpose of TDM were taken into account. 
In case visits were combined with other blood draws or outpatient visits, general 
costs such as nurse’s time or costs related to loss of productivity were not taken into 
account (best-case scenario). In case additional sampling was required, such as in 
instable patients, all costs were taken into account. For conventional sampling, 
these additional blood samples were assumed to be drawn in a shared care center, 
assumed to be closer to a patient’s home.20
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In hemato-oncology, a treatment episode of invasive pulmonary aspergillosis 
(six months) with voriconazole was used to calculate all costs related to blood 
sampling for the purpose of TDM. Six months was considered representative 
based on literature21 and our own experience in treating such infections in this 
population. A learning effect was taken into account for interpretation of the 
result of the voriconazole concentration by the hospital pharmacist from the third 
sample onwards, resulting in less time spent on interpretation and counseling 
(10 vs 20 minutes). This learning effect reflects the current situation in our 
hospital: interpretation and counseling on azole antifungal TDM is performed 
by a selected number of hospital pharmacists who know recurring patients. As 
hemato-oncology patients require regular blood sampling for determination of 
biochemical parameters (liver function, electrolytes), only costs associated with 
sampling for the purpose of voriconazole TDM were taken into account (best-
case scenario). In case extra sampling was required, such as in the first month of 
therapy for dose individualization, all costs as included in the base-case were taken 
into account. Details on the design of these two additional scenarios including 
frequency and location of sampling are presented in S3 Table.
Results
Base case analysis
For children with renal transplants treated with immunosuppressants, total societal 
costs for conventional sampling amount €259 for one sample while home sampling 
costs are €102 for a sample (Tables 1 and 2). Total savings per sample are depicted 
in the last column, i.e. for a nephrology patient, DBS home sampling results in €23 
saving of patient costs, €107 saving of costs related to loss of productivity and €27 
saving of healthcare costs. Clearly, the difference is mainly driven by a reduction in 
costs related to loss of productivity of the parent accompanying his/her child to the 
hospital for the sampling process. The total societal costs of conventional sampling 
in children treated with azole antifungal agents amount €277 while home sampling 
amounts €158. Again, the difference between both methods is mainly associated 
with a decrease in costs related to loss of productivity and less to patient costs and 
healthcare costs. The difference in costs related to DBS sampling between the two 
patient cases lies mainly in doctors/pharmacists time related to interpretation of 
the result and contacting the patient (Tables 1 and 2). 
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Table 1 Base-case analysis for population (1): pediatric nephrology patients
Cost unit Conventional sampling DBS home sampling Difference  
DBS -  
Conventional
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)
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(€
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(€
)
Co
st
s 
(€
)
(€
)
Request of the analysis
Healthcare costs
Doctor orders analysis 3.25 min 1.89 6.16 3.25 min 1.89 6.16 0
Overhead 44 % 2.71 44 % 2.71 0
Subtotal request of analysis 9 9 0
Blood drawing
Patient costs
Travel expenses car 104 km 0.19 19.88 NA -19.88
Travel expenses parking 1 ticket 3.02 3.02 NA -3.02
Costs related to loss of productivity
Travel time 145 min 0.58 84.37 NA -84.37
Time in hospital 45 min 0.58 26.22 NA -26.22
Home sampling NA 10 min 0.23 2.35 2.35
Send the sample by mail NA 6 min 0.23 1.41 1.41
Healthcare costs
Sampling by nurse 15 min 0.54 8.15 NA -8.15
Overhead 44 % 3.58 NA -3.58
Sampling material 1 unit 6 6 1 unit 5.69 5.69 -0.31
Subtotal blood drawing 151 9 -142
Laboratory
Healthcare costs
Cost of laboratory analysis 1 unit 50.00 50.00 1 unit 50.00 50.00 0
Review by hospital pharmacist 5 min 1.89 9.47 3 min 1.89 5.68 -3.79
Overhead 44 % 4.17 44 % 2.50 -1.67
Subtotal laboratory 64 58 -6
Feedback to patient
Healthcare costs
Doctor processes result in 
medical record
7 min 1.89 13.26 3.5 min 1.89 6.63 -6.63
Patient contacted 6 min 1.89 11.37 6 min 1.89 11.37 0
Overhead 44 % 10.84 44 % 7.92 -2.92
Subtotal feed-back to patient 35 26 -9
Total patient costs 23 0 -23
Total costs related to loss of 
productivity
111 4 -107
Total healthcare costs 126 99 -27
Total societal costs 259 102 -157
Discrepancies between multiplications and sums may be due to rounding.
DBS dried blood spot
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Table 2 Base-case analysis for population (2): pediatric hemato-oncology patients
Cost unit Conventional sampling DBS home sampling Difference 
DBS - 
Conventional
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(€
)
Co
st
s 
(€
)
(€
)
Request of the analysis
Healthcare costs
Doctor orders analysis 3.25 min 1.89 6.16
3.25 
min
1.89 6.16 0
Overhead 44 % 2.71 44 % 2.71 0
Subtotal request 9 9 0
Blood drawing
Patient costs
Travel expenses distance 78 km 0.19 14.91 NA -14.91
Travel expenses parking 1 ticket 3.02 3.02 NA -3.02
Costs related to loss of productivity
Travel time 114 min 0.58 66.19 NA -67.59
Time in hospital 45 min 0.58 26.22 NA -26.22
Home sampling NA 10 min 0.23 2.35 2.33
Send the sample by mail NA 6 min 0.23 1.41 1.4
Healthcare costs
Sampling by nurse 15 min 0.54 8.15 NA -8.15
Overhead 44 % 3.58 NA -3.58
Sampling material 1 unit 6 6 1 unit 5.69 5.69 -0.31
Subtotal blood drawing 128 9 -119
Laboratory
Healthcare costs
Cost laboratory analysis 1 unit 50.00 50.00 1 unit 50.00 50.00 0
Review by hospital pharmacist 20 min 1.89 37.89 20 min 1.89 37.89 0
Overhead 44 % 16.67 44 % 16.67 0
Subtotal laboratory 105 105 0
Feedback to patient
Healthcare costs
Doctor processes result in 
medical record
7 min 1.89 13.26 7 min 1.89 13.26 0
Patient contacted 6 min 1.89 11.37 6 min 1.89 11.37 0
Overhead 44 % 10.84 44 % 10.84 0
Subtotal feedback to patient 35 35 0
Total patient costs 18 0 -18
Total costs related to loss of 
productivity
92 4 -88
Total healthcare costs 167 155 -12
Total societal costs 277 158 -119
Discrepancies between multiplications and sums may be due to rounding.
DBS dried blood spot
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Pie charts depicted in Figure 1 represent the distribution of patient costs, costs 
related to loss of productivity and healthcare costs with conventional sampling 
and DBS home sampling for both cases. While for conventional blood sampling 
healthcare costs represent 49-60% of total costs, this is >97% with DBS home 
sampling. With home sampling, patient costs are absent and costs related to loss of 
productivity are reduced with >95% as compared to conventional sampling.
The instruction of the patient and his/her parent by a specialized nurse is 
estimated to be €163 for children with renal transplants and €139 for children 
treated with azole antifungal agents, as shown in Table 3. The variation in costs 
is driven by differences in travel time. The investment of the instruction of home 
sampling by the specialized nurse is almost completely earned back at the second 
occasion of home sampling, both from a societal as from a healthcare perspective.
Figure 1 Pie chart of costs in euro’s (€) ordered by perspective. DBS dried blood spot.
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Table 3 Resources on instruction of home sampling for both populations
Nephrology Hemato-oncology Difference 
between popu-
lations
Nephrology 
– Hemato-on-
cology
Instruction of DBS finger 
prick
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)
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)
Patient costs
Travel expenses car 104 km 0.19 19.88 78 km 0.19 14.91 4.97
Travel expenses parking 1 ticket 3.02 3.02 1 ticket 3.02 3.02 0
subtotal 23 18 5
Costs related to loss of productivity
Travel time 145 min 0.58 84.37 114 min 0.58 66.19 18.18
Time in hospital 45 min 0.58 26.22 45 min 0.58 26.22 0
subtotal 111 92 19
Healthcare costs
Time of nurse for instruction 30 min 0.54 16.29 30 min 0.54 16.29 0
Overhead 44 % 7.17 44 % 7.17 0
Instruction material 1 unit 5.69 5.69 1 unit 5.69 5.69 0
subtotal 29 29 0
Total 163 139 24
Discrepancies between multiplications and sums may be due to rounding
DBS dried blood spot 
Sensitivity analysis
Tables 4 and 5 and tornado plots in Figure 2 show how total costs vary with 
pessimistic or opportunistic inputs. The main factor of influence is the time of 
the hospital pharmacist and doctor related with review of the outcome of the 
sample analysis and feedback to the patient, respectively. For example, if the time 
of feedback to the patient increased from 6 minutes (base case) to 20 minutes, 
total costs of conventional blood drawing increased with 15% from €259 to €297 
for children with immunosuppressant therapy. The costs of sample analysis in the 
laboratory are also influential. If the prize doubled to €100 total costs increased 
with 18-19% for conventional sampling and with about 32-49% for DBS home 
sampling. The time for a nurse to take a sample showed to be less influential on 
total costs, doubling the sampling time from 15 to 30 minutes led to about 4-5% 
increase in total costs.
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Figure 2 One-way sensitivity analysis of the impact of the variation of different items on total 
societal cost as compared to the base-case
DBS dried blood spot
Valuing all caregiver time as informal care in the situation of conventional sampling 
in a healthcare facility, decreased total costs with 20-25%. When all caregiver time 
was valued as loss of productivity instead of informal care in the situation of DBS 
home sampling, this was associated with a 4-6% increase in total cost.
Scenario analyses
Total costs associated with blood sampling for the purpose of TDM of tacrolimus 
in the pediatric nephrology patient in the first three months post discharge after 
renal transplantation amount to €756 for a stable patient conventionally sampled. 
This is based on a total of 7 samples (see S3 Table). As all samples for tacrolimus 
TDM are supposed to be drawn together with routine sample taking, DBS home 
sampling does not play a role in regular patient care and hence does not impact 
costs in a stable transplant patient. For the instable transplant patient, a total of 11 
samples will be drawn which results in a total cost of €1401 for blood sampling 
for the purpose of TDM. DBS home sampling can reduce this total cost to €1226 
in case three samples are taken at home. These three samples were based on 
consultation with two pediatric nephrologists.
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Table 4 Sensitivity analysis population (1): pediatric nephrology patients
Conventional sampling Co
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Resources regarding loss of productivity
Travel time patient  
Base case 84 259 NA   NA
Optimistic scenario 1st quartile 52 227 -32   NA
Pessimistic scenario 3rd 
quartile
128 303 43   NA
Productivity loss time in hospital  
Base case (45 min) 26 259 NA NA
Optimistic scenario (25 min) 15 248 -12 NA
Pessimistic scenario (75 min) 44 277 17 NA
Caregiver time is valued as informal care Caregiver time is valued as loss of paid work
Base case: valued as loss of 
paid work 111 259 NA
Base case: valued as informal 
care 4 102 NA
Caregiver time valued as 
informal care 45 193 -66
Caregiver time valued as loss 
of paid work 9 108 6
Patient costs
Patient travels by public transport  
Base case: car 23 259 NA   NA
Public transport 40 276 17   NA
Healthcare costs
Sampling time nurse Sampling time caregiver
Base case (15 min) 12 259 NA Base case (sampling takes 
10 min) 2
102 NA
Optimistic scenario (sample 
takes 10 min)
8 255 -4 Optimistic scenario (5 min) 1 101 -1
Pessimistic scenario (sample 
takes 30 min)
23 271 12 Pessimistic scenario (20 min) 5 105 2
Costs of the lab analysis Costs of the lab analysis
Base case 50 259 NA Base case 50 102 NA
CTG tariff 31 241 -19 CTG tariff 31 84 -19
Twice base case 100 309 50 Twice base case 100 152 50
Costs related to review by pharmacist Costs related to review by pharmacist
Base case (5 min) 14 259 NA Base case (3 min) 8 102 NA
Optimistic scenario (2.5 min) 7 252 -7 Optimistic scenario (2 min) 5 100 -3
Pessimistic scenario (10 min) 27 273 14 Pessimistic scenario (10 min) 27 121 19
Time related to contacting patient Time related to contacting patient
Base case (total 6 min) 16 259 NA Base case (total 6 min) 16 102 NA
Optimistic scenario (total 3 min) 8 251 -8 Optimistic scenario (total 3 min) 8 94 -8
Pessimistic scenario (20 min) 54 297 38 Pessimistic scenario (20 min) 54 141 38
Discrepancies between multiplications and sums may be due to rounding.
DBS dried blood spot
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Table 5 Sensitivity analysis population (2): pediatric oncology patients
Conventional sampling Co
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Resources regarding loss of productivity
Travel time patient  
Base case 66 277 NA   NA
Optimistic scenario 1st quartile 36 247 -30   NA
Pessimistic scenario 3rd 
quartile
91 302 25   NA
Productivity loss time in hospital  
Base case (45 min) 26 277 NA NA
Optimistic scenario (25 min) 15 265 -12 NA
Pessimistic scenario (75 min) 44 294 17 NA
Patient costs
Patient travels by public transport  
Base case: car 18 277 NA   NA
Public transport 30 289 12   NA
Caregiver time is valued as informal care Caregiver time is valued as loss of paid work
Base case: valued as loss of 
paid work
92 277 NA Base case: valued as informal care 4 158 NA
Caregiver time valued as 
informal care
37 222 -55 Caregiver time valued as loss 
of paid work 9 164 6
 Healthcare costs
Sampling time nurse Sampling time caregiver
Base case (15 min) 12 277 NA Base case 2 158 NA
Optimistic scenario (sample 
takes 10 min) 8 273 -4
Optimistic scenario (5 min) 1 157 -1
Pessimistic scenario (sample 
takes 30 min) 23 289 12
Pessimistic scenario (20 min) 5 161 2
Costs of the lab analysis Costs of the lab analysis
Base case 50 277 NA Base case 50 158 NA
CTG tariff 27 254 -23 CTG tariff 27 135 -23
Twice base case 100 327 50 Twice base case 100 208 50
Costs related to review by pharmacist Costs related to review by pharmacist
Base case (20 min) 55 277 NA Base case 55 158 NA
Optimistic scenario (5 min) 14 236 -41 Optimistic scenario (5 min) 14 117 -41
Pessimistic scenario (40 min) 109 331 54 Pessimistic scenario (40 min) 109 213 54
Time related to contacting patient  Time related to contacting patient
Base case (6 min) 16 277 NA Base case (6 min) 16 158 NA
Optimistic scenario (3 min) 8 269 -8 Optimistic scenario (total 3 min) 8 150 -8
Pessimistic scenario (20 min) 54 315 38 Pessimistic scenario (20 min) 54 196 38
Discrepancies between multiplications and sums may be due to rounding. 
DBS dried blood spot
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Total costs for TDM of voriconazole in a hemato-oncology patient amount to 
€3972 based on a total of 28 samples taken conventionally during a disease episode 
of 6 months. DBS home sampling can reduce total costs to €3553 in case four 
samples are taken at home.
Discussion
This is the first study evaluating the costs of conventional blood sampling in a 
healthcare facility and comparing this to DBS home sampling for the purpose 
of TDM. Costs for a single blood sample as well as costs for a complete disease 
episode were estimated in two populations. From a societal perspective, total 
costs for a single blood draw with DBS home sampling were substantially lower 
compared to conventional blood sampling in a healthcare facility, i.e., 2.5 fold 
lower for nephrology patients and 1.8 fold lower for hemato-oncology patient. 
Total costs associated with conventional sampling for the purpose of TDM in the 
first three or six months post transplantation and in hemato-oncology patients 
with an invasive fungal infection respectively, could be reduced 1.1 fold.
Factors influencing total costs per blood draw were the time of the pharmacist 
and physician, the costs of sample analysis, and the valuation of caregiver time 
(informal care of lost productivity from paid labour). The scenario analyses per 
disease episode showed that the saving as a result of DBS largely depends on the 
proportion of hospital visits that can be avoided. 
Cost reductions are dependent on how many outpatient visits can be avoided, 
as children may travel to the hospital not only for drug concentration measurement 
but also for sampling of biochemical parameters and/or for an outpatient visit with 
their physician. This largely depends on the population and the clinical status of 
individual patient within this population. Implementation of DBS home sampling 
requires alertness and flexibility of the treating physician and the healthcare 
system in order to decide when best to apply home sampling and when not. 
Especially upon titration of the drug, home sampling can substitute outpatient 
visits. Currently, hemato-oncology patients treated from an outpatient basis have 
weekly appointments with their hemato-oncologist. For each additional sample 
required for monitoring of blood concentrations, patients require to travel to our 
center for blood sampling as local general hospitals have no facilities in assessment 
of azole blood concentrations. Clearly, DBS home sampling can reduce costs for 
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every additional sample. Those savings are mainly true from a societal point-of-
view as they mostly cover savings in loss of productivity and loss of patient (travel) 
costs. 
As it stands, no thorough cost evaluation regarding DBS home sampling 
for TDM has been published. DBS sampling was only hypothesized to be cost-
saving as compared to conventional sampling.17, 18 One study evaluated the costs 
of different sampling methods for the assessment of prenatal alcohol exposure 
and concluded that DBS sampling from the newborn was cheaper as compared to 
conventional venous sampling of the mother or meconium analysis. DBS sampling 
was cost-saving in terms of personnel involved in venous sampling and shipping 
costs when compared to venous sampling of the mother.16 DBS sampling resulted 
in a reduction in nurse’s time of 11 minutes, comparable to our 15 minutes time 
reduction. Our results confirm that DBS home sampling is cost-saving.
The calculated costs and figures are inevitably associated with uncertainty. 
Sensitivity analyses identified several items that specifically influenced total costs. 
The costs of the laboratory analysis of the sample depend on several local factors 
including equipment, cost prices of the laboratory, number of samples per run 
and number of runs per year. It is assumed that no specific analytical equipment is 
required for the analysis of DBS samples as mostly liquid chromatography mass-
spectrometry is used for the analysis of both plasma and DBS samples.8 For the 
base-case scenario a general price of €50 was used. The sensitivity analyses showed 
that total costs decreased substantially by using a national maximal tariff (CTG 
tariff)19 that applies for the analysis of outsourced samples in The Netherlands. 
Inversely, doubling the price to €100 also impacted total costs considerably. 
National tariffs do not always cover all costs involved with measurement of 
the sample, especially for drugs that are infrequently measured such as azole 
antifungal agents. A €100 fee probably better reflects the real costs involved in 
sample measurement. The current analysis did not take into account investments 
required for developing a DBS method, which may be more costly than plasma 
method development. On the other hand, several approaches have been made to 
speed-up the analytical method such as automated flow-through desorption or 
reduced sample pre-treatment resulting in a cost-effective analytical method.22, 23 
These technical innovations will further reduce analysis costs in the future.
Another item especially influencing total cost was the time spend by the physician 
and hospital pharmacist for the interpretation of the result of the analysis and feed-
back to the patient respectively, which is explained by the relatively high salary costs 
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of these healthcare professionals. Although this finding has no clinical consequences 
and is equally true for both conventional sampling as DBS home sampling, it can 
be a good starting point for strategies to further decrease costs associated with 
blood sampling (e.g. efficient administration processes, good clinical handover). 
As home sampling has not been implemented yet, assumptions were made on the 
time required for parents to sample their child. Total costs were only marginally 
influenced by time spent by the parent on sampling, as shown by the sensitivity 
analysis. Of note, these costs were indeed influenced by how this caregiver time 
was valued, i.e. as loss of productivity for paid work or as informal care. The 
majority of total cost involved in DBS home sampling included healthcare costs.
Implementing a DBS home sampling method will on one hand lead to cost 
savings from a societal and patient perspective, as patients have less travel costs 
and reduced loss of productivity. Societal costs will decline and social health 
security may benefit from reduced healthcare costs. It may on the other hand lead 
to a loss of income for a healthcare facility. It is difficult to predict how this latter 
aspect will impact hospital related costs. This will become more clear when DBS 
sampling becomes more common practice. Our analysis and results are valid for 
the social and economical situation in the Netherlands. Probably similar trends 
can be expected upon extrapolation to other countries with similar health-care 
systems but this is only hypothetical.
Adequate sampling times are very important for good interpretation of the 
exposure to immunosuppressants and azoles: preferably trough concentrations 
(before a next dose of the drug) are measured.24 With conventional sampling 
during an outpatient visit it is difficult to ‘capture’ this time point as patients 
usually take their medication in the (early) morning before the outpatient visit. 
With home sampling this trough concentration can be ‘captured’ facilitating 
the interpretation by the treating physician and hospital pharmacist. DBS home 
sampling is expected to result in better samples in terms of sampling moments, to 
increase the interpretability of the outcome and to facilitate subsequent decision 
making on dose adaptations. Other advantages of DBS sampling are not easily 
represented in costs, such as the minimal volume required or the less invasive 
nature of sampling.
DBS home sampling may reduce costs even more when biochemical parameters 
such as renal function parameters for nephrology patients or liver function tests 
in case of treatment with azole antifungal agents are measured along with drug 
concentrations. Those parameters are important to take into account in further 
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studies. At this moment, most biochemical parameters require a plasma or serum 
sample to be taken at the hospital. DBS assays for creatinine have been published 
but some are associated with issues of precision.25, 26 Combining home sampling 
for the purpose of TDM with assessment of disease specific parameters will 
probably result in increased benefit for the patient as more outpatient visits may be 
avoided. This will most likely also lead to lower societal costs. Clearly, DBS home 
sampling has a great potential for implementation in regular patient care and this 
can be further improved by combining measurement of different components in 
one sample. When implementing a DBS home sampling method for quantitative 
analysis of compounds, careful instruction with regular feed-back on the spot 
quality and thorough screening of the spot before processing the sample in the 
laboratory is important. Improperly collected samples may impact quality of care 
as the analytical outcome may be modified resulting in improper clinical decision. 
Moreover, improperly collected samples may negatively impact costs.
We would like to stress that DBS sampling is a nice alternative in case patients 
travel to the hospital only for blood sampling and do not have an appointment 
with their physician or (specialized) nurse practitioner. It is obvious that home 
sampling should not replace doctor’s appointments.
Based on the current cost evaluation, DBS home sampling can be considered 
cost-saving. Whether DBS home sampling is more efficient, depends on the 
accuracy and precision of the DBS assay compared to the conventional (plasma) 
assay.27-30 Alongside our clinical study on efficacy of DBS sampling, a cost-
effectiveness of DBS home sampling is performed. Also patient preferences and 
the experience regarding DBS home sampling are subject of study. We anticipate 
that children would prefer a finger prick over regular sampling and that parents 
would be ready to perform finger prick sampling of their child. Literature shows 
that DBS home sampling in a clinical study among female adult cancer patients 
was successful with about 70% participation.18 Another study on islet autoantibody 
screening in patients aged 12-38 years showed that patients would prefer DBS 
home sampling if this would avoid visits to the clinic, despite that DBS finger prick 
sampling was more painful.12
45151 Lisa Martial.indd   250 16-05-17   20:10
Cost evaluation of DBS sampling
251
11
Conclusion
This study is the first evaluation comparing the costs involved in regular blood 
sampling with the costs involved in DBS home sampling for the purpose of 
TDM. From societal perspective, total costs per blood draw decrease drastically 
with home sampling. Patient costs are reduced to zero and cost related to loss of 
productivity are decreased with >95%. Scenario analyses revealed that total cost 
savings depends heavily on how many visits can be avoided. Based on the results of 
this study we can conclude that DBS home sampling is associated with a reduction 
in costs both from a healthcare as from a societal perspective, but the size of the 
reduction differs considerably per individual patient in a population.
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Supporting information
Supplementary Table 1a Sources of volumes and cost items
Cost unit
Source
Volume Cost
Request of the analysis
Healthcare costs
Doctor orders analysis Interview with pediatricians 
(n=5)
Manual cost analysis 20
Overhead Manual cost analysis 20 NA
Conventional blood drawing
Patient costs
Travel expenses car Data Radboudumc, patient 
population 2015
Manual cost analysis 20
Travel expenses parking 1 parking ticket Manual cost analysis 20
Costs related to loss of productivity
Travel time Data Radboudumc Manual cost analysis 20
Time in hospital Survey with patient 
organizations (n=4)
Manual cost analysis 20
Home sampling Estimation Manual cost analysis 20
Send the sample by mail http://www.postnl.nl 
500 m walking = 6 min walking
Manual cost analysis 20
Healthcare costs
Sampling by nurse Interview with nurse (n=2) and 
coordinator housing controller
Manual cost analysis 20 & CAO 
UMC 2013-2015
Overhead Manual cost analysis 20
Sampling material 
conventional 
Data Radboudumc from 
coordinator housing 
Data Radboudumc from 
coordinator housing
Sampling material home 
sampling
Estimation Data on file, from Dried Blood 
Spot Laboratory (DBSL) Geleen, 
The Netherlands
Laboratory
Healthcare costs
Cost of laboratory analysis Estimation Assumption of general price
Review by hospital pharmacist Interview with hospital 
pharmacists (in training) (n=7) 
Manual cost analysis 20
Overhead Manual cost analysis 20
Feedback to patient
Healthcare costs
Doctor processes result in 
medical record
Interview with pediatricians 
(n=5)
Manual cost analysis 20
Patient contacted Interview with pediatricians 
(n=5)
Manual cost analysis 20
Overhead Manual cost analysis 20 Manual cost analysis 20
Instruction of DBS finger prick
Patient costs
Travel expenses car Data Radboudumc, patient 
population 2015
Manual cost analysis 20
Travel expenses parking 1 parking ticket Manual cost analysis 20
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Supplementary Table 1a continued
Cost unit
Source
Volume Cost
Costs related to loss of productivity
Travel time Data Radboudumc Manual cost analysis 20
Time in hospital Estimation Manual cost analysis 20
Healthcare costs
Time of nurse for instruction Estimation
Overhead Manual cost analysis 20
Instruction material Estimation Data on file, from Dried Blood 
Spot Laboratory (DBSL), 
Geleen, The Netherlands
Supplementary Table 2 Ranges used in sensitivity analyses
Cost unit Optimistic 
scenario
Base case Pessimistic 
scenario
Source of 
volume
Source of 
cost
Productivity: travel 
time patient
1st quartile Median 
travel time
3rd quartile Data Radboud 
umc
Manual cost 
analysis 20
Patient costs: patient 
travels by public 
transport
NA By car Public 
transport
NA Manual cost 
analysis 20
Productivity loss time 
in hospital
25 min 45 min 75 min Interviews 
with patient 
organizations 
and nurses
Manual cost 
analysis 20
Conventional sampling 
Productivity: caregiver 
time valued as 
informal care
Time valued 
as informal 
care
Time valued 
as loss of 
paid work
NA NA Manual cost 
analysis 20
DBS home sampling:
Productivity: caregiver 
time valued as loss of 
paid work
NA Time valued 
as informal 
care
Time valued 
as loss of 
paid work
NA Manual cost 
analysis 20
Healthcare: sampling 
time nurse
10 min 15 min 30 min Interviews 
with nurses 
(n=2)
Manual cost 
analysis 20
Healthcare: costs of 
the lab analysis
CTG tariff €50,- €100,- empirical For CTG-
tariff: 19
Healthcare: costs 
related to review by 
pharmacist
Nephrology: 
2.5 min
Hemato-
oncology:
5 min
Nephrology:
5 min
Hemato-
oncology:
20 min
Nephrology: 
20 min
Hemato-
oncology:
40 min
Interviews 
with hospital
pharmacists 
(in training) 
(n=7)
Manual cost 
analysis 20
Healthcare: time 
related to contacting 
patient
3 min 6 min 20 min Interviews 
with 
pediatricians 
(n=5)
Manual cost 
analysis 20
Productivity: home 
sampling time patient
5 min 10 min 20 min Estimation Manual cost 
analysis 20
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Supplementary Table 3a Details of scenario analyses. Total costs related to sampling for TDM of 
tacrolimus the first 3 months post discharge after renal transplantation
Stable patient Nephrology
Conventional 
sampling
Home sampling
Cost unit
co
st
 o
n
e
 
sa
m
p
le
 
n
=
co
st
 
fo
r 
th
e
 
w
h
o
le
 
p
e
ri
o
d
NA
Sampling in Rumc € 7 €
Request of the analysis 9 62
Laboratory 64 445
Feed back to patient 35 248
 
Total stable patient 108 756
Instable patient Nephrology
Conventional 
sampling
Home sampling
Cost unit
co
st
 o
n
e
 
sa
m
p
le
n
=
co
st
 
fo
r 
th
e
 
w
h
o
le
 
p
e
ri
o
d
co
st
 o
n
e
 
sa
m
p
le
n
=
co
st
 
fo
r 
th
e
 
w
h
o
le
 
p
e
ri
o
d
Sampling in Rumc € 8 € Sampling in Rumc € 8 €
Request of the analysis 9 71 Request of the analysis 9 71
Laboratory 64 509 Laboratory 64 509
Feed back to patient 35 284 Feed back to patient 35 284
Total sampling Rumc 108 864 Total sampling Rumc 108 864
Instruction home 
sampling
€ 1 €
Productivity loss 26 26
Instruction nurse 23 23
Material 6 6
Total instruction 55 55
Sampling in shared care center € 3 € Home sampling € 3 €
Request of the analysis 9 27 Request of the analysis 9 27
Sampling Sampling at home
productivity loss patient 48 143 productivity loss patient 4 11
costs travelling 6 17 sampling material 6 17
sampling time nurse 12 35
sampling material 6 18
Total sampling shared care 71 213 Total sampling at home 9 28
Laboratory 64 191 Laboratory 58 175
Feed back to patient 35 106 Feed back to patient 26 78
Total shared care sampling 179 537 Total home sampling 102 307
Total instable patient 
conventional
1401 Total instable patient 
with home sampling
1226
Discrepancies between multiplications and sums may be due to rounding.  
Rumc Radboud University Medical Center
45151 Lisa Martial.indd   256 16-05-17   20:10
Cost evaluation of DBS sampling
257
11
Supplementary table 3b Details of scenario analyses. Total costs related to sampling for TDM of 
voriconazol in hemato-oncology patient, treatment period of 6 months.
Conventional sampling stable patient DBS home sampling stable patient
Cost unit
co
st
 o
n
e
 
sa
m
p
le
n
=
co
st
 fo
r 
th
e 
w
h
o
le
 
pe
ri
o
d
co
st
 o
n
e
 
sa
m
p
le
n
=
co
st
 fo
r 
th
e 
w
h
o
le
 
pe
ri
o
d
First sample € 1 € First sample € 1 €
Request of the analysis 9 9 Request of the analysis 9 9
Laboratory 105 105 Laboratory 105 105
Feed back to patient 35 35 Feed back to patient 35 35
Total first sample 149 149 Total first sample 149 149
Instruction home sampling € 1 €
Productivity loss 26 26
Instruction nurse 23 23
Material 6 6
Total instruction 55 55
Second sample  
[extra appointment]
€ 1 € Second sample [home] € 1 €
Request of the analysis 9 9 Request of the analysis 9 9
Blood drawing 128 128 Blood drawing at home 9 9
Laboratory 105 105 Laboratory 105 105
Feed back to patient 35 35 Feed back to patient 35 35
Total second sample 277 277 total 158 158
Sample no. 4,6,8 
[extra appointment]
€ 3 € € 3 €
Request of the analysis 9 27 Request of the analysis 9 27
Blood drawing 128 384 Blood drawing at home 9 28
Laboratory Laboratory
sample 50 150 sample 50 150
time pharmacist (10 min) 19 57 time pharmacist (10 min) 19 57
overhead 8 25 overhead 8 25
Total laboratory 77 232 total laboratory 77 232
Feed back to patient 35 106 Feed back to patient 35 106
Total samples 4,6,8 250 749 Total blood drawing at home 131 393
Sample no. 3, 5, 7 and rest of 
months [regular samples]
€ 23 € Sample no. 3, 5, 7 and rest of 
months [regular samples]
€ 23 €
Request of the analysis 9 204 Request of the analysis 9 204
Laboratory Laboratory
sample 50 1150 sample 50 1150
time pharmacist (10 min) 19 436 time pharmacist (10 min) 19 436
overhead 8 192 overhead 8 192
total laboratory 77 1778 total laboratory 77 1778
Feed back to patient 35 816 Feed back to patient 35 816
Total samples 3,5,7 and rest 122 2797 Total samples 3,5,7 and rest 122 2797
Total conventional sampling 3972 Total DBS home sampling 3553
Discrepancies between multiplications and or sums may be due to rounding.  
Rumc Radboud University Medical Center
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Supplementary Text 1
Literature search, sources of estimates for volume unit and cost units, basic 
assumptions of the cost analysis.
1. Literature search
The following terms were searched in Pubmed, February 24, 2016: 
(“economics”[Subheading] OR “economics”[All Fields] OR “cost”[All Fields] OR 
“costs and cost analysis”[MeSH Terms] OR (“costs”[All Fields] AND “cost”[All 
Fields] AND “analysis”[All Fields]) OR “costs and cost analysis”[All Fields]) 
AND dried[All Fields] AND (“blood”[Subheading] OR “blood”[All Fields] OR 
“blood”[MeSH Terms]) AND spot[All Fields]). An Embase search, February 24, 
on “cost dried blood spot” and on “economic dried blood spot”. 
2. Sources of estimates for volume and unit costs
The cost estimates for the input parameters were gathered from different sources: 
literature, interviews with experts, and data from the Radboud university medical 
center. Data on personnel costs, transport costs and loss of productivity were 
customary to The Netherlands.20 Costs were valued from a social, patient, and 
healthcare perspective. 
Sources of estimates for volumes in terms of time spent during each step 
were gathered from a survey with representatives from patient organizations, 
pediatricians, nurses and hospital pharmacists (in training). Nurse’s time was 
estimated based on an interview with two nurses and hospital manager. Pharmacist’ 
time was estimated based on interviews with hospital pharmacists (n=7). Doctor’s 
time spend was based on interviews with pediatricians (n= 5). Average waiting 
time was estimated based on surveys with representatives of patient organizations 
(n=4). Average travelling distances from home to the hospital per patient 
reference case were gathered from a consultant from “Consultancy Group Process 
Improvement and Innovation“ (PVI) of Radboud university medical center and 
from the guidelines for costs-analysis.20 The PVI group counsels on processes 
concerning improvement and changes. The resources of conventional and home 
sampling for both cases are presented in Tables 1 and 2. All sources on costs and 
volumes can be found in the supplementary file (Table S1).
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3. Basic assumptions
The following assumptions were incorporated in the model: (a) All reported 
costs are in euros (€), 2015 price level. (b) In case only older prices were available, 
they were recalculated towards 2015 prices using the Dutch consumer price index 
(CPI) as published by Statistics Netherlands, The Hague/Heerlen.31 (c) Loss of 
productivity was valued as loss of paid work for conventional sampling and it was 
valued as unpaid work (e.g. as informal care) for DBS home sampling. (d) Patients 
costs are absent in DBS home sampling and equal travel costs in conventional 
sampling. (e) Costs for the analysis of the samples were set to an integral general 
cost price of €50. (f) The following costs are not included in the analysis (1) costs 
on development of the method of analysis in the laboratory (initial capital costs) 
as they are considered equal for both conventional and DBS sampling; (2) taxes 
(VAT). (g) On all healthcare costs related to personnel costs, a 44% overhead is 
calculated, in line with the guidelines for costs-analysis.20
45151 Lisa Martial.indd   259 16-05-17   20:10
45151 Lisa Martial.indd   260 16-05-17   20:10
261
12
General discussion
45151 Lisa Martial.indd   261 16-05-17   20:10
45151 Lisa Martial.indd   262 16-05-17   20:10
General discussion
263
12
Ideally, drug concentrations are directly predicted by the dose administered. 
This is utopia as there is often a poor correlation between dose administered and 
concentration achieved. As a result, one should focus on drug concentrations 
to improve personalized drug dosing. This thesis studied the pharmacokinetics 
(PK) of several drugs within two subpopulations: immunosuppressive and anti-
TB therapy in children and antifungal agents in both children and critically ill, 
and by assessing PK target attainment rates in those populations. This thesis 
also attempted to improve personalized drug dosing within an individual: by 
simplifying analytical techniques required for therapeutic drug monitoring (TDM) 
through application of dried blood spot sampling (DBS sampling). In this general 
discussion, results are put into perspective and knowledge gaps are summarized 
(see also Table 1). Specific steps are proposed which may form a starting point for 
future research.
Section I -  Studying the PK on a population level - special patient populations
The first part of this thesis focused on the PK of immunosuppressive and anti-
infective drugs in special patient populations: mycophenolic acid (MPA) (chapter 
2) and tacrolimus (chapter 3) to prevent kidney rejection in children, and on 
echinocandin (caspofungin and micafungin) antifungal agents in critically ill 
patients (chapters 4 and 5). We found high inter-individual variability in PK and 
low target attainment of immunosuppressants among children. Similarly, we 
found moderate PK variability but substantial percentage of suboptimal target 
attainment of echinocandins (in case of attenuated susceptibility profiles) among 
critically ill patients. 
Drug-drug interactions are one of the most relevant and frequent causes of 
altered PK. Managing some drug-drug interactions within the transplant patient 
remains a challenge. We provided a six-stepwise approach for the management 
of the interaction of immunosuppressive agents and azole antifungal drugs in the 
transplant patient (chapter 6). This requires a highly individualized approach and 
can be managed deploying TDM.
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Table 1 The aims, findings and implications of the chapters in this thesis in light of the remaining 
challenges to improve individualized drug dosing of antifungal, anti-TB and immunosuppressive 
agents
Aim Main outcome and 
implication
Remaining challenges
Ch
ap
te
r 
2
· To describe the PK of MPA 
in children with kidney 
transplants 
· To evaluate covariates on 
the PK in this population
· To assess PK target 
attainment rates of MPA
· The PK of MPA was highly 
variable among children
· Time since transplantation 
and serum creatinine were 
significantly associated with 
MPA exposure
· Target attainment rate was 
low, i.e. < 50% in recently 
transplanted children
· Variability in the PK of MPA 
among children should be 
evaluated compartmentally
· Higher initial doses of 
MPA should be evaluated 
prospectively 
· Prospective evaluation of 
the best PK-PD index of 
tacrolimus for children
Ch
ap
te
r 
3
· To describe the PK of 
tacrolimus in very young 
kidney transplant patients 
· To assess PK target 
attainment rates of 
tacrolimus with twice-
daily and three-times daily 
regimens
· The PK of tacrolimus was 
highly variable among in 
this population
· Target attainment rate was 
low, i.e. < 38%
· A more aggressive approach 
of higher doses, e.g. 0.4 mg/
kg/day should be evaluated 
prospectively
· AUC should be determined 
more early after 
transplantation 
· Prospective evaluation of the 
best PK-PD index of MPA for 
children
Ch
ap
te
r 
4
· To assess the PK of 
caspofungin among ICU 
patients compartmentally
· To assess the influence of 
covariates on the PK
· To determine PTA following 
different dosing regimens
· A population PK model of 
caspofungin was developed
· No covariates could be 
identified to significantly 
impact PK
· Reducing the dose based 
on Child-Pugh score in non-
cirrhotic patients leads to 
suboptimal exposure
· Higher maintenance doses 
(70mg) are required for 
infections with species with 
an MIC > 0.125 mg/L
· Larger cohorts with more 
variability in e.g. albumin 
will help to better assess the 
impact of covariates on PK
· A human PK-PD target 
should be determined for 
caspofungin
Ch
ap
te
r 
5
· To assess the PK of 
micafungin among ICU 
patients compartmentally
· To assess the influence of 
covariates on the PK
· To determine PTA following 
different dosing regimens
· A population PK model of 
micafungin was developed
· No covariates could be 
identified to significantly 
impact PK
· Higher maintenance doses 
are required for infections 
with species with an MIC > 
0.032 mg/L, e.g. 200 mg QD
· The impact of higher initial 
micafungin dosing (e.g. 200 
mg) on clinical outcome 
should be evaluated 
prospectively 
· Larger cohorts with more 
variability in e.g. albumin 
will help to better assess the 
impact of covariates on PK
Ch
ap
te
r 
6
· To provide a strategy for 
the management of drug-
drug interactions between 
azole antifungal drugs and 
immunosuppressive agents 
· Different tools are 
indispensible for 
assessment of DDI’s
· A stepwise approach was 
developed to manage these 
interactions
· Implementation of the 
strategy
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Table 1 continued
Aim Main outcome and 
implication
Remaining challenges
Ch
ap
te
r 
7
· To develop a DBS method 
for azole antifungal drugs 
(voriconazole, itraconazole, 
fluconazole, posaconazole) 
for the purpose of TDM 
· To clinically validate this 
method in the paediatric 
target population
· To assess feasibility of DBS 
sampling in this population
· A DBS assay for azole 
antifungal drugs was 
successfully developed 
and validated according to 
international guidelines
· Preliminary results show 
good predictability of DBS 
for plasma concentrations 
of posaconazole but not for 
itraconazole
· Over 75% of the children 
would prefer a finger prick 
over conventional sampling
· Implementation of DBS home 
sampling into routine clinical 
care for this population
Ch
ap
te
r 
8
· To develop a DBS method 
for immunosuppressive 
agents (tacrolimus, MPA) for 
the purpose of TDM 
· To clinically validate this 
method in the paediatric 
target population
· To assess feasibility of DBS 
sampling in this population
· A DBS assay for tacrolimus 
and MPA was successfully 
validated
· Passing-Bablock regression 
and Bland-Altman plots 
show good agreement 
between the golden 
standard and DBS
· Tacrolimus venous 
concentrations can be 
predicted from DBS 
concentrations, but not MPA
· About half of the children 
and parents would 
prefer a finger prick over 
conventional sampling
· Implementation of 
DBS home sampling of 
immunosuppressive agents 
into routine clinical care
· Addition of biochemical 
parameters such as 
creatinine to the DBS assay
Ch
ap
te
r 
9
· To clinically validate 
a DBS method for 
first-line anti-TB drugs 
(rifampicin, pyrazinamide 
and ethambutol) in the 
paediatric target population 
and directly assess PK 
parameters with DBS
· Assess PK target attainment 
based on adult population 
mean exposure
· Passing-Bablock regression 
and Bland-Altman plots 
show good agreement 
between the plasma and 
DBS for rifampicin and 
pyrazinamide 
· Ethambutol DBS 
was associated with 
unacceptably high variability 
· Cmax target attainment rate 
was only 25% for rifampicin
· Implementation of DBS 
sampling of first-line anti-
TB drugs rifampicin and 
pyrazinamide for TDM
· Prospective evaluation of 
higher initial rifampicine 
doses in order to attain 
higher exposure
· Evaluation of the new fixed-
dose formulation of first-line 
anti-TB drugs
Ch
ap
te
r 
10
· To cross validate a manual 
punch method with a 
flow-through desorption 
method for DBS samples of 
voriconazole
· To assess agreement 
between plasma and DBS 
using voriconazole patient 
samples
· Both methods were 
analytically validated 
and resulted to be 
interchangeable
· High variability between 
plasma and DBS(A) 
concentrations
· Decrease the variability 
between assays
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Table 1 continued
Aim Main outcome and 
implication
Remaining challenges
Ch
ap
te
r 
11
· To evaluate all costs 
involved in conventional 
and DBS home sampling for 
the purpose of TDM of two 
reference populations
· To assess cost items 
specifically impacting total 
costs
· DBS home sampling 
decreased cost (43-61%) 
by decreasing patient 
(travel) costs and loss of 
productivity
· Influential cost items 
included healthcare 
professionals’ time, analysis 
costs and valuation of 
caregiver time
· Savings depend on the 
amount of hospital visits 
avoided
· Evaluate the effect of home 
sampling of biochemical 
parameters on total costs
· Assessment of the impact 
of home sampling on the 
income of health-care 
facilities
Immunosuppressive agents in paediatric patients
MPA and tacrolimus are the cornerstone of maintenance immunosuppressive 
therapy post kidney transplantation in children.1, 2 Based on small studies, the AUC 
is thought to best link PK to PD for both MPA and tacrolimus3-6 but the optimal 
exposure has not been investigated thoroughly and prospectively in children. The 
current target values are mostly based on data from adults as it is the best we 
have. Future studies should focus on finding the best PK target for tacrolimus and 
MPA, by prospectively evaluating both PK and PD parameters in a larger group of 
patients including paediatric patients. The ideal PD endpoint would be rejection 
of graft. But it is very unlikely that a good relation can be resolved between 
exposure and lost-of-graft. Hence, biomarkers might provide a suitable alternative 
as PD marker. Inosine monophosphate dehydrogenase (IMPDH) activity is such 
a promising biomarker. Future research must demonstrate its validity. A surrogate 
endpoint for efficacy of MPA may be IMPDH activity, but the use of this biomarker 
is still experimental and future research must demonstrate its validity.
It was known that the PK of MPA can be highly variable in children. Factors 
such as creatinine clearance, haemoglobin, albumin and cyclosporine co-
administration may explain part of this variability.6-8 This thesis aimed to add 
knowledge on the extent of variability of these compounds (chapters 2 and 3). We 
concluded that the variability in the AUC of MPA was substantial. Only 36% of the 
variance could be explained by days post transplantation and serum creatinine. 
One of the limitations of our PK analysis of MPA was the multiple linear regression 
methodology to explain variability. Covariates, such as kidney function, do not 
necessarily have a linear relationship with concentrations. In order to better assess 
the influence of patient-factors, non-linear-mixed-effects-modelling (NONMEM) 
45151 Lisa Martial.indd   266 16-05-17   20:10
General discussion
267
12
might prove beneficial. With NONMEM, the effect of covariates on primary PK 
parameters (clearance, volume of distribution) can be assessed leading to a better 
understanding of the underlying physiological processes causing inter-patient 
variability. Compartmental PK analysis of MPA has already been performed 
both for adults9 and children.10 The authors could not identify covariates on MPA 
probably due to a too small sample size.10 Datasets should be combined in the 
near future in order to increase sample size to better explain the inter-individual 
variability in the future.
We found that only 46% of paediatric patients attained the MPA PK target 
short after kidney transplantation (chapter 2) and this was even less for tacrolimus 
among very young transplant patients (37.5%, chapter 3). Higher initial MPA 
and tacrolimus doses may be rational to increase PK target attainment rates. This 
should be evaluated prospectively in a clinical study large enough to also assess 
efficacy (e.g. rejection status).
From our research we learned that both MPA and tacrolimus trough 
concentrations correlated poorly with total exposure (AUC) (the denominator 
linked to efficacy). We recommend implementing AUC based on intensive 
sampling (requiring approximately 7 mL of whole blood). An alternate, more 
patient friendly approach would be a limited-sampling strategy (LSS) assisted by 
a Bayesian prediction approach in order to assess exposure. Such an LSS is not 
without challenges. One group attempted to design a LSS for MPA in liver transplant 
children but the predictive performance was poor so it is not yet suitable for clinical 
use.11 For tacrolimus, an LSS has been successfully developed for paediatric renal 
transplant patients.12 LSS strategies together with DBS sampling may simplify 
the assessment of total exposure in children both for clinical research as well as 
for routine TDM purposes. Also time to first assessment of an AUC needs to be 
improved. Currently, the delay is substantial thereby exposing paediatric patients 
to suboptimal therapy in the most crucial period shortly after transplantation.
Echinocandin antifungal agents in critically ill patients
Critically ill patients may exhibit altered PK as compared to healthy volunteers, 
due to physiological changes, e.g. in fluid balance, protein-binding or multi-organ 
failure.13 Based on two phase IV studies conducted by our group14, 15 this thesis 
further elaborated on the PK of caspofungin and micafungin in the critically ill 
(chapters 4 and 5). The PK was assessed with NONMEM in an attempt to assess 
potential covariates explaining some of the inter-patient variability in primary PK 
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parameters in a more advanced approach. No covariates could be identified which 
could be attributable to the relatively small sample size (20-21 patients). Also the 
overall high variability in PK of ICU patients, due to a mixture of factors and 
physiological changes16 might have obscured individual covariates. Larger studies 
or the combination of different datasets using NONMEM may help to better 
identify covariates of echinocandins among critically ill patients in the future.
In both echinocandin studies we demonstrated that concentration targets were 
not attained specifically for species with attenuated MICs. For echinocandins, the 
AUC:MIC ratio is the index linking PK to PD.17, 18 Much like immunosuppressive 
drugs, target concentrations have only been defined in animal models (caspofungin) 
or from a single analysis from phase II/III studies (micafungin). An additional 
challenging factor is the pathogen susceptibility which will demonstrate variability 
among and within species as well. We have conducted our pharmacokinetic 
target attainment (PTA) analysis with the best available data on breakpoints but 
acknowledge that more solid evidence is needed. Specific limitations are discussed 
in the next paragraph.
A limitation of our PTA analysis with caspofungin is the absence of a human 
PK-PD target for caspofungin. We used a pre-clinical target derived from a 
neutropenic mouse model.18 Future studies are warranted to identify the human 
AUC:MIC ratio of caspofungin associated with better treatment outcome. This 
may be performed similar to a previous analysis on the micafungin PK-PD target 
as proposed by the group of Andes et al., in which a large group of patients was 
evaluated on both PK, susceptibility pattern of the pathogen and clinical outcome.17 
Their statistical analysis yielded the most probable AUC:MIC value associated 
with mycological response based on two phase 2/3 studies.19, 20 
Even this analysis had some limitations. For instance, ‘mycological response’ 
was used for treatment outcome. Mycological cure was based on ‘periodically’20 
or weekly19 mycology laboratory assessment. It is questionable whether weekly 
mycology assessment is frequently enough. Moreover, in case of missing 
information on micafungin exposure, they used population values, despite high 
variability between individual predictions and population predictions (precision 
was about 20%). Such an approach is challenging, as demonstrated by Liu et al. 
She could not identify a solid target for anidulafungin to correlate AUC/MIC 
to outcome based on a “mycological cure endpoint” using data from phase 2/3 
studies.21 Alternative approaches must be found to derive these crucial targets to 
guide therapy. 
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An alternative to direct outcome measures such as ‘mycological cure’ might 
be the use of surrogate parameters such as B-glucan. Currently, this biomarker is 
a promising early diagnostic screening tool for invasive fungal infections22, 23, but 
its role in PK-PD target identification and PD assessment remains to be explored. 
It may prove beneficial to link B-glucan as a PD endpoint to drug concentrations.
The hollow fiber model technique has recently emerged as a successful 
alternative. This dynamic system mimics real human PK, provided that sound PK 
data are available by controlled pumping of the antibiotic and fresh medium into 
a central compartment (mimicking the human circulation), from which medium 
and antibiotic permeate across the hollow fibers into the peripheral compartment 
(mimicking the target organ/tissue), where the target bacteria reside.
This offers several advantages: (I) The biological variation is confined to the 
antifungal response allowing controlled study of the interaction between PK and 
PD; (II) It exposes the drugs to a comparatively harsh test of efficacy, by allowing 
growth of any spontaneous less susceptible variants of the studied pathogens and 
(III) Because of that conservative nature that closely resembles critical illness, a 
drug regimen that is effective in the hollow fiber model is likely to be effective in 
critically ill patients. 
Based on the proposed target concentrations, a prospective evaluation of the 
target concentrations should always be performed. 
Shared topics for improving individualized drug dosing in special patient 
populations in the future
We observed some shared topics in both populations that are worth mentioning 
and that may form a starting point of for future research. They are discussed in the 
following paragraph. 
• More early PK and PD assessment in drug development.  
As some of the investigated drugs are already generically available 
(tacrolimus, MPA, caspofungin), the question rises whether this 
information of highly relevant patient populations should not 
have been gathered in an earlier stage, prior to registration or 
shortly post-marketing. More effort should be put to assess PK 
(and PD) of relevant patient populations in an earlier stage of 
drug development and registration. 
•	 Explain inter-individual variability in PK. The drugs studied in 
both populations showed high inter-individual variability in PK. 
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Although some patient factors were identified as contributing 
factors, not all variability could be explained. Combining data 
sets using data from different studies may be helpful to better 
characterize the PK due to a higher sample size. When combining 
data from multiple studies, it is important to take into account 
differences in study design which may influence the outcome, 
such as patient inclusion criteria, the bioanalytical assay for drug 
concentration measurement, or co-medication. Modelling (e.g. 
NONMEM) and simulation techniques may be used to assess 
which dosing regimens lead to adequate target attainment in 
children.
•	 Suboptimal exposure is observed in vulnerable subpopulations
 (both renal transplant as infectious disease patients in the ICU). 
This points towards higher doses of immunosuppressants in 
children and of micafungin in critically ill. This should be 
evaluated prospectively taking into account both PK and PD. 
For immunosuppressants, DBS assays are becoming more and 
more available and LSS of tacrolimus may be used to decrease the 
amount of samples.
•	 PK-PD targets are insufficiently defined both for 
immunosuppressants in children as well as for echinocandin 
drugs in adults. PK-PD targets of immunosuppressants 
from adults can be used for children, as no differences in PD 
(prevention of organ rejection) are expected, besides differences 
that may be introduced by the immunosuppressive regimen, e.g. 
prednisolone is tapered and stopped in 5 days in children while 
continued for much longer periods in adults. For caspofungin, 
a human target is not available as discussed above. Biomarkers 
may become a helpful tool for earlier PD assessment (IMPDH, 
B-glucan). 
•	 Software tools must become available to guide dosing for 
immunosuppressive drugs and anti-infective drugs. With these 
tools, clinicians may enter the concentration-time data from 
the blood samples together with relevant patient covariates (e.g. 
body weight) and the susceptibility profile of the pathogen in the 
software system.13 The output is a personalized dosing regimen. 
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Several software programs that assist in decision making are 
now available which enables advice at the point of care with an 
easy user-friendly interface keeping complex calculations at the 
background but providing useful dose recommendations (Best 
Dose, InsightRx, DoseMe).24-27 
Section II –  DBS as a tool for personalized medicine on a patient level 
The second part of this thesis focused on the analytical and clinical validation 
of a DBS sampling method for TDM of azole antifungal agents, anti-TB drugs 
and immunosuppressive agents in children (chapters 7, 8 and 9), the evaluation 
of an automated spot desorption method for the analytical assay for voriconazole 
(chapter 10) and the assessment of the impact of DBS on total sampling costs 
(chapter 11). DBS offers various benefits over conventional sampling, i.e. it is 
less invasive, less blood is required, patients can perform sampling themselves, 
it can be performed with optimal timing (‘trough concentrations’) leading to 
better interpretability of the sample which is difficult to ‘capture’ at an outpatient 
visit, and there is no contamination risk for the environment. DBS may be used 
to improve personalized drug dosing on an individual level. In contrast to these 
attractive advantages, DBS methodology is still associated with several challenges 
worth mentioning.
Analytical method development
The first challenge of the DBS methodology concerns the development of a novel 
method of analysis, which is costly as it usually takes several months of full-time 
work for one laboratory technician, given the criteria to comply with as stated 
by regulatory agencies such as the EMA and FDA.28, 29 Remarkably, no specific 
guidelines for DBS sampling and method development are available whereas 
some specific challenges exist when developing a DBS assay that are absent for 
plasma assays. Probably the main challenge is to quantify the concentration 
of the compound of interest based on an uncertain amount (volume) of blood 
spotted on the filter paper. When a fixed part of the spot is analysed, hematocrit 
determines the volume of blood present in the sample.30 The so-called ‘hematocrit 
effect’ influences the spreading of blood onto the filter paper. Not taking this effect 
into account severely biases the concentration measurement of the compound 
of interest. To overcome this issue, Patteet et al. analysed the whole spot in their 
assay of antipsychotics instead of a fixed part of the spot.31 Whole-spot analysis 
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is an option when fixed amounts of blood are spotted onto filter paper, for 
example when patients are sampled under controlled circumstances in a health-
care setting. However, for patients sampling at home it remains a challenge to 
deliver reproducible spots of uniform size. Several innovative solutions have been 
developed in an attempt to overcome the hematocrit effect. DBS assessments of 
hematocrit have been published such as non destructive on-card UV analysis 
or measurement of potassium as a ‘marker’ for hematocrit.30, 32-34 Potassium 
measurement requires an additional development step and dedicated analytical 
equipment not readily present in all routine pharmacy laboratories. Another 
elegant option is a device allowing for a fixed amount of blood to be applied onto 
the filter paper and allowing for whole spot analysis.35 With dried plasma spots, 
the drop of blood is filtered on the paper by ‘trapping’ the blood cells on one 
layer only allowing the plasma to pass onto the second layer which is used for 
analysis.36 Qyntest™ designed a sample card with woven polymer layers allowing 
for a homogenous blood flow with predictable blood volumes.37 Mitra™ completely 
abandoned the filter paper and designed a device that allows for sampling exactly 
10 microliters of blood.38 The main disadvantages of those devices are their high 
costs as compared to the conventional DBS filter paper (Whatman903™).
Numerous attempts have been done to make DBS analyses more efficient, in 
an attempt to overcome the above mentioned challenges. E.g., fully automated 
analysis with flow-through desorption39, 40 (using a Dried Blood Spot Autosampler 
[DBSA]) or limited sample pre-treatment with small organic solvent use41 have 
the goal of speeding-up the analysis resulting in reduced costs. In chapter 10 we 
present a flow-through desorption method (DBSA) for two azole antifungal agents. 
Besides its advantages, also some challenges remain to exist with the DBSA. First, 
the DBSA is costly, a high volume of samples is needed in order to earn back the 
investment. Second, not all compounds seem suitable for the DBSA. Lipophilic 
compounds, such as posaconazole or itraconazole, could not be adequately 
measured with this method. Especially older spots of those compounds, e.g. more 
than 1 week old, resulted in low recovery and seemed not to be extracted from the 
spot easily. Interestingly, no influence of spot age was observed with the punch 
method with these compounds (chapter 7). The difference in recovery may have 
been caused by the extraction method, which differs between manual punch 
method and the DBSA. Third, blood needs to be appropriately spotted onto the 
filter paper when using the DBSA: in case the spots are outside of the detection 
window, they have to be selected manually – increasing runtime. Fourth, different 
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software systems are needed in every step in the process: this requires additional 
set-up time every time you run a batch. Of course, these drawbacks are becoming 
less important in case high volumes are expected and this technique is still under 
development. Nevertheless, these items should be carefully considered prior to 
developing such a method with the idea of implementing this for TDM in routine 
clinical care.
An ideal analytical method would be a bedside point-of care device that can 
process minimal amounts of blood and gives the result within some minutes, such as 
for example glucose meters or bedside creatinine meters. Important requirements 
are the interpretation of the outcome, which should be performed by a trained 
healthcare professional who may consult a clinical pharmacologist/pharmacist, 
and storage of the data in a central and accessible system. Although it would be 
very nice to have such a simple method for measuring drug concentrations, this 
will not be available within the near future. One would need to make an enormous 
effort to downsize current analytical detection equipment (LC-MS/MS or UPCL-
UV). Only for very high volumes it would be interesting to make this effort. This 
is clearly not the case for the drugs studied in this thesis, as minimal numbers of 
samples are processed compared to e.g. glucose or creatinine.
Clinical validation
After analytical validation, a thorough clinical validation is required. This 
thesis presents three clinical validation studies (chapters 7, 8 and 9) in which 
DBS finger prick sampling is compared to conventional venous sampling in the 
paediatric target population. Agreement between both methods was assessed with 
appropriate statistical methods (Passing-Bablock regression, Bland-Altman plots) 
and the predictive performance was quantified. Moreover, we assessed patient 
attitudes towards DBS sampling by means of a questionnaire. This complete 
clinical validation step is not always performed, and sometimes only partially.42 
Another challenge in DBS analysis relates to the agreement between DBS 
concentrations and the gold standard used for clinical interpretation, i.e. plasma 
or serum concentrations. Often, whole blood DBS concentrations have to be 
recalculated towards plasma-based references values for clinical interpretation. 
In case the hematocrit effect is large, or if there are large discrepancies between 
plasma and whole blood concentrations, actual hematocrit values may be required 
for this calculation. In homogenous populations hematocrit values can be 
assumed constant, so a population value can be used as proposed by Jager et al.43 
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No important hematocrit effect was observed in our DBS assay of azole antifungal 
agents. For immunosuppressive agents, tacrolimus did not show a relevant 
hematocrit effect while MPA could be accurately measured with hematocrit 
between 0.20 and 0.30 only.
Based on our clinical validation study we confirm adequate predictive 
performance of DBS sampling for tacrolimus but not for MPA. The assay was 
based on a previously developed assay by Hoogtanders et al.44 As to antifungal 
drugs, we have performed a preliminary analysis of itraconazole and posaconazole 
(our manuscript is still under preparation). Our results confirm the predictive 
performance of those compounds and the positive attitudes of patients towards 
this new method. The amount of samples of voriconazole and fluconazole were 
insufficient to draw any conclusions. We observed that the inclusion of patients on 
some drugs was easier than on other drugs. This is contributable to the prescription 
rate, but also to the willingness of patients to participate. From all azole antifungal 
agents, we collected most patients treated with itraconazole, which is used per 
protocol as antifungal prophylaxis for important groups of paediatric hemato-
oncology patients. In contrast, voriconazole is used for the treatment of invasive 
fungal infections and we have the impression that patients on this drug were 
also less willing to participate, probably due to their severe clinical condition. 
Although it is difficult to extrapolate willingness to participate in a clinical study 
to acceptability to use a novel technology in clinical practice, it is important to 
learn from our observations and identify which factors (‘attributes’) are important 
for blood drawing, as we did in two of our clinical validations (chapters 7 and 8). 
This may help to define subpopulations that will probably benefit most from DBS 
sampling. 
We are the first to clinically validate first-line anti-TB drugs in patients and 
subsequently applied this method to assess the PK of these compounds in children. 
The anti-TB DBS assay may now be used for TDM purposes or for PK research, for 
example on the new paediatric fixed-dose formulation of first-line anti-TB drugs45 
or to evaluate higher rifampicin dosages. 
Clinical validation studies are very important to assess agreement between 
DBS sampling and the golden standard. This ensures the clinician that DBS 
sampling actually works for their patients and is a reliable alternative to 
conventional sampling. Although the analytical validation may be successful, DBS 
sampling in patients helps to assess actual agreement. As mentioned before, we 
observed unacceptably high variability with ethambutol DBS. This variability is 
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only identifiable with proper statistical assessment of agreement. Unfortunately, 
extensive clinical validation studies are very often lacking. Until the agreement of 
the DBS method is properly investigated and confirmed, DBS may be considered 
only as a semi-quantitative method to detect either very low or very high 
concentrations.
Implementation of DBS sampling in routine care and research
No literature exists on the application or implementation of DBS sampling for 
the purpose of TDM in clinical practice. Given the relative absence of clinical 
validation studies42, we feel that implementation may be lagging behind, which 
was also concluded in a review on the status of remote sampling with DBS in the 
field of psychiatry.46
The implementation of home sampling into clinical practice for TDM 
purposes requires attention as patients will need to sample themselves or parents 
need to sample their child. Our experience in the case of DBS home sampling 
with tacrolimus by adult patients is that with repetitive feed-back on spot quality, 
the proportion of adequate spots delivered by the patients is about 90% (data not 
published). For routine plasma measurement this would be unacceptably low. It 
should be acknowledged that good quality spots can only be obtained after careful 
instruction and regular practice. Implementation of DBS sampling requires 
time investment and a change of routines. Patients performing the finger prick 
themselves should thus be carefully trained.
DBS sampling might prove beneficial also within healthcare settings, e.g. in 
case of remote areas and limited resource settings, but also in patients with needle 
phobia or other complicating factors. In addition to routine clinical care, DBS 
sampling has already been proven beneficial in research-settings. This was not 
only illustrated in this thesis (chapter 9) where DBS samples of anti-TB drugs were 
directly used to assess PK for research purposes but also previously in PK studies 
of different formulations of tacrolimus, or in a study on the influence of diarrhoea 
on tacrolimus PK.47-49 In addition, epidemiological50, 51 or PK research on drug 
metabolism has been performed with DBS sampling.52, 53
Costs involved in DBS technology
In chapter 11, a cost evaluation of blood sampling is presented, which shows that 
DBS home sampling can significantly reduce costs; up to 60% from a societal point-
of-view and healthcare costs may decrease up to 20%. Although not calculated 
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within the current cost-evaluation of this thesis, investments associated with the 
development of the DBS assay should be earned back. It is challenging to calculate 
these investments costs, as they depend very much on how the laboratory is 
organised financially and on many details such as squared meter price, the status of 
the laboratory equipment and how much (time) the equipment is used for the DBS 
assay, overhead, etc. Nevertheless, based on our experience with the development 
of DBS methods we consider DBS method development costly. A laboratory 
technician needs at least a year to develop a robust DBS method which complies 
with international guidelines on method validation.28, 29 This time investment also 
depends on his/her experience, the available laboratory equipment, the physical-
chemical properties of the drug(s) of interest and the amount of drugs present 
within the assay. After analytical method development, clinical validation in 
patients is required. For validation among children, a clinical study is performed, 
which is costly again in terms of time from the researchers and/or research nurse, 
the physician and the laboratory technician. Calculating all costs involved in the 
development of DBS assays would be very valuable for policy makers. Clearly, only 
widespread use of the method will earn the costs back.
Biochemical parameters measured along with the DBS sample
For optimal and efficient monitoring, home sampling should ideally also allow 
for measurement of biochemical blood tests that are frequently assessed in the 
patient population. For instance, kidney function is monitored more frequently 
than tacrolimus exposure among kidney transplant patients, so ideally creatinine 
is also measured along with the drug of interest. Similarly, liver function (e.g. ALT, 
AST, AP and bilirubin) is often assessed in patients treated with azole antifungal 
drugs (especially with voriconazole).
To the best of our knowledge, only DBS assays for creatinine have been 
published.54, 55 The precision of those assays is usually about 10-15% coefficient of 
variation (CV). In comparison, routine plasma assays for creatinine reach 2% CV. 
This difference in precision is related to analytical issues intrinsic to whole blood 
measurement inherent to DBS analysis. Consequently, current DBS assays for 
creatinine can be used for assessment of either very high or very low concentrations 
and are not yet suitable for a reliable follow-up of renal function. Development 
of such assays is warranted in order to really improve blood sampling and avoid 
additional hospital visits for blood sampling. This will lead to more patient-
friendly care and, based on our cost evaluation (chapter 11), this will probably 
reduce costs even more.
45151 Lisa Martial.indd   276 16-05-17   20:10
General discussion
277
12
Summarizing remarks of section II and topics for future research
The second part of this thesis evaluated the potential benefits and aspects of DBS 
sampling for the purpose of individualizing drug dosing on an individual patient’s 
level. Some remaining challenges form a starting point for future research. These 
are discussed below.
• Careful selection of the patient population that may benefit from 
DBS sampling. Given the challenges of developing DBS assays 
and the investments needed, careful selection of the population 
is highly advised for DBS home sampling to be rational fur the 
purpose of TDM. Based on our cost evaluation, total cost savings 
of home sampling heavily depend on the amount of visits that 
can be avoided. Volumes should be high enough to make DBS 
sampling feasible.
•	 Extensive clinical validation. Until the agreement of the DBS 
method with the gold standard (often plasma) is properly 
investigated and confirmed, DBS may be considered only as a 
semi-quantitative method to detect either very low or very high 
exposures. Given the incomplete clinical validation studies 
among the published assays developed so far, more attention 
should be paid on the clinical validation in the target population. 
Our results confirm that despite good results with the analytical 
validation, clinical validation may detect unacceptably high 
variability resulting in disapproval of the DBS method. 
•	 Measurement of biochemical parameters with DBS. Relevant 
biochemical parameters should be assessed with DBS sampling. 
This will further improve patient care and will probably lead to 
more use of DBS sampling.
•	 Investigation of financial investment. The financial investments 
of developing an analytical DBS assay should be assessed. 
Subsequently, based on our cost evaluation, the volume of DBS 
samples needed to earn back the investments can be determined.
•	 Improving current plasma assays. There are clearly still some 
remaining challenges when developing DBS assays for the 
purpose of TDM. Some of them are related to the analytical 
development such as the hematocrit effect, others relate to 
the sampling itself as ‘perfect’ spots are required for adequate 
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concentration measurement. Ideally, sampling methods are 
patient-friendly, non-invasive, easy, and the analytical assay 
should be robust, i.e. the outcome should be insensitive to small 
differences in the performance of the sampling, the sample 
volume or the patient’s hematocrit. DBS is patient friendly and 
non-invasive but it is not always as robust as a plasma assay. 
It is associated with higher variability as compared to plasma 
assays, both for drugs as for clinical chemical parameters such 
as creatinine. DBS sampling is probably most interesting when 
applied in PK studies as instructed personnel will probably 
produce good quality spots as they regularly perform it. When 
additional clinical laboratory values are needed, such as for most 
routine clinical care, the benefits of DBS will not always outweigh 
the remaining challenges and investments required.
Based on the results of this thesis, also investments in making current 
conventional assays ready to process minimal amounts of blood (<50 µL) would 
be beneficial, under the condition that stability is no issue. The blood should be 
obtained from a finger prick, using ‘micro tubes’ (e.g. Li-heparin). When only 
limited amounts of plasma are required for drug analysis, also biochemical 
parameters may be analysed from the same sample. This requires good collaboration 
between the different laboratories within health-care settings. Combining several 
analyses based on one ‘micro-tube’ sample will be even more patient-friendly and 
will further reduce the costs as more hospital visits may be avoided.
In conclusion, this thesis focused on drug concentrations to improve 
individualized drug dosing. On a population level, the PK of immunosuppressive 
agents in children and echinocandin antifungal agents in critically ill patients was 
characterized and PK target attainment was assessed. In addition, DBS sampling 
was intensively explored as a tool for individualizing drug dosing on an individual 
level, in the context of TDM. Although some additional items require attention 
before DBS can be widely implemented for the purpose of TDM (e.g. sampling 
of biochemical parameters), for now, already small groups of patients may benefit 
from this sampling technique to individualize drug doses. In addition, DBS 
sampling has proven very valuable in clinical PK studies. 
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Personalized medicine remains an important topic in pharmacotherapy. From 
basic clinical pharmacology principles it is known that the administered dose 
impacts the drug concentration achieved, which on its turn impacts the effect of 
the drug. Clearly, the prevailing ‘one-dose-fits-all’ approach in drug treatment 
is failing as the same dose does not lead to the same effect in two different 
individuals. This is because the pharmacokinetics (PK) of a drug, defined as the 
relationship between the dose administered and (the time course of) resulting drug 
concentrations, may be different in sub-populations such as children or critically 
ill patients as compared to - more intensively studied - healthy male volunteers. 
The PK of children is different compared to adults due to developmental and 
maturation processes that result in changes in organ function which may 
influence the clearance of a drug. Differences in body composition may impact 
the volume of distribution of a drug. The PK of anti-infective agents in critically ill 
(Intensive Care Unit [ICU]) patients can be highly variable. Antimicrobial dosing 
recommendations are inadequate in up to 40% of ICU patients and it is thought 
to be one of the main drivers of treatment failure in this population. Physiological 
processes such as hypoalbuminemia, changes in protein-binding, fluid retention 
with subsequent administration of diuretics, sepsis, multi-organ failure, capillary 
leak and differences in cardiac output contribute to the high variability in PK 
among these patients. In order to provide a valuable advice on the optimal dose of 
a drug for an individual patient, it is important to characterize both the PK and the 
pharmacodynamics (PD) of the drug for that patient.
Identifying factors influencing the PK might help to understand the mechanisms 
behind the variability observed in the PK and response among different patient 
populations and within patients. This information can be used to design better 
a priori dosing regimens for a patient population to which an individual patient 
belongs. To further individualize the dose on a patient’s level, adequate drug assays 
are required to measure and individualize the exposure in the individual patient. 
Novel tools facilitating blood sampling may be useful for such individualized 
concentration measurements. Dried blood spot (DBS) sampling is one of these 
promising novel sampling tools.
This thesis focuses on individualizing drug dosing of a selection of drugs used 
by vulnerable patient populations and comprises ten chapters divided in two 
sections.
In section I, entitled ‘Studying the pharmacokinetics on a population level - 
special patient populations’, the PK is studied on a population level by investigating 
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two drug classes - immunosuppressants in children and antifungal agents in ICU 
patients.
Section II, entitled ‘Dried blood spot as a tool for personalized medicine on a 
patient level’, describes the analytical development of four DBS assays, their clinical 
validation and an economic evaluation of DBS home sampling.
Both approaches have the ultimate goal of finding the optimal dose for each 
individual patient. The thesis ends with a general discussion that puts the results 
into perspective and proposes specific future steps for further improvement of 
individualized drug dosing.
Section I - Studying the pharmacokinetics on a population level - special 
patient populations
Tacrolimus and mycophenolic acid (MPA) are the two mainstay maintenance 
immunosuppressive agents to prevent graft rejection in pediatric renal transplant 
patients. Both agents have a narrow therapeutic window. In other words, small 
changes in drug concentrations have an important impact on efficacy or toxicity. 
From small PK studies it is known that the PK of these agents is highly variable 
among pediatric patients and children may have increased clearance of tacrolimus. 
Chapters 2 and 3 study the PK of MPA and tacrolimus among pediatric renal 
transplant patients, respectively. Drug concentrations collected for routine 
clinical care were used to determine PK parameters and (concentration) target 
attainment rates. In addition, the cohort of patients treated with MPA allowed 
for assessment of potential covariates explaining the variability in PK (chapter 2). 
Chapter 3 focuses on the very young transplant patient, as this population is only 
eligible for kidney transplantation since a few years and little is known on the PK 
of tacrolimus in this population. Both immunosuppressive agents demonstrate 
low target attainment rates, namely in only 40-50% of patients. Furthermore, the 
studies confirm high variability in PK for both drugs and time since transplantation 
and serum creatinine were found to significantly affect the PK of MPA. Based on 
our results, we propose higher initial MPA and tacrolimus doses and (more) early 
assessment of total exposure (area under the concentration time curve [AUC], the 
best measure of exposure or ‘concentration’).
In critically ill patients with candidemia or invasive candidiasis, echinocandins 
are the best treatment option. It is well-known that the PK of (anti-infective) 
drugs is highly variable in this patient population due to physiological changes, 
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i.e. changes in organ function or hemodynamics. In chapters 4 and 5, the PK of 
caspofungin and micafungin is characterized in ICU patients using non-linear 
mixed effects modelling (NONMEM). NONMEM allows for the identification of 
potential covariates on primary PK parameters such as clearance and volume of 
distribution. In addition, based on the developed model, we are able to perform 
simulations of various (alternative) dosing regimens. Both PK analyses do not 
identify any covariates that significantly impact PK of echinocandins in ICU 
patients. Potential covariates may have been obscured by the overall high variability 
observed in these ICU patients and the limited sample size. Simulations show that 
the probability of target attainment (PTA) of caspofungin decreases when the 
maintenance dose is decreased from 50 to 35 mg, required for cirrhotic patients 
classified with Child-Pugh score B. This scale is often used unjustifiably among 
non-cirrhotic ICU patients for judgement of hepatic function. Non-cirrhotic 
patients are misclassified as having hepatic dysfunction (a high Child-Pugh score) 
but this classification is mainly driven by their hypoalbumenia rather than hepatic 
dysfunction itself. Furthermore, PTA analyses show that for both drugs, higher 
doses are required with Candida species with attenuated susceptibility profiles (as 
measured by the minimal inhibitory concentration [MIC]) in order to attain the 
PK target that is associated with improved clinical outcome.
Drug-drug-interactions may also be an important source of PK variability 
and managing these interactions can be very challenging. Azole antifungal agents 
interfere with the metabolism of important immunosuppressive agents (tacrolimus, 
cyclosporine, sirolimus, everolimus) by inhibiting their enzymatic metabolism. 
Chapter 6 provides a stepwise approach to manage drug-drug interactions 
between azole antifungal agents and immunosuppressive agents. Different tools 
are identified that are indispensable for the assessment and management of these 
specific drug-drug interactions.
Overall, section I identifies multiple key topics, that form a starting point for 
future research in special patient populations:
•	 More early PK and PD assessment in drug development. 
Some of the investigated drugs are already available for a very 
long time: more effort should be put to assess PK (and PD) of 
relevant patient populations – preferably in an earlier stage of 
drug development and registration.
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•	 Explain inter-individual variability in PK. The drugs in section 
I show high inter-individual variability in PK and not all 
variability could be explained. Combining data sets using data 
from different studies may be helpful to better characterize the 
PK by expanding the sample size.
•	 Suboptimal exposure is observed in vulnerable subpopulations 
– both in pediatric renal transplant patients as in ICU patients 
treated for a fungal infection. This points towards higher doses 
of these agents, which should be evaluated prospectively taking 
into account both PK and PD.
•	 PK-PD targets are insufficiently defined both for 
immunosuppressants in children as well as for echinocandin 
drugs in adults. Research should focus on the definition of these 
PK-PD targets. The role of biomarkers (e.g. IMPDH, ß-glucan) as 
an early evaluation of treatment efficacy should be investigated.
•	 Software tools must become available to guide dosing for 
immunosuppressive drugs and anti-infective drugs. With these 
tools (MwPharm, Best Dose, InsightRx, DoseMe), clinicians may 
enter the concentration-time data and obtain a personalized 
dosing regimen.
Section II - Dried blood spot as a tool for personalized medicine on a patient 
level
To personalize drug doses for individual patients, therapeutic drug monitoring 
(TDM) is a very useful tool. TDM is defined as the measurement of drug 
concentrations in individual patients with subsequent dose adaptation in order 
to attain predefined therapeutic target concentrations. Conventionally, drug 
concentrations are measured in blood or plasma obtained by vena puncture in 
a healthcare facility. Repeated sampling is associated with additional visits to the 
hospital. Especially for children, this causes anxiety and interferes with their daily 
activities like school attendance. DBS sampling by means of a finger prick is an 
attractive alternative.
Chapters 7, 8 and 9 describe the development and clinical validation in children of 
assays for azole antifungal agents, immunosuppressive agents and anti-tuberculosis 
(TB) agents, respectively. These drug classes are subject of (intensive) TDM. 
The analytical assays were validated for standard validation parameters, such as 
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accuracy, precision, matrix effect, and relevant DBS-specific parameters, including 
hematocrit effect, spot volume and extensive stability assessment. Subsequently, DBS 
sampling was tested in a prospective observational study among children treated 
with these agents. Statistical methods including Passing-Bablok regression analysis, 
Bland-Altman plots and the quantification of the median (absolute) prediction 
error assessed whether DBS samples could adequately predict venous (plasma) 
concentrations. DBS sampling of tacrolimus (chapter 7), posaconazole (preliminary 
results, chapter 8), rifampicin and pyrazinamide (chapter 9) could adequately predict 
venous concentrations. DBS sampling of MPA (chapter 7), itraconazole (chapter 8) 
and ethambutol (chapter 9) is associated with high variability and are only suitable 
for semi-quantitative analyses. Furthermore, results show good patient acceptability 
of DBS finger prick sampling, and 50-75% of patients prefer the finger prick over 
normal sampling (either vena puncture or sampling from a port-a-cath). Most 
parents (>80%) would be willing to perform a finger prick.
Chapter 9 shows the results for DBS sampling of rifampicin and pyrazinamide 
directly applied in a the study population composed of Paraguayan pediatric TB 
patients. Children were treated according to the revised (higher rifampicin dose) 
WHO dosing schedule. The PK was characterized and target attainment rates were 
assessed. Despite the higher dosing regimen, we demonstrate that still only 25% of 
patients reach the plasma concentration target for rifampicin.
Conventionally, DBS sample preparation is performed by manually punching 
out a paper disk of the dried blood spot, after which extraction fluid is added, with 
subsequent further processing. In chapter 10, an innovative fully automated DBS 
sample pre-processing methodology using a dried blood spot auto sampler (DBSA) 
is described for the measurement of voriconazole. This method demonstrates to 
reduce sample preprocessing from 1.5 hours to 3 minutes which will save time of 
the laboratory personnel and ultimately reduce costs.
Although cost reductions are often stated as an advantage of DBS sampling, 
no formal cost evaluation has been performed previously. Chapter 11 presents 
an economical evaluation (Health Technology Assessment [HTA]), in which 
total costs associated with DBS sampling are compared to conventional sampling 
taking into account the societal, healthcare and patient perspective. DBS home 
sampling decreases costs (43-61%) by decreasing patient (travel) costs and loss of 
productivity. Total savings depend on the amount of hospital visits avoided and 
influential cost items included healthcare professionals’ time, and analysis costs 
and valuation of caregiver time.
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Based on the results of section II the following topics may form a starting point 
for future research:
•	 Careful selection of the patient population that may benefit 
from DBS sampling. Given the challenges encountered with 
developing DBS assays and the related financial investments, 
careful selection of the population is highly advised before 
developing a DBS home sampling  method for the purpose of 
TDM.
•	 Extensive clinical validation. Until the agreement of the DBS 
method with the gold standard is properly investigated and 
confirmed, DBS may be considered only as a semi-quantitative 
method to detect either very low or very high exposures. Our 
results confirm that despite good results with the analytical 
validation, clinical validation may show high variability between 
DBS and conventional concentration measurements, resulting 
in suitability of the DBS method for semi-quantitative purposes 
only.
•	 Measurement of biochemical parameters with DBS. Relevant 
biochemical parameters should be assessed with DBS sampling. 
This will further improve patient care and will probably lead to 
increased use of DBS sampling.
•	 Investigation of financial investment. The financial investments 
of developing an analytical DBS assay should be assessed. 
Subsequently, the volume of DBS samples needed to earn back 
the investments can be determined.
•	 Improving current plasma assays. Clearly still some remaining 
challenges when developing DBS assays for the purpose of TDM. 
Based on the results of this thesis, also investments in making 
current conventional assays ready to process minimal amounts 
of  blood (<50 µL) would be beneficial. Combining drugs and 
biochemical parameters from one ‘micro-tube’ sample will be 
even more patient-friendly and will further reduce costs.
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This thesis focuses on drug concentrations to improve individualized drug 
dosing. It characterizes the PK of immunosuppressive agents in children and 
echinocandin antifungal agents in critically ill patients, providing the base for 
dose adaptations for patients in these populations. In addition, DBS sampling 
is intensively explored as a tool for real individualization of drug dosing on an 
individual level, in the context of TDM. Although some additional items require 
attention before DBS can be widely implemented for the purpose of TDM, groups 
of patients may already benefit from this sampling technique to individualize drug 
doses.
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Nederlandse samenvatting
Personalized medicine is een belangrijk thema in de farmacotherapie. Vanuit de 
basale farmacologie weten we dat de dosis van een geneesmiddel van invloed is op 
de geneesmiddelconcentratie in het bloed, die weer het uiteindelijke effect van het 
geneesmiddel bepaalt. We weten inmiddels dat een one-dose-fits-all benadering 
vaak niet adequaat is, omdat dezelfde dosering van een geneesmiddel bij twee 
verschillende patiënten tot verschillende concentraties kan leiden. Dit komt door 
verschillen in farmacokinetiek (PK), wat je kunt definiëren als de relatie tussen 
de toegediende dosis en (het tijdsverloop van) de geneesmiddelconcentratie. De 
geneesmiddelconcentratie wordt ook wel ‘spiegel’ genoemd. Kinderen of zeer 
kritiek zieke patiënten kunnen een andere PK hebben vergeleken met gezonde 
mannen, terwijl deze laatste groep vaak uitvoerig(er) bestudeerd wordt tijdens 
de vroege fase van geneesmiddelontwikkeling. De PK in kinderen onderscheidt 
zich van die van volwassenen doordat kinderen zich nog ontwikkelen. Met name 
maturatieprocessen van belangrijke organen zoals de lever en de nieren dragen 
bij aan een andere PK. Dit kan resulteren in een veranderde klaring van het 
geneesmiddel. Verder hebben kinderen een andere lichaamssamenstelling, wat 
kan resulteren in een veranderd verdelingvolume van het geneesmiddel. De PK 
van geneesmiddelen is ook anders en veel variabeler bij kritiek zieke patiënten 
opgenomen op de Intensive Care (IC) afdeling. Het blijkt dat tot 40% van de 
doseeradviezen van antimicrobiële middelen inadequaat is bij patiënten op de IC. 
Sepsis, multi-orgaan falen en hypoalbuminemie met veranderingen in eiwitbinding 
verklaren in ieder geval gedeeltelijk de enorme variatie in PK bij deze patiënten. 
Hieruit voortkomende lage bloedspiegels dragen op hun beurt in grote mate bij 
aan falen van therapie. Ondanks dat geneesmiddelen door verschillende van dit 
soort groepen (populaties) van patiënten veelvuldig gebruikt worden, blijkt de PK 
van de gebruikte geneesmiddelen nog niet voldoende opgehelderd. Om tot een 
goed doseeradvies te komen is het dus belangrijk om de PK van geneesmiddelen 
in specifieke patiëntpopulaties in kaart te brengen.
Door factoren te identificeren die van invloed zijn op de PK, kan verklaard 
worden waarom de PK varieert tussen patiënten (of patiëntgroepen) maar 
ook binnen patiënten. Deze kennis kan helpen bij het beter doseren van 
geneesmiddelen in een specifieke patiëntengroep. Behoudens de PK is het van 
belang de farmacodynamiek (PD), hetgeen gedefinieerd wordt als de relatie tussen 
de geneesmiddelconcentraties en het uiteindelijke effect van het geneesmiddel, in 
kaart te brengen.
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Een andere manier om de farmacotherapie te optimaliseren betreft het 
individualizeren van therapie door het meten van geneesmiddelconcentraties 
(‘spiegels’) van een individuele patiënt. Op basis van deze gegevens kan de dosering 
dan worden aangepast. Alternatieve methoden van bloedafname zoals de dried 
blood spot (DBS) methode zijn veelbelovend, omdat ze het proces van bloedafname 
kunnen versimpelen. Hiervoor zijn wel robuuste analytische methoden nodig.
Dit proefschrift richt zich op het individualizeren van de dosering van een 
reeks aan geneesmidden bij kwetsbare patiëntgroepen. Het proefschrift telt 
tien hoofdstukken die verdeeld zijn over twee secties. In sectie I, getiteld ‘Het 
bestuderen van de farmacokinetiek op groepsniveau – kwetsbare patiëntgroepen’, 
wordt de PK van twee geneesmiddelklassen bestudeerd: immunosuppressiva bij 
kinderen en antifungale geneesmiddelen bij IC patiënten. Sectie II, met als titel 
‘Dried blood spot als een hulpmiddel voor personalized medicine op patiëntniveau’, 
beschrijft de ontwikkeling van vier DBS methoden met hun klinische validatie, 
alsook een economische evaluatie van thuis bloed afnemen met behulp van DBS.
Het doel van deze tweeledige aanpak is om de optimale dosering voor elke 
individuele patiënt te vinden. Het proefschrift eindigt met een algemene discussie 
waarin de resultaten in perspectief worden geplaatst. Hieruit volgen specifieke 
onderdelen die een startpunt van nieuw onderzoek zouden kunnen zijn.
Sectie I - Het bestuderen van de farmacokinetiek op groepsniveau – 
kwetsbare patiëntgroepen
Tacrolimus en mycofenolzuur zijn de twee belangrijkste geneesmiddelen ter 
preventie van orgaanafstoting na een niertransplantatie bij kinderen. Beide 
middelen hebben een nauwe therapeutische index: dit betekent dat kleine 
veranderingen in de bloedconcentratie kunnen leiden tot ernstige bijwerkingen 
of juist onvoldoende therapeutisch effect. Uit een aantal kleine onderzoeken 
blijkt dat de PK van deze middelen zeer variabel is bij kinderen. Deze variatie 
kan leiden tot onder- of overbehandeling. In hoofdstuk 2 en 3 wordt de PK van 
respectievelijk mycofenolzuur en tacrolimus in (jonge) patiënten bestudeerd. 
Geneesmiddelconcentraties die voor routinezorg worden verzameld, konden 
worden gebruikt om PK parameters te bepalen en om te toetsen in hoeverre 
patiënten de van tevoren vastgestelde therapeutische ‘doel’ concentraties 
behalen. Met het patiëntencohort in hoofdstuk 2 tonen we aan dat zowel de tijd 
na transplantatie als het serum creatinine (een maat voor de nierfunctie) een 
deel van de variatie van de PK van mycofenolzuur kan verklaren. Uit de studie 
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blijkt verder dat de variatie in PK groot is en dat slechts 46% van de kinderen 
de targetconcentratie behaalt. In hoofdstuk 3 ligt de focus op zeer jonge kinderen 
(vier jaar of jonger). Sinds enkele jaren komen ook deze kinderen in aanmerking 
voor een niertransplantatie. Uit kleine onderzoeken weten we dat kinderen een 
hogere klaring van tacrolimus hebben, maar verder is er weinig bekend over deze 
zeer jonge groep kinderen. Ook in dit onderzoek blijkt de variatie in PK groot en 
behaalt nog geen 40% van de kinderen de gewenste doelconcentratie. Op basis van 
de resultaten uit hoofdstuk 2 en 3 zouden kinderen een hogere startdosis van zowel 
tacrolimus als mycofenolzuur moeten krijgen, met daarbij vroege vaststelling 
van de geneesmiddelspiegels, met name van de totale geneesmiddelblootstelling 
over de tijd (AUC, area under the concentration time curve). De AUC is de beste 
kwantitatieve maat voor blootstelling van tacrolimus en mycofenolzuur.
Echinocandines zijn de beste behandeloptie bij kritiek zieke patiënten met een 
candidemie of candidasis. Het is bekend dat de PK van antimicrobiële middelen 
zeer variabel is in deze patiëntpopulatie, onder andere vanwege de fysiologische 
veranderingen in orgaanfunctie en hemodynamiek. Hoofdstuk 4 en 5 bestuderen 
de PK van de echinocandines caspofungin en micafungin in IC patiënten met 
behulp van Non-Linear Mixed Effects Modelling (NONMEM). Met NONMEM 
is het mogelijk om covariabelen te identificeren die de variatie in primaire PK 
parameters, zoals klaring en verdelingsvolume, kunnen verklaren. In geen van de 
PK analyses worden covariabelen gevonden die de significant geassocieerd zijn 
met de PK parameters van de echinocandines in IC patiënten. Mogelijk worden 
bestaande covariabele-PK parameter relaties overschaduwd door de grote variatie 
in PK tussen individuen. Met NONMEM is het ook mogelijk om doseerregimes te 
simuleren op basis van het ontwikkelde PK model. Het meest gunstige doseerregime 
kan dan worden geselecteerd om te testen in echte patiënten. Simulaties in hoofdstuk 
4 wijzen uit dat het verlagen van de onderhoudsdosering van caspofungin van 50 
naar 35 mg, zoals geïndiceerd bij cirrotische patiënten geclassificeerd met Child-
Pugh score B, de kans op het behalen van de targetconcentratie sterk verlaagt. Deze 
Child-Pugh schaal wordt soms ten onrechte gebruikt bij IC patiënten, waarbij 
het lage albumine de score dan sterk beïnvloedt. Daarnaast laten simulaties zien 
dat hogere doseringen van de echinocandines zijn geïndiceerd in het geval van 
infecties met schimmels met verlaagde gevoeligheid (gemeten met de minimal 
inhibitory concentration [MIC]).
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Voorbeeld:
Het model uit hoofdstuk 4 heeft ons geholpen om voorspellingen te 
doen voor adequate blootstelling aan caspofungin. Op dit moment 
wordt caspofungin in een lagere dosering gegeven aan patiënten waarbij 
er sprake is van een geprikkelde lever. Deze dosisaanpassing wordt 
gedaan op basis van een scoresysteem dat enkel mag worden toegepast 
bij patiënten met een cirrotische lever (vorming van littekenweefsel). 
Middels simulaties hebben we aangetoond dat IC patiënten zonder 
cirrotische lever baat hebben bij de volledige dosis in plaats van de 
verlaagde dosis. Verlagen zou leiden tot suboptimale blootstelling met 
een grotere kans op therapeutisch falen. 
Wisselwerkingen tussen geneesmiddelen (geneesmiddelinteracties) kunnen 
een andere bron van variatie in PK zijn. Sommige van deze geneesmiddelinteracties 
zijn lastig te managen, zo ook de interactie tussen azool antifungale geneesmiddelen 
en immunosuppressiva. Zo remmen azolen het metabolisme van tacrolimus, 
cyclosporine, everolimus en sirolimus. Hoofdstuk 6 beschrijft een systematische 
aanpak voor het managen van deze interacties. Hierin worden specifieke handvaten 
voor het goed beoordelen en afhandelen van deze geneesmiddelinteracties 
gegeven.
Een aantal bevindingen uit de hoofdstukken van sectie I vormen een concreet 
startpunt voor vervolgonderzoek:
•	 Meer PK en PD onderzoek tijdens de ontwikkeling van 
geneesmiddelen. Sommige van de onderzochte geneesmiddelen 
zijn al lang op de markt: meer onderzoek naar PK en de relatie 
met PD van geneesmiddelen in relevante patiëntgroepen zou 
moeten plaatsvinden – bij voorkeur al in vroege fases van 
geneesmiddelontwikkeling en registratie.
•	 Verklaren van inter-individuele variatie in PK. De 
geneesmiddelen onderzocht in sectie I laten een grote inter-
individuele variatie in PK zien, die slechts ten dele kan worden 
verklaard. Het combineren van datasets van verschillende 
onderzoeken kan deze variatie mogelijk beter verklaren.
•	 Suboptimale blootstelling in kwetsbare patiëntgroepen. Zowel 
bij kinderen na een niertransplantatie, als bij IC patiënten 
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behandeld voor een invasieve schimmelinfectie, moeten hogere 
doseringen, inclusief PK en PD eindpunten, prospectief worden 
onderzocht.
•	 PK-PD targets zijn onvoldoende gedefinieerd in zowel kinderen 
als IC patiënten. Verder onderzoek moet doelconcentraties 
vaststellen. Daarbij is er mogelijk een rol weggelegd voor 
biomarkers (inosine-5'-monophosphate dehydrogenase, beta-
glucan). Deze biomarkers kunnen mogelijk al eerder na start van 
farmacotherapie het effect evalueren. 
•	 Sofware die de clinicus ondersteunt in het individualizeren 
van de dosering op basis van geneesmiddelspiegels (MwPharm, 
Best Dose, InsightRx, DoseMe) zou beschikbaar moeten worden 
gemaakt.
Sectie II – Dried blood spot als een hulpmiddel voor personalized medicine 
op patiëntniveau 
Therapeutic drug monitoring (TDM) is gedefinieerd als het aanpassen van de 
dosering op basis van geneesmiddelspiegels van een individuele patiënt om de 
blootstelling binnen vooraf vastgestelde waarden te verkrijgen en te houden. 
TDM is zeer belangrijk bij het individualizeren van de dosering bij patiënten. Van 
oudsher wordt er bloed afgenomen uit een ader, van waaruit meestal plasma wordt 
verkregen waarin de geneesmiddelspiegel wordt gemeten. Voor de bloedafname is 
een zorgverlener nodig en voor elk monster moeten patiënten naar het ziekenhuis 
reizen. Zeker voor kinderen zijn herhaalde bloedafnames belastend, ze zijn er vaak 
bang voor en het verstoort hun dagelijkse activiteiten zoals school. DBS afname 
met behulp van een vingerprik zou een mooi alternatief kunnen zijn. Spots 
kunnen door patiënten thuis worden afgenomen, waarna het monster met de 
gewone post kan worden opgestuurd naar het laboratorium voor de analyse. Ook 
in afgelegen gebieden en in landen met weinig financiële middelen is DBS afname 
een veelbelovend alternatief voor conventionele bloedafname.
Hoofdstuk 7, 8 en 9 beschrijven de ontwikkeling in het laboratorium en de 
klinische validatie in kinderen van drie DBS methodes voor respectievelijk 
azool antifungale middelen, immunosuppressiva en anti-tuberculose middelen. 
Van deze geneesmiddelgroepen wordt in de dagelijkse praktijk vaak (herhaald) 
de bloed- of plasmaconcentratie bepaald in het kader van TDM. De analytische 
methodes zijn gevalideerd op basis van standaard validatieparameters zoals 
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juistheid, precisie en matrixeffect. Daarnaast zijn DBS-specifieke parameters 
zoals hematocrieteffect, spotvolume en stabiliteit bij bewaren getoetst. Na deze 
uitgebreide validatie is de DBS afname getest in een klinisch onderzoek bij 
kinderen. Met behulp van statistische methoden (o.a. Passing-Bablok regressie-
analyse en Bland-Altman plots) werd getest hoe goed het DBS monster de veneuze 
concentratie kon voorspellen. 
Uit de resultaten blijkt dat DBS monsters van tacrolimus (hoofdstuk 7), 
posaconazol (hoofdstuk 8) en rifampicine en pyrazinamide (hoofdstuk 9) de 
veneuze concentraties van deze geneesmiddelen goed kunnen voorspellen. 
Geneesmiddelconcentraties van mycofenolzuur, itraconazol en ethambutol in DBS 
monsters blijken juist erg variabel in vergelijking met de veneuze concentraties. 
We concluderen dat de DBS methode voor deze middelen (nog) niet geschikt is 
voor de toepassing van TDM, maar als een semi-kwantitatieve methode moet 
worden beschouwd. De patiëntacceptatie van DBS vingerprikken in de studies 
is goed en 50-75% van de kinderen geeft een voorkeur aan voor de vingerprik 
ten opzichte van een reguliere bloedafname. Verreweg de meeste ouders (>80%) 
geven bovendien aan bereid te zijn om een DBS vingerprik monster af te nemen 
bij hun kind.
In hoofdstuk 9 zijn tevens de DBS monsters van rifampicine en pyrazinamide 
gebruikt om de PK van deze geneesmiddelen bij de tuberculose patiënten in kaart 
te brengen. Dit waren allemaal kinderen behandeld volgens de laatste richtlijn van 
de Wereld Gezondheidsorganisatie, waarin een hogere dosering rifampicine wordt 
geadviseerd dan voorheen. Ondanks deze hogere rifampicine dosering haalt maar 
25% van de kinderen in deze studie de targetconcentratie.
Bij de meeste DBS analyse methodes wordt eerst een perforatie van de spot 
gedaan, en aan dit stukje bloedspot wordt vervolgens extractievloeistof toegevoegd, 
waarna het monster verder wordt verwerkt. In hoofdstuk 10 wordt een innovatieve 
methode van voorbehandelen van DBS monsters beschreven. Met behulp van een 
zogenaamde DBS autosampler kunnen tot 96 kaartjes worden ingeladen en vol 
automatisch worden verwerkt. Dit apparaat reduceert de tijd van voorbewerken 
van het een bloedspotmonster van 1.5 uur naar 3 minuten (hoofdstuk 10). Deze 
tijdsbesparing zou een kostenbesparing kunnen betekenen.
Ondanks dat kostenbesparing als één van de voordelen van DBS afnames 
wordt gezien, was er nog geen formele kostenanalyse uitgevoerd. In hoofdstuk 11 
voeren we een dergelijke kostenanalyse uit. Alle kosten geassocieerd met gewone 
bloedafname zijn afgezet tegen de kosten gemoeid met DBS thuisafname. Alle 
45151 Lisa Martial.indd   296 16-05-17   20:10
297
S
Nederlandse samenvatting
relevante kosten zijn hierin meegenomen, vanuit het maatschappelijk perspectief: 
dus zowel de kosten voor de maatschappij, de zorgkosten, als ook de kosten voor 
de patiënt. Uit de resultaten volgt dat DBS thuisafname 43-63% van de kosten kan 
besparen door een reductie in reiskosten en minder productiviteitsverlies van de 
ouder. Met name de kosten van de zorgprofessional (in tijd), de kosten voor de 
laboratoriumbepaling en de manier van het waarderen van mantelzorgtijd blijken 
de totale kosten sterk te beïnvloeden. De totale besparing hangt sterk af van het 
aantal reguliere bloedafnames dat door DBS thuisafname kan worden vervangen.
Op basis van de resultaten uit sectie II vormen de volgende onderwerpen en over-
wegingen een aanknopingspunt of les voor toekomstig onderzoek:
•	 Zorgvuldige selectie van de patiëntengroep die kan profiteren 
van DBS afname. De ervaring leert dat het ontwikkelen van een 
DBS analysemethode veel tijd vergt en soms een analytische 
uitdaging vormt. Het is daarom van belang van te voren duidelijk 
vast te stellen welke patiënten het meest van deze nieuwe methode 
gebruik zullen maken.
•	 Uitgebreide klinische validatie. Zolang de voorspelbaarheid van 
DBS voor veneuze concentraties niet uitvoerig is bestudeerd, 
kan de DBS methode alleen als een semikwantitatieve methode 
worden gezien, die alleen heel lage of juist heel hoge concentraties 
kan vaststellen. Ondanks goede resultaten van de analytische 
validatie, kan uit de klinische validatie zodanig grote variatie 
blijken, dat de DBS methode voor routine zorg minder bruikbaar 
is.
•	 Klinisch-chemische parameters meten uit DBS. Relevante 
klinisch-chemische parameters, zoals nierfunctie bij 
immunosuppressiva, zouden idealiter direct met de DBS 
analysemethode moeten worden meebepaald. Dit zal de 
patiëntenzorg verder verbeteren en de inzetbaarheid van DBS 
mogelijk vergroten.
•	 In kaart brengen van de kosten van het opzetten van een DBS 
assay. De ervaring uit sectie II leert dat het tijdrovend is om een 
DBS methode te ontwikkelen die aan alle eisen voldoet van TDM 
en routine zorg. De omvang van deze investering in tijd (en 
dus geld) zou vooraf duidelijk moeten zijn, zodat kan worden 
45151 Lisa Martial.indd   297 16-05-17   20:10
Epilogue
298
bepaald welk volume aan DBS monsters nodig is om deze terug 
te verdienen.
•	 Optimaliseren van bestaande plasmabepalingen. Er bestaan 
nog steeds analytisch-technische uitdagingen bij de toepassing 
van DBS, zoals het hematocrieteffect en de veelal onbekende 
volumina in het monster. De ervaring en resultaten van dit 
proefschrift in ogenschouw nemend, zou het waardevol zijn 
bestaande plasma-assays zodanig te verbeteren dat ze minimale 
hoeveelheden plasma (<50 µL) kunnen verwerken. Wanneer 
uit een dergelijk ‘micro buisje’ zowel geneesmiddelen als 
klinisch-chemische parameters kunnen worden bepaald, zal de 
bloedafname patiëntvriendelijker zijn, en zullen de kosten verder 
verlagen.
Samenvattend richt dit proefschrift zich op geneesmiddelconcentraties ter 
bevordering van geïndividualiseerd doseren bij patiënten. In het proefschrift is eerst 
de PK van immunosuppressiva en echinocandines in kwetsbare patiëntgroepen 
bestudeerd, als basis voor dosisaanpassingen binnen deze populaties. Daarnaast 
is de DBS methode onderzocht in het kader van daadwerkelijke individualizering 
van de dosis middels TDM bij kinderen. Sommige patiëntgroepen kunnen nu al 
van deze nieuwe methode van bloedafname profiteren.
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